[go: up one dir, main page]

WO2025257023A1 - Fungicidal compositions - Google Patents

Fungicidal compositions

Info

Publication number
WO2025257023A1
WO2025257023A1 PCT/EP2025/065673 EP2025065673W WO2025257023A1 WO 2025257023 A1 WO2025257023 A1 WO 2025257023A1 EP 2025065673 W EP2025065673 W EP 2025065673W WO 2025257023 A1 WO2025257023 A1 WO 2025257023A1
Authority
WO
WIPO (PCT)
Prior art keywords
methyl
fluoro
carboxamide
quinoline
benzyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/EP2025/065673
Other languages
French (fr)
Inventor
Mathias Blum
Christopher Charles SCARBOROUGH
Martin Pouliot
Nicolas Germain
Damien BONVALOT
Stephane André Marie JEANMART
Camille LE CHAPELAIN
Peter FINKBEINER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Syngenta Crop Protection AG Switzerland
Original Assignee
Syngenta Crop Protection AG Switzerland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syngenta Crop Protection AG Switzerland filed Critical Syngenta Crop Protection AG Switzerland
Publication of WO2025257023A1 publication Critical patent/WO2025257023A1/en
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/48—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with two nitrogen atoms as the only ring hetero atoms
    • A01N43/56—1,2-Diazoles; Hydrogenated 1,2-diazoles
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N37/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids
    • A01N37/18—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids containing the group —CO—N<, e.g. carboxylic acid amides or imides; Thio analogues thereof
    • A01N37/20—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids containing the group —CO—N<, e.g. carboxylic acid amides or imides; Thio analogues thereof containing the group, wherein Cn means a carbon skeleton not containing a ring; Thio analogues thereof
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N37/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids
    • A01N37/44—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids containing at least one carboxylic group or a thio analogue, or a derivative thereof, and a nitrogen atom attached to the same carbon skeleton by a single or double bond, this nitrogen atom not being a member of a derivative or of a thio analogue of a carboxylic group, e.g. amino-carboxylic acids
    • A01N37/46—N-acyl derivatives
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/34—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom
    • A01N43/36—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom five-membered rings
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/34—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom
    • A01N43/40—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/48—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with two nitrogen atoms as the only ring hetero atoms
    • A01N43/54—1,3-Diazines; Hydrogenated 1,3-diazines
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/64—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with three nitrogen atoms as the only ring hetero atoms
    • A01N43/647—Triazoles; Hydrogenated triazoles
    • A01N43/653—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/72—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms as ring hetero atoms
    • A01N43/80—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms as ring hetero atoms five-membered rings with one nitrogen atom and either one oxygen atom or one sulfur atom in positions 1,2
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/90—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having two or more relevant hetero rings, condensed among themselves or with a common carbocyclic ring system
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N47/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom not being member of a ring and having no bond to a carbon or hydrogen atom, e.g. derivatives of carbonic acid
    • A01N47/02—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom not being member of a ring and having no bond to a carbon or hydrogen atom, e.g. derivatives of carbonic acid the carbon atom having no bond to a nitrogen atom
    • A01N47/04—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom not being member of a ring and having no bond to a carbon or hydrogen atom, e.g. derivatives of carbonic acid the carbon atom having no bond to a nitrogen atom containing >N—S—C≡(Hal)3 groups
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N47/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom not being member of a ring and having no bond to a carbon or hydrogen atom, e.g. derivatives of carbonic acid
    • A01N47/08—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom not being member of a ring and having no bond to a carbon or hydrogen atom, e.g. derivatives of carbonic acid the carbon atom having one or more single bonds to nitrogen atoms
    • A01N47/10—Carbamic acid derivatives, i.e. containing the group —O—CO—N<; Thio analogues thereof
    • A01N47/20—N-Aryl derivatives thereof
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N47/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom not being member of a ring and having no bond to a carbon or hydrogen atom, e.g. derivatives of carbonic acid
    • A01N47/08—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom not being member of a ring and having no bond to a carbon or hydrogen atom, e.g. derivatives of carbonic acid the carbon atom having one or more single bonds to nitrogen atoms
    • A01N47/28—Ureas or thioureas containing the groups >N—CO—N< or >N—CS—N<
    • A01N47/34—Ureas or thioureas containing the groups >N—CO—N< or >N—CS—N< containing the groups, e.g. biuret; Thio analogues thereof; Urea-aldehyde condensation products
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N63/00—Biocides, pest repellants or attractants, or plant growth regulators containing microorganisms, viruses, microbial fungi, animals or substances produced by, or obtained from, microorganisms, viruses, microbial fungi or animals, e.g. enzymes or fermentates
    • A01N63/20—Bacteria; Substances produced thereby or obtained therefrom
    • A01N63/28—Streptomyces
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01P—BIOCIDAL, PEST REPELLANT, PEST ATTRACTANT OR PLANT GROWTH REGULATORY ACTIVITY OF CHEMICAL COMPOUNDS OR PREPARATIONS
    • A01P3/00—Fungicides

Definitions

  • the present invention relates to novel fungicidal compositions, to their use in agriculture or horticulture for controlling diseases caused by phytopathogens, especially phytopathogenic fungi and more particularly oomycetes, and to methods of controlling diseases on useful plants.
  • many fungicidal compounds and compositions, belonging to various different chemical classes, have been/are being developed for use as fungicides in crops of useful plants, crop tolerance and activity against particular phytopathogenic fungi do not always satisfy the needs of agricultural practice in many respects. Therefore, there is a continuing need to find new compounds and compositions having superior biological properties for use in controlling or preventing infestation of plants by phytopathogenic fungi.
  • compositions possessing a greater biological activity, an advantageous spectrum of activity, an increased safety profile, improved physico-chemical properties, or increased biodegradability are also possible.
  • compositions comprising mixtures of different fungicidal compounds possessing different modes of action can address some of these needs (eg, by combining fungicides with differing spectrums of activity).
  • component (A) is a compound of formula (I): wherein A1 is a carbon atom; A 2 is a carbon atom or a nitrogen atom; ring W is selected from ring W being unsubstituted or substituted with one substituent selected from R1, R1 being selected from C1-6alkyl and C1-6alkoxy-C1-6alkyl, and preferably R1 being CH3 or -CH2OCH3; R 2a is H; R 2b is selected from H, CN, C1-6alkyl, C3-6cycloalkyl, C1-6alkoxy-C1-6alkyl, amino, and -NHC(O)C1-6alkyl; R 2c is H; A31
  • ring W is selected from wherein R1 is selected from C1-6alkyl and C1-6alkoxy-C1-6alkyl, and preferably R1 is CH3 or -CH2OCH3.
  • R1 is selected from C1-6alkyl and C1-6alkoxy-C1-6alkyl, and preferably R1 is CH3 or -CH2OCH3.
  • Streptomyces chrestomyceticus comprises a nucleotide sequence which has at least 99.8 %, preferably at least 99.9%,, preferably at least 99.91%, 99.92%, 99.93%, 99.94%, 99.95%, 99.96%, 99.97%, 99.98%, or 99.99% identity to SEQ ID NO: 1.
  • the Streptomyces chrestomyceticus comprises a nucleotide sequence which has 100% identity to SEQ ID NO:1.
  • SEQ ID NO: 1 comprises the 16S RNA gene of Streptomyces chrestomyceticus Saigon413 deposited on September 9, 2022, with the Westerdijk Fungal Biodiversity Institute (CBS), Uppsalalaan 8, NL-3584 CT Utrecht, Nederland, under accession number CBS149411.
  • composition stands for the various mixtures or combinations of components (A) and (B) (including the above-defined embodiments), for example in a single “ready- mix” form, in a combined spray mixture composed from separate formulations of the single active ingredient components, such as a “tank-mix”, and in a combined use of the single active ingredients when applied in a sequential manner, i.e. one after the other with a reasonably short period, such as a few hours or days.
  • halogen refers to fluorine (fluoro or F), chlorine (chloro or Cl), bromine (bromo or Br) or iodine (iodo or I), and preferably fluoro or chloro.
  • amino refers to a -NH2 group.
  • Alkyl as used herein- in isolation or as part of a chemical group – represents straight-chain or branched hydrocarbons, preferably with 1 to 6 carbon atoms, for example methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, s-butyl, t-butyl, pentyl, 1- methylbutyl, 2-methylbutyl, 3-methylbutyl, 1,2- dimethylpropyl, 1,1 -dimethylpropyl, 2,2- dimethylpropyl, 1 -ethylpropyl, hexyl, 1 -methylpentyl, 2- methylpentyl, 3-methylpentyl, 4- methylpentyl, 1,2-dimethylpropyl, 1,3-dimethylbutyl, 1,4-dimethylbutyl, 2,3-dimethylbutyl, 1,1- dimethylbutyl, 2,2-dimethylbutyl
  • Alkyl groups with 1 to 4 carbon atoms are preferred, for example methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, s-butyl or t-butyl.
  • cycloalkyl in isolation or as part of a chemical group - represents saturated or partially unsaturated mono-, bi- or tricyclic hydrocarbons, preferably with 3 to 10 carbon atoms, for example cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, bicyclo[2.2.1]heptyl, bicyclo[2.2.2]octyl or adamantyl. Cycloalkyls with 3, 4, 5, 6 or 7 carbon atoms are preferred, for example cyclopropyl or cyclobutyl.
  • alkoxy refers to a radical of the formula -ORa wherein Ra is an alkyl radical as generally defined above. Examples of alkoxy include, but are not limited to methoxy, ethoxy, propoxy, iso-propoxy, and tert-butoxy.
  • alkoxyalkyl refers to an alkyl radical (as mentioned above) substituted with said alkoxy group. Examples are methoxymethyl, methoxyethyl, ethoxymethyl and propoxymethyl.
  • alkylamino refers to a radical of the formula RaNH- wherein Ra is an alkyl radical as generally defined above.
  • alkoxyamino refers to a radical of the formula RaNH-, wherein Ra is an alkoxy radical as generally defined above.
  • the weight ratio of component (A) to component (B) may preferably be from 100:1 to 1:100, from 50:1 to 1:50, from 20:1 to 1:40, from 15:1 to 1:30, from 12:1 to 1:25, from 10:1 to 1:20, from 5:1 and 1:15, from 3:1 to 1:10 or from 2:1 to 1:5.
  • fungicidal compositions according to the invention may also include, inter alia, advantageous levels of biological activity for protecting plants against diseases that are caused by fungi or superior properties for use as agrochemical active ingredients (for example, greater biological activity, an advantageous spectrum of activity, an increased safety profile, improved physico-chemical properties, or increased biodegradability).
  • the compounds of formula (I) according to the invention are in free form, in oxidized form as a N-oxide or in salt form, e.g. an agronomically usable salt form.
  • N-oxides are oxidized forms of tertiary amines or oxidized forms of nitrogen containing heteroaromatic compounds. They are described for instance in the book “Heterocyclic N-oxides” by A. Albini and S. Pietra, CRC Press, Boca Raton 1991.
  • Preferred groups and values for the substituents A, R 2a , R 2b , R 2c , R 31 , R 32 , and R 4 in the compounds of formula (I) are, in any combination thereof, as set out below:
  • A is N;
  • R 2a is H;
  • R2b is selected from H, C1-6alkyl, C3-6cycloalkyl, C1-6alkoxy-C1-6alkyl, amino, and -NHC(O)C1-6alkyl, and preferably selected from H, CH3, cyclopropyl, -CH2OCH3, NH2, and -NHC(O)CH3;
  • R 2c is H;
  • R31 is selected from H, C1-6alkyl, C1-6alkoxy-, and halogen, and preferably selected from H, CH3, -OCH3, and fluoro;
  • R32 is selected from halogen and CN, and preferably selected from chloro, fluoro, and CN;
  • R4 is selected from C1-6
  • component (A) is a compound selected from compound no. X.01, X.02, X.03, X.04, X.05, X.06, X.07, X.08, X.09, X.10, X.11 and X.12, as defined in the Table X below. More preferably, component (A) is a compound selected from compound no. X.03, X.07, and X.11, as defined in the Table X below.
  • component (B) is a compound selected from the group consisting of azoxystrobin, cyclobutrifluram, cymoxanil, difenoconazole, disodium phosphonate, florylpicoxamid, fluazinam, fludioxonil, fluopicolide, fluoxapiprolin, folpet, mandipropamid, mefentrifluconazole, metalaxyl-M, oxathiapiprolin, picarbutrazox, pydiflumetofen, sedaxane, Streptomyces chrestomyceticus, zoxamide, and Compound Z (feneptamidoquin).
  • component (B) compounds are referred to herein and above by a so-called "ISO common name” or another "common name” being used in individual cases or a trademark name.
  • the component (B) compounds are known and are commercially available and/or can be prepared using procedures known in the art and/or procedures reported in the literature.
  • component (A) is compound no.
  • component (B) is a compound selected from the group consisting of acetamiprid, acibenzolar-S-methyl, ametoctradin, amisulbrom, azoxystrobin, Bacillus amyloliquefaciens, benzovindiflupyr, broflanilid, chlorothalonil, chlothianidin, chlorantraniliprole, Cis-Jasmone, cyantraniliprole, cyazofamid, cyclobutrifluram, cymoxanil, difenoconazole, disodium phosphonate, etha
  • component (A) is compound no. X.02 (methyl N-[5-[6-[1-(4-fluoro-3-methoxy-phenyl)imidazol-2-yl]-8-methyl-imidazo[1,2-a]pyridin-3-yl]-2- pyridyl]carbamate) or a salt, or N-oxide thereof
  • component (B) is a compound selected from the group consisting of acetamiprid, acibenzolar-S-methyl, ametoctradin, amisulbrom, azoxystrobin, Bacillus amyloliquefaciens, benzovindiflupyr, broflanilid, chlorothalonil, chlothianidin, chlorantraniliprole, Cis-Jasmone, cyantraniliprole, cyazofamid, cyclobutrifluram, cymoxanil, difenoconazole, diso
  • component (A) is compound no. X.03 (methyl N-[5-[6-[4-(4-fluoro-3-methoxy-phenyl)-5,6-dihydro-1,2,4-oxadiazin-3-yl]-8-methyl-imidazo[1,2- a]pyridin-3-yl]-2-pyridyl]carbamate) or a salt, or N-oxide thereof
  • component (B) is a compound selected from the group consisting of acetamiprid, acibenzolar-S-methyl, ametoctradin, amisulbrom, azoxystrobin, Bacillus amyloliquefaciens, benzovindiflupyr, broflanilid, chlorothalonil, chlothianidin, chlorantraniliprole, Cis-Jasmone, cyantraniliprole, cyazofamid, cyclobutrifluram, cymoxan
  • component (A) is compound no. X.04 (methyl N-[5-[6-[4-(4-fluorophenyl)-5,6-dihydro-1,2,4-oxadiazin-3-yl]-8-methyl-imidazo[1,2-a]pyridin-3- yl]-2-pyridyl]carbamate) or a salt, or N-oxide thereof
  • component (B) is a compound selected from the group consisting of acetamiprid, acibenzolar-S-methyl, ametoctradin, amisulbrom, azoxystrobin, Bacillus amyloliquefaciens, benzovindiflupyr, broflanilid, chlorothalonil, chlothianidin, chlorantraniliprole, Cis-Jasmone, cyantraniliprole, cyazofamid, cyclobutrifluram, cymoxanil, difen
  • component (A) is compound no. X.05 (methyl N-[5-[6-[5-(4-fluoro-3-methoxy-phenyl)-1-methyl-pyrazol-4-yl]imidazo[1,2-a]pyridin-3-yl]-2- pyridyl]carbamate) or a salt, or N-oxide thereof
  • component (B) is a compound selected from the group consisting of acetamiprid, acibenzolar-S-methyl, ametoctradin, amisulbrom, azoxystrobin, Bacillus amyloliquefaciens, benzovindiflupyr, broflanilid, chlorothalonil, chlothianidin, chlorantraniliprole, Cis-Jasmone, cyantraniliprole, cyazofamid,cyazofamid, cyclobutrifluram, cymoxanil, difeno
  • component (A) is compound no. X.06 (methyl N-[5-[6-[4-(4-fluoro-3-methoxy-phenyl)-5,6-dihydro-1,2,4-oxadiazin-3-yl]imidazo[1,2-a]pyridin- 3-yl]-2-pyridyl]carbamate) or a salt, or N-oxide thereof
  • component (B) is a compound selected from the group consisting of acetamiprid, acibenzolar-S-methyl, ametoctradin, amisulbrom, azoxystrobin, Bacillus amyloliquefaciens, benzovindiflupyr, broflanilid, chlorothalonil, chlothianidin, chlorantraniliprole, Cis-Jasmone, cyantraniliprole, cyazofamid, cyclobutrifluram, cymoxanil, dif
  • component (A) is compound no. X.07 (methyl N-[5-[6-[2-(4-fluoro-3-methoxy-phenyl)-1,2,4-triazol-3-yl]-8-methyl-imidazo[1,2-a]pyridin-3-yl]-2- pyridyl]carbamate) or a salt, or N-oxide thereof
  • component (B) is a compound selected from the group consisting of acetamiprid, acibenzolar-S-methyl, ametoctradin, amisulbrom, azoxystrobin, Bacillus amyloliquefaciens, benzovindiflupyr, broflanilid, chlorothalonil, chlothianidin, chlorantraniliprole, Cis-Jasmone, cyantraniliprole, cyazofamid, cyclobutrifluram, cymoxanil, difenoconazole
  • component (A) is compound no. X.08 (methyl N-[5-[6-[4-(4-fluoro-3-methoxy-phenyl)-5-methyl-1,2,4-triazol-3-yl]imidazo[1,2-a]pyridin-3-yl]-2- pyridyl]carbamate) or a salt, or N-oxide thereof
  • component (B) is a compound selected from the group consisting of acetamiprid, acibenzolar-S-methyl, ametoctradin, amisulbrom, azoxystrobin, Bacillus amyloliquefaciens, benzovindiflupyr, broflanilid, chlorothalonil, chlothianidin, chlorantraniliprole, Cis-Jasmone, cyantraniliprole, cyazofamid, cyclobutrifluram, cymoxanil, difenoconazole
  • component (A) is compound no. X.09 (methyl N-[5-[6-[1-(4-fluoro-3-methoxy-phenyl)imidazol-2-yl]imidazo[1,2-a]pyridin-3-yl]-2- pyridyl]carbamate) or a salt, or N-oxide thereof
  • component (B) is a compound selected from the group consisting of acetamiprid, acibenzolar-S-methyl, ametoctradin, amisulbrom, azoxystrobin, Bacillus amyloliquefaciens, benzovindiflupyr, broflanilid, chlorothalonil, chlothianidin, chlorantraniliprole, Cis-Jasmone, cyantraniliprole, cyazofamid, cyclobutrifluram, cymoxanil, difenoconazole, disodium phosphon
  • component (A) is compound no. X.10 (methyl N-[5-[6-[2-(4-chloro-3-methoxy-phenyl)-1,2,4-triazol-3-yl]imidazo[1,2-a]pyridin-3-yl]-2- pyridyl]carbamate) or a salt, or N-oxide thereof
  • component (B) is a compound selected from the group consisting of acetamiprid, acibenzolar-S-methyl, ametoctradin, amisulbrom, azoxystrobin, Bacillus amyloliquefaciens, benzovindiflupyr, broflanilid, chlorothalonil, chlothianidin, chlorantraniliprole, Cis-Jasmone, cyantraniliprole, cyazofamid, cyclobutrifluram, cymoxanil, difenoconazole, disodium
  • component (A) is compound no. X.11 (methyl N-[5-[6-[2-(4-fluoro-3-methoxy-phenyl)-1,2,4-triazol-3-yl]imidazo[1,2-a]pyridin-3-yl]-2- pyridyl]carbamate) or a salt, or N-oxide thereof
  • component (B) is a compound selected from the group consisting of acetamiprid, acibenzolar-S-methyl, ametoctradin, amisulbrom, azoxystrobin, Bacillus amyloliquefaciens, benzovindiflupyr, broflanilid, chlorothalonil, chlothianidin, chlorantraniliprole, Cis-Jasmone, cyantraniliprole, cyazofamid, cyclobutrifluram, cymoxanil, difenoconazole, disodium
  • component (A) is compound no. X.12 (methyl N-[5-[6-[4-(4-fluoro-3-methoxy-phenyl)-5-(methoxymethyl)-1,2,4-triazol-3-yl]-8-methyl- imidazo[1,2-a]pyridin-3-yl]-2-pyridyl]carbamate) or a salt, or N-oxide thereof
  • component (B) is a compound selected from the group consisting of acetamiprid, acibenzolar-S-methyl, ametoctradin, amisulbrom, azoxystrobin, Bacillus amyloliquefaciens, benzovindiflupyr, broflanilid, chlorothalonil, chlothianidin, chlorantraniliprole, Cis-Jasmone, cyantraniliprole, cyazofamid, cyclobutrifluram, cymoxanil,
  • component (A) is compound no. X.01 (methyl N-[5-[8-cyclopropyl-6-[4-(4-fluoro-3-methoxy-phenyl)-1,2,4-triazol-3-yl]imidazo[1,2-a]pyridin-3- yl]-2-pyridyl]carbamate) or a salt, or N-oxide thereof
  • component (B) is a compound selected from the group consisting of acibenzolar-S-methyl, ametoctradin, amisulbrom, azoxystrobin, chlorothalonil, cyazofamid, cyclobutrifluram, cymoxanil, difenoconazole, disodium phosphonate, florylpicoxamid, fluazinam, fludioxonil, fluopicolide, fluoxapiprolin, folpet, mandipropamid, mefentriflu
  • component (A) is compound no. X.02 (methyl N-[5-[6-[1-(4-fluoro-3-methoxy-phenyl)imidazol-2-yl]-8-methyl-imidazo[1,2-a]pyridin-3-yl]-2- pyridyl]carbamate) or a salt, or N-oxide thereof
  • component (B) is a compound selected from the group consisting of acibenzolar-S-methyl, ametoctradin, amisulbrom, azoxystrobin, chlorothalonil, cyazofamid, cyclobutrifluram, cymoxanil, difenoconazole, disodium phosphonate, florylpicoxamid, fluazinam, fludioxonil, fluopicolide, fluoxapiprolin, folpet, mandipropamid, mefentrifluconazole, metalaxy
  • component (A) is compound no. X.03 (methyl N-[5-[6-[4-(4-fluoro-3-methoxy-phenyl)-5,6-dihydro-1,2,4-oxadiazin-3-yl]-8-methyl-imidazo[1,2- a]pyridin-3-yl]-2-pyridyl]carbamate) or a salt, or N-oxide thereof
  • component (B) is a compound selected from the group consisting of acibenzolar-S-methyl, ametoctradin, amisulbrom, azoxystrobin, chlorothalonil, cyazofamid, cyclobutrifluram, cymoxanil, difenoconazole, disodium phosphonate, florylpicoxamid, fluazinam, fludioxonil, fluopicolide, fluoxapiprolin, folpet, mandipropamid,
  • component (A) is compound no. X.04 (methyl N-[5-[6-[4-(4-fluorophenyl)-5,6-dihydro-1,2,4-oxadiazin-3-yl]-8-methyl-imidazo[1,2-a]pyridin-3- yl]-2-pyridyl]carbamate) or a salt, or N-oxide thereof
  • component (B) is a compound selected from the group consisting of acibenzolar-S-methyl, ametoctradin, amisulbrom, azoxystrobin, chlorothalonil, cyazofamid, cyclobutrifluram, cymoxanil, difenoconazole, disodium phosphonate, florylpicoxamid, fluazinam, fludioxonil, fluopicolide, fluoxapiprolin, folpet, mandipropamid, mefentriflucon
  • component (A) is compound no. X.05 (methyl N-[5-[6-[5-(4-fluoro-3-methoxy-phenyl)-1-methyl-pyrazol-4-yl]imidazo[1,2-a]pyridin-3-yl]-2- pyridyl]carbamate) or a salt, or N-oxide thereof
  • component (B) is a compound selected from the group consisting of acibenzolar-S-methyl, ametoctradin, amisulbrom, azoxystrobin, chlorothalonil, cyazofamid, cyclobutrifluram, cymoxanil, difenoconazole, disodium phosphonate, florylpicoxamid, fluazinam, fludioxonil, fluopicolide, fluoxapiprolin, folpet, mandipropamid, mefentrifluconazole, metalaxyl
  • component (A) is compound no. X.06 (methyl N-[5-[6-[4-(4-fluoro-3-methoxy-phenyl)-5,6-dihydro-1,2,4-oxadiazin-3-yl]imidazo[1,2-a]pyridin- 3-yl]-2-pyridyl]carbamate) or a salt, or N-oxide thereof
  • component (B) is a compound selected from the group consisting of acibenzolar-S-methyl, ametoctradin, amisulbrom, azoxystrobin, chlorothalonil, cyazofamid, cyclobutrifluram, cymoxanil, difenoconazole, disodium phosphonate, florylpicoxamid, fluazinam, fludioxonil, fluopicolide, fluoxapiprolin, folpet, mandipropamid, mefentriflu
  • component (A) is compound no. X.07 (methyl N-[5-[6-[2-(4-fluoro-3-methoxy-phenyl)-1,2,4-triazol-3-yl]-8-methyl-imidazo[1,2-a]pyridin-3-yl]-2- pyridyl]carbamate) or a salt, or N-oxide thereof
  • component (B) is a compound selected from the group consisting of acibenzolar-S-methyl, ametoctradin, amisulbrom, azoxystrobin, chlorothalonil, cyazofamid, cyclobutrifluram, cymoxanil, difenoconazole, disodium phosphonate, florylpicoxamid, fluazinam, fludioxonil, fluopicolide, fluoxapiprolin, folpet, mandipropamid, mefentrifluconazole, metal
  • component (A) is compound no. X.08 (methyl N-[5-[6-[4-(4-fluoro-3-methoxy-phenyl)-5-methyl-1,2,4-triazol-3-yl]imidazo[1,2-a]pyridin-3-yl]-2- pyridyl]carbamate) or a salt, or N-oxide thereof
  • component (B) is a compound selected from the group consisting of acibenzolar-S-methyl, ametoctradin, amisulbrom, azoxystrobin, chlorothalonil, cyazofamid, cyclobutrifluram, cymoxanil, difenoconazole, disodium phosphonate, florylpicoxamid, fluazinam, fludioxonil, fluopicolide, fluoxapiprolin, folpet, mandipropamid, mefentrifluconazole, metal
  • component (A) is compound no. X.09 (methyl N-[5-[6-[1-(4-fluoro-3-methoxy-phenyl)imidazol-2-yl]imidazo[1,2-a]pyridin-3-yl]-2- pyridyl]carbamate) or a salt, or N-oxide thereof
  • component (B) is a compound selected from the group consisting of acibenzolar-S-methyl, ametoctradin, amisulbrom, azoxystrobin, chlorothalonil, cyazofamid, cyclobutrifluram, cymoxanil, difenoconazole, disodium phosphonate, florylpicoxamid, fluazinam, fludioxonil, fluopicolide, fluoxapiprolin, folpet, mandipropamid, mefentrifluconazole, metalaxyl-M,
  • component (A) is compound no. X.10 (methyl N-[5-[6-[2-(4-chloro-3-methoxy-phenyl)-1,2,4-triazol-3-yl]imidazo[1,2-a]pyridin-3-yl]-2- pyridyl]carbamate) or a salt, or N-oxide thereof
  • component (B) is a compound selected from the group consisting of acibenzolar-S-methyl, ametoctradin, amisulbrom, azoxystrobin, chlorothalonil, cyazofamid, cyclobutrifluram, cymoxanil, difenoconazole, disodium phosphonate, florylpicoxamid, fluazinam, fludioxonil, fluopicolide, fluoxapiprolin, folpet, mandipropamid, mefentrifluconazole, metalaxyl
  • component (A) is compound no. X.11 (methyl N-[5-[6-[2-(4-fluoro-3-methoxy-phenyl)-1,2,4-triazol-3-yl]imidazo[1,2-a]pyridin-3-yl]-2- pyridyl]carbamate) or a salt, or N-oxide thereof
  • component (B) is a compound selected from the group consisting of acibenzolar-S-methyl, ametoctradin, amisulbrom, azoxystrobin, chlorothalonil, cyazofamid, cyclobutrifluram, cymoxanil, difenoconazole, disodium phosphonate, florylpicoxamid, fluazinam, fludioxonil, fluopicolide, fluoxapiprolin, folpet, mandipropamid, mefentrifluconazole, metalaxyl
  • component (A) is compound no. X.12 (methyl N-[5-[6-[4-(4-fluoro-3-methoxy-phenyl)-5-(methoxymethyl)-1,2,4-triazol-3-yl]-8-methyl- imidazo[1,2-a]pyridin-3-yl]-2-pyridyl]carbamate) or a salt, or N-oxide thereof
  • component (B) is a compound selected from the group consisting of acibenzolar-S-methyl, ametoctradin, amisulbrom, azoxystrobin, chlorothalonil, cyazofamid, cyclobutrifluram, cymoxanil, difenoconazole, disodium phosphonate, florylpicoxamid, fluazinam, fludioxonil, fluopicolide, fluoxapiprolin, folpet, mandipropamid, mef
  • component (A) is compound no. X.01 (methyl N-[5-[8-cyclopropyl-6-[4-(4-fluoro-3-methoxy-phenyl)-1,2,4-triazol-3-yl]imidazo[1,2-a]pyridin-3- yl]-2-pyridyl]carbamate) or a salt, or N-oxide thereof
  • component (B) is a compound selected from the group consisting of acetamiprid, acibenzolar-S-methyl, ametoctradin, amisulbrom, azoxystrobin, Bacillus amyloliquefaciens, benzovindiflupyr, broflanilid, chlorothalonil, chlothianidin, chlorantraniliprole, Cis-Jasmone, cyantraniliprole, cyazofamid, cyclobutrifluram, cymoxanil,
  • component (A) is compound no. X.02 (methyl N-[5-[6-[1-(4-fluoro-3-methoxy-phenyl)imidazol-2-yl]-8-methyl-imidazo[1,2-a]pyridin-3-yl]- 2-pyridyl]carbamate) or a salt, or N-oxide thereof
  • component (B) is a compound selected from the group consisting of acetamiprid, acibenzolar-S-methyl, ametoctradin, amisulbrom, azoxystrobin, Bacillus amyloliquefaciens, benzovindiflupyr, broflanilid, chlorothalonil, chlothianidin, chlorantraniliprole, Cis-Jasmone, cyantraniliprole, cyazofamid, cyclobutrifluram, cymoxanil, difenoconazole, dis
  • component (A) is compound no. X.03 (methyl N-[5-[6-[4-(4-fluoro-3-methoxy-phenyl)-5,6-dihydro-1,2,4-oxadiazin-3-yl]-8-methyl- imidazo[1,2-a]pyridin-3-yl]-2-pyridyl]carbamate) or a salt, or N-oxide thereof
  • component (B) is a compound selected from the group consisting of acetamiprid, acibenzolar-S-methyl, ametoctradin, amisulbrom, azoxystrobin, Bacillus amyloliquefaciens, benzovindiflupyr, broflanilid, chlorothalonil, chlothianidin, chlorantraniliprole, Cis-Jasmone, cyantraniliprole, cyazofamid, cyclobutrifluram, cymox
  • component (A) is compound no. X.04 (methyl N-[5-[6-[4-(4-fluorophenyl)-5,6-dihydro-1,2,4-oxadiazin-3-yl]-8-methyl-imidazo[1,2- a]pyridin-3-yl]-2-pyridyl]carbamate) or a salt, or N-oxide thereof
  • component (B) is a compound selected from the group consisting of acetamiprid, acibenzolar-S-methyl, ametoctradin, amisulbrom, azoxystrobin, Bacillus amyloliquefaciens, benzovindiflupyr, broflanilid, chlorothalonil, chlothianidin, chlorantraniliprole, Cis-Jasmone, cyantraniliprole, cyazofamid, cyclobutrifluram, cymoxanil, d
  • component (A) is compound no. X.05 (methyl N-[5-[6-[5-(4-fluoro-3-methoxy-phenyl)-1-methyl-pyrazol-4-yl]imidazo[1,2-a]pyridin-3-yl]-2- pyridyl]carbamate) or a salt, or N-oxide thereof
  • component (B) is a compound selected from the group consisting of acetamiprid, acibenzolar-S-methyl, ametoctradin, amisulbrom, azoxystrobin, Bacillus amyloliquefaciens, benzovindiflupyr, broflanilid, chlorothalonil, chlothianidin, chlorantraniliprole, Cis-Jasmone, cyantraniliprole, cyazofamid, cyclobutrifluram, cymoxanil, difenoconazole, dis
  • component (A) is compound no. X.06 (methyl N-[5-[6-[4-(4-fluoro-3-methoxy-phenyl)-5,6-dihydro-1,2,4-oxadiazin-3-yl]imidazo[1,2- a]pyridin-3-yl]-2-pyridyl]carbamate) or a salt, or N-oxide thereof
  • component (B) is a compound selected from the group consisting of acetamiprid, acibenzolar-S-methyl, ametoctradin, amisulbrom, azoxystrobin, Bacillus amyloliquefaciens, benzovindiflupyr, broflanilid, chlorothalonil, chlothianidin, chlorantraniliprole, Cis-Jasmone, cyantraniliprole, cyazofamid, cyclobutrifluram, cymoxanil,
  • component (A) is compound no. X.07 (methyl N-[5-[6-[2-(4-fluoro-3-methoxy-phenyl)-1,2,4-triazol-3-yl]-8-methyl-imidazo[1,2-a]pyridin- 3-yl]-2-pyridyl]carbamate) or a salt, or N-oxide thereof
  • component (B) is a compound selected from the group consisting of acetamiprid, acibenzolar-S-methyl, ametoctradin, amisulbrom, azoxystrobin, Bacillus amyloliquefaciens, benzovindiflupyr, broflanilid, chlorothalonil, chlothianidin, chlorantraniliprole, Cis-Jasmone, cyantraniliprole, cyazofamid, cyclobutrifluram, cymoxanil, difenoconazo
  • component (A) is compound no. X.08 (methyl N-[5-[6-[4-(4-fluoro-3-methoxy-phenyl)-5-methyl-1,2,4-triazol-3-yl]imidazo[1,2-a]pyridin-3- yl]-2-pyridyl]carbamate) or a salt, or N-oxide thereof
  • component (B) is a compound selected from the group consisting of acetamiprid, acibenzolar-S-methyl, ametoctradin, amisulbrom, azoxystrobin, Bacillus amyloliquefaciens, benzovindiflupyr, broflanilid, chlorothalonil, chlothianidin, chlorantraniliprole, Cis-Jasmone, cyantraniliprole, cyazofamid, cyclobutrifluram, cymoxanil, difenocon
  • component (A) is compound no. X.09 (methyl N-[5-[6-[1-(4-fluoro-3-methoxy-phenyl)imidazol-2-yl]imidazo[1,2-a]pyridin-3-yl]-2- pyridyl]carbamate) or a salt, or N-oxide thereof
  • component (B) is a compound selected from the group consisting of acetamiprid, acibenzolar-S-methyl, ametoctradin, amisulbrom, azoxystrobin, Bacillus amyloliquefaciens, benzovindiflupyr, broflanilid, chlorothalonil, chlothianidin, chlorantraniliprole, Cis-Jasmone, cyantraniliprole, cyazofamid, cyclobutrifluram, cymoxanil, difenoconazole, disodium
  • component (A) is compound no. X.10 (methyl N-[5-[6-[2-(4-chloro-3-methoxy-phenyl)-1,2,4-triazol-3-yl]imidazo[1,2-a]pyridin-3-yl]-2- pyridyl]carbamate) or a salt, or N-oxide thereof
  • component (B) is a compound selected from the group consisting of acetamiprid, acibenzolar-S-methyl, ametoctradin, amisulbrom, azoxystrobin, Bacillus amyloliquefaciens, benzovindiflupyr, broflanilid, chlorothalonil, chlothianidin, chlorantraniliprole, Cis-Jasmone, cyantraniliprole, cyazofamid, cyclobutrifluram, cymoxanil, difenoconazole, dis
  • component (A) is compound no. X.11 (methyl N-[5-[6-[2-(4-fluoro-3-methoxy-phenyl)-1,2,4-triazol-3-yl]imidazo[1,2-a]pyridin-3-yl]-2- pyridyl]carbamate) or a salt, or N-oxide thereof
  • component (B) is a compound selected from the group consisting of acetamiprid, acibenzolar-S-methyl, ametoctradin, amisulbrom, azoxystrobin, Bacillus amyloliquefaciens, benzovindiflupyr, broflanilid, chlorothalonil, chlothianidin, chlorantraniliprole, Cis-Jasmone, cyantraniliprole, cyazofamid, cyclobutrifluram, cymoxanil, difenoconazole, dis
  • component (A) is compound no. X.12 (methyl N-[5-[6-[4-(4-fluoro-3-methoxy-phenyl)-5-(methoxymethyl)-1,2,4-triazol-3-yl]-8-methyl- imidazo[1,2-a]pyridin-3-yl]-2-pyridyl]carbamate) or a salt, or N-oxide thereof
  • component (B) is a compound selected from the group consisting of acetamiprid, acibenzolar-S-methyl, ametoctradin, amisulbrom, azoxystrobin, Bacillus amyloliquefaciens, benzovindiflupyr, broflanilid, chlorothalonil, chlothianidin, chlorantraniliprole, Cis-Jasmone, cyantraniliprole, cyazofamid, cyclobutrifluram, cymoxan
  • component (A) is compound no. X.01 (methyl N-[5-[8-cyclopropyl-6-[4-(4-fluoro-3-methoxy-phenyl)-1,2,4-triazol-3-yl]imidazo[1,2-a]pyridin-3-yl]-2- pyridyl]carbamate) or a salt, or N-oxide thereof
  • component (B) is a compound selected from the group consisting of azoxystrobin, cyclobutrifluram, cymoxanil, difenoconazole, disodium phosphonate, florylpicoxamid, fluazinam, fludioxonil, fluopicolide, fluoxapiprolin, folpet, mandipropamid, mefentrifluconazole, metalaxyl-M, oxathiapiprolin, picarbutrazox, pydiflu
  • component (A) is compound no. X.02 (methyl N-[5-[6-[1-(4-fluoro-3-methoxy-phenyl)imidazol-2-yl]-8-methyl-imidazo[1,2-a]pyridin-3-yl]-2- pyridyl]carbamate) or a salt, or N-oxide thereof
  • component (B) is a compound selected from the group consisting of azoxystrobin, cyclobutrifluram, cymoxanil, difenoconazole, disodium phosphonate, florylpicoxamid, fluazinam, fludioxonil, fluopicolide, fluoxapiprolin, folpet, mandipropamid, mefentrifluconazole, metalaxyl-M, oxathiapiprolin, picarbutrazox, pydiflumetofen, sedax
  • component (A) is compound no. X.03 (methyl N-[5-[6-[4-(4-fluoro-3-methoxy-phenyl)-5,6-dihydro-1,2,4-oxadiazin-3-yl]-8-methyl-imidazo[1,2- a]pyridin-3-yl]-2-pyridyl]carbamate) or a salt, or N-oxide thereof
  • component (B) is a compound selected from the group consisting of acibenzolar-S-methyl, ametoctradin, amisulbrom, azoxystrobin, chlorothalonil, cyazofamid, cyclobutrifluram, cymoxanil, difenoconazole, disodium phosphonate, florylpicoxamid, fluazinam, fludioxonil, fluopicolide, fluoxapiprolin, folpet, mandipropamid,
  • component (A) is compound no. X.04 (methyl N-[5-[6-[4-(4-fluorophenyl)-5,6-dihydro-1,2,4-oxadiazin-3-yl]-8-methyl-imidazo[1,2-a]pyridin-3- yl]-2-pyridyl]carbamate) or a salt, or N-oxide thereof
  • component (B) is a compound selected from the group consisting of acibenzolar-S-methyl, ametoctradin, amisulbrom, azoxystrobin, chlorothalonil, cyazofamid, cyclobutrifluram, cymoxanil, difenoconazole, disodium phosphonate, florylpicoxamid, fluazinam, fludioxonil, fluopicolide, fluoxapiprolin, folpet, mandipropamid, mefentriflucon
  • component (A) is compound no. X.05 (methyl N-[5-[6-[5-(4-fluoro-3-methoxy-phenyl)-1-methyl-pyrazol-4-yl]imidazo[1,2-a]pyridin-3-yl]-2- pyridyl]carbamate) or a salt, or N-oxide thereof
  • component (B) is a compound selected from the group consisting of acibenzolar-S-methyl, ametoctradin, amisulbrom, azoxystrobin, chlorothalonil, cyazofamid, cyclobutrifluram, cymoxanil, difenoconazole, disodium phosphonate, florylpicoxamid, fluazinam, fludioxonil, fluopicolide, fluoxapiprolin, folpet, mandipropamid, mefentrifluconazole, metalaxyl
  • component (A) is compound no. X.06 (methyl N-[5-[6-[4-(4-fluoro-3-methoxy-phenyl)-5,6-dihydro-1,2,4-oxadiazin-3-yl]imidazo[1,2-a]pyridin- 3-yl]-2-pyridyl]carbamate) or a salt, or N-oxide thereof
  • component (B) is a compound selected from the group consisting of acibenzolar-S-methyl, ametoctradin, amisulbrom, azoxystrobin, chlorothalonil, cyazofamid, cyclobutrifluram, cymoxanil, difenoconazole, disodium phosphonate, florylpicoxamid, fluazinam, fludioxonil, fluopicolide, fluoxapiprolin, folpet, mandipropamid, mefentriflu
  • component (A) is compound no. X.08 (methyl N-[5-[6-[4-(4-fluoro-3-methoxy-phenyl)-5-methyl-1,2,4-triazol-3-yl]imidazo[1,2-a]pyridin-3-yl]-2- pyridyl]carbamate) or a salt, or N-oxide thereof
  • component (B) is a compound selected from the group consisting of acibenzolar-S-methyl, ametoctradin, amisulbrom, azoxystrobin, chlorothalonil, cyazofamid, cyclobutrifluram, cymoxanil, difenoconazole, disodium phosphonate, florylpicoxamid, fluazinam, fludioxonil, fluopicolide, fluoxapiprolin, folpet, mandipropamid, mefentrifluconazole, metal
  • component (A) is compound no. X.09 (methyl N-[5-[6-[1-(4-fluoro-3-methoxy-phenyl)imidazol-2-yl]imidazo[1,2-a]pyridin-3-yl]-2- pyridyl]carbamate) or a salt, or N-oxide thereof
  • component (B) is a compound selected from the group consisting of acibenzolar-S-methyl, ametoctradin, amisulbrom, azoxystrobin, chlorothalonil, cyazofamid, cyclobutrifluram, cymoxanil, difenoconazole, disodium phosphonate, florylpicoxamid, fluazinam, fludioxonil, fluopicolide, fluoxapiprolin, folpet, mandipropamid, mefentrifluconazole, metalaxyl-M,
  • component (A) is compound no. X.10 (methyl N-[5-[6-[2-(4-chloro-3-methoxy-phenyl)-1,2,4-triazol-3-yl]imidazo[1,2-a]pyridin-3-yl]-2- pyridyl]carbamate) or a salt, or N-oxide thereof
  • component (B) is a compound selected from the group consisting of acibenzolar-S-methyl, ametoctradin, amisulbrom, azoxystrobin, chlorothalonil, cyazofamid, cyclobutrifluram, cymoxanil, difenoconazole, disodium phosphonate, florylpicoxamid, fluazinam, fludioxonil, fluopicolide, fluoxapiprolin, folpet, mandipropamid, mefentrifluconazole, metalaxyl
  • component (A) is compound no. X.11 (methyl N-[5-[6-[2-(4-fluoro-3-methoxy-phenyl)-1,2,4-triazol-3-yl]imidazo[1,2-a]pyridin-3-yl]-2- pyridyl]carbamate) or a salt, or N-oxide thereof
  • component (B) is a compound selected from the group consisting of acibenzolar-S-methyl, ametoctradin, amisulbrom, azoxystrobin, chlorothalonil, cyazofamid, cyclobutrifluram, cymoxanil, difenoconazole, disodium phosphonate, florylpicoxamid, fluazinam, fludioxonil, fluopicolide, fluoxapiprolin, folpet, mandipropamid, mefentrifluconazole, metalaxyl
  • component (A) is compound no. X.12 (methyl N-[5-[6-[4-(4-fluoro-3-methoxy-phenyl)-5-(methoxymethyl)-1,2,4-triazol-3-yl]-8-methyl- imidazo[1,2-a]pyridin-3-yl]-2-pyridyl]carbamate) or a salt, or N-oxide thereof
  • component (B) is a compound selected from the group consisting of acibenzolar-S-methyl, ametoctradin, amisulbrom, azoxystrobin, chlorothalonil, cyazofamid, cyclobutrifluram, cymoxanil, difenoconazole, disodium phosphonate, florylpicoxamid, fluazinam, fludioxonil, fluopicolide, fluoxapiprolin, folpet, mandipropamid, mef
  • the composition may comprise an additional active ingredient component (C), which is different to component (B), and is selected from the group consisting of acetamiprid, acibenzolar-S-methyl, ametoctradin, amisulbrom, azoxystrobin, Bacillus amyloliquefaciens, benzovindiflupyr, broflanilid, chlorothalonil, chlothianidin, chlorantraniliprole, Cis-Jasmone, cyantraniliprole, cyazofamid, cyclobutrifluram, cymoxanil, difenoconazole, disodium phosphonate, ethaboxam, fenpicoxamid, florylpicoxamid, fluazinam, fludioxonil, fluindapyr, fluopicolide, fluopyram, fluoxapiprolin, fluoxytioconazole, fluxamet
  • C additional active ingredient component
  • the composition according to the present invention can be used in the agricultural sector and related fields of use for controlling plant pests or on non-living materials for control of spoilage microorganisms or organisms potentially harmful to man.
  • the composition can be used to inhibit or destroy the pests that occur on plants or parts of plants (fruit, blossoms, leaves, stems, tubers, roots) of different crops of useful plants, while at the same time protecting also those parts of the plants that grow later e.g. from phytopathogenic microorganisms.
  • the term “fungicide” as used herein means a compound that controls, modifies, or prevents the growth of fungi.
  • fungicidally effective amount means the quantity of such a compound or combination of such compounds that is capable of producing an effect on the growth of fungi. Controlling or modifying effects include all deviation from natural development, such as killing, retardation and the like, and prevention includes barrier or other defensive formation in or on a plant to prevent fungal infection.
  • the composition according to the present invention can comprise a fungicidally effective amount of the component A and/or the component B.
  • locus as used herein means fields in or on which plants are growing, or where seeds of cultivated plants are sown, or where seed will be placed into the soil. It includes soil, seeds, and seedlings, as well as established vegetation.
  • plants refers to all physical parts of a plant, including seeds, seedlings, saplings, roots, tubers, stems, stalks, foliage, and fruits. It is also possible to use the composition according to the present invention as dressing agents for the treatment of plant propagation material for the protection against fungal infections as well as against phytopathogenic fungi occurring in the soil.
  • the propagation material can be treated with a composition according to the present invention before planting: seed, for example, can be dressed before being sown.
  • the composition according to the present invention can also be applied to grains (coating), either by impregnating the seeds in a liquid formulation or by coating them with a solid formulation.
  • the composition can also be applied to the planting site when the propagation material is being planted, for example, to the seed furrow during sowing.
  • the invention relates also to such methods of treating plant propagation material and to the plant propagation material so treated.
  • plant propagation material is understood to denote generative parts of the plant, such as seeds, which can be used for the multiplication of the latter, and vegetative material, such as cuttings or tubers, for example potatoes. There may be mentioned for example seeds (in the strict sense), roots, fruits, tubers, bulbs, rhizomes and parts of plants. Germinated plants and young plants which are to be transplanted after germination or after emergence from the soil, may also be mentioned. These young plants may be protected before transplantation by a total or partial treatment by immersion.
  • plant propagation material is understood to denote seeds.
  • Pesticidal agents referred to herein using their common name are known, for example, from "The Pesticide Manual", 19th Ed., British Crop Protection Council 2021.
  • the composition accorindg to the present invention can be used for controlling fungi in related areas, for example in the protection of technical materials, including wood and wood related technical products, in food storage, in hygiene management.
  • the invention could be used to protect non-living materials from fungal attack, e.g. lumber, wall boards and paint.
  • the composition according to the invention is effective against harmful microorganisms, such as microorganisms, that cause phytopathogenic diseases, in particular against phytopathogenic fungi and bacteria.
  • the composition of the invention may be used to control plant diseases caused by a broad spectrum of fungal plant pathogens in the Basidiomycete, Ascomycete, Oomycete and/or Deuteromycete, Blasocladiomycete, Chrytidiomycete, Glomeromycete and/or Mucoromycete classes, and more preferably in the Oomycete classes.
  • the composition of the invention is effective in controlling a broad spectrum of plant diseases, such as foliar pathogens of ornamental, turf, vegetable, field, cereal, and fruit crops.
  • pathogens may include: Oomycetes, including Phytophthora diseases such as those caused by Phytophthora capsici, Phytophthora infestans, Phytophthora sojae, Phytophthora fragariae, Phytophthora nicotianae, Phytophthora cinnamomi, Phytophthora citricola, Phytophthora citrophthora and Phytophthora erythroseptica; Pythium diseases such as those caused by Pythium aphanidermatum, Pythium arrhenomanes, Pythium graminicola, Pythium irregulare, Pythium sylvaticum and Pythium ultimum; diseases caused by Peronosporales such as Peronospora destructor, Peronospora parasitica, Plasmopara viticola, Plasmopara halstedii, Pseudoperonospora cubens
  • Puccinia striiformis f.sp. Secalis Pucciniastrum coryli, or Uredinales such as Cronartium ribicola, Gymnosporangium juniperi-viginianae, Melampsora medusae, Phakopsora pachyrhizi, Phragmidium mucronatum, Physopella ampelosidis, Tranzschelia discolor and Uromyces viciae-fabae; and other rots and diseases such as those caused by Cryptococcus spp., Exobasidium vexans, Marasmiellus inoderma, Mycena spp., Sphacelotheca reiliana, Typhula ishikariensis, Urocystis agropyri, Itersonilia perplexans, Corticium invisum, Laetisaria fuciformis, Waitea circinata, Rhizoctonia solani, Tha
  • composition accorindg to the present invention may also have activity against bacteria such as Erwinia amylovora, Erwinia caratovora, Xanthomonas campestris, Pseudomonas syringae, Strptomyces scabies and other related species as well as certain protozoa.
  • bacteria such as Erwinia amylovora, Erwinia caratovora, Xanthomonas campestris, Pseudomonas syringae, Strptomyces scabies and other related species as well as certain protozoa.
  • target crops and/or useful plants to be protected typically comprise perennial and annual crops, such as berry plants for example blackberries, blueberries, cranberries, raspberries and strawberries; cereals for example barley, maize (corn), millet, oats, rice, rye, sorghum triticale and wheat; fibre plants for example cotton, flax, hemp, jute and sisal; field crops for example sugar and fodder beet, coffee, hops, mustard, oilseed rape (canola), poppy, sugar cane, sunflower, tea and tobacco; fruit trees for example apple, apricot, avocado, banana, cherry, citrus, nectarine, peach, pear and plum; grasses for example Bermuda grass, bluegrass, bentgrass, centipede grass, fescue, ryegrass, St.
  • perennial and annual crops such as berry plants for example blackberries, blueberries, cranberries, raspberries and strawberries
  • cereals for example barley, maize (corn), millet, oats
  • Augustine grass and Zoysia grass herbs such as basil, borage, chives, coriander, lavender, lovage, mint, oregano, parsley, rosemary, sage and thyme; legumes for example beans, lentils, peas and soya beans; nuts for example almond, cashew, ground nut, hazelnut, peanut, pecan, pistachio and walnut; palms for example oil palm; ornamentals for example flowers, shrubs and trees; other trees, for example cacao, coconut, olive and rubber; vegetables for example asparagus, aubergine, broccoli, cabbage, carrot, cucumber, garlic, lettuce, marrow, melon, okra, onion, pepper, potato, pumpkin, rhubarb, spinach and tomato; and vines for example grapes.
  • herbs such as basil, borage, chives, coriander, lavender, lovage, mint, oregano, parsley, rosemary, sage and thyme
  • legumes for example beans, lentils, peas and soya beans
  • the useful plants and / or target crops in accordance with the invention include conventional as well as genetically enhanced or engineered varieties such as, for example, insect resistant (e.g. Bt. and VIP varieties) as well as disease resistant, herbicide tolerant (e.g. glyphosate- and glufosinate-resistant maize varieties commercially available under the trade names RoundupReady® and LibertyLink®) and nematode tolerant varieties.
  • suitable genetically enhanced or engineered crop varieties include the Stoneville 5599BR cotton and Stoneville 4892BR cotton varieties.
  • useful plants and/or “target crops” is to be understood as including also useful plants that have been rendered tolerant to herbicides like bromoxynil or classes of herbicides (such as, for example, HPPD inhibitors, ALS inhibitors, for example primisulfuron, prosulfuron and trifloxysulfuron, EPSPS (5- enol-pyrovyl-shikimate-3-phosphate-synthase) inhibitors, GS (glutamine synthetase) inhibitors or PPO (protoporphyrinogen-oxidase) inhibitors) as a result of conventional methods of breeding or genetic engineering.
  • herbicides like bromoxynil or classes of herbicides
  • EPSPS 5- enol-pyrovyl-shikimate-3-phosphate-synthase
  • GS glutamine synthetase
  • PPO protoporphyrinogen-oxidase
  • An example of a crop that has been rendered tolerant to imidazolinones, e.g. imazamox, by conventional methods of breeding (mutagenesis) is Clearfield® summer rape (Canola).
  • crops that have been rendered tolerant to herbicides or classes of herbicides by genetic engineering methods include glyphosate- and glufosinate-resistant maize varieties commercially available under the trade names RoundupReady® , Herculex I® and LibertyLink®.
  • the term "useful plants" and/or “target crops” is to be understood as including those which naturally are or have been rendered resistant to harmful insects.
  • toxins which can be expressed include ⁇ -endotoxins, vegetative insecticidal proteins (Vip), insecticidal proteins of bacteria colonising nematodes, and toxins produced by scorpions, arachnids, wasps and fungi.
  • An example of a crop that has been modified to express the Bacillus thuringiensis toxin is the Bt maize KnockOut ⁇ (Syngenta Seeds).
  • VipCot ⁇ Surgera Seeds
  • Crops or seed material thereof can also be resistant to multiple types of pests (so-called stacked transgenic events when created by genetic modification).
  • a plant can have the ability to express an insecticidal protein while at the same time being herbicide tolerant, for example Herculex I ⁇ (Dow AgroSciences, Pioneer Hi-Bred International).
  • useful plants and/or “target crops” is to be understood as including also useful plants which have been so transformed by the use of recombinant DNA techniques that they are capable of synthesising antipathogenic substances having a selective action, such as, for example, the so-called "pathogenesis-related proteins" (PRPs, see e.g. EP-A-0392225).
  • PRPs pathogenesis-related proteins
  • Examples of such antipathogenic substances and transgenic plants capable of synthesising such antipathogenic substances are known, for example, from EP-A-0392225, WO 95/33818, and EP-A-0353191.
  • the methods of producing such transgenic plants are generally known to the person skilled in the art and are described, for example, in the publications mentioned above.
  • Toxins that can be expressed by transgenic plants include, for example, insecticidal proteins from Bacillus cereus or Bacillus popilliae; or insecticidal proteins from Bacillus thuringiensis, such as ⁇ - endotoxins, e.g. Cry1Ab, Cry1Ac, Cry1F, Cry1Fa2, Cry2Ab, Cry3A, Cry3Bb1 or Cry9C, or vegetative insecticidal proteins (Vip), e.g. Vip1, Vip2, Vip3 or Vip3A; or insecticidal proteins of bacteria colonising nematodes, for example Photorhabdus spp.
  • insecticidal proteins from Bacillus cereus or Bacillus popilliae such as ⁇ - endotoxins, e.g. Cry1Ab, Cry1Ac, Cry1F, Cry1Fa2, Cry2Ab, Cry3A, Cry3Bb1 or Cry9C, or vegetative
  • Xenorhabdus spp. such as Photorhabdus luminescens, Xenorhabdus nematophilus
  • toxins produced by animals such as scorpion toxins, arachnid toxins, wasp toxins and other insect-specific neurotoxins
  • toxins produced by fungi such as Streptomycetes toxins, plant lectins, such as pea lectins, barley lectins or snowdrop lectins
  • agglutinins proteinase inhibitors, such as trypsin inhibitors, serine protease inhibitors, patatin, cystatin, papain inhibitors
  • ribosome- inactivating proteins (RIP) such as ricin, maize-RIP, abrin, luffin, saporin or bryodin
  • steroid metabolism enzymes such as 3-hydroxysteroidoxidase, ecdysteroid-UDP-glycosyl-transferase, cholesterol oxidases, ecd
  • ⁇ -endotoxins for example Cry1Ab, Cry1Ac, Cry1F, Cry1Fa2, Cry2Ab, Cry3A, Cry3Bb1 or Cry9C, or vegetative insecticidal proteins (Vip), for example Vip1, Vip2, Vip3 or Vip3A
  • Vip vegetative insecticidal proteins
  • Hybrid toxins are produced recombinantly by a new combination of different domains of those proteins (see, for example, WO 02/15701).
  • Truncated toxins for example a truncated Cry1Ab, are known.
  • modified toxins one or more amino acids of the naturally occurring toxin are replaced.
  • preferably non-naturally present protease recognition sequences are inserted into the toxin, such as, for example, in the case of Cry3A055, a cathepsin-G- recognition sequence is inserted into a Cry3A toxin (see WO03/018810).
  • More examples of such toxins or transgenic plants capable of synthesising such toxins are disclosed, for example, in EP-A-0374753, WO93/07278, WO95/34656, EP-A-0427529, EP-A-451878 and WO03/052073.
  • transgenic plants are generally known to the person skilled in the art and are described, for example, in the publications mentioned above.
  • CryI-type deoxyribonucleic acids and their preparation are known, for example, from WO 95/34656, EP-A-0367 474, EP-A-0401979 and WO 90/13651.
  • the toxin contained in the transgenic plants imparts to the plants tolerance to harmful insects.
  • Such insects can occur in any taxonomic group of insects, but are especially commonly found in the beetles (Coleoptera), two-winged insects (Diptera) and butterflies (Lepidoptera).
  • Transgenic plants containing one or more genes that code for an insecticidal resistance and express one or more toxins are known and some of them are commercially available. Examples of such plants are: YieldGard ⁇ (maize variety that expresses a Cry1Ab toxin); YieldGard Rootworm ⁇ (maize variety that expresses a Cry3Bb1 toxin); YieldGard Plus ⁇ (maize variety that expresses a Cry1Ab and a Cry3Bb1 toxin); Starlink ⁇ (maize variety that expresses a Cry9C toxin); Herculex I ⁇ (maize variety that expresses a Cry1Fa2 toxin and the enzyme phosphinothricine N-acetyltransferase (PAT) to achieve tolerance to the herbicide glufosinate ammonium); NuCOTN 33B ⁇ (cotton variety that expresses a Cry1Ac toxin); Bollgard I ⁇ (cotton variety that express
  • transgenic crops are: 1. Bt11 Maize from Syngenta Seeds SAS, Chemin de l'Hobit 27, F-31 790 St. Sauveur, France, registration number C/FR/96/05/10. Genetically modified Zea mays which has been rendered resistant to attack by the European corn borer (Ostrinia nubilalis and Sesamia nonagrioides) by transgenic expression of a truncated Cry1Ab toxin. Bt11 maize also transgenically expresses the enzyme PAT to achieve tolerance to the herbicide glufosinate ammonium. 2. Bt176 Maize from Syngenta Seeds SAS, Chemin de l'Hobit 27, F-31 790 St.
  • This toxin is Cry3A055 modified by insertion of a cathepsin-G- protease recognition sequence.
  • the preparation of such transgenic maize plants is described in WO 03/018810.
  • MON 863 Maize from Monsanto Europe S.A. 270-272 Avenue de Tervuren, B-1150 Brussels, Belgium, registration number C/DE/02/9.
  • MON 863 expresses a Cry3Bb1 toxin and has resistance to certain Coleoptera insects. 5.
  • NK603 ⁇ MON 810 Maize transgenically expresses the protein CP4 EPSPS, obtained from Agrobacterium sp. strain CP4, which imparts tolerance to the herbicide Roundup® (contains glyphosate), and also a Cry1Ab toxin obtained from Bacillus thuringiensis subsp. kurstaki which brings about tolerance to certain Lepidoptera, include the European corn borer.
  • CP4 EPSPS obtained from Agrobacterium sp. strain CP4
  • Rup® contains glyphosate
  • Cry1Ab toxin obtained from Bacillus thuringiensis subsp. kurstaki which brings about tolerance to certain Lepidoptera, include the European corn borer.
  • Compounds of formula (I) according to the invention can be made as shown in the following schemes 1 to 20, in which, unless otherwise stated, the definition of each variable is as defined in the present invention.
  • Compounds of formula (I) can be prepared via Suzuki cross coupling of compounds of formula (II), wherein X is Cl, Br or I, and a compound of formula (III), wherein either R 8 is independently from each other hydrogen, C 1 -C 6 alkyl or wherein two R 8 together can form a C 3 -C 8 cycloalkyl, in the presence of a base, such as Cs2CO3, K2CO3 or NaOtBu, and a suitable palladium catalyst, such as tetrakistriphenylphosphinepalladium, palladium dichloride, [1,1- bis(diphenylphosphino)ferrocene]dichloropalladium(II), palladium acetate, chloro(2- dicyclohexylphosphino-2′,4′,6′-triisopropyl-1,1′-biphenyl)[2-(2′-amino-1,1′-biphenyl)]palladium(
  • compounds of formula (Va), wherein X is Cl, Br, I or a triflate group can be prepared by the reaction of a compound of formula (VIIa) with triflic anhydride and, optionally, a base, such as triethylamine or pyridine, or a halogenating agent such as phosphorus oxychloride, phosphorus oxybromide, or by successive reaction with phosphorus oxychloride and sodium iodide.
  • bases such as triethylamine or pyridine
  • a halogenating agent such as phosphorus oxychloride, phosphorus oxybromide
  • These transformations are performed neat or in a suitable solvent such as dichloromethane, toluene or xylene. These transformations are depicted in Scheme 3.
  • Compounds of formula (IV) wherein X is Cl, Br or I, and wherein X is more preferably Cl, and wherein either R 8 is independently from each other hydrogen, C1-C6 alkyl or wherein two R 8 together can form a C3-C8 cycloalkyl can be prepared by the reaction of a compound of formula (VIII) with a halogenating agent such as N-chlorosuccinimide, N-bromosuccinimide or N-iodosuccinimide in a suitable solvent, such as DMF, acetonitrile, dichloromethane or tetrahydrofuran. This transformation is depicted in Scheme 4.
  • a halogenating agent such as N-chlorosuccinimide, N-bromosuccinimide or N-iodosuccinimide
  • Alternatively compounds of formula (VIII) wherein either R 8 is independently from each other hydrogen, C1-C6 alkyl or wherein two R 8 together can form a C3-C8 cycloalkyl can be prepared by the reaction of a compound of formula (IX), wherein X is Cl, Br or I, with a compounds of formula (XI) wherein either R 8 is independently from each other hydrogen, C1-C6 alkyl or wherein two R 8 together can form a C3-C8 cycloalkyl, such as trimethyl borate, triisopropyl borate, isopropoxy 4,4,5,5-tetramethyl-1,3,2- dioxaborolane, or 2-methoxy-4,4,5,5-tetramethyl-1,3,2-dioxaborolane, and a metal halogen exchange reagent, such as butyl lithium or ethylmagnesium bromide, in a suitable solvent, such as tetrahydrofuran, diethyl ether or di
  • Scheme 5 Compounds of formula (IX) are commercially available or, alternatively, can be prepared by the reaction of a compound of formula (XII), wherein X is Cl, Br or I, and a compound of formula (XIII), wherein X is Cl, Br or I, or its corresponding acetal of formula (XIV), wherein X is Cl, Br or I and either R 10 is independently from each other C1-C6 alkyl or wherein two R 10 together can form a C3-C8 cycloalkyl, in a solvent, such as water, ethanol, acetone or acetonitrile.
  • a solvent such as water, ethanol, acetone or acetonitrile.
  • the outcome of the reaction can be improved by using a base, such as sodium bicarbonate or potassium carbonate, or by using an acid, such as p-toluenesulfonic acid or hydrogen bromide.
  • a base such as sodium bicarbonate or potassium carbonate
  • an acid such as p-toluenesulfonic acid or hydrogen bromide.
  • compounds of formula (II), wherein X is Cl, Br or I, and wherein X is more preferably Cl can be prepared by the reaction of a compound of formula (XV), with a halogenating agent such as N- chlorosuccinimide, N-bromosuccinimide or N-iodosuccinimide in a suitable solvent, such as DMF, acetonitrile, dichloromethane or tetrahydrofuran.
  • a halogenating agent such as N- chlorosuccinimide, N-bromosuccinimide or N-iodosuccinimide in a suitable solvent, such as DMF, acetonitrile, dichloromethane or tetrahydrofuran.
  • compounds of formula (IIa), wherein A1 is a carbon atom in formula (II) wherein X is Cl, Br or I, and wherein X is more preferably Cl can be prepared by the reaction of a compound of formula (XVIII), wherein either X is independently from each other Cl, Br or I, with a compounds of formula (XIXa) wherein either R 8 is independently from each other hydrogen, C1-C6 alkyl or wherein two R 8 together can form a C3-C8 cycloalkyl, in the presence of a base, such as Cs2CO3, K2CO3 or NaOtBu, and a suitable palladium catalyst, such as tetrakistriphenylphosphinepalladium, palladium dichloride, [1,1- bis(diphenylphosphino)ferrocene]dichloropalladium(II), palladium acetate or bis(diphenylphosphine)palladium(II
  • the example 4 describes the preparation of methyl N-[5-[6-[4-(4-fluoro-3- methoxy-phenyl)-5-methyl-1,2,4-triazol-3-yl]imidazo[1,2-a]pyridin-3-yl]-2-pyridyl]carbamate (compound X.08),the example 7 describes the preparation of methyl N-[5-[6-[4-(4-fluoro-3-methoxy-phenyl)-5- (methoxymethyl)-1,2,4-triazol-3-yl]-8-methyl-imidazo[1,2-a]pyridin-3-yl]-2-pyridyl]carbamate (compound X.12) and the example 8 describes the preparation of methyl N-[5-[8-cyclopropyl-6-[4-(4- fluoro-3-methoxy-phenyl)-1,2,4-triazol-3-yl]imidazo[1,2-a]pyridin-3-y
  • the example 3 describes the preparation of methyl N-[5-[6-[2-(4-fluoro-3- methoxy-phenyl)-1,2,4-triazol-3-yl]-8-methyl-imidazo[1,2-a]pyridin-3-yl]-2-pyridyl]carbamate (compound X.07) and the example 6 describes the preparation of methyl N-[5-[6-[2-(4-fluoro-3-methoxy- phenyl)-1,2,4-triazol-3-yl]imidazo[1,2-a]pyridin-3-yl]-2-pyridyl]carbamate (compound X.11).
  • the example 2 describes the preparation of methyl N-[5-[6-[4-(4-fluoro- 3-methoxy-phenyl)-5,6-dihydro-1,2,4-oxadiazin-3-yl]imidazo[1,2-a]pyridin-3-yl]-2-pyridyl]carbamate (compound X.06), the example 10 describes the preparation of methyl N-[5-[6-[4-(4-fluoro-3-methoxy- phenyl)-5,6-dihydro-1,2,4-oxadiazin-3-yl]-8-methyl-imidazo[1,2-a]pyridin-3-yl]-2-pyridyl]carbamate (compound X.03) and example 11 describes the preparation of methyl N-[5-[6-[4-(4-fluorophenyl)-5,6- dihydro-1,2,4-oxadiazin-3-yl]-8-methyl-imidazo[1,2-a]
  • the example 9 describes the preparation of methyl N-[5-[6-[1-(4-fluoro-3-methoxy- phenyl)imidazol-2-yl]-8-methyl-imidazo[1,2-a]pyridin-3-yl]-2-pyridyl]carbamate (compound X.02).
  • This synthetic route describes the synthesis of a compound of formula (I), wherein ring W is an imidazole (compounds of formula (I-g)) as well as the synthesis of compounds of formula (II), wherein W is an imidazole and X is Cl, Br or I (compounds of formula (II-g)).
  • This methodology can be used in general terms to access analogous compounds of formula (I-g) and formula (II-g).
  • the below compounds of formula (I-h) and (II-h) can be prepared following the synthetic route used in the example 1.
  • the example 1 describes the preparation of methyl N-[5-[6-[5-(4-fluoro-3-methoxy- phenyl)-1-methyl-pyrazol-4-yl]imidazo[1,2-a]pyridin-3-yl]-2-pyridyl]carbamate (compound X.05).
  • This synthetic route describes the synthesis of a compound of formula (I), wherein ring W is a pyrazole (compounds of formula (I-h)) as well as the synthesis of compounds of formula (II), wherein W is a pyrazole and X is Cl, Br or I (compounds of formula (II-h)).
  • This methodology can be used in general terms to access analogous compounds of formula (I-h) and formula (II-h).
  • these de novo synthesis might require using compounds of formula (XVI), wherein X is Cl, Br or I, and R 9 is hydrogen or C1-C6 alkyl, or the use of compound of formula (XVII), wherein R 9 is hydrogen or C1-C6 alkyl.
  • compounds of formula (XVII), wherein R 9 is hydrogen or C1-C6 alkyl can be prepared by the reaction of a compound of formula (XXV), wherein R 9 is hydrogen or C1-C6 alkyl, and a compound of formula (XIII), wherein X is Cl, Br or I, or its corresponding acetal of formula (XIV), wherein X is Cl, Br or I and either R 10 is independently from each other C1-C6 alkyl or wherein two R 10 together can form a C 3 -C 8 cycloalkyl, in a solvent, such as water, ethanol, acetone or acetonitrile.
  • a solvent such as water, ethanol, acetone or acetonitrile.
  • the outcome of the reaction can be improved by using a base, such as sodium bicarbonate or potassium carbonate, or by using an acid, such as p-toluenesulfonic acid or hydrogen bromide.
  • a base such as sodium bicarbonate or potassium carbonate
  • an acid such as p-toluenesulfonic acid or hydrogen bromide.
  • Compounds of formula (XXV), wherein R 9 is hydrogen or C1-C6 alkyl are prepared by known methods or are commercially available. This transformation is depicted in Scheme 19.
  • Scheme 19 Alternatively, compounds of formula (I) can be obtained by acylation of compounds of formula (XXVI) using an acylation reagent of formula (XXVII), wherein X is Cl or Br, in the presence of a base such as triethylamine, pyridine or potassium carbonate.
  • Compounds of formula (XXVI) can be prepared via Suzuki cross coupling of compounds of formula (II), wherein X is Cl, Br or I, and a compound of formula (XXVIII), wherein either R 8 is independently from each other hydrogen, C1-C6 alkyl or wherein two R 8 together can form a C3-C8 cycloalkyl, in the presence of a base, such as Cs2CO3, K2CO3 or NaOtBu, and a suitable palladium catalyst, such as tetrakistriphenylphosphinepalladium, palladium dichloride, [1,1-bis(diphenylphosphino)ferrocene]dichloropalladium(II), palladium acetate, chloro(2- dicyclohexylphosphino-2′,4′,6′-triisopropyl-1,1′-biphenyl)[2-(2′-amino-1,1′-biphenyl)]pal
  • Non-exhaustive examples include oxidation reactions, reduction reactions, hydrolysis reactions, coupling reactions, aromatic nucleophilic or electrophilic substitution reactions, nucleophilic substitution reactions, nucleophilic addition reactions, olefination reactions, oxime formation, alkylation and halogenation reactions.
  • oxidation reactions reduction reactions, hydrolysis reactions, coupling reactions, aromatic nucleophilic or electrophilic substitution reactions, nucleophilic substitution reactions, nucleophilic addition reactions, olefination reactions, oxime formation, alkylation and halogenation reactions.
  • the composition according to the present invention may be used in unmodified form or, preferably, together with the adjuvants conventionally employed in the art of formulation.
  • compositions may be conveniently formulated in known manner to emulsifiable concentrates, coatable pastes, directly sprayable or dilutable solutions or suspensions, dilute emulsions, wettable powders, soluble powders, dusts, granulates, and also encapsulations e.g. in polymeric substances.
  • the methods of application such as spraying, atomising, dusting, scattering, coating or pouring, are chosen in accordance with the intended objectives and the prevailing circumstances.
  • compositions may also contain further adjuvants such as stabilizers, antifoams, viscosity regulators, binders or tackifiers as well as fertilizers, micronutrient donors or other formulations for obtaining special effects.
  • Suitable carriers and/or adjuvants e.g. for agricultural use, can be solid or liquid and are substances useful in formulation technology, e.g. natural or regenerated mineral substances, solvents, dispersants, wetting agents, tackifiers, thickeners, binders or fertilizers. Such carriers are for example described in WO 97/33890.
  • Suspension concentrates are aqueous formulations in which finely divided solid particles of the active compound are suspended.
  • Such formulations include anti-settling agents and dispersing agents and may further include a wetting agent to enhance activity as well an anti-foam and a crystal growth inhibitor.
  • these concentrates are diluted in water and normally applied as a spray to the area to be treated.
  • the amount of active ingredient may range from 0.5% to 95% of the concentrate.
  • Wettable powders are in the form of finely divided particles which disperse readily in water or other liquid carriers. The particles contain the active ingredient retained in a solid matrix. Typical solid matrices include fuller’s earth, kaolin clays, silicas and other readily wet organic or inorganic solids. Wettable powders normally contain from 5% to 95% of the active ingredient plus a small amount of wetting, dispersing or emulsifying agent.
  • Emulsifiable concentrates are homogeneous liquid compositions dispersible in water or other liquid and may consist entirely of the active compound with a liquid or solid emulsifying agent, or may also contain a liquid carrier, such as xylene, heavy aromatic naphthas, isophorone and other non-volatile organic solvents. In use, these concentrates are dispersed in water or other liquid and normally applied as a spray to the area to be treated. The amount of active ingredient may range from 0.5% to 95% of the concentrate.
  • Granular formulations include both extrudates and relatively coarse particles and are usually applied without dilution to the area in which treatment is required.
  • Typical carriers for granular formulations include sand, fuller’s earth, attapulgite clay, bentonite clays, montmorillonite clay, vermiculite, perlite, calcium carbonate, brick, pumice, pyrophyllite, kaolin, dolomite, plaster, wood flour, ground corn cobs, ground peanut hulls, sugars, sodium chloride, sodium sulphate, sodium silicate, sodium borate, magnesia, mica, iron oxide, zinc oxide, titanium oxide, antimony oxide, cryolite, gypsum, diatomaceous earth, calcium sulphate and other organic or inorganic materials which absorb or which can be coated with the active compound.
  • Granular formulations normally contain 5% to 25% of active ingredients which may include surface-active agents such as heavy aromatic naphthas, kerosene and other petroleum fractions, or vegetable oils; and/or stickers such as dextrins, glue or synthetic resins.
  • Dusts are free-flowing admixtures of the active ingredient with finely divided solids such as talc, clays, flours and other organic and inorganic solids which act as dispersants and carriers.
  • Microcapsules are typically droplets or granules of the active ingredient enclosed in an inert porous shell which allows escape of the enclosed material to the surroundings at controlled rates. Encapsulated droplets are typically 1 to 50 microns in diameter.
  • the enclosed liquid typically constitutes 50 to 95% of the weight of the capsule and may include solvent in addition to the active compound.
  • Encapsulated granules are generally porous granules with porous membranes sealing the granule pore openings, retaining the active species in liquid form inside the granule pores.
  • Granules typically range from 1 millimetre to 1 centimetre and preferably 1 to 2 millimetres in diameter.
  • Granules are formed by extrusion, agglomeration or prilling, or are naturally occurring. Examples of such materials are vermiculite, sintered clay, kaolin, attapulgite clay, sawdust and granular carbon.
  • Shell or membrane materials include natural and synthetic rubbers, cellulosic materials, styrene-butadiene copolymers, polyacrylonitriles, polyacrylates, polyesters, polyamides, polyureas, polyurethanes and starch xanthates.
  • Other useful formulations for agrochemical applications include simple solutions of the comopnents A and B in a solvent in which it is completely soluble at the desired concentration, such as acetone, alkylated naphthalenes, xylene and other organic solvents.
  • Pressurised sprayers wherein the active ingredient is dispersed in finely-divided form as a result of vaporisation of a low boiling dispersant solvent carrier, may also be used.
  • Liquid carriers that can be employed include, for example, water, toluene, xylene, petroleum naphtha, crop oil, acetone, methyl ethyl ketone, cyclohexanone, acetic anhydride, acetonitrile, acetophenone, amyl acetate, 2-butanone, chlorobenzene, cyclohexane, cyclohexanol, alkyl acetates, diacetonalcohol, 1,2-dichloropropane, diethanolamine, p-diethylbenzene, diethylene glycol, diethylene glycol abietate, diethylene glycol butyl ether, diethylene glycol ethyl ether, diethylene glycol methyl ether, N,N-dimethyl formamide, dimethyl sulfoxide,
  • Water is generally the carrier of choice for the dilution of concentrates.
  • suitable solid carriers include, for example, talc, titanium dioxide, pyrophyllite clay, silica, attapulgite clay, kieselguhr, chalk, diatomaxeous earth, lime, calcium carbonate, bentonite clay, fuller’s earth, cotton seed hulls, wheat flour, soybean flour, pumice, wood flour, walnut shell flour and lignin.
  • a broad range of surface-active agents are advantageously employed in both said liquid and solid compositions, especially those designed to be diluted with carrier before application. These agents, when used, normally comprise from 0.1% to 15% by weight of the formulation.
  • Typical surface active agents include salts of alkyl sulfates, such as diethanolammonium lauryl sulphate; alkylarylsulfonate salts, such as calcium dodecylbenzenesulfonate; alkylphenol-alkylene oxide addition products, such as nonylphenol-C.sub.18 ethoxylate; alcohol-alkylene oxide addition products, such as tridecyl alcohol-C.sub.
  • soaps such as sodium stearate
  • alkylnaphthalenesulfonate salts such as sodium dibutylnaphthalenesulfonate
  • dialkyl esters of sulfosuccinate salts such as sodium di(2-ethylhexyl) sulfosuccinate
  • sorbitol esters such as sorbitol oleate
  • quaternary amines such as lauryl trimethylammonium chloride
  • polyethylene glycol esters of fatty acids such as polyethylene glycol stearate
  • block copolymers of ethylene oxide and propylene oxide and salts of mono and dialkyl phosphate esters.
  • adjuvants commonly utilized in agricultural compositions include crystallisation inhibitors, viscosity modifiers, suspending agents, spray droplet modifiers, pigments, antioxidants, foaming agents, anti- foaming agents, light-blocking agents, compatibilizing agents, antifoam agents, sequestering agents, neutralising agents and buffers, corrosion inhibitors, dyes, odorants, spreading agents, penetration aids, micronutrients, emollients, lubricants and sticking agents.
  • compositions of this invention can be mixed with one or more further pesticides including further fungicides, insecticides, nematocides, bactericides, acaricides, growth regulators, chemosterilants, semiochemicals, repellents, attractants, pheromones, feeding stimulants or other biologically active compounds to form a multi-component pesticide giving an even broader spectrum of agricultural protection.
  • further active ingredient component (C) are as follows, wherein the term “TX” represents a compound according to the definition of component (A) of the composition of the present invention selected from compound no.
  • Israelensis + TX Bacillus thuringiensis subsp. Japonensis + TX, Bacillus thuringiensis subsp. Kurstaki + TX, Bacillus thuringiensis subsp. Tenebrionis + TX, Bacillus thuringiensis subspec.
  • lecontei NPV + TX nickel bis(dimethyldithiocarbamate) + TX, niclosamide + TX, niclosamide-olamine + TX, nicofluprole + TX, nitenpyram + TX, nithiazine + TX, nitrapyrin + TX, octadeca-2,13-dien-1-yl acetate + TX, octadeca- 3,13-dien-1-yl acetate + TX, octhilinone + TX, omethoate + TX, orfralure + TX, Orius spp.
  • TX trifenmorph + TX, trifluenfuronate + TX, triflumezopyrim + TX, trimedlure + TX, trimedlure A + TX, trimedlure B1 + TX, trimedlure B2 + TX, trimedlure C + TX, trimethacarb + TX, triphenyltin acetate + TX, triphenyltin hydroxide + TX, trunc-call + TX, tyclopyrazoflor + TX, Typhlodromus occidentalis + TX, uredepa + TX, Verticillium lecanii + TX, Verticillium spp.
  • acridum + TX Metarhizium anisopliae var. anisopliae + TX, metarylpicoxamid + TX, metconazole + TX, metepa + TX, methacrifos + TX, methanesulfonyl fluoride + TX, methasulfocarb + TX, methiotepa + TX, methocrotophos + TX, methoprene + TX, methoquin-butyl + TX, methothrin + TX, methoxychlor + TX, methyl (Z)-2-(5- cyclohexyl-2-methyl-phenoxy)-3-methoxy-prop-2-enoate + TX, methyl (Z)-2-(5-cyclopentyl-2-methyl- phenoxy)-3-methoxy-prop-2-enoate (these compounds may be prepared from the methods described in WO2020/193387) + TX,
  • Bacillus subtilis strain AQ178 + TX Bacillus subtilis strain AQ153 + TX, Bacillus subtilis strain AQ743 + TX, Bacillus subtilis strain QST 713 (CEASE®, Serenade®, Rhapsody®) + TX, Bacillus subtilis strain QST 714 (JAZZ®) + TX, Bacillus subtilis strain QST3002 + TX, Bacillus subtilis strain QST3004 + TX, Bacillus subtilis var.
  • amyloliquefaciens strain FZB24 (Taegro®, Rhizopro®) + TX, Bacillus thuringiensis aizawai GC 91 (Agree®) + TX, Bacillus thuringiensis Cry 2Ae + TX, Bacillus thuringiensis Cry1Ab + TX, Bacillus thuringiensis israelensis (BMP123®, Aquabac®, VectoBac®) + TX, Bacillus thuringiensis kurstaki (Javelin®, Deliver®, CryMax®, Bonide®, Scutella WP®, Turilav WP ®, Astuto®, Dipel WP®, Biobit®, Foray®) + TX, Bacillus thuringiensis kurstaki BMP 123 (Baritone®) + TX, Bacillus thuringiensis kurstaki HD-1 (Bioprotec-CAF / 3P®) + TX
  • TX Botrytis cineria + TX, Bradyrhizobium japonicum (TerraMax®) + TX, Brevibacillus brevis + TX, Burkholderia cepacia (Deny®, Intercept®, Blue Circle®) + TX, Burkholderia gladii + TX, Burkholderia gladioli + TX, Burkholderia spp.
  • TX Canadian thistle fungus (CBH Canadian Bioherbicide®) + TX, Candida butyri + TX, Candida famata + TX, Candida fructus + TX, Candida glabrata + TX, Candida guilliermondii + TX, Candida melibiosica + TX, Candida oleophila strain O + TX, Candida parapsilosis + TX, Candida pelliculosa + TX, Candida pulcherrima + TX, Candida reuêtii + TX, Candida saitoana (Bio-Coat®, Biocure®) + TX, Candida sake + TX, Candida spp.
  • TX Cladosporium tenuissimum + TX, Clonostachys rosea (EndoFine®) + TX, Colletotrichum acutatum + TX, Coniothyrium minitans (Cotans WG®) + TX, Coniothyrium spp.
  • TX Filobasidium floriforme + TX, Fusarium acuminatum + TX, Fusarium chlamydosporum + TX, Fusarium oxysporum (Fusaclean®, Biofox C®) + TX, Fusarium proliferatum + TX, Fusarium spp. + TX, Galactomyces geotrichum + TX, Gliocladium catenulatum (Primastop®, Prestop®) + TX, Gliocladium roseum + TX, Gliocladium spp.
  • TX Lagenidium giganteum (Laginex®) + TX, Lecanicillium lecanii (formerly known as Verticillium lecanii (Mycotal®) conidia of strain KV01 (e.g. Vertalec® by Koppert/Arysta) + TX, Lecanicillium longisporum (Vertiblast®) + TX, Lecanicillium muscarium (Vertikil®) + TX, Lymantria Dispar nucleopolyhedrosis virus (Disparvirus®) + TX, Marinococcus halophilus + TX, Meira geulakonigii + TX, Metarhizium anisopliae (Destruxin WP®) + TX, Metarhizium anisopliae (Met52®) + TX, Metschnikowia fruticola (Shemer®) + TX, Metschnikowia pulcherrima + TX, Microdochium dimerum (Antibot®) + TX
  • NRRL 305408 + TX, Mycorrhizae spp. (AMykor®, Root Maximizer®) + TX, Myrothecium verrucaria strain AARC-0255 (DiTera®, BROS PLUS®) + TX, Ophiostoma piliferum strain D97 (Sylvanex®) + TX, Paecilomyces farinosus + TX, Paecilomyces lilacinus strain 251 (MeloCon WG®) + TX, Paecilomyces linacinus (Biostat WP®) + TX, Paenibacillus polymyxa + TX, Pantoea agglomerans (BlightBan C9-1®) + TX, Pantoea spp.
  • TX Pasteuria nishizawae in particular strain Pn1 (CLARIVA from Syngenta/ChemChina); + TX, Pasteuria spp. (Econem®) + TX, Penicillium aurantiogriseum + TX, Penicillium billai (Jumpstart®, TagTeam®) + TX, Penicillium brevicompactum + TX, Penicillium frequentans + TX, Penicillium griseofulvum + TX, Penicillium purpurogenum + TX, Penicillium spp.
  • TX Penicillium viridicatum + TX, Phlebiopsis gigantean (Rotstop®) + TX, phosphate solubilizing bacteria (Phosphomeal®) + TX, Phytophthora cryptogea + TX, Phytophthora palmivora (Devine®) + TX, Pichia anomala + TX, Pichia guilliermondii + TX, Pichia membranaefaciens + TX, Pichia onychis + TX, Pichia stipites + TX, Pseudomonas aeruginosa + TX, Pseudomonas aureofasciens (Spot-Less Biofungicide®) + TX, Pseudomonas cepacia + TX, Pseudomonas chlororaphis (AtEze®) + TX, Pseudomonas corrugate + TX, P
  • TX Pseudomonas syringae (Bio-Save®) + TX, Pseudomonas viridiflava + TX, Pseudozyma flocculosa strain PF-A22 UL (Sporodex L®) + TX, Puccinia canaliculata + TX, Puccinia thlaspeos (Wood Warrior®) + TX, Pythium paroecandrum + TX, Pythium oligandrum (Polygandron®, Polyversum®) + TX, Pythium periplocum + TX, Rhanella aquatilis + TX, Rhanella spp.
  • Rhizobia Distal®, Vault®
  • Rhizoctonia + TX Rhodococcus globerulus strain AQ719 + TX, Rhodosporidium diobovatum + TX, Rhodosporidium toruloides + TX, Rhodotorula glutinis + TX, Rhodotorula graminis + TX, Rhodotorula mucilagnosa + TX, Rhodotorula rubra + TX, Rhodotorula spp.
  • Trichoderma asperellum T34 Biocontrol®
  • TX Trichoderma atroviride
  • Trichoderma gamsii TX
  • Trichoderma hamatum TH 382 + TX Trichoderma harzianum rifai (Mycostar®) + TX
  • Trichoderma harzianum T-22 Trianum- P®, PlantShield HC®, RootShield®, Trianum-G® + TX, Trichoderma harzianum T-39 (Trichodex®) + TX, Trichoderma inhamatum + TX, Trichoderma koningii + TX, Trichoderma lignorum + TX, Trichoderma longibrachiatum + TX, Trichoderma polysporum (Binab T®) + TX, Trichoderma spp.
  • LC 52 (Sentinel®) + TX, Trichoderma taxi + TX, Trichoderma virens (formerly Gliocladium virens GL-21) (SoilGuard®) + TX, Trichoderma virens + TX, Trichoderma viride + TX, Trichoderma viride strain ICC 080 (Remedier®) + TX, Trichosporon pullulans + TX, Trichosporon spp. + TX, Trichothecium roseum + TX, Trichothecium spp.
  • TX maydis + TX, various bacteria and supplementary micronutrients (Natural II®) + TX, various fungi (Millennium Microbes®) + TX, Verticillium chlamydosporium + TX, Vip3Aa20 (VIPtera®) + TX, Virgibaclillus marismortui + TX, Xanthomonas campestris pv.
  • TX Bombus terrestris (Beeline®, Tripol®) + TX, Bombus terrestris (Natupol Beehive®) + TX, Cephalonomia stephanoderis + TX, Chilocorus nigritus + TX, Chrysoperla carnea (Chrysoline®, Chrysopa®) + TX, Chrysoperla rufilabris + TX, Cirrospilus ingenuus + TX, Cirrospilus quadristriatus + TX, Citrostichus phyllocnistoides + TX, Closterocerus chamaeleon + TX, Closterocerus spp.
  • TX Coccidoxenoides perminutus (Planopar®) + TX, Coccophagus cowperi + TX, Coccophagus lycimnia + TX, Cotesia flavipes + TX, Cotesia plutellae + TX, Cryptolaemus montrouzieri (Cryptobug®, Cryptoline®) + TX, Cybocephalus nipponicus + TX, Dacnusa sibirica (Minusa®, DacDigline®, Minex®) + TX, Delphastus catalinae (Delphastus®) + TX, Delphastus pusillus + TX, Diachasmimorpha krausii + TX, Diachasmimorpha longicaudata + TX, Diaparsis jucunda + TX, Diaphorencyrtus aligarhensis + TX, Diglyphus isaea (Diminex®, Miglyphus,
  • TX Steinernematid spp. (Guardian Nematodes®) + TX, Stethorus punctillum (Stethorus®) + TX, Tamarixia radiate + TX, Tetrastichus setifer + TX, Thripobius semiluteus + TX, Torymus sinensis + TX, Trichogramma brassicae (Tricholine b®) + TX, Trichogramma brassicae (Tricho-Strip®) + TX, Trichogramma evanescens + TX, Trichogramma minutum + TX, Trichogramma ostriniae + TX, Trichogramma platneri + TX, Trichogramma pretiosum + TX, Xanthopimpla stemmator + TX; abscisic acid + TX, Aminomite® + TX, BioGain® + TX, bioSea® + TX, CAS Number: 2643947-26-4 + TX, Chondroster
  • NCAIM (P) B001389) (WO 2013/034938) from Certis USA LLC + TX
  • Bacillus pumilus in particular strain BU F-33, having NRRL Accession No. 50185 (CARTISSA® from BASF, EPA Reg. No.71840-19) + TX
  • Bacillus subtilis CX-9060 from Certis USA LLC
  • Bacillus sp. in particular strain D747 (available as DOUBLE NICKEL® from Kumiai Chemical Industry Co., Ltd.), having Accession No. FERM BP-8234, U.S.
  • Patent No.7,094,592 + TX Bacillus subtilis strain BU1814, (VELONDIS® PLUS, VELONDIS® FLEX and VELONDIS® EXTRA from BASF SE) + TX, Bacillus subtilis var. amyloliquefaciens strain FZB24 having Accession No. DSM 10271 (available from Novozymes as TAEGRO® or TAEGRO® ECO (EPA Registration No.70127-5)) + TX, Bacillus subtilis, in particular strain QST713/AQ713 (having NRRL Accession No. B-21661 and described in U.S.
  • Patent No.6,060,051 available as SERENADE® OPTI or SERENADE® ASO from Bayer CropScience LP, US
  • TX Paenibacillus polymyxa
  • strain AC-1 e.g. TOPSEED® from Green Biotech Company Ltd.
  • TX Paenibacillus sp. strain having Accession No. NRRL B-50972 or Accession No. NRRL B-67129, WO 2016/154297 + TX, Pantoea agglomerans, in particular strain E325 (Accession No.
  • NRRL B-21856 (available as BLOOMTIME BIOLOGICALTM FD BIOPESTICIDE from Northwest Agri Products) + TX, Pseudomonas proradix (e.g. PRORADIX® from Sourcon Padena) + TX; Aureobasidium pullulans, in particular blastospores of strain DSM14940, blastospores of strain DSM 14941 or mixtures of blastospores of strains DSM14940 and DSM14941 (e.g., BOTECTOR® and BLOSSOM PROTECT® from bio-ferm, CH) + TX, Pseudozyma aphidis (as disclosed in WO2011/151819 by Yissum Research Development Company of the Hebrew University of Jerusalem) + TX, Saccharomyces cerevisiae, in particular strains CNCM No.1-3936, CNCM No.1-3937, CNCM No.1-3938 or CNCM No.1-3939 (WO 2010/086790) from
  • DSM 23117 (available as RHIZOVITAL® from ABiTEP, DE) + TX
  • Bacillus amyloliquefaciens in particular strain D747 (available as Double NickelTM from Kumiai Chemical Industry Co., Ltd., having accession number FERM BP-8234, US Patent No.7,094,592) + TX
  • Bacillus licheniformis FMCH001 and Bacillus subtilis FMCH002 (QUARTZO® (WG) and PRESENCE® (WP) from FMC Corporation) + TX
  • Bacillus licheniformis in particular strain SB3086, having Accession No.
  • ATCC 55406, WO 2003/000051 (available as ECOGUARD® Biofungicide and GREEN RELEAFTM from Novozymes) + TX, Bacillus methylotrophicus strain BAC-9912 (from Chinese Academy of Sciences’ Institute of Applied Ecology) + TX, Bacillus mycoides, isolate, having Accession No. B-30890 (available as BMJ TGAI® or WG and LifeGardTM from Certis USA LLC) + TX, Bacillus pumilus, in particular strain GB34 (available as Yield Shield® from Bayer AG, DE) + TX, Bacillus pumilus, in particular strain QST2808 (available as SONATA® from Bayer CropScience LP, US, having Accession No.
  • Patent No.5,061,495 + TX Bacillus subtilis strain Y1336 (available as BIOBAC® WP from Bion- Tech, Taiwan, registered as a biological fungicide in Taiwan under Registration Nos.4764, 5454, 5096 and 5277) + TX, Bacillus subtilis var. amyloliquefaciens strain FZB24 having Accession No. DSM 10271 (available from Novozymes as TAEGRO® or TAEGRO® ECO (EPA Registration No.70127-5)) + TX, Bacillus subtilis Y1336 (available as BIOBAC® WP from Bion-Tech, Taiwan, registered as a biological fungicide in Taiwan under Registration Nos.
  • NRRL B-50897, WO 2017/019448 e.g., HOWLERTM and ZIO® from AgBiome Innovations, US
  • TX Pseudomonas chlororaphis
  • strain MA342 e.g. CEDOMON®, CERALL®, and CEDRESS® by Bioagri and Koppert
  • TX Pseudomonas fluorescens strain A506 (e.g. BLIGHTBAN® A506 by NuFarm) + TX
  • Pseudomonas proradix e.g.
  • PRORADIX® from Sourcon Padena + TX
  • Streptomyces griseoviridis strain K61 also known as Streptomyces galbus strain K61
  • DSM 7206 Streptomyces galbus strain K61
  • MYCOSTOP® from Verdera, PREFENCE® from BioWorks, cf.
  • BIOKUPRUMTM by AgriLife + TX
  • Chaetomium globosum available as RIVADIOM® by Rivale
  • TX Cladosporium cladosporioides
  • strain H39 having Accession No. CBS122244, US 2010/0291039 (by Stichting Moowgrass Onderzoek) + TX
  • Coniothyrium minitans in particular strain CON/M/91-8 (Accession No. DSM9660, e.g.
  • strain ICC 080 having Accession No. IMI 392151 (e.g., BIO-TAMTM from Isagro USA, Inc. or BIODERMA® by Agrobiosol de Mexico, S.A. de C.V.) + TX, Penicillium vermiculatum + TX, Phlebiopsis gigantea strain VRA 1992 (ROTSTOP® C from danstar Ferment) + TX, Pseudozyma flocculosa, strain PF-A22 UL (available as SPORODEX® L by Plant Products Co., CA) + TX, Saccharomyces cerevisiae strain LAS117 cell walls (CEREVISANE® from Lesaffre, ROMEO® from BASF SE) + TX, Saccharomyces cerevisiae strains CNCM No.1-3936, CNCM No.1-3937, CNCM No.1-3938, CNCM No.1-3939 (WO 2010/086790) from Lesaffre et Compag
  • T- Gro from Andermatt Biocontrol + TX
  • Trichoderma atroviride strain 77B T77 from Andermatt Biocontrol
  • Trichoderma atroviride strain ATCC 20476 IMI 206040
  • Trichoderma atroviride strain LC52 e.g. Tenet by Agrimm Technologies Limited
  • Trichoderma atroviride strain LU132 e.g. Sentinel from Agrimm Technologies Limited
  • TX Trichoderma atroviride strain NMI no. V08/002388 + TX
  • Trichoderma atroviride strain NMI no. V08/002389 + TX Trichoderma atroviride strain NMI no.
  • Patent No.8,431,120 (from Bi-PA)) + TX, Trichoderma atroviride,strain CNCM 1-1237 (e.g. Esquive® WP from Agrauxine, FR) + TX, Trichoderma fertile (e.g. product TrichoPlus from BASF) + TX, Trichoderma gamsii (formerly T. viride) + TX, Trichoderma gamsii (formerly T. viride) strain ICC 080 (IMI CC 392151 CABI) (available as BIODERMA® by AGROBIOSOL DE MEXICO, S.A.
  • Trichoderma gamsii strain ICC080 IMI CC 392151 CABI, e.g. BioDerma by AGROBIOSOL DE MEXICO, S.A. DE C.V.
  • + TX Trichoderma harmatum + TX
  • Trichoderma harmatum having Accession No. ATCC 28012 + TX, Trichoderma harzianum + TX, Trichoderma harzianum rifai T39 (e.g.
  • Trichodex® from Makhteshim, US + TX, Trichoderma harzianum strain Cepa SimbT5 (from Simbiose Agro), + TX, Trichoderma harzianum strain DB 103 (available as T-GRO® 7456 by Dagutat Biolab) + TX, Trichoderma harzianum strain ITEM 908 (e.g. Trianum-P from Koppert) + TX, Trichoderma harzianum strain T-22 (e.g. Trianum-P from Andermatt Biocontrol or Koppert) + TX, Trichoderma harzianum strain TH35 (e.g.
  • Trichoderma polysporum strain IMI 206039 e.g. Binab TF WP by BINAB Bio- Innovation AB, Sweden
  • TX Trichoderma stromaticum having Accession No. Ts3550 (e.g. Tricovab by CEPLAC, Brazil) + TX
  • Trichoderma virens also known as Gliocladium virens
  • strain GL-21 e.g. SoilGard by Certis, US
  • Trichoderma virens strain G-41 formerly known as Gliocladium virens (Accession No.
  • ATCC 20906 (e.g., ROOTSHIELD® PLUS WP and TURFSHIELD® PLUS WP from BioWorks, US) + TX, Trichoderma viride in particular strain B35 (Pietr et al., 1993, Zesz. Nauk. A R w Szczecinie 161: 125-137) + TX, Trichoderma viride strain TV1(e.g. Trianum-P by Koppert) + TX, Ulocladium oudemansii strain U3, having Accession No.
  • NM 99/06216 e.g., BOTRY-ZEN® by Botry-Zen Ltd, New Zealand and BOTRYSTOP® from BioWorks, Inc.
  • TX Verticillium albo-atrum (formerly V. dahliae) strain WCS850 having Accession No.
  • WCS850 deposited at the Central Bureau for Fungi Cultures (e.g., DUTCH TRIG® by Tree Care Innovations) + TX, Verticillium chlamydosporium + TX; a mixture of Azotobacter vinelandii and Clostridium pasteurianum (available as INVIGORATE® from Agrinos) + TX, a mixture of Bacillus licheniformis FMCH001 and Bacillus subtilis FMCH002 (available as QUARTZO® (WG), PRESENCE® (WP) from FMC Corporation) + TX, Azorhizobium caulinodans, in particular strain ZB-SK-5 + TX, Azospirillum brasilense (e.g., VIGOR® from KALO, Inc.) + TX, Azospirillum lipoferum (e.g., VERTEX-IFTM from TerraMax, Inc.) + TX, Azotobacter chroococcum, in particular strain H
  • NRRL B-5015 + TX
  • Bacillus amyloliquefaciens in particular strain FZB42 e.g. RHIZOVITAL® from ABiTEP, DE
  • Bacillus amyloliquefaciens in particular strain IN937a + TX Bacillus amyloliquefaciens pm414 (LOLI-PEPTA® from Biofilm Crop Protection) + TX
  • Bacillus amyloliquefaciens SB3281 ATCC # PTA-7542, WO 2017/205258
  • Bacillus amyloliquefaciens TJ1000 available as QUIKROOTS® from Novozymes
  • Bacillus cereus family member EE128 NRRL No.
  • YIELD SHIELD® from Bayer Crop Science, DE
  • + TX Bacillus pumilus in particular strain QST2808 (Accession No. NRRL No. B-30087) + TX, Bacillus siamensis in particular strain KCTC 13613T + TX, Bacillus subtilis in particular strain AQ30002 (Accession No. NRRL No. B-50421 and described in U.S. Patent Application No.13/330,576) + TX, Bacillus subtilis in particular strain AQ30004 (NRRL No. B-50455 and described in U.S. Patent Application No. 13/330,576) + TX, Bacillus subtilis in particular strain MBI 600 (e.g.
  • BIOBOOST® from Brett Young Seeds + TX, Lactobacillus sp. (e.g. LACTOPLANT® from LactoPAFI) + TX, Mesorhizobium cicer (e.g., NODULATOR from BASF SE) + TX, Paenibacillus polymyxa in particular strain AC-1 (e.g. TOPSEED® from Green Biotech Company Ltd.) + TX, Pseudomonas aeruginosa in particular strain PN1 + TX, Pseudomonas proradix (e.g.
  • PRORADIX® from Sourcon Padena + TX, Rhizobium leguminosarium biovar viciae (e.g., NODULATOR from BASF SE) + TX, Rhizobium leguminosarum in particular bv. viceae strain Z25 (Accession No. CECT 4585) + TX, Serratia marcescens in particular strain SRM (Accession No. MTCC 8708), + TX, Sinorhizobium meliloti strain NRG-185-1 (NITRAGIN® GOLD from Bayer CropScience) + TX, Thiobacillus sp. (e.g.
  • Trichoderma atroviride strain SC1 (described in WO2009/116106) + TX, Trichoderma harzianum strain 1295-22 + TX, Trichoderma harzianum strain ITEM 908 + TX, Trichoderma harzianum strain T-22 (e.g. Trianum-P from Andermatt Biocontrol or Koppert) + TX, Trichoderma harzianum strain TSTh20, + TX, Trichoderma virens strain GI-3 + TX, Trichoderma virens strain GL-21 (e.g.
  • aizawai in particular serotype H-7 (e.g. FLORBAC® WG from Valent BioSciences, US) + TX, Bacillus thuringiensis subsp. aizawai, in particular strain ABTS-1857 (SD-1372, e.g. XENTARI® from Valent BioSciences) + TX, Bacillus thuringiensis subsp. israelensis (serotype H-14) strain AM65-52 (Accession No. ATCC 1276) (e.g. VECTOBAC® by Valent BioSciences, US) + TX, Bacillus thuringiensis subsp.
  • serotype H-7 e.g. FLORBAC® WG from Valent BioSciences, US
  • TX Bacillus thuringiensis subsp. aizawai, in particular strain ABTS-1857 (SD-1372, e.g. XENTARI® from Valent BioSciences) + TX
  • israeltaki strain ABTS 351 + TX Bacillus thuringiensis subsp. kurstaki strain BMP 123 (from Becker Microbial Products, IL, BARITONE from Bayer CropScience) + TX, Bacillus thuringiensis subsp. kurstaki strain EG 2348 (LEPINOX from Certis, US) + TX, Bacillus thuringiensis subsp. kurstaki strain EG 7841 (CRYMAX from Certis, US) + TX, Bacillus thuringiensis subsp. kurstaki strain HD-1 (e.g. DIPEL® ES from Valent BioSciences, US) + TX, Bacillus thuringiensis subsp.
  • BMP 123 from Becker Microbial Products, IL, BARITONE from Bayer CropScience
  • TX Bacillus thuringiensis subsp. kurstaki strain EG 2348 (LEPINOX from Certis, US) + TX
  • israeltaki strain PB 54 + TX Bacillus thuringiensis subsp. kurstaki strain SA 11 (JAVELIN from Certis, US) + TX, Bacillus thuringiensis subsp. kurstaki strain SA 12 (THURICIDE from Certis, US) + TX, Bacillus thuringiensis subsp. tenebrionis strain NB 176 (SD-5428, e.g. NOVODOR® FC from BioFa DE) + TX, Bacillus thuringiensis var. Colmeri (e.g. TIANBAOBTC by Changzhou Jianghai Chemical Factory) + TX, Bacillus thuringiensis var.
  • SD-5428 e.g. NOVODOR® FC from BioFa DE
  • Bacillus thuringiensis var. Colmeri e.g. TIANBAOBTC by Changzhou Jianghai Chemical Factory
  • MBI206 TGAI and ZELTO® from Marrone Bio Innovations + TX
  • Chromobacterium subtsugae in particular strain PRAA4-1T e.g. MBI-203, e.g. GRANDEVO® from Marrone Bio Innovations
  • TX Chromobacterium subtsugae in particular strain PRAA4-1T
  • MBI-203 e.g. GRANDEVO® from Marrone Bio Innovations
  • TX Lecanicillium muscarium Ve6 (MYCOTAL from Koppert) + TX
  • Paenibacillus popilliae (formerly Bacillus popilliae, e.g. MILKY SPORE POWDERTM or MILKY SPORE GRANULARTM from St. Gabriel Laboratories) + TX
  • Serratia entomophila e.g.
  • ATCC74250 e.g. BOTANIGUARD® ES and MYCONTROL-O® from Laverlam International Corporation
  • TX Metarhizium anisopliae 3213-1 (deposited under NRRL accession number 67074 disclosed in WO 2017/066094, Pioneer Hi-Bred International) + TX, Metarhizium robertsii 15013-1 (deposited under NRRL accession number 67073) + TX, Metarhizium robertsii 23013-3 (deposited under NRRL accession number 67075) + TX, Paecilomyces lilacinus strain 251 (MELOCON from Certis, US) + TX; Cydia pomonella (codling moth) granulosis virus (GV) + TX, Helicoverpa armigera (cotton bollworm) nuclear polyhedrosis virus (NPV) + TX, of Adoxophyes orana (summer fruit tortrix) granul
  • Burkholderia cepacia (formerly known as Pseudomonas cepacia) + TX, Gigaspora spp. + TX, Glomus spp. + TX, Laccaria spp. + TX, LactoBacillus buchneri + TX, Paraglomus spp. + TX, Pisolithus tinctorus + TX, Pseudomonas spp. + TX, Rhizobium spp. in particular Rhizobium trifolii + TX, Rhizopogon spp. + TX, Scleroderma spp. + TX, Streptomyces spp. + TX, Suillus spp.
  • the weight ratio of component (A) to component (C) may preferably be from 100:1 to 1:100, from 50:1 to 1:50, from 20:1 to 1:40, from 15:1 to 1:30, from 12:1 to 1:25, from 10:1 to 1:20, from 5:1 and 1:15, from 3:1 to 1:10 or from 2:1 to 1:5.
  • a further aspect of invention is related to a method of controlling or preventing an infestation of plants, e.g. useful plants such as crop plants, propagation material thereof, e.g. seeds, harvested crops, e.g.
  • Controlling or preventing means reducing infestation by insects or by phytopathogenic or spoilage microorganisms or organisms potentially harmful to man, especially fungal organisms, to such a level that an improvement is demonstrated.
  • a preferred method of controlling or preventing an infestation of crop plants by phytopathogenic microorganisms, especially fungal organisms, which comprises the application of a composition according to the present invention is foliar application.
  • the frequencies of application and the rate of application will depend on the risk of infestation by the corresponding pathogen or insect.
  • the compounds A and/or B of the composition according to the present invention can also penetrate the plant through the roots via the soil (systemic action) by drenching the locus of the plant with a liquid formulation, or by applying said compounds in solid form to the soil, e.g. in granular form (soil application). In crops of water rice such granulates can be applied to the flooded rice field.
  • the compounds A and B as defined in the present invention may also be applied to seeds (coating) by impregnating the seeds or tubers either with a liquid formulation of the fungicide or coating them with a solid formulation.
  • composition according to the present invention may be prepared in a known manner, typically by intimately mixing and/or grinding the compound with extenders, for example solvents, solid carriers and, optionally, surface active compounds (surfactants).
  • extenders for example solvents, solid carriers and, optionally, surface active compounds (surfactants).
  • surfactants surface active compounds
  • the application methods for the compositions that is the methods of controlling pests of the abovementioned type, such as spraying, atomizing, dusting, brushing on, dressing, scattering or pouring - which are to be selected to suit the intended aims of the prevailing circumstances - and the use of the composition for controlling pests of the abovementioned type are other subjects of the invention.
  • Typical rates of concentration are between 0.1 and 1000 ppm, preferably between 0.1 and 500 ppm, of active ingredient.
  • the rate of application per hectare is preferably 1g to 2000 g of active ingredient per hectare, more preferably 10 to 1000 g/ha, most preferably 10 to 600 g/ha.
  • convenient dosages are from 10mg to 1g of active substance per kg of seeds.
  • rates of 0.001 to 50 g of a compound of formula (I) per kg of seed preferably from 0.01 to 10g per kg of seed are generally sufficient.
  • the composition according to the present invention can be applied either preventative, meaning prior to disease development or curative, meaning after disease development.
  • compositions of the invention may be employed in any conventional form, for example in the form of a twin pack, a powder for dry seed treatment (DS), an emulsion for seed treatment (ES), a flowable concentrate for seed treatment (FS), a solution for seed treatment (LS), a water dispersible powder for seed treatment (WS), a capsule suspension for seed treatment (CF), a gel for seed treatment (GF), an emulsion concentrate (EC), a suspension concentrate (SC), a suspo-emulsion (SE), a capsule suspension (CS), a water dispersible granule (WG), an emulsifiable granule (EG), an emulsion, water in oil (EO), an emulsion, oil in water (EW), a micro-emulsion (ME), an oil dispersion (OD), an oil miscible flowable (OF), an oil miscible liquid (OL), a soluble concentrate (SL), an ultra-low volume suspension (SU), an ultra-low volume liquid (UL), a technical concentrate (TK
  • compositions may be produced in conventional manner, e.g. by mixing the active ingredients with appropriate formulation inerts (diluents, solvents, fillers and optionally other formulating ingredients such as surfactants, biocides, anti-freeze, stickers, thickeners and compounds that provide adjuvancy effects).
  • appropriate formulation inerts diiluents, solvents, fillers and optionally other formulating ingredients such as surfactants, biocides, anti-freeze, stickers, thickeners and compounds that provide adjuvancy effects.
  • conventional slow release formulations may be employed where long lasting efficacy is intended.
  • Particularly formulations to be applied in spraying forms such as water dispersible concentrates (e.g. EC, SC, DC, OD, SE, EW, EO and the like), wettable powders and granules, may contain surfactants such as wetting and dispersing agents and other compounds that provide adjuvancy effects, e.g.
  • a seed dressing formulation is applied in a manner known per se to the seeds employing the combination of the invention and a diluent in suitable seed dressing formulation form, e.g. as an aqueous suspension or in a dry powder form having good adherence to the seeds.
  • suitable seed dressing formulation form e.g. as an aqueous suspension or in a dry powder form having good adherence to the seeds.
  • seed dressing formulations are known in the art.
  • Seed dressing formulations may contain the single active ingredients or the combination of active ingredients in encapsulated form, e.g.
  • the formulations include from 0.01 to 90% by weight of active ingredients, from 0 to 20% agriculturally acceptable surfactant and 10 to 99.99% solid or liquid formulation inerts and adjuvant(s), the active ingredients consisting of at least the components A and B as defined in the present invention, and optionally other active agents, particularly microbiocides or conservatives or the like.
  • Concentrated forms of compositions generally contain in between about 2 and 80%, preferably between about 5 and 70% by weight of active ingredients.
  • Application forms of formulation may for example contain from 0.01 to 20% by weight, preferably from 0.01 to 5% by weight of active ingredients. Whereas commercial products will preferably be formulated as concentrates, the end user will normally employ diluted formulations.
  • W ettable powders a) b) c) active ingredients [components (A) and (B)] 25 % 50 % 75 % sodium lignosulfonate 5 % 5 % - sodium lauryl sulfate 3 % - 5 % sodium diisobutylnaphthalenesulfonate - 6 % 10 % phenol polyethylene glycol ether - 2 % - (7-8 mol of ethylene oxide) highly dispersed silicic acid 5 % 10 % 10 % K aolin 62 % 27 % -
  • the active ingredient is thoroughly mixed with the adjuvants and the mixture is thoroughly ground in a suitable mill, affording wettable powders that can be diluted with water to give suspensions of the desired concentration.
  • P owders for dry seed treatment a) b) c) active ingredients [components (A) and (B)] 25 % 50 % 75 % light mineral oil 5 % 5 % 5 % highly dispersed silicic acid 5 % 5 % - Kaolin 65 % 40 % - Talcum - - 20 %
  • the active ingredient is thoroughly mixed with the adjuvants and the mixture is thoroughly ground in a suitable mill, affording powders that can be used directly for seed treatment.
  • Emulsifiable concentrate a ctive ingredients [components (A) and (B)] 10 % octylphenol polyethylene glycol ether 3 % (4-5 mol of ethylene oxide) c alcium dodecylbenzenesulfonate 3 % castor oil polyglycol ether (35 mol of ethylene oxide) 4 % Cyclohexanone 30 % xylene mixture 50 % Emulsions of any required dilution, which can be used in plant protection, can be obtained from this concentrate by dilution with water.
  • Dusts a) b) c) active ingredients [components (A) and (B)] 5 % 6 % 4 % talcum 95 % - - Kaolin - 94 % - mineral filler - - 96 % Ready-for-use dusts are obtained by mixing the active ingredient with the carrier and grinding the mixture in a suitable mill. Such powders can also be used for dry dressings for seed. Extruder granules a ctive ingredients [components (A) and (B)] 15 % sodium lignosulfonate 2 % carboxymethylcellulose 1 % Kaolin 82 % The active ingredient is mixed and ground with the adjuvants, and the mixture is moistened with water.
  • the mixture is extruded and then dried in a stream of air.
  • Coated granules a ctive ingredients [components (A) and (B)] 8 % polyethylene glycol (mol. wt.200) 3 % Kaolin 89 %
  • the finely ground active ingredient is uniformly applied, in a mixer, to the kaolin moistened with polyethylene glycol.
  • Non-dusty coated granules are obtained in this manner.
  • Suspension concentrate a ctive ingredients [components (A) and (B)] 40 % propylene glycol 10 % nonylphenol polyethylene glycol ether (15 mol of ethylene oxide) 6 % Sodium lignosulfonate 10 % carboxymethylcellulose 1 % silicone oil (in the form of a 75 % emulsion in water) 1 % Water 32 %
  • the finely ground active ingredient is intimately mixed with the adjuvants, giving a suspension concentrate from which suspensions of any desired dilution can be obtained by dilution with water. Using such dilutions, living plants as well as plant propagation material can be treated and protected against infestation by microorganisms, by spraying, pouring or immersion.
  • Flowable concentrate for seed treatment a ctive ingredients [components (A) and (B)] 40 % propylene glycol 5 % copolymer butanol PO/EO 2 % tristyrenephenole with 10-20 moles EO 2 % 1,2-benzisothiazolin-3-one (in the form of a 20% solution in water) 0.5 % monoazo-pigment calcium salt 5 % Silicone oil (in the form of a 75 % emulsion in water) 0.2 % Water 45.3 %
  • the finely ground active ingredient is intimately mixed with the adjuvants, giving a suspension concentrate from which suspensions of any desired dilution can be obtained by dilution with water.
  • a mixture of 2.8 parts 1,6-diaminohexane in 5.3 parts of water is added.
  • the mixture is agitated until the polymerization reaction is completed.
  • the obtained capsule suspension is stabilized by adding 0.25 parts of a thickener and 3 parts of a dispersing agent.
  • the capsule suspension formulation contains 28% of the active ingredients.
  • the medium capsule diameter is 8-15 microns.
  • the resulting formulation is applied to seeds as an aqueous suspension in an apparatus suitable for that purpose.
  • reaction mixture was heated at 80 °C and stirred for 2 hours under a nitrogen atmosphere.
  • the reaction mixture was then cooled, diluted with water and extracted with dichloromethane.
  • the combined organic layers were concentrated under reduced pressure and the crude residue was purified by flash chromatography over silica gel (ethyl acetate/petroleum ether) to afford the desired target which was further purified by trituration with acetonitrile to afford 5-(4-fluoro-3- methoxy-phenyl)-1-methyl-pyrazole as a colorless oil.
  • reaction mixture was heated at 80 °C and stirred for 2 hours under nitrogen atmosphere.
  • the combined organic layers were concentrated under reduced pressure and the resulting residue was purified by flash chromatography over silica gel (dichloromethane/MeOH) to afford the desired target, which was further purified by trituration with acetonitrile to ultimately afford 3-chloro-6-[5-(4-fluoro-3-methoxy-phenyl)-1-methyl-pyrazol-4- yl]imidazo[1,2-a]pyridine as a white solid.
  • Example 2 preparation of methyl N-[5-[6-[4-(4-fluoro-3-methoxy-phenyl)-5,6-dihydro-1,2,4- oxadiazin-3-yl]imidazo[1,2-a]pyridin-3-yl]-2-pyridyl]carbamate (compound X.06) (Compound X.06) Step 1: Preparation of 2-chloro-N-(-4-fluoro-3-methoxy-phenyl)acetamide To a suspension of 4-fluoro-3-methoxy-aniline (10.0 g, 70.9 mmol) and potassium carbonate (10.8 g, 77.9 mmol, 1.10 eq.) in dimethylformamide (50.0 mL) at 0 °C was added, dropwise, a solution of 2- chloroacetyl chloride (8.80 g, 77.9 mmol, 1.00 eq.) in dimethylformamide (5.00 mL).
  • reaction mixture was stirred at room temperature for 3 hours, then it was diluted with water and extracted with ethyl acetate. The combined organic layers were washed with water and brine, dried over sodium sulfate, filtered, and concentrated under reduced pressure. The crude residue was purified by flash chromatography over silica gel (petroleum ether/ethyl acetate) to afford 2-chloro-N-(4-fluoro-3-methoxy- phenyl)acetamide as a colorless oil.
  • reaction mixture was warmed to room temperature and stirred for an additional 3 hours, after which it was poured into ice water and extracted with ethyl acetate. The combined organic layer was washed with brine, dried over sodium sulfate, filtered, and concentrated under reduced pressure. The crude residue was purified by flash chromatography over silica gel (petroleum ether/ethyl acetate) to afford N-(2-chloroethyl)-4- fluoro-3-methoxy-aniline as a colorless liquid.
  • reaction mixture was concentrated to dryness under reduced pressure and the crude residue was purified by flash chromatography over silica gel (dichloromethane/MeOH) to afford ethyl 3- bromoimidazo[1,2-a]pyridine-6-carboximidate as white solid.
  • Example 3 preparation of methyl N-[5-[6-[2-(4-fluoro-3-methoxy-phenyl)-1,2,4-triazol-3-yl]-8- methyl-imidazo[1,2-a]pyridin-3-yl]-2-pyridyl]carbamate (compound X.07) (Compound X.07) Step 1: Preparation of methyl 8-methylimidazo[1,2-a]pyridine-6-carboxylate To a stirred solution of methyl 8-bromoimidazo[1,2-a]pyridine-6-carboxylate (500 mg, 1.76 mmol) and methylboronic acid (216 mg, 3.53 mmol) in THF was added potassium carbonate (488 mg, 3.53 mmol) and Pd(dppf)Cl2 (129 mg, 0.176 mmol), and the reaction mixture was degassed with argon for 2 min.
  • the reaction mixture was heated at 80 °C and stirred for 16 hours.
  • the reaction mixture was then cooled to room temperature, filtered through a pad of celite, and the filtrate was washed with water, brine, dried over sodium sulfate, filtered and concentrated under reduced pressure.
  • the crude residue was purified by flash chromatography over silica gel (ethyl acetate/hexane) to afford methyl 8- methylimidazo[1,2-a]pyridine-6-carboxylate as an off white solid.
  • Step 2 Preparation of methyl 3-bromo-8-methyl-imidazo[1,2-a]pyridine-6-carboxylate
  • acetonitrile 13 mL
  • N-bromosuccinimide 0.53 g, 2.9 mmol, 1.1 eq.
  • Step 4 Preparation of 3-bromo-8-methyl-imidazo[1,2-a]pyridine-6-carboxamide
  • THF 14 mL
  • dimethylformamide 0.1 mL
  • oxalyl chloride 584 mg, 4.51 mmol, 1.10 eq.
  • the reaction mixture was then cooled to room temperature, and an ammonium hydroxide solution (25% in water), (2.30 g, 16.4 mmol) was added dropwise.
  • Step 5 Preparation of (N)-3-bromo-N-(dimethylaminomethylene)-8-methyl-imidazo[1,2-a]pyridine-6- carboxamide
  • 3-bromo-8-methyl-imidazo[1,2-a]pyridine-6-carboxamide (2.40 g, 8.97 mmol) in N.N-dimethylformamide dimethyl acetal (18.4 mL) was added acetic acid (1.13 g, 17.9 mmol, 2.00 eq.) and the reaction mixture was heated at 95 °C and stirred for 3 hours.
  • Step 7 Preparation of methyl N-[5-[6-[2-(4-fluoro-3-methoxy-phenyl)-1,2,4-triazol-3-yl]-8-methyl- imidazo[1,2-a]pyridin-3-yl]-2-pyridyl]carbamate (Compound X.07)
  • 3-bromo-6-[2-(4-fluoro-3-methoxy-phenyl)-1,2,4-triazol-3-yl]-8-methyl- imidazo[1,2-a]pyridine 400 mg, 0.975 mmol
  • Example 4 preparation of methyl N-[5-[6-[4-(4-fluoro-3-methoxy-phenyl)-5-methyl-1,2,4-triazol-3- yl]imidazo[1,2-a]pyridin-3-yl]-2-pyridyl]carbamate (compound X.08) (Compound X.08) Step 1: Preparation of 3-bromoimidazo[1,2-a]pyridine-6-carbohydrazide To a solution of methyl 3-bromoimidazo[1,2-a]pyridine-6-carboxylate (1.00 g, 3.80 mmol) in methanol (5.43 mL) was added hydrazine hydrate (0.226 mL, 4.56 mmol, 1.20 eq.).
  • Step 2 Preparation of 2-(3-bromoimidazo[1,2-a]pyridin-6-yl)-5-methyl-1,3,4-oxadiazole
  • 3-bromoimidazo[1,2-a]pyridine-6-carbohydrazide 500 mg, 1.96 mmol
  • triethyl orthoacetate 3.67 mL, 19.6 mmol, 10.0 eq.
  • the reaction mixture was heated at 130 °C and stirred for 90 min.
  • the reaction mixture was cooled and 1,8-diazabicyclo[5.4.0]undec-7-ene (0.359 mL, 2.35 mmol, 1.20 eq.) was added.
  • the reaction mixture was heated again at 130 °C and stirred for an additional 20 min.
  • the reaction mixture was then cooled down to room temperature, mixed with saturated aqueous NaHCO3 solution and dichloromethane and stirred for 15 minutes at room temperature.
  • the suspension was filtered through a pad of celite, and the filtrate was extracted with dichloromethane.
  • the combined organic layers were washed with brine, dried over sodium sulfate, filtered, and concentrated under reduced pressure.
  • the crude residue was purified by flash chromatography over silica gel (ethyl acetate/ethanol) to afford 1-(4-fluorophenyl)imidazole as a yellow liquid.
  • the reaction mixture was heated at 100 °C and stirred overnight, then it was cooled to room temperature and stirred in a mixture of saturated aqueous NaHCO3 solution and ethyl acetate for 20 minutes. The mixture was then extracted with ethyl acetate, and the combined organic layers were washed with brine, dried over sodium sulfate, filtered, and concentrated under reduced pressure. The crude residue was purified by flash chromatography over silica gel (cyclohexane/ethyl acetate/ethanol) to afford 3-bromo-6-[1-(4-fluorophenyl)imidazol-2- yl]imidazo[1,2-a]pyridine as a yellow solid.
  • Step 3 Preparation of methyl N-[5-[6-[1-(4-fluorophenyl)imidazol-2-yl]imidazo[1,2-a]pyridin-3-yl]-2- pyridyl]carbamate
  • 3-bromo-6-[1-(4-fluorophenyl) imidazol-2-yl]imidazo[1,2-a]pyridine 80.0 mg, 0.220 mmol
  • 2-methoxycarbonylaminopyridine-5-boronic acid, pinacol ester (92.0 mg, 0.310 mmol.1.40 eq.), cesium carbonate (110 mg, 0.340 mmol, 1.50 eq.), 2-methyltetrahydrofuran (2.90 mL), water (0.970 mL) and tetrakis(triphenylphosphine) palladium(0) (13.0 mg, 0.011 mmol, 0.0500 eq.).
  • the reaction mixture was purged with argon and heated at 100 °C for 30 minutes under microwave irradiation.
  • the solution was cooled to room temperature, water was added, and the solution was extracted with ethyl acetate.
  • the combined organic layers were washed with brine, dried over sodium sulfate, filtered, and concentrated under reduced pressure.
  • the crude residue was purified by flash chromatography over silica gel (dichloromethane/methanol) to afford methyl N-[5-[6-[1-(4- fluorophenyl)imidazol-2-yl]imidazo[1,2-a]pyridin-3-yl]-2-pyridyl]carbamate as a white solid.
  • Step 3 Preparation of methyl N-[5-[6-[2-(4-fluoro-3-methoxy-phenyl)-1,2,4-triazol-3-yl]imidazo[1,2- a]pyridin-3-yl]-2-pyridyl]carbamate (Compound X.11)
  • 3-bromo-6-[2-(4-fluoro-3-methoxy-phenyl)-1,2,4-triazol-3-yl]imidazo[1,2- a]pyridine (Intermediate I-1, 785 mg, 1.92 mmol) and methyl N-[5-(4,4,5,5-tetramethyl-1,3,2- dioxaborolan-2-yl)-2-pyridyl]carbamate (748 mg, 2.69 mmol, 1.40 eq.) were dissolved in 2- methyltetrahydrofuran (11.5 mL) and water (3.84 mL).
  • Example 7 Preparation of methyl N-[5-[6-[4-(4-fluoro-3-methoxy-phenyl)-5-(methoxymethyl)- 1,2,4-triazol-3-yl]-8-methyl-imidazo[1,2-a]pyridin-3-yl]-2-pyridyl]carbamate (Compound X.12) (Compound X.12) Step 1: Preparation of 6-Bromo-8-methylimidazo[1,2-a]pyridine A solution of 2-amino-5-bromo-3-methylpyridine (2.0 g, 10.7 mmol) in ethanol (42.8 mL) was stirred under nitrogen atmosphere.
  • Step 2 Preparation of methyl 8-methylimidazo[1,2-a]pyridine-6-carboxylate To a mixture of 6-bromo-8-methyl-imidazo[1,2-a]pyridine (9.00 g, 42.6 mmol) in methanol (100.0 mL) was added 1,1'-bis(diphenylphosphino)ferrocene-palladium(II)dichloride dichloromethane complex (1.73 g, 2.13 mmol, 0.05 eq.) and N,N-diethylethanamine (12.9 g, 128 mmol, 3.00 eq.).
  • the bomb was then flushed with carbon monoxide, sealed, and pressurized to 2.5 MPa with carbon monoxide.
  • the reaction was stirred at 100 °C for 8 hours.
  • the vessel was then cooled to room temperature and the pressure released.
  • the reaction mixture was concentrated to dryness and purified by silica gel column chromatography (eluting with dichloromethane/MeOH) to obtain the methyl 8-methylimidazo[1,2- a]pyridine-6-carboxylate as a brown solid.
  • Step 3 Preparation of methyl 3-bromo-8-methyl-imidazo[1,2-a]pyridine-6-carboxylate
  • acetonitrile 13 mL
  • N-bromosuccinimide 0.53 g, 2.9 mmol, 1.1 eq.
  • Step 5 Preparation of 2-(3-bromo-8-methyl-imidazo[1,2-a]pyridin-6-yl)-5-(methoxymethyl)-1,3,4- oxadiazole
  • 3-bromo-8-methyl-imidazo[1,2-a]pyridine-6-carbohydrazide (Intermediate I-2, 0.50 g, 2.0 mmol) was added toluene (7 mL) 1,1,1,2-tetramethoxyethane (0.30 g, 0.30 mL, 2.0 mmol) and the reaction mixture was stirred for 1h at 100 °C.
  • the aqueous layer was extracted ethyl acetate and the combined organic layers were washed with brine, dried over sodium sulfate, filtered, and concentrated under reduced pressure.
  • the crude residue was purified over a silica gel cartridge (cyclohexane/ethyl acetate, 3:2) to afford methyl 8-cyclopropylimidazo[1,2-a]pyridine-6-carboxylate as brown solid.
  • the reaction mixture was stirred for overnight at 120 °C.
  • the reaction mixture was cooled down to room temperature and then water was added.
  • the aqueous layer was extracted with ethyl acetate and the combined organic layers were washed with brine, dried over sodium sulfate, filtered, and concentrated under reduced pressure.
  • the crude residue was purified over a silica gel cartridge (eluting cyclohexane/ethyl acetate, 3:7) to afford 2-(8-cyclopropylimidazo[1,2-a]pyridin-6-yl)- 1,3,4-oxadiazole as white solid.
  • the aqueous layer was extracted with ethyl acetate, the combined organic layers were washed with sodium thiosulphate pentahydrate, dried over sodium sulfate, filtered, and concentrated under reduced pressure.
  • the crude was purified by flash chromatography over silical gel (eluting cyclohexane/ethyl acetate, 8:2) to afford ethyl acetate 2-(3-bromo-8-cyclopropyl-imidazo[1,2-a]pyridin-6-yl)-1,3,4-oxadiazole as a yellow solid.
  • reaction mixture was stirred at 80 °C for 16 hours. The reaction mixture was then concentrated under reduced pressure. Saturated aqueous NaHCO3 and dichloromethane were added. The aqueous layer was extracted with dichloromethane, the combined organic phases were dried with sodium sulfate, filtered and concentrated under reduced pressure. The residual was purified by silica gel column chromatography (eluting with ethyl acetate/petroleum ether, 0% to 75%) to afford 6-iodo-8-methyl-imidazo[1,2-a]pyridine as a yellow solid.
  • Example 10 Preparation of methyl N-[5-[6-[4-(4-fluoro-3-methoxy-phenyl)-5,6-dihydro-1,2,4- oxadiazin-3-yl]-8-methyl-imidazo[1,2-a]pyridin-3-yl]-2-pyridyl]carbamate (compound X.03) (Compound X.03) Step 1: Preparation of 8-methylimidazo[1,2-a]pyridine-6-carbonitrile To a solution of 6-iodo-8-methyl-imidazo[1,2-a]pyridine (Intermediate I-4, 17.0 g, 59.3 mmol), zinc cyanide (13.9 g, 119 mmol, 2 eq.) and 1,1'-bis(diphenylphosphino)ferrocene (3.29 g, 5.93 mmol, 0.10 eq.) in dimethylformamide (300 mL) was added Pd2(dba
  • reaction mixture was stirred at 120 °C for 3 hours under nitrogen. After being cooled to room temperature, the reaction mixture was diluted with water and the mixture was filtered through celite. The filtrate was extracted with ethyl acetate, the combined organic layers were washed with water and brine, dried with sodium sulfate, and concentrated under vacuum. The residue was purified by silica gel column chromatography (eluting with dichloromethane/MeOH, 2% to 5%) to provide 8-methylimidazo[1,2-a]pyridine-6-carbonitrile as a brown solid.
  • reaction mixture was stirred at room temperature for 3 hours, then it was diluted with water and extracted with ethyl acetate. The combined organic layers were washed with water and brine, dried over sodium sulfate, filtered, and concentrated under reduced pressure. The crude residue was purified by flash chromatography over silical gel (petroleum ether/ethyl acetate) to afford 2-chloro-N-(4-fluoro-3-methoxy- phenyl)acetamide as a colorless oil.
  • reaction mixture was warmed to room temperature and stirred for an additional 3 hours, after which it was poured into ice water and extracted with ethyl acetate. The combined organic layer was washed with brine, dried over sodium sulfate, filtered, and concentrated under reduced pressure. The crude residue was purified by flash chromatography over silica gel (petroleum ether/ethyl acetate) to afford N-(2-chloroethyl)-4- fluoro-3-methoxy-aniline as a colorless liquid.
  • Example 11 Preparation of methyl N-[5-[6-[4-(4-fluorophenyl)-5,6-dihydro-1,2,4-oxadiazin-3-yl]- 8-methyl-imidazo[1,2-a]pyridin-3-yl]-2-pyridyl]carbamate (Compound X.04) (Compound X.04) Step 1: Preparation of N-(2-chloroethyl)-4-fluoro-aniline To a solution of 4-fluoroaniline (2.00 g, 18.0 mmol) in a mixture of methanol (30 mL) and acetic acid (1.03 mL, 18.0 mmol, 1.00 eq.) at room temperature was added portionwise sodium cyanoborohydride (1.79 g, 27.0 mmol, 1.50 eq.) followed by 2-chloroacetaldehyde (2.59 mL, 21.6 mmol, 1.20 eq.).
  • Step 3 Preparation of O-[2-(4-fluoroanilino)ethyl]hydroxylamine N-[2-(benzhydrylideneamino)oxyethyl]-4-fluoro-aniline (3.80 g, 11.4 mmol) in 6 M HCl (80.0 mL) was refluxed under nitrogen for 12 hours. Saturated aqueous NaHCO3 was added. The aqueous layer was extracted with dichloromethane. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure.
  • Method B Spectra were recorded on a Mass Spectrometer from Waters (Acquity QDa Mass Spectrometer) equipped with an electrospray source (Polarity: Positive and Negative Polarity Switch), Capillary: 0.8 kV, Cone range: 25 V, Extractor: V (No extractor voltage for QDa detector) Source Temperature: 120°C, Desolvation Temperature: 600°C, Cone Gas Flow: 50 L/h, Desolvation Gas Flow: 1000 L/h, Mass range: 110 to 850 Da) and an Acquity UPLC from Waters: Quaternary solvent manager, heated column compartment , diode-array detector.
  • Method C Spectra were recorded on a Mass Spectrometer from Waters Corporation (SQD, SQDII or QDA Single quadrupole mass spectrometer) equipped with an electrospray source (Polarity: positive and negative ions), Capillary: 0.8-3.00 kV, Cone: 5-30 V, Source Temperature: 120-150°C, Desolvation Temperature: 350-600°C, Cone Gas Flow: 50-150 l/h, Desolvation Gas Flow: 650-1000 l/h, Mass range: 110 to 950 Da and an Acquity UPLC from Waters Corporation: Binary pump, heated column compartment, diode- array detector and ELSD.
  • Method E Spectra were recorded on a Mass Spectrometer from Agilent (Single quad mass spectrometer) equipped with a Multimode- Electron Spray and APCI (Polarity: positive and negative ions), Capillary: 4.00 kV, Corona Current 4.0 ⁇ A, Charging Voltage: 2.00 kV, Nitrogen Gas Flow: 12.0 L/min, Nebulizer Pressure: 40 psig, Mass range: 100 to 1000 m/z), dry gas temperature 250 °C, Vaporizer temperature 200 °C and an UPLC from Waters: quaternary pump, heated column compartment, Variable wave length detector.
  • Agilent Single quad mass spectrometer
  • APCI Multimode- Electron Spray and APCI
  • Method F Spectra were recorded on a on a Mass Spectrometer from Agilent (Single quad mass spectrometer) equipped with Electron Spray (Polarity: positive and negative ions), Capillary: 4.00 kV, Charging Voltage: 2.00 kV, Nitrogen Gas Flow: 12.0 L/min, Nebulizer Pressure: 40 psig, Mass range: 100 to 1000 m/z, dry gas temperature 250 °C, Vaporizer temperature 200 °C and an UPLC from Waters: quaternary pump, heated column compartment, Variable wave length detector.
  • the cut leaf disks or segments are placed in multiwell plates (24-well format) onto water agar.
  • the leaf disks are sprayed with a test solution before (preventative) or after (curative) inoculation.
  • Compounds to be tested are prepared as DMSO solutions (max.10 mg/ml) which are diluted to the appropriate concentration with 0.025% Tween20 just before spraying.
  • the inoculated leaf disks or segments are incubated under defined conditions (temperature, relative humidity, light, etc.) according to the respective test system.
  • a single evaluation of disease level is carried out 3 to 14 days after inoculation, depending on the pathosystem. Percent disease control relative to the untreated check leaf disks or segments is then calculated.
  • Example A1 Activity against Phytophthora infestans / tomato / leaf disc preventative (late blight) Tomato leaf disks are placed on water agar in multiwell plates (24-well format) and sprayed with the formulated test compound diluted in water. The leaf disks are inoculated with a spore suspension of the fungus 1 day after application.
  • the inoculated leaf disks are incubated at 16 °C and 75% rh under a light regime of 24 h darkness followed by 12 h light / 12 h darkness in a climate cabinet and the activity of a compound is assessed as percent disease control compared to untreated when an appropriate level of disease damage appears in untreated check leaf disks (5 - 7 days after application).
  • Example A2 Activity against Plasmopara viticola / grape / leaf disc preventative (late blight) Grape vine leaf disks are placed on water agar in multiwell plates (24-well format) and sprayed with the formulated test compound diluted in water.
  • the leaf disks are inoculated with a spore suspension of the fungus 1 day after application.
  • the inoculated leaf disks are incubated at 19 °C and 80% rh under a light regime of 12 h light / 12 h darkness in a climate cabinet and the activity of a compound is assessed as percent disease control compared to untreated when an appropriate level of disease damage appears in untreated check leaf disks (6 - 8 days after application).
  • Example A3 Activity against Pythium ultimum / liquid culture (seedling damping off) Mycelia fragments and oospores of a newly grown liquid culture of the fungus are directly mixed into nutrient broth (PDB potato dextrose broth).
  • test compound After placing a (DMSO) solution of test compound into a microtiter plate (96-well format), the nutrient broth containing the fungal mycelia/spore mixture is added. The test plates are incubated at 24 °C and the inhibition of growth is determined photometrically 2-3 days after application.
  • the following compounds (from Table T1) gave at least 80% control of Pythium ultimum at 20 ppm when compared to untreated control under the same conditions, which showed extensive disease development: X.01, X.02, X.03, X.04, X.05, X.06, X.07, X.08, X.09, X.10, X.11 and X.12.
  • Streptomyces chrestomyceticus CBS149411 (used as Component B) are as follows: - Fermentation of Streptomyces sp.: Streptomyces sp. Saigon413, isolated in Vietnam before 1961, was deposited at the Westerdijk institute under accession number CBS149411. The deposit was made by Syngenta Ltd., Jealott’s Hill Research International Centre, Bracknell, Berkshire, RG426EY, UK under the terms of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure.
  • the Streptomyces was cultivated in Erlenmeyer flasks with a liquid medium consisting of (g / l) casein hydrolysate 10, glucose 40, K2HPO41.25, soytone 2, tryptone, 8 and incubated at 28oC in an incubator shaking 150 rpm with 25 mm throw for 4 days.
  • a liquid medium consisting of (g / l) casein hydrolysate 10, glucose 40, K2HPO41.25, soytone 2, tryptone, 8 and incubated at 28oC in an incubator shaking 150 rpm with 25 mm throw for 4 days.
  • Large scale fermentations For large scale production, standard procedures were applied for cultivating Streptomyces chrestomyceticus CBS149411 to high cell density using fed-batch fermentation. After harvesting, the broth was spray dried or freeze dried according to methods known to a person skilled in the art. The final product (TGAI) after spray- or freeze drying had a cell count of 1*105 to 1*1013 CFU
  • TGAI technical grade active ingredient (unformulated product).
  • Example B1 Activity against Pythium ultimum (Damping off) Mycelial fragments of the pathogen, prepared from a fresh liquid culture, were directly mixed into nutrient broth (PDB potato dextrose broth). After placing a (DMSO) solution of the test compounds into a microtiter plate (96-well format) the nutrient broth containing the fungal spores was added. The test plates were incubated at 24 C and the inhibition of growth was determined photometrically after 48 hrs. The following mixture compositions (A:B) at the reported concentration (in ppm) gave at least 80% disease control in this test. Component A Conc.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Environmental Sciences (AREA)
  • Plant Pathology (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pest Control & Pesticides (AREA)
  • Agronomy & Crop Science (AREA)
  • Dentistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

The current invention relates to a fungicidal composition comprising components (A) and (B), wherein components (A) and (B) are as defined in claim 1, and use of the compositions in agriculture or horticulture for controlling or preventing infestation of plants by phytopathogenic microorganisms, 5 preferably fungi.

Description

FUNGICIDAL COMPOSITIONS The present invention relates to novel fungicidal compositions, to their use in agriculture or horticulture for controlling diseases caused by phytopathogens, especially phytopathogenic fungi and more particularly oomycetes, and to methods of controlling diseases on useful plants. Whilst many fungicidal compounds and compositions, belonging to various different chemical classes, have been/are being developed for use as fungicides in crops of useful plants, crop tolerance and activity against particular phytopathogenic fungi do not always satisfy the needs of agricultural practice in many respects. Therefore, there is a continuing need to find new compounds and compositions having superior biological properties for use in controlling or preventing infestation of plants by phytopathogenic fungi. For example, compounds possessing a greater biological activity, an advantageous spectrum of activity, an increased safety profile, improved physico-chemical properties, or increased biodegradability. Or else, compositions possessing a broader spectrum of activity, improved crop tolerance, synergistic interactions or potentiating properties, or compositions which display a more rapid onset of action or which have longer lasting residual activity or which enable a reduction in the number of applications and/or a reduction in the application rate of the compounds and compositions required for effective control of a phytopathogen, thereby enabling beneficial resistance-management practices, reduced environmental impact and reduced operator exposure. The use of compositions comprising mixtures of different fungicidal compounds possessing different modes of action can address some of these needs (eg, by combining fungicides with differing spectrums of activity). According to the present invention, there is provided a fungicidal composition comprising components (A) and (B) as active ingredients, wherein component (A) is a compound of formula (I): wherein A1 is a carbon atom; A2 is a carbon atom or a nitrogen atom; ring W is selected from ring W being unsubstituted or substituted with one substituent selected from R1, R1 being selected from C1-6alkyl and C1-6alkoxy-C1-6alkyl, and preferably R1 being CH3 or -CH2OCH3; R2a is H; R2b is selected from H, CN, C1-6alkyl, C3-6cycloalkyl, C1-6alkoxy-C1-6alkyl, amino, and -NHC(O)C1-6alkyl; R2c is H; A31 is CR31; R31 is selected from H, C1-6alkyl, C1-6alkoxy, and halogen; A32 is N or CR32; R32 is halogen or CN; A is CH or N; and R4 is selected from C1-6alkyl, C1-6alkoxy, C3-6cycloalkyl, C1-6alkylamino, C1-6alkoxyamino, and C1-6alkylC1- 6alkoxyamino; or a salt or N-oxide thereof; and component (B) is a compound selected from the group consisting of acetamiprid, acibenzolar-S-methyl, ametoctradin, amisulbrom, azoxystrobin, Bacillus amyloliquefaciens, benzovindiflupyr, broflanilid, chlorothalonil, chlothianidin, chlorantraniliprole, Cis-Jasmone, cyantraniliprole, cyazofamid, cyclobutrifluram, cymoxanil, difenoconazole, disodium phosphonate, ethaboxam, fenpicoxamid, florylpicoxamid, fluazinam, fludioxonil, fluindapyr, fluopicolide, fluopyram, fluoxapiprolin, fluoxytioconazole, fluxametamide, fluxapyroxad, folpet, imidaclprid, inpyrfluxam, ipconazole, ipflufenoquin, isocycloseram, isoflucypram, isotianil, mandipropamid, mefentrifulconazole, metalaxyl, metalaxyl-M (mefenoxam), metyltetraprole, oxathiapiprolin, penflufen, phosphite (phosphonate), picarbutrazox, prothioconazole, pydiflumetofen, pyraclostrobin, quinofumerin, sedaxane, silthiofam, Streptomyces chrestomyceticus, tebuconazole, tetraniliprole, thiabendazole, thiamethoxam, tolprocarb, triticonazole, zoxamide, N-[(1R)-1-benzyl-3-chloro-1-methyl-but-3-enyl]-8-fluoro-quinoline-3- carboxamide, N-[(1S)-1-benzyl-3-chloro-1-methyl-but-3-enyl]-8-fluoro-quinoline-3-carboxamide, N- [(1R)-1-benzyl-3,3,3-trifluoro-1-methyl-propyl]-8-fluoro-quinoline-3-carboxamide, N-[(1S)-1-benzyl- 3,3,3-trifluoro-1-methyl-propyl]-8-fluoro-quinoline-3-carboxamide, N-[(1R)-1-benzyl-1,3-dimethyl-butyl]- 7,8-difluoro-quinoline-3-carboxamide, N-[(1S)-1-benzyl-1,3-dimethyl-butyl]-7,8-difluoro-quinoline-3- carboxamide, 8-fluoro-N-[(1R)-1-[(3-fluorophenyl)methyl]-1,3-dimethyl-butyl]quinoline-3-carboxamide, 8-fluoro-N-[(1S)-1-[(3-fluorophenyl)methyl]-1,3-dimethyl-butyl]quinoline-3-carboxamide, N-[(1R)-1- benzyl-1,3-dimethyl-butyl]-8-fluoro-quinoline-3-carboxamide, N-[(1S)-1-benzyl-1,3-dimethyl-butyl]-8- fluoro-quinoline-3-carboxamide, N-((1R)-1-benzyl-3-chloro-1-methyl-but-3-enyl)-8-fluoro-quinoline-3- carboxamide, and N-((1S)-1-benzyl-3-chloro-1-methyl-but-3-enyl)-8-fluoro-quinoline-3-carboxamide. In a preferred embodiment, ring W is selected from wherein R1 is selected from C1-6alkyl and C1-6alkoxy-C1-6alkyl, and preferably R1 is CH3 or -CH2OCH3. In the present invention, N-[(1R)-1-benzyl-3-chloro-1-methyl-but-3-enyl]-8-fluoro-quinoline-3- carboxamide, N-[(1S)-1-benzyl-3-chloro-1-methyl-but-3-enyl]-8-fluoro-quinoline-3-carboxamide, N- [(1R)-1-benzyl-3,3,3-trifluoro-1-methyl-propyl]-8-fluoro-quinoline-3-carboxamide, N-[(1S)-1-benzyl- 3,3,3-trifluoro-1-methyl-propyl]-8-fluoro-quinoline-3-carboxamide, N-[(1R)-1-benzyl-1,3-dimethyl-butyl]- 7,8-difluoro-quinoline-3-carboxamide, N-[(1S)-1-benzyl-1,3-dimethyl-butyl]-7,8-difluoro-quinoline-3- carboxamide, 8-fluoro-N-[(1R)-1-[(3-fluorophenyl)methyl]-1,3-dimethyl-butyl]quinoline-3-carboxamide, 8-fluoro-N-[(1S)-1-[(3-fluorophenyl)methyl]-1,3-dimethyl-butyl]quinoline-3-carboxamide, N-[(1R)-1- benzyl-1,3-dimethyl-butyl]-8-fluoro-quinoline-3-carboxamide, N-[(1S)-1-benzyl-1,3-dimethyl-butyl]-8- fluoro-quinoline-3-carboxamide, N-((1R)-1-benzyl-3-chloro-1-methyl-but-3-enyl)-8-fluoro-quinoline-3- carboxamide, and N-((1S)-1-benzyl-3-chloro-1-methyl-but-3-enyl)-8-fluoro-quinoline-3-carboxamide may be prepared from the methods described in WO2017/153380. In the present invention, among the components selected from N-[(1R)-1-benzyl-3-chloro-1-methyl-but- 3-enyl]-8-fluoro-quinoline-3-carboxamide, N-[(1S)-1-benzyl-3-chloro-1-methyl-but-3-enyl]-8-fluoro- quinoline-3-carboxamide, N-[(1R)-1-benzyl-3,3,3-trifluoro-1-methyl-propyl]-8-fluoro-quinoline-3- carboxamide, N-[(1S)-1-benzyl-3,3,3-trifluoro-1-methyl-propyl]-8-fluoro-quinoline-3-carboxamide, N- [(1R)-1-benzyl-1,3-dimethyl-butyl]-7,8-difluoro-quinoline-3-carboxamide, N-[(1S)-1-benzyl-1,3- dimethyl-butyl]-7,8-difluoro-quinoline-3-carboxamide, 8-fluoro-N-[(1R)-1-[(3-fluorophenyl)methyl]-1,3- dimethyl-butyl]quinoline-3-carboxamide, 8-fluoro-N-[(1S)-1-[(3-fluorophenyl)methyl]-1,3-dimethyl- butyl]quinoline-3-carboxamide, N-[(1R)-1-benzyl-1,3-dimethyl-butyl]-8-fluoro-quinoline-3-carboxamide, N-[(1S)-1-benzyl-1,3-dimethyl-butyl]-8-fluoro-quinoline-3-carboxamide, N-((1R)-1-benzyl-3-chloro-1- methyl-but-3-enyl)-8-fluoro-quinoline-3-carboxamide, and N-((1S)-1-benzyl-3-chloro-1-methyl-but-3- enyl)-8-fluoro-quinoline-3-carboxamide, the preferred compound (Compound Z) is the one having the following CAS number: 2132414-04-9 (feneptamidoquin). Compound Z is more particularly N-[(1RS)-1- benzyl-1,3-dimethyl-butyl]-8-fluoro-quinoline-3-carboxamide containing 80-100% of the R-enantiomer. In the present invention, Streptomyces chrestomyceticus comprises a nucleotide sequence which has at least 99.8 %, preferably at least 99.9%,, preferably at least 99.91%, 99.92%, 99.93%, 99.94%, 99.95%, 99.96%, 99.97%, 99.98%, or 99.99% identity to SEQ ID NO: 1. In a particular embodiment, the Streptomyces chrestomyceticus comprises a nucleotide sequence which has 100% identity to SEQ ID NO:1. SEQ ID NO: 1 comprises the 16S RNA gene of Streptomyces chrestomyceticus Saigon413 deposited on September 9, 2022, with the Westerdijk Fungal Biodiversity Institute (CBS), Uppsalalaan 8, NL-3584 CT Utrecht, Nederland, under accession number CBS149411. Throughout this document the expression “composition” stands for the various mixtures or combinations of components (A) and (B) (including the above-defined embodiments), for example in a single “ready- mix” form, in a combined spray mixture composed from separate formulations of the single active ingredient components, such as a “tank-mix”, and in a combined use of the single active ingredients when applied in a sequential manner, i.e. one after the other with a reasonably short period, such as a few hours or days. The order of applying the components (A) and (B) is not essential for working the present invention The term "halogen" refers to fluorine (fluoro or F), chlorine (chloro or Cl), bromine (bromo or Br) or iodine (iodo or I), and preferably fluoro or chloro. The term “amino” refers to a -NH2 group. The term "Alkyl" as used herein- in isolation or as part of a chemical group – represents straight-chain or branched hydrocarbons, preferably with 1 to 6 carbon atoms, for example methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, s-butyl, t-butyl, pentyl, 1- methylbutyl, 2-methylbutyl, 3-methylbutyl, 1,2- dimethylpropyl, 1,1 -dimethylpropyl, 2,2- dimethylpropyl, 1 -ethylpropyl, hexyl, 1 -methylpentyl, 2- methylpentyl, 3-methylpentyl, 4- methylpentyl, 1,2-dimethylpropyl, 1,3-dimethylbutyl, 1,4-dimethylbutyl, 2,3-dimethylbutyl, 1,1- dimethylbutyl, 2,2-dimethylbutyl, 3,3-dimethylbutyl, 1,1,2-trimethylpropyl, 1,2,2- trimethylpropyl, 1- ethylbutyl and 2-ethylbutyl. Alkyl groups with 1 to 4 carbon atoms are preferred, for example methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, s-butyl or t-butyl. The term "cycloalkyl" - in isolation or as part of a chemical group - represents saturated or partially unsaturated mono-, bi- or tricyclic hydrocarbons, preferably with 3 to 10 carbon atoms, for example cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, bicyclo[2.2.1]heptyl, bicyclo[2.2.2]octyl or adamantyl. Cycloalkyls with 3, 4, 5, 6 or 7 carbon atoms are preferred, for example cyclopropyl or cyclobutyl. The term “alkoxy" refers to a radical of the formula -ORa wherein Ra is an alkyl radical as generally defined above. Examples of alkoxy include, but are not limited to methoxy, ethoxy, propoxy, iso-propoxy, and tert-butoxy. The term “alkoxyalkyl” refers to an alkyl radical (as mentioned above) substituted with said alkoxy group. Examples are methoxymethyl, methoxyethyl, ethoxymethyl and propoxymethyl. The term “alkylamino” refers to a radical of the formula RaNH- wherein Ra is an alkyl radical as generally defined above. The term “alkoxyamino” refers to a radical of the formula RaNH-, wherein Ra is an alkoxy radical as generally defined above. In the present invention, the weight ratio of component (A) to component (B) may preferably be from 100:1 to 1:100, from 50:1 to 1:50, from 20:1 to 1:40, from 15:1 to 1:30, from 12:1 to 1:25, from 10:1 to 1:20, from 5:1 and 1:15, from 3:1 to 1:10 or from 2:1 to 1:5. Further according to the invention, there is provided a method of controlling or preventing phytopathogenic diseases, especially phytopathogenic fungi, on useful plants or on propagation material thereof, which comprises applying to the useful plants, the locus thereof or propagation material thereof a fungicidal composition according to the invention. The benefits provided by certain fungicidal mixture compositions according to the invention may also include, inter alia, advantageous levels of biological activity for protecting plants against diseases that are caused by fungi or superior properties for use as agrochemical active ingredients (for example, greater biological activity, an advantageous spectrum of activity, an increased safety profile, improved physico-chemical properties, or increased biodegradability). In each case, the compounds of formula (I) according to the invention are in free form, in oxidized form as a N-oxide or in salt form, e.g. an agronomically usable salt form. N-oxides are oxidized forms of tertiary amines or oxidized forms of nitrogen containing heteroaromatic compounds. They are described for instance in the book “Heterocyclic N-oxides” by A. Albini and S. Pietra, CRC Press, Boca Raton 1991. Preferred groups and values for the substituents A, R2a, R2b, R2c, R31, R32, and R4 in the compounds of formula (I) are, in any combination thereof, as set out below: A is N; R2a is H; R2b is selected from H, C1-6alkyl, C3-6cycloalkyl, C1-6alkoxy-C1-6alkyl, amino, and -NHC(O)C1-6alkyl, and preferably selected from H, CH3, cyclopropyl, -CH2OCH3, NH2, and -NHC(O)CH3; R2c is H; R31 is selected from H, C1-6alkyl, C1-6alkoxy-, and halogen, and preferably selected from H, CH3, -OCH3, and fluoro; R32 is selected from halogen and CN, and preferably selected from chloro, fluoro, and CN; and R4 is selected from C1-6alkyl, C3-6cycloalkyl, and C1-6alkoxy, and preferably selected from CH3, cyclopropyl, and -OCH3; or a salt or N-oxide thereof. Most preferably, component (A) is a compound selected from compound no. X.01, X.02, X.03, X.04, X.05, X.06, X.07, X.08, X.09, X.10, X.11 and X.12, as defined in the Table X below. More preferably, component (A) is a compound selected from compound no. X.03, X.07, and X.11, as defined in the Table X below. Table X Compound name Molecule X.01 methyl N-[5-[8-cyclopropyl-6-[4-(4- fluoro-3-methoxy-phenyl)-1,2,4- triazol-3-yl]imidazo[1,2-a]pyridin-3- yl]-2-pyridyl]carbamate Compound name Molecule X.02 methyl N-[5-[6-[1-(4-fluoro-3- methoxy-phenyl)imidazol-2-yl]-8- methyl-imidazo[1,2-a]pyridin-3-yl]-2- pyridyl]carbamate X.03 methyl N-[5-[6-[4-(4-fluoro-3- methoxy-phenyl)-5,6-dihydro-1,2,4- oxadiazin-3-yl]-8-methyl-imidazo[1,2- a]pyridin-3-yl]-2-pyridyl]carbamate X.04 methyl N-[5-[6-[4-(4-fluorophenyl)- 5,6-dihydro-1,2,4-oxadiazin-3-yl]-8- methyl-imidazo[1,2-a]pyridin-3-yl]-2- pyridyl]carbamate X.05 methyl N-[5-[6-[5-(4-fluoro-3- methoxy-phenyl)-1-methyl-pyrazol-4- yl]imidazo[1,2-a]pyridin-3-yl]-2- pyridyl]carbamate X.06 methyl N-[5-[6-[4-(4-fluoro-3- methoxy-phenyl)-5,6-dihydro-1,2,4- oxadiazin-3-yl]imidazo[1,2-a]pyridin- 3-yl]-2-pyridyl]carbamate X.07 methyl N-[5-[6-[2-(4-fluoro-3- methoxy-phenyl)-1,2,4-triazol-3-yl]-8- methyl-imidazo[1,2-a]pyridin-3-yl]-2- pyridyl]carbamate X.08 methyl N-[5-[6-[4-(4-fluoro-3- methoxy-phenyl)-5-methyl-1,2,4- triazol-3-yl]imidazo[1,2-a]pyridin-3- yl]-2-pyridyl]carbamate X.09 methyl N-[5-[6-[1-(4-fluoro-3- methoxy-phenyl)imidazol-2- yl]imidazo[1,2-a]pyridin-3-yl]-2- pyridyl]carbamate X.10 methyl N-[5-[6-[2-(4-chloro-3- methoxy-phenyl)-1,2,4-triazol-3- yl]imidazo[1,2-a]pyridin-3-yl]-2- pyridyl]carbamate Compound name Molecule X.11 methyl N-[5-[6-[2-(4-fluoro-3- methoxy-phenyl)-1,2,4-triazol-3- yl]imidazo[1,2-a]pyridin-3-yl]-2- pyridyl]carbamate X.12 methyl N-[5-[6-[4-(4-fluoro-3- methoxy-phenyl)-5-(methoxymethyl)- 1,2,4-triazol-3-yl]-8-methyl- imidazo[1,2-a]pyridin-3-yl]-2- pyridyl]carbamate Preferably, component (B) is a compound selected from the group consisting of acibenzolar-S-methyl, ametoctradin, amisulbrom, azoxystrobin, chlorothalonil, cyazofamid, cyclobutrifluram, cymoxanil, difenoconazole, disodium phosphonate, florylpicoxamid, fluazinam, fludioxonil, fluopicolide, fluoxapiprolin, folpet, mandipropamid, mefentrifluconazole, metalaxyl-M, oxathiapiprolin, picarbutrazox, pydiflumetofen, sedaxane, Streptomyces chrestomyceticus, zoxamide, N-[(1R)-1-benzyl-1,3-dimethyl- butyl]-8-fluoro-quinoline-3-carboxamide, and N-[(1S)-1-benzyl-1,3-dimethyl-butyl]-8-fluoro-quinoline-3- carboxamide. More preferably, component (B) is a compound selected from the group consisting of azoxystrobin, cyclobutrifluram, cymoxanil, difenoconazole, disodium phosphonate, florylpicoxamid, fluazinam, fludioxonil, fluopicolide, fluoxapiprolin, folpet, mandipropamid, mefentrifluconazole, metalaxyl-M, oxathiapiprolin, picarbutrazox, pydiflumetofen, sedaxane, Streptomyces chrestomyceticus, zoxamide, and Compound Z (feneptamidoquin). The component (B) compounds are referred to herein and above by a so-called "ISO common name" or another "common name" being used in individual cases or a trademark name. The component (B) compounds are known and are commercially available and/or can be prepared using procedures known in the art and/or procedures reported in the literature. In a preferred composition according to the invention, component (A) is compound no. X.01 (methyl N- [5-[8-cyclopropyl-6-[4-(4-fluoro-3-methoxy-phenyl)-1,2,4-triazol-3-yl]imidazo[1,2-a]pyridin-3-yl]-2- pyridyl]carbamate) or a salt, or N-oxide thereof, and component (B) is a compound selected from the group consisting of acetamiprid, acibenzolar-S-methyl, ametoctradin, amisulbrom, azoxystrobin, Bacillus amyloliquefaciens, benzovindiflupyr, broflanilid, chlorothalonil, chlothianidin, chlorantraniliprole, Cis-Jasmone, cyantraniliprole, cyazofamid, cyclobutrifluram, cymoxanil, difenoconazole, disodium phosphonate, ethaboxam, fenpicoxamid, florylpicoxamid, fluazinam, fludioxonil, fluindapyr, fluopicolide, fluopyram, fluoxapiprolin, fluoxytioconazole, fluxametamide, fluxapyroxad, folpet, imidaclprid, inpyrfluxam, ipconazole, ipflufenoquin, isocycloseram, isoflucypram, isotianil, mandipropamid, mefentrifulconazole, metalaxyl, metalaxyl-M (mefenoxam), metyltetraprole, oxathiapiprolin, penflufen, phosphite (phosphonate), picarbutrazox, prothioconazole, pydiflumetofen, pyraclostrobin, quinofumerin, sedaxane, silthiofam, Streptomyces chrestomyceticus, tebuconazole, tetraniliprole, thiabendazole, thiamethoxam, tolprocarb, triticonazole, zoxamide, N-[(1R)-1-benzyl-3-chloro-1-methyl-but-3-enyl]-8- fluoro-quinoline-3-carboxamide, N-[(1S)-1-benzyl-3-chloro-1-methyl-but-3-enyl]-8-fluoro-quinoline-3- carboxamide, N-[(1R)-1-benzyl-3,3,3-trifluoro-1-methyl-propyl]-8-fluoro-quinoline-3-carboxamide, N- [(1S)-1-benzyl-3,3,3-trifluoro-1-methyl-propyl]-8-fluoro-quinoline-3-carboxamide, N-[(1R)-1-benzyl-1,3- dimethyl-butyl]-7,8-difluoro-quinoline-3-carboxamide, N-[(1S)-1-benzyl-1,3-dimethyl-butyl]-7,8-difluoro- quinoline-3-carboxamide, 8-fluoro-N-[(1R)-1-[(3-fluorophenyl)methyl]-1,3-dimethyl-butyl]quinoline-3- carboxamide, 8-fluoro-N-[(1S)-1-[(3-fluorophenyl)methyl]-1,3-dimethyl-butyl]quinoline-3-carboxamide, N-[(1R)-1-benzyl-1,3-dimethyl-butyl]-8-fluoro-quinoline-3-carboxamide, N-[(1S)-1-benzyl-1,3-dimethyl- butyl]-8-fluoro-quinoline-3-carboxamide, N-((1R)-1-benzyl-3-chloro-1-methyl-but-3-enyl)-8-fluoro- quinoline-3-carboxamide, and N-((1S)-1-benzyl-3-chloro-1-methyl-but-3-enyl)-8-fluoro-quinoline-3- carboxamide, wherein the weight ratio of component (A) to component (B) is from 15:1 to 1:30. In another preferred composition according to the invention, component (A) is compound no. X.02 (methyl N-[5-[6-[1-(4-fluoro-3-methoxy-phenyl)imidazol-2-yl]-8-methyl-imidazo[1,2-a]pyridin-3-yl]-2- pyridyl]carbamate) or a salt, or N-oxide thereof, and component (B) is a compound selected from the group consisting of acetamiprid, acibenzolar-S-methyl, ametoctradin, amisulbrom, azoxystrobin, Bacillus amyloliquefaciens, benzovindiflupyr, broflanilid, chlorothalonil, chlothianidin, chlorantraniliprole, Cis-Jasmone, cyantraniliprole, cyazofamid, cyclobutrifluram, cymoxanil, difenoconazole, disodium phosphonate, ethaboxam, fenpicoxamid, florylpicoxamid, fluazinam, fludioxonil, fluindapyr, fluopicolide, fluopyram, fluoxapiprolin, fluoxytioconazole, fluxametamide, fluxapyroxad, folpet, imidaclprid, inpyrfluxam, ipconazole, ipflufenoquin, isocycloseram, isoflucypram, isotianil, mandipropamid, mefentrifulconazole, metalaxyl, metalaxyl-M (mefenoxam), metyltetraprole, oxathiapiprolin, penflufen, phosphite (phosphonate), picarbutrazox, prothioconazole, pydiflumetofen, pyraclostrobin, quinofumerin, sedaxane, silthiofam, Streptomyces chrestomyceticus, tebuconazole, tetraniliprole, thiabendazole, thiamethoxam, tolprocarb, triticonazole, zoxamide, N-[(1R)-1-benzyl-3-chloro-1-methyl-but-3-enyl]-8- fluoro-quinoline-3-carboxamide, N-[(1S)-1-benzyl-3-chloro-1-methyl-but-3-enyl]-8-fluoro-quinoline-3- carboxamide, N-[(1R)-1-benzyl-3,3,3-trifluoro-1-methyl-propyl]-8-fluoro-quinoline-3-carboxamide, N- [(1S)-1-benzyl-3,3,3-trifluoro-1-methyl-propyl]-8-fluoro-quinoline-3-carboxamide, N-[(1R)-1-benzyl-1,3- dimethyl-butyl]-7,8-difluoro-quinoline-3-carboxamide, N-[(1S)-1-benzyl-1,3-dimethyl-butyl]-7,8-difluoro- quinoline-3-carboxamide, 8-fluoro-N-[(1R)-1-[(3-fluorophenyl)methyl]-1,3-dimethyl-butyl]quinoline-3- carboxamide, 8-fluoro-N-[(1S)-1-[(3-fluorophenyl)methyl]-1,3-dimethyl-butyl]quinoline-3-carboxamide, N-[(1R)-1-benzyl-1,3-dimethyl-butyl]-8-fluoro-quinoline-3-carboxamide, N-[(1S)-1-benzyl-1,3-dimethyl- butyl]-8-fluoro-quinoline-3-carboxamide, N-((1R)-1-benzyl-3-chloro-1-methyl-but-3-enyl)-8-fluoro- quinoline-3-carboxamide, and N-((1S)-1-benzyl-3-chloro-1-methyl-but-3-enyl)-8-fluoro-quinoline-3- carboxamide, wherein the weight ratio of component (A) to component (B) is from 15:1 to 1:30. In another preferred composition according to the invention, component (A) is compound no. X.03 (methyl N-[5-[6-[4-(4-fluoro-3-methoxy-phenyl)-5,6-dihydro-1,2,4-oxadiazin-3-yl]-8-methyl-imidazo[1,2- a]pyridin-3-yl]-2-pyridyl]carbamate) or a salt, or N-oxide thereof, and component (B) is a compound selected from the group consisting of acetamiprid, acibenzolar-S-methyl, ametoctradin, amisulbrom, azoxystrobin, Bacillus amyloliquefaciens, benzovindiflupyr, broflanilid, chlorothalonil, chlothianidin, chlorantraniliprole, Cis-Jasmone, cyantraniliprole, cyazofamid, cyclobutrifluram, cymoxanil, difenoconazole, disodium phosphonate, ethaboxam, fenpicoxamid, florylpicoxamid, fluazinam, fludioxonil, fluindapyr, fluopicolide, fluopyram, fluoxapiprolin, fluoxytioconazole, fluxametamide, fluxapyroxad, folpet, imidaclprid, inpyrfluxam, ipconazole, ipflufenoquin, isocycloseram, isoflucypram, isotianil, mandipropamid, mefentrifulconazole, metalaxyl, metalaxyl-M (mefenoxam), metyltetraprole, oxathiapiprolin, penflufen, phosphite (phosphonate), picarbutrazox, prothioconazole, pydiflumetofen, pyraclostrobin, quinofumerin, sedaxane, silthiofam, Streptomyces chrestomyceticus, tebuconazole, tetraniliprole, thiabendazole, thiamethoxam, tolprocarb, triticonazole, zoxamide, N-[(1R)-1-benzyl-3- chloro-1-methyl-but-3-enyl]-8-fluoro-quinoline-3-carboxamide, N-[(1S)-1-benzyl-3-chloro-1-methyl-but- 3-enyl]-8-fluoro-quinoline-3-carboxamide, N-[(1R)-1-benzyl-3,3,3-trifluoro-1-methyl-propyl]-8-fluoro- quinoline-3-carboxamide, N-[(1S)-1-benzyl-3,3,3-trifluoro-1-methyl-propyl]-8-fluoro-quinoline-3- carboxamide, N-[(1R)-1-benzyl-1,3-dimethyl-butyl]-7,8-difluoro-quinoline-3-carboxamide, N-[(1S)-1- benzyl-1,3-dimethyl-butyl]-7,8-difluoro-quinoline-3-carboxamide, 8-fluoro-N-[(1R)-1-[(3- fluorophenyl)methyl]-1,3-dimethyl-butyl]quinoline-3-carboxamide, 8-fluoro-N-[(1S)-1-[(3- fluorophenyl)methyl]-1,3-dimethyl-butyl]quinoline-3-carboxamide, N-[(1R)-1-benzyl-1,3-dimethyl-butyl]- 8-fluoro-quinoline-3-carboxamide, N-[(1S)-1-benzyl-1,3-dimethyl-butyl]-8-fluoro-quinoline-3- carboxamide, N-((1R)-1-benzyl-3-chloro-1-methyl-but-3-enyl)-8-fluoro-quinoline-3-carboxamide, and N- ((1S)-1-benzyl-3-chloro-1-methyl-but-3-enyl)-8-fluoro-quinoline-3-carboxamide, wherein the weight ratio of component (A) to component (B) is from 15:1 to 1:30. In another preferred composition according to the invention, component (A) is compound no. X.04 (methyl N-[5-[6-[4-(4-fluorophenyl)-5,6-dihydro-1,2,4-oxadiazin-3-yl]-8-methyl-imidazo[1,2-a]pyridin-3- yl]-2-pyridyl]carbamate) or a salt, or N-oxide thereof, and component (B) is a compound selected from the group consisting of acetamiprid, acibenzolar-S-methyl, ametoctradin, amisulbrom, azoxystrobin, Bacillus amyloliquefaciens, benzovindiflupyr, broflanilid, chlorothalonil, chlothianidin, chlorantraniliprole, Cis-Jasmone, cyantraniliprole, cyazofamid, cyclobutrifluram, cymoxanil, difenoconazole, disodium phosphonate, ethaboxam, fenpicoxamid, florylpicoxamid, fluazinam, fludioxonil, fluindapyr, fluopicolide, fluopyram, fluoxapiprolin, fluoxytioconazole, fluxametamide, fluxapyroxad, folpet, imidaclprid, inpyrfluxam, ipconazole, ipflufenoquin, isocycloseram, isoflucypram, isotianil, mandipropamid, mefentrifulconazole, metalaxyl, metalaxyl-M (mefenoxam), metyltetraprole, oxathiapiprolin, penflufen, phosphite (phosphonate), picarbutrazox, prothioconazole, pydiflumetofen, pyraclostrobin, quinofumerin, sedaxane, silthiofam, Streptomyces chrestomyceticus, tebuconazole, tetraniliprole, thiabendazole, thiamethoxam, tolprocarb, triticonazole, zoxamide, N-[(1R)-1-benzyl-3-chloro-1-methyl-but-3-enyl]-8- fluoro-quinoline-3-carboxamide, N-[(1S)-1-benzyl-3-chloro-1-methyl-but-3-enyl]-8-fluoro-quinoline-3- carboxamide, N-[(1R)-1-benzyl-3,3,3-trifluoro-1-methyl-propyl]-8-fluoro-quinoline-3-carboxamide, N- [(1S)-1-benzyl-3,3,3-trifluoro-1-methyl-propyl]-8-fluoro-quinoline-3-carboxamide, N-[(1R)-1-benzyl-1,3- dimethyl-butyl]-7,8-difluoro-quinoline-3-carboxamide, N-[(1S)-1-benzyl-1,3-dimethyl-butyl]-7,8-difluoro- quinoline-3-carboxamide, 8-fluoro-N-[(1R)-1-[(3-fluorophenyl)methyl]-1,3-dimethyl-butyl]quinoline-3- carboxamide, 8-fluoro-N-[(1S)-1-[(3-fluorophenyl)methyl]-1,3-dimethyl-butyl]quinoline-3-carboxamide, N-[(1R)-1-benzyl-1,3-dimethyl-butyl]-8-fluoro-quinoline-3-carboxamide, N-[(1S)-1-benzyl-1,3-dimethyl- butyl]-8-fluoro-quinoline-3-carboxamide, N-((1R)-1-benzyl-3-chloro-1-methyl-but-3-enyl)-8-fluoro- quinoline-3-carboxamide, and N-((1S)-1-benzyl-3-chloro-1-methyl-but-3-enyl)-8-fluoro-quinoline-3- carboxamide, wherein the weight ratio of component (A) to component (B) is from 15:1 to 1:30. In another preferred composition according to the invention, component (A) is compound no. X.05 (methyl N-[5-[6-[5-(4-fluoro-3-methoxy-phenyl)-1-methyl-pyrazol-4-yl]imidazo[1,2-a]pyridin-3-yl]-2- pyridyl]carbamate) or a salt, or N-oxide thereof, and component (B) is a compound selected from the group consisting of acetamiprid, acibenzolar-S-methyl, ametoctradin, amisulbrom, azoxystrobin, Bacillus amyloliquefaciens, benzovindiflupyr, broflanilid, chlorothalonil, chlothianidin, chlorantraniliprole, Cis-Jasmone, cyantraniliprole, cyazofamid,cyazofamid, cyclobutrifluram, cymoxanil, difenoconazole, disodium phosphonate, ethaboxam, fenpicoxamid, florylpicoxamid, fluazinam, fludioxonil, fluindapyr, fluopicolide, fluopyram, fluoxapiprolin, fluoxytioconazole, fluxametamide, fluxapyroxad, folpet, imidaclprid, inpyrfluxam, ipconazole, ipflufenoquin, isocycloseram, isoflucypram, isotianil, mandipropamid, mefentrifulconazole, metalaxyl, metalaxyl-M (mefenoxam), metyltetraprole, oxathiapiprolin, penflufen, phosphite (phosphonate), picarbutrazox, prothioconazole, pydiflumetofen, pyraclostrobin, quinofumerin, sedaxane, silthiofam, Streptomyces chrestomyceticus, tebuconazole, tetraniliprole, thiabendazole, thiamethoxam, tolprocarb, triticonazole, zoxamide, N-[(1R)-1-benzyl-3- chloro-1-methyl-but-3-enyl]-8-fluoro-quinoline-3-carboxamide, N-[(1S)-1-benzyl-3-chloro-1-methyl-but- 3-enyl]-8-fluoro-quinoline-3-carboxamide, N-[(1R)-1-benzyl-3,3,3-trifluoro-1-methyl-propyl]-8-fluoro- quinoline-3-carboxamide, N-[(1S)-1-benzyl-3,3,3-trifluoro-1-methyl-propyl]-8-fluoro-quinoline-3- carboxamide, N-[(1R)-1-benzyl-1,3-dimethyl-butyl]-7,8-difluoro-quinoline-3-carboxamide, N-[(1S)-1- benzyl-1,3-dimethyl-butyl]-7,8-difluoro-quinoline-3-carboxamide, 8-fluoro-N-[(1R)-1-[(3- fluorophenyl)methyl]-1,3-dimethyl-butyl]quinoline-3-carboxamide, 8-fluoro-N-[(1S)-1-[(3- fluorophenyl)methyl]-1,3-dimethyl-butyl]quinoline-3-carboxamide, N-[(1R)-1-benzyl-1,3-dimethyl-butyl]- 8-fluoro-quinoline-3-carboxamide, N-[(1S)-1-benzyl-1,3-dimethyl-butyl]-8-fluoro-quinoline-3- carboxamide, N-((1R)-1-benzyl-3-chloro-1-methyl-but-3-enyl)-8-fluoro-quinoline-3-carboxamide, and N- ((1S)-1-benzyl-3-chloro-1-methyl-but-3-enyl)-8-fluoro-quinoline-3-carboxamide, wherein the weight ratio of component (A) to component (B) is from 15:1 to 1:30. In another preferred composition according to the invention, component (A) is compound no. X.06 (methyl N-[5-[6-[4-(4-fluoro-3-methoxy-phenyl)-5,6-dihydro-1,2,4-oxadiazin-3-yl]imidazo[1,2-a]pyridin- 3-yl]-2-pyridyl]carbamate) or a salt, or N-oxide thereof, and component (B) is a compound selected from the group consisting of acetamiprid, acibenzolar-S-methyl, ametoctradin, amisulbrom, azoxystrobin, Bacillus amyloliquefaciens, benzovindiflupyr, broflanilid, chlorothalonil, chlothianidin, chlorantraniliprole, Cis-Jasmone, cyantraniliprole, cyazofamid, cyclobutrifluram, cymoxanil, difenoconazole, disodium phosphonate, ethaboxam, fenpicoxamid, florylpicoxamid, fluazinam, fludioxonil, fluindapyr, fluopicolide, fluopyram, fluoxapiprolin, fluoxytioconazole, fluxametamide, fluxapyroxad, folpet, imidaclprid, inpyrfluxam, ipconazole, ipflufenoquin, isocycloseram, isoflucypram, isotianil, mandipropamid, mefentrifulconazole, metalaxyl, metalaxyl-M (mefenoxam), metyltetraprole, oxathiapiprolin, penflufen, phosphite (phosphonate), picarbutrazox, prothioconazole, pydiflumetofen, pyraclostrobin, quinofumerin, sedaxane, silthiofam, Streptomyces chrestomyceticus, tebuconazole, tetraniliprole, thiabendazole, thiamethoxam, tolprocarb, triticonazole, zoxamide, N-[(1R)-1-benzyl-3-chloro-1-methyl-but-3-enyl]-8- fluoro-quinoline-3-carboxamide, N-[(1S)-1-benzyl-3-chloro-1-methyl-but-3-enyl]-8-fluoro-quinoline-3- carboxamide, N-[(1R)-1-benzyl-3,3,3-trifluoro-1-methyl-propyl]-8-fluoro-quinoline-3-carboxamide, N- [(1S)-1-benzyl-3,3,3-trifluoro-1-methyl-propyl]-8-fluoro-quinoline-3-carboxamide, N-[(1R)-1-benzyl-1,3- dimethyl-butyl]-7,8-difluoro-quinoline-3-carboxamide, N-[(1S)-1-benzyl-1,3-dimethyl-butyl]-7,8-difluoro- quinoline-3-carboxamide, 8-fluoro-N-[(1R)-1-[(3-fluorophenyl)methyl]-1,3-dimethyl-butyl]quinoline-3- carboxamide, 8-fluoro-N-[(1S)-1-[(3-fluorophenyl)methyl]-1,3-dimethyl-butyl]quinoline-3-carboxamide, N-[(1R)-1-benzyl-1,3-dimethyl-butyl]-8-fluoro-quinoline-3-carboxamide, N-[(1S)-1-benzyl-1,3-dimethyl- butyl]-8-fluoro-quinoline-3-carboxamide, N-((1R)-1-benzyl-3-chloro-1-methyl-but-3-enyl)-8-fluoro- quinoline-3-carboxamide, and N-((1S)-1-benzyl-3-chloro-1-methyl-but-3-enyl)-8-fluoro-quinoline-3- carboxamide, wherein the weight ratio of component (A) to component (B) is from 15:1 to 1:30. In another preferred composition according to the invention, component (A) is compound no. X.07 (methyl N-[5-[6-[2-(4-fluoro-3-methoxy-phenyl)-1,2,4-triazol-3-yl]-8-methyl-imidazo[1,2-a]pyridin-3-yl]-2- pyridyl]carbamate) or a salt, or N-oxide thereof, and component (B) is a compound selected from the group consisting of acetamiprid, acibenzolar-S-methyl, ametoctradin, amisulbrom, azoxystrobin, Bacillus amyloliquefaciens, benzovindiflupyr, broflanilid, chlorothalonil, chlothianidin, chlorantraniliprole, Cis-Jasmone, cyantraniliprole, cyazofamid, cyclobutrifluram, cymoxanil, difenoconazole, disodium phosphonate, ethaboxam, fenpicoxamid, florylpicoxamid, fluazinam, fludioxonil, fluindapyr, fluopicolide, fluopyram, fluoxapiprolin, fluoxytioconazole, fluxametamide, fluxapyroxad, folpet, imidaclprid, inpyrfluxam, ipconazole, ipflufenoquin, isocycloseram, isoflucypram, isotianil, mandipropamid, mefentrifulconazole, metalaxyl, metalaxyl-M (mefenoxam), metyltetraprole, oxathiapiprolin, penflufen, phosphite (phosphonate), picarbutrazox, prothioconazole, pydiflumetofen, pyraclostrobin, quinofumerin, sedaxane, silthiofam, Streptomyces chrestomyceticus, tebuconazole, tetraniliprole, thiabendazole, thiamethoxam, tolprocarb, triticonazole, zoxamide, N-[(1R)-1-benzyl-3-chloro-1-methyl-but-3-enyl]-8- fluoro-quinoline-3-carboxamide, N-[(1S)-1-benzyl-3-chloro-1-methyl-but-3-enyl]-8-fluoro-quinoline-3- carboxamide, N-[(1R)-1-benzyl-3,3,3-trifluoro-1-methyl-propyl]-8-fluoro-quinoline-3-carboxamide, N- [(1S)-1-benzyl-3,3,3-trifluoro-1-methyl-propyl]-8-fluoro-quinoline-3-carboxamide, N-[(1R)-1-benzyl-1,3- dimethyl-butyl]-7,8-difluoro-quinoline-3-carboxamide, N-[(1S)-1-benzyl-1,3-dimethyl-butyl]-7,8-difluoro- quinoline-3-carboxamide, 8-fluoro-N-[(1R)-1-[(3-fluorophenyl)methyl]-1,3-dimethyl-butyl]quinoline-3- carboxamide, 8-fluoro-N-[(1S)-1-[(3-fluorophenyl)methyl]-1,3-dimethyl-butyl]quinoline-3-carboxamide, N-[(1R)-1-benzyl-1,3-dimethyl-butyl]-8-fluoro-quinoline-3-carboxamide, N-[(1S)-1-benzyl-1,3-dimethyl- butyl]-8-fluoro-quinoline-3-carboxamide, N-((1R)-1-benzyl-3-chloro-1-methyl-but-3-enyl)-8-fluoro- quinoline-3-carboxamide, and N-((1S)-1-benzyl-3-chloro-1-methyl-but-3-enyl)-8-fluoro-quinoline-3- carboxamide, wherein the weight ratio of component (A) to component (B) is from 15:1 to 1:30. In another preferred composition according to the invention, component (A) is compound no. X.08 (methyl N-[5-[6-[4-(4-fluoro-3-methoxy-phenyl)-5-methyl-1,2,4-triazol-3-yl]imidazo[1,2-a]pyridin-3-yl]-2- pyridyl]carbamate) or a salt, or N-oxide thereof, and component (B) is a compound selected from the group consisting of acetamiprid, acibenzolar-S-methyl, ametoctradin, amisulbrom, azoxystrobin, Bacillus amyloliquefaciens, benzovindiflupyr, broflanilid, chlorothalonil, chlothianidin, chlorantraniliprole, Cis-Jasmone, cyantraniliprole, cyazofamid, cyclobutrifluram, cymoxanil, difenoconazole, disodium phosphonate, ethaboxam, fenpicoxamid, florylpicoxamid, fluazinam, fludioxonil, fluindapyr, fluopicolide, fluopyram, fluoxapiprolin, fluoxytioconazole, fluxametamide, fluxapyroxad, folpet, imidaclprid, inpyrfluxam, ipconazole, ipflufenoquin, isocycloseram, isoflucypram, isotianil, mandipropamid, mefentrifulconazole, metalaxyl, metalaxyl-M (mefenoxam), metyltetraprole, oxathiapiprolin, penflufen, phosphite (phosphonate), picarbutrazox, prothioconazole, pydiflumetofen, pyraclostrobin, quinofumerin, sedaxane, silthiofam, Streptomyces chrestomyceticus, tebuconazole, tetraniliprole, thiabendazole, thiamethoxam, tolprocarb, triticonazole, zoxamide, N-[(1R)-1-benzyl-3-chloro-1-methyl-but-3-enyl]-8- fluoro-quinoline-3-carboxamide, N-[(1S)-1-benzyl-3-chloro-1-methyl-but-3-enyl]-8-fluoro-quinoline-3- carboxamide, N-[(1R)-1-benzyl-3,3,3-trifluoro-1-methyl-propyl]-8-fluoro-quinoline-3-carboxamide, N- [(1S)-1-benzyl-3,3,3-trifluoro-1-methyl-propyl]-8-fluoro-quinoline-3-carboxamide, N-[(1R)-1-benzyl-1,3- dimethyl-butyl]-7,8-difluoro-quinoline-3-carboxamide, N-[(1S)-1-benzyl-1,3-dimethyl-butyl]-7,8-difluoro- quinoline-3-carboxamide, 8-fluoro-N-[(1R)-1-[(3-fluorophenyl)methyl]-1,3-dimethyl-butyl]quinoline-3- carboxamide, 8-fluoro-N-[(1S)-1-[(3-fluorophenyl)methyl]-1,3-dimethyl-butyl]quinoline-3-carboxamide, N-[(1R)-1-benzyl-1,3-dimethyl-butyl]-8-fluoro-quinoline-3-carboxamide, N-[(1S)-1-benzyl-1,3-dimethyl- butyl]-8-fluoro-quinoline-3-carboxamide, N-((1R)-1-benzyl-3-chloro-1-methyl-but-3-enyl)-8-fluoro- quinoline-3-carboxamide, and N-((1S)-1-benzyl-3-chloro-1-methyl-but-3-enyl)-8-fluoro-quinoline-3- carboxamide, wherein the weight ratio of component (A) to component (B) is from 15:1 to 1:30. In another preferred composition according to the invention, component (A) is compound no. X.09 (methyl N-[5-[6-[1-(4-fluoro-3-methoxy-phenyl)imidazol-2-yl]imidazo[1,2-a]pyridin-3-yl]-2- pyridyl]carbamate) or a salt, or N-oxide thereof, and component (B) is a compound selected from the group consisting of acetamiprid, acibenzolar-S-methyl, ametoctradin, amisulbrom, azoxystrobin, Bacillus amyloliquefaciens, benzovindiflupyr, broflanilid, chlorothalonil, chlothianidin, chlorantraniliprole, Cis-Jasmone, cyantraniliprole, cyazofamid, cyclobutrifluram, cymoxanil, difenoconazole, disodium phosphonate, ethaboxam, fenpicoxamid, florylpicoxamid, fluazinam, fludioxonil, fluindapyr, fluopicolide, fluopyram, fluoxapiprolin, fluoxytioconazole, fluxametamide, fluxapyroxad, folpet, imidaclprid, inpyrfluxam, ipconazole, ipflufenoquin, isocycloseram, isoflucypram, isotianil, mandipropamid, mefentrifulconazole, metalaxyl, metalaxyl-M (mefenoxam), metyltetraprole, oxathiapiprolin, penflufen, phosphite (phosphonate), picarbutrazox, prothioconazole, pydiflumetofen, pyraclostrobin, quinofumerin, sedaxane, silthiofam, Streptomyces chrestomyceticus, tebuconazole, tetraniliprole, thiabendazole, thiamethoxam, tolprocarb, triticonazole, zoxamide, N-[(1R)-1-benzyl-3-chloro-1-methyl-but-3-enyl]-8- fluoro-quinoline-3-carboxamide, N-[(1S)-1-benzyl-3-chloro-1-methyl-but-3-enyl]-8-fluoro-quinoline-3- carboxamide, N-[(1R)-1-benzyl-3,3,3-trifluoro-1-methyl-propyl]-8-fluoro-quinoline-3-carboxamide, N- [(1S)-1-benzyl-3,3,3-trifluoro-1-methyl-propyl]-8-fluoro-quinoline-3-carboxamide, N-[(1R)-1-benzyl-1,3- dimethyl-butyl]-7,8-difluoro-quinoline-3-carboxamide, N-[(1S)-1-benzyl-1,3-dimethyl-butyl]-7,8-difluoro- quinoline-3-carboxamide, 8-fluoro-N-[(1R)-1-[(3-fluorophenyl)methyl]-1,3-dimethyl-butyl]quinoline-3- carboxamide, 8-fluoro-N-[(1S)-1-[(3-fluorophenyl)methyl]-1,3-dimethyl-butyl]quinoline-3-carboxamide, N-[(1R)-1-benzyl-1,3-dimethyl-butyl]-8-fluoro-quinoline-3-carboxamide, N-[(1S)-1-benzyl-1,3-dimethyl- butyl]-8-fluoro-quinoline-3-carboxamide, N-((1R)-1-benzyl-3-chloro-1-methyl-but-3-enyl)-8-fluoro- quinoline-3-carboxamide, and N-((1S)-1-benzyl-3-chloro-1-methyl-but-3-enyl)-8-fluoro-quinoline-3- carboxamide, wherein the weight ratio of component (A) to component (B) is from 15:1 to 1:30. In another preferred composition according to the invention, component (A) is compound no. X.10 (methyl N-[5-[6-[2-(4-chloro-3-methoxy-phenyl)-1,2,4-triazol-3-yl]imidazo[1,2-a]pyridin-3-yl]-2- pyridyl]carbamate) or a salt, or N-oxide thereof, and component (B) is a compound selected from the group consisting of acetamiprid, acibenzolar-S-methyl, ametoctradin, amisulbrom, azoxystrobin, Bacillus amyloliquefaciens, benzovindiflupyr, broflanilid, chlorothalonil, chlothianidin, chlorantraniliprole, Cis-Jasmone, cyantraniliprole, cyazofamid, cyclobutrifluram, cymoxanil, difenoconazole, disodium phosphonate, ethaboxam, fenpicoxamid, florylpicoxamid, fluazinam, fludioxonil, fluindapyr, fluopicolide, fluopyram, fluoxapiprolin, fluoxytioconazole, fluxametamide, fluxapyroxad, folpet, imidaclprid, inpyrfluxam, ipconazole, ipflufenoquin, isocycloseram, isoflucypram, isotianil, mandipropamid, mefentrifulconazole, metalaxyl, metalaxyl-M (mefenoxam), metyltetraprole, oxathiapiprolin, penflufen, phosphite (phosphonate), picarbutrazox, prothioconazole, pydiflumetofen, pyraclostrobin, quinofumerin, sedaxane, silthiofam, Streptomyces chrestomyceticus, tebuconazole, tetraniliprole, thiabendazole, thiamethoxam, tolprocarb, triticonazole, zoxamide, N-[(1R)-1-benzyl-3-chloro-1-methyl-but-3-enyl]-8- fluoro-quinoline-3-carboxamide, N-[(1S)-1-benzyl-3-chloro-1-methyl-but-3-enyl]-8-fluoro-quinoline-3- carboxamide, N-[(1R)-1-benzyl-3,3,3-trifluoro-1-methyl-propyl]-8-fluoro-quinoline-3-carboxamide, N- [(1S)-1-benzyl-3,3,3-trifluoro-1-methyl-propyl]-8-fluoro-quinoline-3-carboxamide, N-[(1R)-1-benzyl-1,3- dimethyl-butyl]-7,8-difluoro-quinoline-3-carboxamide, N-[(1S)-1-benzyl-1,3-dimethyl-butyl]-7,8-difluoro- quinoline-3-carboxamide, 8-fluoro-N-[(1R)-1-[(3-fluorophenyl)methyl]-1,3-dimethyl-butyl]quinoline-3- carboxamide, 8-fluoro-N-[(1S)-1-[(3-fluorophenyl)methyl]-1,3-dimethyl-butyl]quinoline-3-carboxamide, N-[(1R)-1-benzyl-1,3-dimethyl-butyl]-8-fluoro-quinoline-3-carboxamide, N-[(1S)-1-benzyl-1,3-dimethyl- butyl]-8-fluoro-quinoline-3-carboxamide, N-((1R)-1-benzyl-3-chloro-1-methyl-but-3-enyl)-8-fluoro- quinoline-3-carboxamide, and N-((1S)-1-benzyl-3-chloro-1-methyl-but-3-enyl)-8-fluoro-quinoline-3- carboxamide, wherein the weight ratio of component (A) to component (B) is from 15:1 to 1:30. In another preferred composition according to the invention, component (A) is compound no. X.11 (methyl N-[5-[6-[2-(4-fluoro-3-methoxy-phenyl)-1,2,4-triazol-3-yl]imidazo[1,2-a]pyridin-3-yl]-2- pyridyl]carbamate) or a salt, or N-oxide thereof, and component (B) is a compound selected from the group consisting of acetamiprid, acibenzolar-S-methyl, ametoctradin, amisulbrom, azoxystrobin, Bacillus amyloliquefaciens, benzovindiflupyr, broflanilid, chlorothalonil, chlothianidin, chlorantraniliprole, Cis-Jasmone, cyantraniliprole, cyazofamid, cyclobutrifluram, cymoxanil, difenoconazole, disodium phosphonate, ethaboxam, fenpicoxamid, florylpicoxamid, fluazinam, fludioxonil, fluindapyr, fluopicolide, fluopyram, fluoxapiprolin, fluoxytioconazole, fluxametamide, fluxapyroxad, folpet, imidaclprid, inpyrfluxam, ipconazole, ipflufenoquin, isocycloseram, isoflucypram, isotianil, mandipropamid, mefentrifulconazole, metalaxyl, metalaxyl-M (mefenoxam), metyltetraprole, oxathiapiprolin, penflufen, phosphite (phosphonate), picarbutrazox, prothioconazole, pydiflumetofen, pyraclostrobin, quinofumerin, sedaxane, silthiofam, Streptomyces chrestomyceticus, tebuconazole, tetraniliprole, thiabendazole, thiamethoxam, tolprocarb, triticonazole, zoxamide, N-[(1R)-1-benzyl-3-chloro-1-methyl-but-3-enyl]-8- fluoro-quinoline-3-carboxamide, N-[(1S)-1-benzyl-3-chloro-1-methyl-but-3-enyl]-8-fluoro-quinoline-3- carboxamide, N-[(1R)-1-benzyl-3,3,3-trifluoro-1-methyl-propyl]-8-fluoro-quinoline-3-carboxamide, N- [(1S)-1-benzyl-3,3,3-trifluoro-1-methyl-propyl]-8-fluoro-quinoline-3-carboxamide, N-[(1R)-1-benzyl-1,3- dimethyl-butyl]-7,8-difluoro-quinoline-3-carboxamide, N-[(1S)-1-benzyl-1,3-dimethyl-butyl]-7,8-difluoro- quinoline-3-carboxamide, 8-fluoro-N-[(1R)-1-[(3-fluorophenyl)methyl]-1,3-dimethyl-butyl]quinoline-3- carboxamide, 8-fluoro-N-[(1S)-1-[(3-fluorophenyl)methyl]-1,3-dimethyl-butyl]quinoline-3-carboxamide, N-[(1R)-1-benzyl-1,3-dimethyl-butyl]-8-fluoro-quinoline-3-carboxamide, N-[(1S)-1-benzyl-1,3-dimethyl- butyl]-8-fluoro-quinoline-3-carboxamide, N-((1R)-1-benzyl-3-chloro-1-methyl-but-3-enyl)-8-fluoro- quinoline-3-carboxamide, and N-((1S)-1-benzyl-3-chloro-1-methyl-but-3-enyl)-8-fluoro-quinoline-3- carboxamide, wherein the weight ratio of component (A) to component (B) is from 15:1 to 1:30. In another preferred composition according to the invention, component (A) is compound no. X.12 (methyl N-[5-[6-[4-(4-fluoro-3-methoxy-phenyl)-5-(methoxymethyl)-1,2,4-triazol-3-yl]-8-methyl- imidazo[1,2-a]pyridin-3-yl]-2-pyridyl]carbamate) or a salt, or N-oxide thereof, and component (B) is a compound selected from the group consisting of acetamiprid, acibenzolar-S-methyl, ametoctradin, amisulbrom, azoxystrobin, Bacillus amyloliquefaciens, benzovindiflupyr, broflanilid, chlorothalonil, chlothianidin, chlorantraniliprole, Cis-Jasmone, cyantraniliprole, cyazofamid, cyclobutrifluram, cymoxanil, difenoconazole, disodium phosphonate, ethaboxam, fenpicoxamid, florylpicoxamid, fluazinam, fludioxonil, fluindapyr, fluopicolide, fluopyram, fluoxapiprolin, fluoxytioconazole, fluxametamide, fluxapyroxad, folpet, imidaclprid, inpyrfluxam, ipconazole, ipflufenoquin, isocycloseram, isoflucypram, isotianil, mandipropamid, mefentrifulconazole, metalaxyl, metalaxyl-M (mefenoxam), metyltetraprole, oxathiapiprolin, penflufen, phosphite (phosphonate), picarbutrazox, prothioconazole, pydiflumetofen, pyraclostrobin, quinofumerin, sedaxane, silthiofam, Streptomyces chrestomyceticus, tebuconazole, tetraniliprole, thiabendazole, thiamethoxam, tolprocarb, triticonazole, zoxamide, N-[(1R)- 1-benzyl-3-chloro-1-methyl-but-3-enyl]-8-fluoro-quinoline-3-carboxamide, N-[(1S)-1-benzyl-3-chloro-1- methyl-but-3-enyl]-8-fluoro-quinoline-3-carboxamide, N-[(1R)-1-benzyl-3,3,3-trifluoro-1-methyl-propyl]- 8-fluoro-quinoline-3-carboxamide, N-[(1S)-1-benzyl-3,3,3-trifluoro-1-methyl-propyl]-8-fluoro-quinoline- 3-carboxamide, N-[(1R)-1-benzyl-1,3-dimethyl-butyl]-7,8-difluoro-quinoline-3-carboxamide, N-[(1S)-1- benzyl-1,3-dimethyl-butyl]-7,8-difluoro-quinoline-3-carboxamide, 8-fluoro-N-[(1R)-1-[(3- fluorophenyl)methyl]-1,3-dimethyl-butyl]quinoline-3-carboxamide, 8-fluoro-N-[(1S)-1-[(3- fluorophenyl)methyl]-1,3-dimethyl-butyl]quinoline-3-carboxamide, N-[(1R)-1-benzyl-1,3-dimethyl-butyl]- 8-fluoro-quinoline-3-carboxamide, N-[(1S)-1-benzyl-1,3-dimethyl-butyl]-8-fluoro-quinoline-3- carboxamide, N-((1R)-1-benzyl-3-chloro-1-methyl-but-3-enyl)-8-fluoro-quinoline-3-carboxamide, and N- ((1S)-1-benzyl-3-chloro-1-methyl-but-3-enyl)-8-fluoro-quinoline-3-carboxamide, wherein the weight ratio of component (A) to component (B) is from 15:1 to 1:30. In a more preferred composition according to the invention, component (A) is compound no. X.01 (methyl N-[5-[8-cyclopropyl-6-[4-(4-fluoro-3-methoxy-phenyl)-1,2,4-triazol-3-yl]imidazo[1,2-a]pyridin-3- yl]-2-pyridyl]carbamate) or a salt, or N-oxide thereof, and component (B) is a compound selected from the group consisting of acibenzolar-S-methyl, ametoctradin, amisulbrom, azoxystrobin, chlorothalonil, cyazofamid, cyclobutrifluram, cymoxanil, difenoconazole, disodium phosphonate, florylpicoxamid, fluazinam, fludioxonil, fluopicolide, fluoxapiprolin, folpet, mandipropamid, mefentrifluconazole, metalaxyl-M, oxathiapiprolin, picarbutrazox, pydiflumetofen, sedaxane, Streptomyces chrestomyceticus, zoxamide, and Compound Z (feneptamidoquin),wherein the weight ratio of component (A) to component (B) is from 15:1 to 1:30. In another more preferred composition according to the invention, component (A) is compound no. X.02 (methyl N-[5-[6-[1-(4-fluoro-3-methoxy-phenyl)imidazol-2-yl]-8-methyl-imidazo[1,2-a]pyridin-3-yl]-2- pyridyl]carbamate) or a salt, or N-oxide thereof, and component (B) is a compound selected from the group consisting of acibenzolar-S-methyl, ametoctradin, amisulbrom, azoxystrobin, chlorothalonil, cyazofamid, cyclobutrifluram, cymoxanil, difenoconazole, disodium phosphonate, florylpicoxamid, fluazinam, fludioxonil, fluopicolide, fluoxapiprolin, folpet, mandipropamid, mefentrifluconazole, metalaxyl-M, oxathiapiprolin, picarbutrazox, pydiflumetofen, sedaxane, Streptomyces chrestomyceticus, zoxamide, and Compound Z (feneptamidoquin),wherein the weight ratio of component (A) to component (B) is from 15:1 to 1:30. In another more preferred composition according to the invention, component (A) is compound no. X.03 (methyl N-[5-[6-[4-(4-fluoro-3-methoxy-phenyl)-5,6-dihydro-1,2,4-oxadiazin-3-yl]-8-methyl-imidazo[1,2- a]pyridin-3-yl]-2-pyridyl]carbamate) or a salt, or N-oxide thereof, and component (B) is a compound selected from the group consisting of acibenzolar-S-methyl, ametoctradin, amisulbrom, azoxystrobin, chlorothalonil, cyazofamid, cyclobutrifluram, cymoxanil, difenoconazole, disodium phosphonate, florylpicoxamid, fluazinam, fludioxonil, fluopicolide, fluoxapiprolin, folpet, mandipropamid, mefentrifluconazole, metalaxyl-M, oxathiapiprolin, picarbutrazox, pydiflumetofen, sedaxane, Streptomyces chrestomyceticus, zoxamide, and Compound Z (feneptamidoquin),wherein the weight ratio of component (A) to component (B) is from 15:1 to 1:30. In another more preferred composition according to the invention, component (A) is compound no. X.04 (methyl N-[5-[6-[4-(4-fluorophenyl)-5,6-dihydro-1,2,4-oxadiazin-3-yl]-8-methyl-imidazo[1,2-a]pyridin-3- yl]-2-pyridyl]carbamate) or a salt, or N-oxide thereof, and component (B) is a compound selected from the group consisting of acibenzolar-S-methyl, ametoctradin, amisulbrom, azoxystrobin, chlorothalonil, cyazofamid, cyclobutrifluram, cymoxanil, difenoconazole, disodium phosphonate, florylpicoxamid, fluazinam, fludioxonil, fluopicolide, fluoxapiprolin, folpet, mandipropamid, mefentrifluconazole, metalaxyl-M, oxathiapiprolin, picarbutrazox, pydiflumetofen, sedaxane, Streptomyces chrestomyceticus, zoxamide, and Compound Z (feneptamidoquin),wherein the weight ratio of component (A) to component (B) is from 15:1 to 1:30. In another more preferred composition according to the invention, component (A) is compound no. X.05 (methyl N-[5-[6-[5-(4-fluoro-3-methoxy-phenyl)-1-methyl-pyrazol-4-yl]imidazo[1,2-a]pyridin-3-yl]-2- pyridyl]carbamate) or a salt, or N-oxide thereof, and component (B) is a compound selected from the group consisting of acibenzolar-S-methyl, ametoctradin, amisulbrom, azoxystrobin, chlorothalonil, cyazofamid, cyclobutrifluram, cymoxanil, difenoconazole, disodium phosphonate, florylpicoxamid, fluazinam, fludioxonil, fluopicolide, fluoxapiprolin, folpet, mandipropamid, mefentrifluconazole, metalaxyl-M, oxathiapiprolin, picarbutrazox, pydiflumetofen, sedaxane, Streptomyces chrestomyceticus, zoxamide, and Compound Z (feneptamidoquin),wherein the weight ratio of component (A) to component (B) is from 15:1 to 1:30. In another more preferred composition according to the invention, component (A) is compound no. X.06 (methyl N-[5-[6-[4-(4-fluoro-3-methoxy-phenyl)-5,6-dihydro-1,2,4-oxadiazin-3-yl]imidazo[1,2-a]pyridin- 3-yl]-2-pyridyl]carbamate) or a salt, or N-oxide thereof, and component (B) is a compound selected from the group consisting of acibenzolar-S-methyl, ametoctradin, amisulbrom, azoxystrobin, chlorothalonil, cyazofamid, cyclobutrifluram, cymoxanil, difenoconazole, disodium phosphonate, florylpicoxamid, fluazinam, fludioxonil, fluopicolide, fluoxapiprolin, folpet, mandipropamid, mefentrifluconazole, metalaxyl-M, oxathiapiprolin, picarbutrazox, pydiflumetofen, sedaxane, Streptomyces chrestomyceticus, zoxamide, and Compound Z (feneptamidoquin),wherein the weight ratio of component (A) to component (B) is from 15:1 to 1:30. In another more preferred composition according to the invention, component (A) is compound no. X.07 (methyl N-[5-[6-[2-(4-fluoro-3-methoxy-phenyl)-1,2,4-triazol-3-yl]-8-methyl-imidazo[1,2-a]pyridin-3-yl]-2- pyridyl]carbamate) or a salt, or N-oxide thereof, and component (B) is a compound selected from the group consisting of acibenzolar-S-methyl, ametoctradin, amisulbrom, azoxystrobin, chlorothalonil, cyazofamid, cyclobutrifluram, cymoxanil, difenoconazole, disodium phosphonate, florylpicoxamid, fluazinam, fludioxonil, fluopicolide, fluoxapiprolin, folpet, mandipropamid, mefentrifluconazole, metalaxyl-M, oxathiapiprolin, picarbutrazox, pydiflumetofen, sedaxane, Streptomyces chrestomyceticus, zoxamide, and Compound Z (feneptamidoquin),wherein the weight ratio of component (A) to component (B) is from 15:1 to 1:30. In another more preferred composition according to the invention, component (A) is compound no. X.08 (methyl N-[5-[6-[4-(4-fluoro-3-methoxy-phenyl)-5-methyl-1,2,4-triazol-3-yl]imidazo[1,2-a]pyridin-3-yl]-2- pyridyl]carbamate) or a salt, or N-oxide thereof, and component (B) is a compound selected from the group consisting of acibenzolar-S-methyl, ametoctradin, amisulbrom, azoxystrobin, chlorothalonil, cyazofamid, cyclobutrifluram, cymoxanil, difenoconazole, disodium phosphonate, florylpicoxamid, fluazinam, fludioxonil, fluopicolide, fluoxapiprolin, folpet, mandipropamid, mefentrifluconazole, metalaxyl-M, oxathiapiprolin, picarbutrazox, pydiflumetofen, sedaxane, Streptomyces chrestomyceticus, zoxamide, and Compound Z (feneptamidoquin),wherein the weight ratio of component (A) to component (B) is from 15:1 to 1:30. In another more preferred composition according to the invention, component (A) is compound no. X.09 (methyl N-[5-[6-[1-(4-fluoro-3-methoxy-phenyl)imidazol-2-yl]imidazo[1,2-a]pyridin-3-yl]-2- pyridyl]carbamate) or a salt, or N-oxide thereof, and component (B) is a compound selected from the group consisting of acibenzolar-S-methyl, ametoctradin, amisulbrom, azoxystrobin, chlorothalonil, cyazofamid, cyclobutrifluram, cymoxanil, difenoconazole, disodium phosphonate, florylpicoxamid, fluazinam, fludioxonil, fluopicolide, fluoxapiprolin, folpet, mandipropamid, mefentrifluconazole, metalaxyl-M, oxathiapiprolin, picarbutrazox, pydiflumetofen, sedaxane, Streptomyces chrestomyceticus, zoxamide, and Compound Z (feneptamidoquin),wherein the weight ratio of component (A) to component (B) is from 15:1 to 1:30. In another more preferred composition according to the invention, component (A) is compound no. X.10 (methyl N-[5-[6-[2-(4-chloro-3-methoxy-phenyl)-1,2,4-triazol-3-yl]imidazo[1,2-a]pyridin-3-yl]-2- pyridyl]carbamate) or a salt, or N-oxide thereof, and component (B) is a compound selected from the group consisting of acibenzolar-S-methyl, ametoctradin, amisulbrom, azoxystrobin, chlorothalonil, cyazofamid, cyclobutrifluram, cymoxanil, difenoconazole, disodium phosphonate, florylpicoxamid, fluazinam, fludioxonil, fluopicolide, fluoxapiprolin, folpet, mandipropamid, mefentrifluconazole, metalaxyl-M, oxathiapiprolin, picarbutrazox, pydiflumetofen, sedaxane, Streptomyces chrestomyceticus, zoxamide, and Compound Z (feneptamidoquin),wherein the weight ratio of component (A) to component (B) is from 15:1 to 1:30. In another more preferred composition according to the invention, component (A) is compound no. X.11 (methyl N-[5-[6-[2-(4-fluoro-3-methoxy-phenyl)-1,2,4-triazol-3-yl]imidazo[1,2-a]pyridin-3-yl]-2- pyridyl]carbamate) or a salt, or N-oxide thereof, and component (B) is a compound selected from the group consisting of acibenzolar-S-methyl, ametoctradin, amisulbrom, azoxystrobin, chlorothalonil, cyazofamid, cyclobutrifluram, cymoxanil, difenoconazole, disodium phosphonate, florylpicoxamid, fluazinam, fludioxonil, fluopicolide, fluoxapiprolin, folpet, mandipropamid, mefentrifluconazole, metalaxyl-M, oxathiapiprolin, picarbutrazox, pydiflumetofen, sedaxane, Streptomyces chrestomyceticus, zoxamide, and Compound Z (feneptamidoquin),wherein the weight ratio of component (A) to component (B) is from 15:1 to 1:30. In another more preferred composition according to the invention, component (A) is compound no. X.12 (methyl N-[5-[6-[4-(4-fluoro-3-methoxy-phenyl)-5-(methoxymethyl)-1,2,4-triazol-3-yl]-8-methyl- imidazo[1,2-a]pyridin-3-yl]-2-pyridyl]carbamate) or a salt, or N-oxide thereof, and component (B) is a compound selected from the group consisting of acibenzolar-S-methyl, ametoctradin, amisulbrom, azoxystrobin, chlorothalonil, cyazofamid, cyclobutrifluram, cymoxanil, difenoconazole, disodium phosphonate, florylpicoxamid, fluazinam, fludioxonil, fluopicolide, fluoxapiprolin, folpet, mandipropamid, mefentrifluconazole, metalaxyl-M, oxathiapiprolin, picarbutrazox, pydiflumetofen, sedaxane, Streptomyces chrestomyceticus, zoxamide, and Compound Z (feneptamidoquin),wherein the weight ratio of component (A) to component (B) is from 15:1 to 1:30. In a still more preferred composition according to the invention, component (A) is compound no. X.01 (methyl N-[5-[8-cyclopropyl-6-[4-(4-fluoro-3-methoxy-phenyl)-1,2,4-triazol-3-yl]imidazo[1,2-a]pyridin-3- yl]-2-pyridyl]carbamate) or a salt, or N-oxide thereof, and component (B) is a compound selected from the group consisting of acetamiprid, acibenzolar-S-methyl, ametoctradin, amisulbrom, azoxystrobin, Bacillus amyloliquefaciens, benzovindiflupyr, broflanilid, chlorothalonil, chlothianidin, chlorantraniliprole, Cis-Jasmone, cyantraniliprole, cyazofamid, cyclobutrifluram, cymoxanil, difenoconazole, disodium phosphonate, ethaboxam, fenpicoxamid, florylpicoxamid, fluazinam, fludioxonil, fluindapyr, fluopicolide, fluopyram, fluoxapiprolin, fluoxytioconazole, fluxametamide, fluxapyroxad, folpet, imidaclprid, inpyrfluxam, ipconazole, ipflufenoquin, isocycloseram, isoflucypram, isotianil, mandipropamid, mefentrifulconazole, metalaxyl, metalaxyl-M (mefenoxam), metyltetraprole, oxathiapiprolin, penflufen, phosphite (phosphonate), picarbutrazox, prothioconazole, pydiflumetofen, pyraclostrobin, quinofumerin, sedaxane, silthiofam, Streptomyces chrestomyceticus, tebuconazole, tetraniliprole, thiabendazole, thiamethoxam, tolprocarb, triticonazole, zoxamide, N-[(1R)-1-benzyl-3-chloro-1-methyl-but-3-enyl]-8- fluoro-quinoline-3-carboxamide, N-[(1S)-1-benzyl-3-chloro-1-methyl-but-3-enyl]-8-fluoro-quinoline-3- carboxamide, N-[(1R)-1-benzyl-3,3,3-trifluoro-1-methyl-propyl]-8-fluoro-quinoline-3-carboxamide, N- [(1S)-1-benzyl-3,3,3-trifluoro-1-methyl-propyl]-8-fluoro-quinoline-3-carboxamide, N-[(1R)-1-benzyl-1,3- dimethyl-butyl]-7,8-difluoro-quinoline-3-carboxamide, N-[(1S)-1-benzyl-1,3-dimethyl-butyl]-7,8-difluoro- quinoline-3-carboxamide, 8-fluoro-N-[(1R)-1-[(3-fluorophenyl)methyl]-1,3-dimethyl-butyl]quinoline-3- carboxamide, 8-fluoro-N-[(1S)-1-[(3-fluorophenyl)methyl]-1,3-dimethyl-butyl]quinoline-3-carboxamide, N-[(1R)-1-benzyl-1,3-dimethyl-butyl]-8-fluoro-quinoline-3-carboxamide, N-[(1S)-1-benzyl-1,3-dimethyl- butyl]-8-fluoro-quinoline-3-carboxamide, N-((1R)-1-benzyl-3-chloro-1-methyl-but-3-enyl)-8-fluoro- quinoline-3-carboxamide, and N-((1S)-1-benzyl-3-chloro-1-methyl-but-3-enyl)-8-fluoro-quinoline-3- carboxamide, wherein the weight ratio of component (A) to component (B) is from 10:1 to 1:10 (or even more preferably, 5:1 to 1:5). In another still more preferred composition according to the invention, component (A) is compound no. X.02 (methyl N-[5-[6-[1-(4-fluoro-3-methoxy-phenyl)imidazol-2-yl]-8-methyl-imidazo[1,2-a]pyridin-3-yl]- 2-pyridyl]carbamate) or a salt, or N-oxide thereof, and component (B) is a compound selected from the group consisting of acetamiprid, acibenzolar-S-methyl, ametoctradin, amisulbrom, azoxystrobin, Bacillus amyloliquefaciens, benzovindiflupyr, broflanilid, chlorothalonil, chlothianidin, chlorantraniliprole, Cis-Jasmone, cyantraniliprole, cyazofamid, cyclobutrifluram, cymoxanil, difenoconazole, disodium phosphonate, ethaboxam, fenpicoxamid, florylpicoxamid, fluazinam, fludioxonil, fluindapyr, fluopicolide, fluopyram, fluoxapiprolin, fluoxytioconazole, fluxametamide, fluxapyroxad, folpet, imidaclprid, inpyrfluxam, ipconazole, ipflufenoquin, isocycloseram, isoflucypram, isotianil, mandipropamid, mefentrifulconazole, metalaxyl, metalaxyl-M (mefenoxam), metyltetraprole, oxathiapiprolin, penflufen, phosphite (phosphonate), picarbutrazox, prothioconazole, pydiflumetofen, pyraclostrobin, quinofumerin, sedaxane, silthiofam, Streptomyces chrestomyceticus, tebuconazole, tetraniliprole, thiabendazole, thiamethoxam, tolprocarb, triticonazole, zoxamide, N-[(1R)-1-benzyl-3-chloro-1-methyl-but-3-enyl]-8- fluoro-quinoline-3-carboxamide, N-[(1S)-1-benzyl-3-chloro-1-methyl-but-3-enyl]-8-fluoro-quinoline-3- carboxamide, N-[(1R)-1-benzyl-3,3,3-trifluoro-1-methyl-propyl]-8-fluoro-quinoline-3-carboxamide, N- [(1S)-1-benzyl-3,3,3-trifluoro-1-methyl-propyl]-8-fluoro-quinoline-3-carboxamide, N-[(1R)-1-benzyl-1,3- dimethyl-butyl]-7,8-difluoro-quinoline-3-carboxamide, N-[(1S)-1-benzyl-1,3-dimethyl-butyl]-7,8-difluoro- quinoline-3-carboxamide, 8-fluoro-N-[(1R)-1-[(3-fluorophenyl)methyl]-1,3-dimethyl-butyl]quinoline-3- carboxamide, 8-fluoro-N-[(1S)-1-[(3-fluorophenyl)methyl]-1,3-dimethyl-butyl]quinoline-3-carboxamide, N-[(1R)-1-benzyl-1,3-dimethyl-butyl]-8-fluoro-quinoline-3-carboxamide, N-[(1S)-1-benzyl-1,3-dimethyl- butyl]-8-fluoro-quinoline-3-carboxamide, N-((1R)-1-benzyl-3-chloro-1-methyl-but-3-enyl)-8-fluoro- quinoline-3-carboxamide, and N-((1S)-1-benzyl-3-chloro-1-methyl-but-3-enyl)-8-fluoro-quinoline-3- carboxamide, wherein the weight ratio of component (A) to component (B) is from 10:1 to 1:10 (or even more preferably, 5:1 to 1:5). In another still more preferred composition according to the invention, component (A) is compound no. X.03 (methyl N-[5-[6-[4-(4-fluoro-3-methoxy-phenyl)-5,6-dihydro-1,2,4-oxadiazin-3-yl]-8-methyl- imidazo[1,2-a]pyridin-3-yl]-2-pyridyl]carbamate) or a salt, or N-oxide thereof, and component (B) is a compound selected from the group consisting of acetamiprid, acibenzolar-S-methyl, ametoctradin, amisulbrom, azoxystrobin, Bacillus amyloliquefaciens, benzovindiflupyr, broflanilid, chlorothalonil, chlothianidin, chlorantraniliprole, Cis-Jasmone, cyantraniliprole, cyazofamid, cyclobutrifluram, cymoxanil, difenoconazole, disodium phosphonate, ethaboxam, fenpicoxamid, florylpicoxamid, fluazinam, fludioxonil, fluindapyr, fluopicolide, fluopyram, fluoxapiprolin, fluoxytioconazole, fluxametamide, fluxapyroxad, folpet, imidaclprid, inpyrfluxam, ipconazole, ipflufenoquin, isocycloseram, isoflucypram, isotianil, mandipropamid, mefentrifulconazole, metalaxyl, metalaxyl-M (mefenoxam), metyltetraprole, oxathiapiprolin, penflufen, phosphite (phosphonate), picarbutrazox, prothioconazole, pydiflumetofen, pyraclostrobin, quinofumerin, sedaxane, silthiofam, Streptomyces chrestomyceticus, tebuconazole, tetraniliprole, thiabendazole, thiamethoxam, tolprocarb, triticonazole, zoxamide, N-[(1R)- 1-benzyl-3-chloro-1-methyl-but-3-enyl]-8-fluoro-quinoline-3-carboxamide, N-[(1S)-1-benzyl-3-chloro-1- methyl-but-3-enyl]-8-fluoro-quinoline-3-carboxamide, N-[(1R)-1-benzyl-3,3,3-trifluoro-1-methyl-propyl]- 8-fluoro-quinoline-3-carboxamide, N-[(1S)-1-benzyl-3,3,3-trifluoro-1-methyl-propyl]-8-fluoro-quinoline- 3-carboxamide, N-[(1R)-1-benzyl-1,3-dimethyl-butyl]-7,8-difluoro-quinoline-3-carboxamide, N-[(1S)-1- benzyl-1,3-dimethyl-butyl]-7,8-difluoro-quinoline-3-carboxamide, 8-fluoro-N-[(1R)-1-[(3- fluorophenyl)methyl]-1,3-dimethyl-butyl]quinoline-3-carboxamide, 8-fluoro-N-[(1S)-1-[(3- fluorophenyl)methyl]-1,3-dimethyl-butyl]quinoline-3-carboxamide, N-[(1R)-1-benzyl-1,3-dimethyl-butyl]- 8-fluoro-quinoline-3-carboxamide, N-[(1S)-1-benzyl-1,3-dimethyl-butyl]-8-fluoro-quinoline-3- carboxamide, N-((1R)-1-benzyl-3-chloro-1-methyl-but-3-enyl)-8-fluoro-quinoline-3-carboxamide, and N- ((1S)-1-benzyl-3-chloro-1-methyl-but-3-enyl)-8-fluoro-quinoline-3-carboxamide, wherein the weight ratio of component (A) to component (B) is from 10:1 to 1:10 (or even more preferably, 5:1 to 1:5). In another still more preferred composition according to the invention, component (A) is compound no. X.04 (methyl N-[5-[6-[4-(4-fluorophenyl)-5,6-dihydro-1,2,4-oxadiazin-3-yl]-8-methyl-imidazo[1,2- a]pyridin-3-yl]-2-pyridyl]carbamate) or a salt, or N-oxide thereof, and component (B) is a compound selected from the group consisting of acetamiprid, acibenzolar-S-methyl, ametoctradin, amisulbrom, azoxystrobin, Bacillus amyloliquefaciens, benzovindiflupyr, broflanilid, chlorothalonil, chlothianidin, chlorantraniliprole, Cis-Jasmone, cyantraniliprole, cyazofamid, cyclobutrifluram, cymoxanil, difenoconazole, disodium phosphonate, ethaboxam, fenpicoxamid, florylpicoxamid, fluazinam, fludioxonil, fluindapyr, fluopicolide, fluopyram, fluoxapiprolin, fluoxytioconazole, fluxametamide, fluxapyroxad, folpet, imidaclprid, inpyrfluxam, ipconazole, ipflufenoquin, isocycloseram, isoflucypram, isotianil, mandipropamid, mefentrifulconazole, metalaxyl, metalaxyl-M (mefenoxam), metyltetraprole, oxathiapiprolin, penflufen, phosphite (phosphonate), picarbutrazox, prothioconazole, pydiflumetofen, pyraclostrobin, quinofumerin, sedaxane, silthiofam, Streptomyces chrestomyceticus, tebuconazole, tetraniliprole, thiabendazole, thiamethoxam, tolprocarb, triticonazole, zoxamide, N-[(1R)-1-benzyl-3- chloro-1-methyl-but-3-enyl]-8-fluoro-quinoline-3-carboxamide, N-[(1S)-1-benzyl-3-chloro-1-methyl-but- 3-enyl]-8-fluoro-quinoline-3-carboxamide, N-[(1R)-1-benzyl-3,3,3-trifluoro-1-methyl-propyl]-8-fluoro- quinoline-3-carboxamide, N-[(1S)-1-benzyl-3,3,3-trifluoro-1-methyl-propyl]-8-fluoro-quinoline-3- carboxamide, N-[(1R)-1-benzyl-1,3-dimethyl-butyl]-7,8-difluoro-quinoline-3-carboxamide, N-[(1S)-1- benzyl-1,3-dimethyl-butyl]-7,8-difluoro-quinoline-3-carboxamide, 8-fluoro-N-[(1R)-1-[(3- fluorophenyl)methyl]-1,3-dimethyl-butyl]quinoline-3-carboxamide, 8-fluoro-N-[(1S)-1-[(3- fluorophenyl)methyl]-1,3-dimethyl-butyl]quinoline-3-carboxamide, N-[(1R)-1-benzyl-1,3-dimethyl-butyl]- 8-fluoro-quinoline-3-carboxamide, N-[(1S)-1-benzyl-1,3-dimethyl-butyl]-8-fluoro-quinoline-3- carboxamide, N-((1R)-1-benzyl-3-chloro-1-methyl-but-3-enyl)-8-fluoro-quinoline-3-carboxamide, and N- ((1S)-1-benzyl-3-chloro-1-methyl-but-3-enyl)-8-fluoro-quinoline-3-carboxamide, wherein the weight ratio of component (A) to component (B) is from 10:1 to 1:10 (or even more preferably, 5:1 to 1:5). In another still more preferred composition according to the invention, component (A) is compound no. X.05 (methyl N-[5-[6-[5-(4-fluoro-3-methoxy-phenyl)-1-methyl-pyrazol-4-yl]imidazo[1,2-a]pyridin-3-yl]-2- pyridyl]carbamate) or a salt, or N-oxide thereof, and component (B) is a compound selected from the group consisting of acetamiprid, acibenzolar-S-methyl, ametoctradin, amisulbrom, azoxystrobin, Bacillus amyloliquefaciens, benzovindiflupyr, broflanilid, chlorothalonil, chlothianidin, chlorantraniliprole, Cis-Jasmone, cyantraniliprole, cyazofamid, cyclobutrifluram, cymoxanil, difenoconazole, disodium phosphonate, ethaboxam, fenpicoxamid, florylpicoxamid, fluazinam, fludioxonil, fluindapyr, fluopicolide, fluopyram, fluoxapiprolin, fluoxytioconazole, fluxametamide, fluxapyroxad, folpet, imidaclprid, inpyrfluxam, ipconazole, ipflufenoquin, isocycloseram, isoflucypram, isotianil, mandipropamid, mefentrifulconazole, metalaxyl, metalaxyl-M (mefenoxam), metyltetraprole, oxathiapiprolin, penflufen, phosphite (phosphonate), picarbutrazox, prothioconazole, pydiflumetofen, pyraclostrobin, quinofumerin, sedaxane, silthiofam, Streptomyces chrestomyceticus, tebuconazole, tetraniliprole, thiabendazole, thiamethoxam, tolprocarb, triticonazole, zoxamide, N-[(1R)-1-benzyl-3-chloro-1-methyl-but-3-enyl]-8- fluoro-quinoline-3-carboxamide, N-[(1S)-1-benzyl-3-chloro-1-methyl-but-3-enyl]-8-fluoro-quinoline-3- carboxamide, N-[(1R)-1-benzyl-3,3,3-trifluoro-1-methyl-propyl]-8-fluoro-quinoline-3-carboxamide, N- [(1S)-1-benzyl-3,3,3-trifluoro-1-methyl-propyl]-8-fluoro-quinoline-3-carboxamide, N-[(1R)-1-benzyl-1,3- dimethyl-butyl]-7,8-difluoro-quinoline-3-carboxamide, N-[(1S)-1-benzyl-1,3-dimethyl-butyl]-7,8-difluoro- quinoline-3-carboxamide, 8-fluoro-N-[(1R)-1-[(3-fluorophenyl)methyl]-1,3-dimethyl-butyl]quinoline-3- carboxamide, 8-fluoro-N-[(1S)-1-[(3-fluorophenyl)methyl]-1,3-dimethyl-butyl]quinoline-3-carboxamide, N-[(1R)-1-benzyl-1,3-dimethyl-butyl]-8-fluoro-quinoline-3-carboxamide, N-[(1S)-1-benzyl-1,3-dimethyl- butyl]-8-fluoro-quinoline-3-carboxamide, N-((1R)-1-benzyl-3-chloro-1-methyl-but-3-enyl)-8-fluoro- quinoline-3-carboxamide, and N-((1S)-1-benzyl-3-chloro-1-methyl-but-3-enyl)-8-fluoro-quinoline-3- carboxamide, wherein the weight ratio of component (A) to component (B) is from 10:1 to 1:10 (or even more preferably, 5:1 to 1:5). In another still more preferred composition according to the invention, component (A) is compound no. X.06 (methyl N-[5-[6-[4-(4-fluoro-3-methoxy-phenyl)-5,6-dihydro-1,2,4-oxadiazin-3-yl]imidazo[1,2- a]pyridin-3-yl]-2-pyridyl]carbamate) or a salt, or N-oxide thereof, and component (B) is a compound selected from the group consisting of acetamiprid, acibenzolar-S-methyl, ametoctradin, amisulbrom, azoxystrobin, Bacillus amyloliquefaciens, benzovindiflupyr, broflanilid, chlorothalonil, chlothianidin, chlorantraniliprole, Cis-Jasmone, cyantraniliprole, cyazofamid, cyclobutrifluram, cymoxanil, difenoconazole, disodium phosphonate, ethaboxam, fenpicoxamid, florylpicoxamid, fluazinam, fludioxonil, fluindapyr, fluopicolide, fluopyram, fluoxapiprolin, fluoxytioconazole, fluxametamide, fluxapyroxad, folpet, imidaclprid, inpyrfluxam, ipconazole, ipflufenoquin, isocycloseram, isoflucypram, isotianil, mandipropamid, mefentrifulconazole, metalaxyl, metalaxyl-M (mefenoxam), metyltetraprole, oxathiapiprolin, penflufen, phosphite (phosphonate), picarbutrazox, prothioconazole, pydiflumetofen, pyraclostrobin, quinofumerin, sedaxane, silthiofam, Streptomyces chrestomyceticus, tebuconazole, tetraniliprole, thiabendazole, thiamethoxam, tolprocarb, triticonazole, zoxamide, N-[(1R)-1-benzyl-3- chloro-1-methyl-but-3-enyl]-8-fluoro-quinoline-3-carboxamide, N-[(1S)-1-benzyl-3-chloro-1-methyl-but- 3-enyl]-8-fluoro-quinoline-3-carboxamide, N-[(1R)-1-benzyl-3,3,3-trifluoro-1-methyl-propyl]-8-fluoro- quinoline-3-carboxamide, N-[(1S)-1-benzyl-3,3,3-trifluoro-1-methyl-propyl]-8-fluoro-quinoline-3- carboxamide, N-[(1R)-1-benzyl-1,3-dimethyl-butyl]-7,8-difluoro-quinoline-3-carboxamide, N-[(1S)-1- benzyl-1,3-dimethyl-butyl]-7,8-difluoro-quinoline-3-carboxamide, 8-fluoro-N-[(1R)-1-[(3- fluorophenyl)methyl]-1,3-dimethyl-butyl]quinoline-3-carboxamide, 8-fluoro-N-[(1S)-1-[(3- fluorophenyl)methyl]-1,3-dimethyl-butyl]quinoline-3-carboxamide, N-[(1R)-1-benzyl-1,3-dimethyl-butyl]- 8-fluoro-quinoline-3-carboxamide, N-[(1S)-1-benzyl-1,3-dimethyl-butyl]-8-fluoro-quinoline-3- carboxamide, N-((1R)-1-benzyl-3-chloro-1-methyl-but-3-enyl)-8-fluoro-quinoline-3-carboxamide, and N- ((1S)-1-benzyl-3-chloro-1-methyl-but-3-enyl)-8-fluoro-quinoline-3-carboxamide, wherein the weight ratio of component (A) to component (B) is from 10:1 to 1:10 (or even more preferably, 5:1 to 1:5). In another still more preferred composition according to the invention, component (A) is compound no. X.07 (methyl N-[5-[6-[2-(4-fluoro-3-methoxy-phenyl)-1,2,4-triazol-3-yl]-8-methyl-imidazo[1,2-a]pyridin- 3-yl]-2-pyridyl]carbamate) or a salt, or N-oxide thereof, and component (B) is a compound selected from the group consisting of acetamiprid, acibenzolar-S-methyl, ametoctradin, amisulbrom, azoxystrobin, Bacillus amyloliquefaciens, benzovindiflupyr, broflanilid, chlorothalonil, chlothianidin, chlorantraniliprole, Cis-Jasmone, cyantraniliprole, cyazofamid, cyclobutrifluram, cymoxanil, difenoconazole, disodium phosphonate, ethaboxam, fenpicoxamid, florylpicoxamid, fluazinam, fludioxonil, fluindapyr, fluopicolide, fluopyram, fluoxapiprolin, fluoxytioconazole, fluxametamide, fluxapyroxad, folpet, imidaclprid, inpyrfluxam, ipconazole, ipflufenoquin, isocycloseram, isoflucypram, isotianil, mandipropamid, mefentrifulconazole, metalaxyl, metalaxyl-M (mefenoxam), metyltetraprole, oxathiapiprolin, penflufen, phosphite (phosphonate), picarbutrazox, prothioconazole, pydiflumetofen, pyraclostrobin, quinofumerin, sedaxane, silthiofam, Streptomyces chrestomyceticus, tebuconazole, tetraniliprole, thiabendazole, thiamethoxam, tolprocarb, triticonazole, zoxamide, N-[(1R)-1-benzyl-3-chloro-1-methyl-but-3-enyl]-8- fluoro-quinoline-3-carboxamide, N-[(1S)-1-benzyl-3-chloro-1-methyl-but-3-enyl]-8-fluoro-quinoline-3- carboxamide, N-[(1R)-1-benzyl-3,3,3-trifluoro-1-methyl-propyl]-8-fluoro-quinoline-3-carboxamide, N- [(1S)-1-benzyl-3,3,3-trifluoro-1-methyl-propyl]-8-fluoro-quinoline-3-carboxamide, N-[(1R)-1-benzyl-1,3- dimethyl-butyl]-7,8-difluoro-quinoline-3-carboxamide, N-[(1S)-1-benzyl-1,3-dimethyl-butyl]-7,8-difluoro- quinoline-3-carboxamide, 8-fluoro-N-[(1R)-1-[(3-fluorophenyl)methyl]-1,3-dimethyl-butyl]quinoline-3- carboxamide, 8-fluoro-N-[(1S)-1-[(3-fluorophenyl)methyl]-1,3-dimethyl-butyl]quinoline-3-carboxamide, N-[(1R)-1-benzyl-1,3-dimethyl-butyl]-8-fluoro-quinoline-3-carboxamide, N-[(1S)-1-benzyl-1,3-dimethyl- butyl]-8-fluoro-quinoline-3-carboxamide, N-((1R)-1-benzyl-3-chloro-1-methyl-but-3-enyl)-8-fluoro- quinoline-3-carboxamide, and N-((1S)-1-benzyl-3-chloro-1-methyl-but-3-enyl)-8-fluoro-quinoline-3- carboxamide, wherein the weight ratio of component (A) to component (B) is from 10:1 to 1:10 (or even more preferably, 5:1 to 1:5). In another still more preferred composition according to the invention, component (A) is compound no. X.08 (methyl N-[5-[6-[4-(4-fluoro-3-methoxy-phenyl)-5-methyl-1,2,4-triazol-3-yl]imidazo[1,2-a]pyridin-3- yl]-2-pyridyl]carbamate) or a salt, or N-oxide thereof, and component (B) is a compound selected from the group consisting of acetamiprid, acibenzolar-S-methyl, ametoctradin, amisulbrom, azoxystrobin, Bacillus amyloliquefaciens, benzovindiflupyr, broflanilid, chlorothalonil, chlothianidin, chlorantraniliprole, Cis-Jasmone, cyantraniliprole, cyazofamid, cyclobutrifluram, cymoxanil, difenoconazole, disodium phosphonate, ethaboxam, fenpicoxamid, florylpicoxamid, fluazinam, fludioxonil, fluindapyr, fluopicolide, fluopyram, fluoxapiprolin, fluoxytioconazole, fluxametamide, fluxapyroxad, folpet, imidaclprid, inpyrfluxam, ipconazole, ipflufenoquin, isocycloseram, isoflucypram, isotianil, mandipropamid, mefentrifulconazole, metalaxyl, metalaxyl-M (mefenoxam), metyltetraprole, oxathiapiprolin, penflufen, phosphite (phosphonate), picarbutrazox, prothioconazole, pydiflumetofen, pyraclostrobin, quinofumerin, sedaxane, silthiofam, Streptomyces chrestomyceticus, tebuconazole, tetraniliprole, thiabendazole, thiamethoxam, tolprocarb, triticonazole, zoxamide, N-[(1R)-1-benzyl-3-chloro-1-methyl-but-3-enyl]-8- fluoro-quinoline-3-carboxamide, N-[(1S)-1-benzyl-3-chloro-1-methyl-but-3-enyl]-8-fluoro-quinoline-3- carboxamide, N-[(1R)-1-benzyl-3,3,3-trifluoro-1-methyl-propyl]-8-fluoro-quinoline-3-carboxamide, N- [(1S)-1-benzyl-3,3,3-trifluoro-1-methyl-propyl]-8-fluoro-quinoline-3-carboxamide, N-[(1R)-1-benzyl-1,3- dimethyl-butyl]-7,8-difluoro-quinoline-3-carboxamide, N-[(1S)-1-benzyl-1,3-dimethyl-butyl]-7,8-difluoro- quinoline-3-carboxamide, 8-fluoro-N-[(1R)-1-[(3-fluorophenyl)methyl]-1,3-dimethyl-butyl]quinoline-3- carboxamide, 8-fluoro-N-[(1S)-1-[(3-fluorophenyl)methyl]-1,3-dimethyl-butyl]quinoline-3-carboxamide, N-[(1R)-1-benzyl-1,3-dimethyl-butyl]-8-fluoro-quinoline-3-carboxamide, N-[(1S)-1-benzyl-1,3-dimethyl- butyl]-8-fluoro-quinoline-3-carboxamide, N-((1R)-1-benzyl-3-chloro-1-methyl-but-3-enyl)-8-fluoro- quinoline-3-carboxamide, and N-((1S)-1-benzyl-3-chloro-1-methyl-but-3-enyl)-8-fluoro-quinoline-3- carboxamide, wherein the weight ratio of component (A) to component (B) is from 10:1 to 1:10 (or even more preferably, 5:1 to 1:5). In another still more preferred composition according to the invention, component (A) is compound no. X.09 (methyl N-[5-[6-[1-(4-fluoro-3-methoxy-phenyl)imidazol-2-yl]imidazo[1,2-a]pyridin-3-yl]-2- pyridyl]carbamate) or a salt, or N-oxide thereof, and component (B) is a compound selected from the group consisting of acetamiprid, acibenzolar-S-methyl, ametoctradin, amisulbrom, azoxystrobin, Bacillus amyloliquefaciens, benzovindiflupyr, broflanilid, chlorothalonil, chlothianidin, chlorantraniliprole, Cis-Jasmone, cyantraniliprole, cyazofamid, cyclobutrifluram, cymoxanil, difenoconazole, disodium phosphonate, ethaboxam, fenpicoxamid, florylpicoxamid, fluazinam, fludioxonil, fluindapyr, fluopicolide, fluopyram, fluoxapiprolin, fluoxytioconazole, fluxametamide, fluxapyroxad, folpet, imidaclprid, inpyrfluxam, ipconazole, ipflufenoquin, isocycloseram, isoflucypram, isotianil, mandipropamid, mefentrifulconazole, metalaxyl, metalaxyl-M (mefenoxam), metyltetraprole, oxathiapiprolin, penflufen, phosphite (phosphonate), picarbutrazox, prothioconazole, pydiflumetofen, pyraclostrobin, quinofumerin, sedaxane, silthiofam, Streptomyces chrestomyceticus, tebuconazole, tetraniliprole, thiabendazole, thiamethoxam, tolprocarb, triticonazole, zoxamide, N-[(1R)-1-benzyl-3-chloro-1-methyl-but-3-enyl]-8- fluoro-quinoline-3-carboxamide, N-[(1S)-1-benzyl-3-chloro-1-methyl-but-3-enyl]-8-fluoro-quinoline-3- carboxamide, N-[(1R)-1-benzyl-3,3,3-trifluoro-1-methyl-propyl]-8-fluoro-quinoline-3-carboxamide, N- [(1S)-1-benzyl-3,3,3-trifluoro-1-methyl-propyl]-8-fluoro-quinoline-3-carboxamide, N-[(1R)-1-benzyl-1,3- dimethyl-butyl]-7,8-difluoro-quinoline-3-carboxamide, N-[(1S)-1-benzyl-1,3-dimethyl-butyl]-7,8-difluoro- quinoline-3-carboxamide, 8-fluoro-N-[(1R)-1-[(3-fluorophenyl)methyl]-1,3-dimethyl-butyl]quinoline-3- carboxamide, 8-fluoro-N-[(1S)-1-[(3-fluorophenyl)methyl]-1,3-dimethyl-butyl]quinoline-3-carboxamide, N-[(1R)-1-benzyl-1,3-dimethyl-butyl]-8-fluoro-quinoline-3-carboxamide, N-[(1S)-1-benzyl-1,3-dimethyl- butyl]-8-fluoro-quinoline-3-carboxamide, N-((1R)-1-benzyl-3-chloro-1-methyl-but-3-enyl)-8-fluoro- quinoline-3-carboxamide, and N-((1S)-1-benzyl-3-chloro-1-methyl-but-3-enyl)-8-fluoro-quinoline-3- carboxamide, wherein the weight ratio of component (A) to component (B) is from 10:1 to 1:10 (or even more preferably, 5:1 to 1:5). In another still more preferred composition according to the invention, component (A) is compound no. X.10 (methyl N-[5-[6-[2-(4-chloro-3-methoxy-phenyl)-1,2,4-triazol-3-yl]imidazo[1,2-a]pyridin-3-yl]-2- pyridyl]carbamate) or a salt, or N-oxide thereof, and component (B) is a compound selected from the group consisting of acetamiprid, acibenzolar-S-methyl, ametoctradin, amisulbrom, azoxystrobin, Bacillus amyloliquefaciens, benzovindiflupyr, broflanilid, chlorothalonil, chlothianidin, chlorantraniliprole, Cis-Jasmone, cyantraniliprole, cyazofamid, cyclobutrifluram, cymoxanil, difenoconazole, disodium phosphonate, ethaboxam, fenpicoxamid, florylpicoxamid, fluazinam, fludioxonil, fluindapyr, fluopicolide, fluopyram, fluoxapiprolin, fluoxytioconazole, fluxametamide, fluxapyroxad, folpet, imidaclprid, inpyrfluxam, ipconazole, ipflufenoquin, isocycloseram, isoflucypram, isotianil, mandipropamid, mefentrifulconazole, metalaxyl, metalaxyl-M (mefenoxam), metyltetraprole, oxathiapiprolin, penflufen, phosphite (phosphonate), picarbutrazox, prothioconazole, pydiflumetofen, pyraclostrobin, quinofumerin, sedaxane, silthiofam, Streptomyces chrestomyceticus, tebuconazole, tetraniliprole, thiabendazole, thiamethoxam, tolprocarb, triticonazole, zoxamide, N-[(1R)-1-benzyl-3-chloro-1-methyl-but-3-enyl]-8- fluoro-quinoline-3-carboxamide, N-[(1S)-1-benzyl-3-chloro-1-methyl-but-3-enyl]-8-fluoro-quinoline-3- carboxamide, N-[(1R)-1-benzyl-3,3,3-trifluoro-1-methyl-propyl]-8-fluoro-quinoline-3-carboxamide, N- [(1S)-1-benzyl-3,3,3-trifluoro-1-methyl-propyl]-8-fluoro-quinoline-3-carboxamide, N-[(1R)-1-benzyl-1,3- dimethyl-butyl]-7,8-difluoro-quinoline-3-carboxamide, N-[(1S)-1-benzyl-1,3-dimethyl-butyl]-7,8-difluoro- quinoline-3-carboxamide, 8-fluoro-N-[(1R)-1-[(3-fluorophenyl)methyl]-1,3-dimethyl-butyl]quinoline-3- carboxamide, 8-fluoro-N-[(1S)-1-[(3-fluorophenyl)methyl]-1,3-dimethyl-butyl]quinoline-3-carboxamide, N-[(1R)-1-benzyl-1,3-dimethyl-butyl]-8-fluoro-quinoline-3-carboxamide, N-[(1S)-1-benzyl-1,3-dimethyl- butyl]-8-fluoro-quinoline-3-carboxamide, N-((1R)-1-benzyl-3-chloro-1-methyl-but-3-enyl)-8-fluoro- quinoline-3-carboxamide, and N-((1S)-1-benzyl-3-chloro-1-methyl-but-3-enyl)-8-fluoro-quinoline-3- carboxamide, wherein the weight ratio of component (A) to component (B) is from 10:1 to 1:10 (or even more preferably, 5:1 to 1:5). In another still more preferred composition according to the invention, component (A) is compound no. X.11 (methyl N-[5-[6-[2-(4-fluoro-3-methoxy-phenyl)-1,2,4-triazol-3-yl]imidazo[1,2-a]pyridin-3-yl]-2- pyridyl]carbamate) or a salt, or N-oxide thereof, and component (B) is a compound selected from the group consisting of acetamiprid, acibenzolar-S-methyl, ametoctradin, amisulbrom, azoxystrobin, Bacillus amyloliquefaciens, benzovindiflupyr, broflanilid, chlorothalonil, chlothianidin, chlorantraniliprole, Cis-Jasmone, cyantraniliprole, cyazofamid, cyclobutrifluram, cymoxanil, difenoconazole, disodium phosphonate, ethaboxam, fenpicoxamid, florylpicoxamid, fluazinam, fludioxonil, fluindapyr, fluopicolide, fluopyram, fluoxapiprolin, fluoxytioconazole, fluxametamide, fluxapyroxad, folpet, imidaclprid, inpyrfluxam, ipconazole, ipflufenoquin, isocycloseram, isoflucypram, isotianil, mandipropamid, mefentrifulconazole, metalaxyl, metalaxyl-M (mefenoxam), metyltetraprole, oxathiapiprolin, penflufen, phosphite (phosphonate), picarbutrazox, prothioconazole, pydiflumetofen, pyraclostrobin, quinofumerin, sedaxane, silthiofam, Streptomyces chrestomyceticus, tebuconazole, tetraniliprole, thiabendazole, thiamethoxam, tolprocarb, triticonazole, zoxamide, N-[(1R)-1-benzyl-3-chloro-1-methyl-but-3-enyl]-8- fluoro-quinoline-3-carboxamide, N-[(1S)-1-benzyl-3-chloro-1-methyl-but-3-enyl]-8-fluoro-quinoline-3- carboxamide, N-[(1R)-1-benzyl-3,3,3-trifluoro-1-methyl-propyl]-8-fluoro-quinoline-3-carboxamide, N- [(1S)-1-benzyl-3,3,3-trifluoro-1-methyl-propyl]-8-fluoro-quinoline-3-carboxamide, N-[(1R)-1-benzyl-1,3- dimethyl-butyl]-7,8-difluoro-quinoline-3-carboxamide, N-[(1S)-1-benzyl-1,3-dimethyl-butyl]-7,8-difluoro- quinoline-3-carboxamide, 8-fluoro-N-[(1R)-1-[(3-fluorophenyl)methyl]-1,3-dimethyl-butyl]quinoline-3- carboxamide, 8-fluoro-N-[(1S)-1-[(3-fluorophenyl)methyl]-1,3-dimethyl-butyl]quinoline-3-carboxamide, N-[(1R)-1-benzyl-1,3-dimethyl-butyl]-8-fluoro-quinoline-3-carboxamide, N-[(1S)-1-benzyl-1,3-dimethyl- butyl]-8-fluoro-quinoline-3-carboxamide, N-((1R)-1-benzyl-3-chloro-1-methyl-but-3-enyl)-8-fluoro- quinoline-3-carboxamide, and N-((1S)-1-benzyl-3-chloro-1-methyl-but-3-enyl)-8-fluoro-quinoline-3- carboxamide, wherein the weight ratio of component (A) to component (B) is from 10:1 to 1:10 (or even more preferably, 5:1 to 1:5). In another still more preferred composition according to the invention, component (A) is compound no. X.12 (methyl N-[5-[6-[4-(4-fluoro-3-methoxy-phenyl)-5-(methoxymethyl)-1,2,4-triazol-3-yl]-8-methyl- imidazo[1,2-a]pyridin-3-yl]-2-pyridyl]carbamate) or a salt, or N-oxide thereof, and component (B) is a compound selected from the group consisting of acetamiprid, acibenzolar-S-methyl, ametoctradin, amisulbrom, azoxystrobin, Bacillus amyloliquefaciens, benzovindiflupyr, broflanilid, chlorothalonil, chlothianidin, chlorantraniliprole, Cis-Jasmone, cyantraniliprole, cyazofamid, cyclobutrifluram, cymoxanil, difenoconazole, disodium phosphonate, ethaboxam, fenpicoxamid, florylpicoxamid, fluazinam, fludioxonil, fluindapyr, fluopicolide, fluopyram, fluoxapiprolin, fluoxytioconazole, fluxametamide, fluxapyroxad, folpet, imidaclprid, inpyrfluxam, ipconazole, ipflufenoquin, isocycloseram, isoflucypram, isotianil, mandipropamid, mefentrifulconazole, metalaxyl, metalaxyl-M (mefenoxam), metyltetraprole, oxathiapiprolin, penflufen, phosphite (phosphonate), picarbutrazox, prothioconazole, pydiflumetofen, pyraclostrobin, quinofumerin, sedaxane, silthiofam, Streptomyces chrestomyceticus, tebuconazole, tetraniliprole, thiabendazole, thiamethoxam, tolprocarb, triticonazole, zoxamide, N-[(1R)- 1-benzyl-3-chloro-1-methyl-but-3-enyl]-8-fluoro-quinoline-3-carboxamide, N-[(1S)-1-benzyl-3-chloro-1- methyl-but-3-enyl]-8-fluoro-quinoline-3-carboxamide, N-[(1R)-1-benzyl-3,3,3-trifluoro-1-methyl-propyl]- 8-fluoro-quinoline-3-carboxamide, N-[(1S)-1-benzyl-3,3,3-trifluoro-1-methyl-propyl]-8-fluoro-quinoline- 3-carboxamide, N-[(1R)-1-benzyl-1,3-dimethyl-butyl]-7,8-difluoro-quinoline-3-carboxamide, N-[(1S)-1- benzyl-1,3-dimethyl-butyl]-7,8-difluoro-quinoline-3-carboxamide, 8-fluoro-N-[(1R)-1-[(3- fluorophenyl)methyl]-1,3-dimethyl-butyl]quinoline-3-carboxamide, 8-fluoro-N-[(1S)-1-[(3- fluorophenyl)methyl]-1,3-dimethyl-butyl]quinoline-3-carboxamide, N-[(1R)-1-benzyl-1,3-dimethyl-butyl]- 8-fluoro-quinoline-3-carboxamide, N-[(1S)-1-benzyl-1,3-dimethyl-butyl]-8-fluoro-quinoline-3- carboxamide, N-((1R)-1-benzyl-3-chloro-1-methyl-but-3-enyl)-8-fluoro-quinoline-3-carboxamide, and N- ((1S)-1-benzyl-3-chloro-1-methyl-but-3-enyl)-8-fluoro-quinoline-3-carboxamide, wherein the weight ratio of component (A) to component (B) is from 10:1 to 1:10 (or even more preferably, 5:1 to 1:5). In a most preferred composition according to the invention, component (A) is compound no. X.01 (methyl N-[5-[8-cyclopropyl-6-[4-(4-fluoro-3-methoxy-phenyl)-1,2,4-triazol-3-yl]imidazo[1,2-a]pyridin-3-yl]-2- pyridyl]carbamate) or a salt, or N-oxide thereof, and component (B) is a compound selected from the group consisting of azoxystrobin, cyclobutrifluram, cymoxanil, difenoconazole, disodium phosphonate, florylpicoxamid, fluazinam, fludioxonil, fluopicolide, fluoxapiprolin, folpet, mandipropamid, mefentrifluconazole, metalaxyl-M, oxathiapiprolin, picarbutrazox, pydiflumetofen, sedaxane, Streptomyces chrestomyceticus, zoxamide, and Compound Z (feneptamidoquin), wherein the weight ratio of component (A) to component (B) is from 10:1 to 1:10 (or even more preferably, 5:1 to 1:5). In another most preferred composition according to the invention, component (A) is compound no. X.02 (methyl N-[5-[6-[1-(4-fluoro-3-methoxy-phenyl)imidazol-2-yl]-8-methyl-imidazo[1,2-a]pyridin-3-yl]-2- pyridyl]carbamate) or a salt, or N-oxide thereof, and component (B) is a compound selected from the group consisting of azoxystrobin, cyclobutrifluram, cymoxanil, difenoconazole, disodium phosphonate, florylpicoxamid, fluazinam, fludioxonil, fluopicolide, fluoxapiprolin, folpet, mandipropamid, mefentrifluconazole, metalaxyl-M, oxathiapiprolin, picarbutrazox, pydiflumetofen, sedaxane, Streptomyces chrestomyceticus, zoxamide, and Compound Z (feneptamidoquin), wherein the weight ratio of component (A) to component (B) is from 10:1 to 1:10 (or even more preferably, 5:1 to 1:5). In another most preferred composition according to the invention, component (A) is compound no. X.03 (methyl N-[5-[6-[4-(4-fluoro-3-methoxy-phenyl)-5,6-dihydro-1,2,4-oxadiazin-3-yl]-8-methyl-imidazo[1,2- a]pyridin-3-yl]-2-pyridyl]carbamate) or a salt, or N-oxide thereof, and component (B) is a compound selected from the group consisting of acibenzolar-S-methyl, ametoctradin, amisulbrom, azoxystrobin, chlorothalonil, cyazofamid, cyclobutrifluram, cymoxanil, difenoconazole, disodium phosphonate, florylpicoxamid, fluazinam, fludioxonil, fluopicolide, fluoxapiprolin, folpet, mandipropamid, mefentrifluconazole, metalaxyl-M, oxathiapiprolin, picarbutrazox, pydiflumetofen, sedaxane, Streptomyces chrestomyceticus, zoxamide, and Compound Z (feneptamidoquin), wherein the weight ratio of component (A) to component (B) is from 10:1 to 1:10 (or even more preferably, 5:1 to 1:5). In another most preferred composition according to the invention, component (A) is compound no. X.04 (methyl N-[5-[6-[4-(4-fluorophenyl)-5,6-dihydro-1,2,4-oxadiazin-3-yl]-8-methyl-imidazo[1,2-a]pyridin-3- yl]-2-pyridyl]carbamate) or a salt, or N-oxide thereof, and component (B) is a compound selected from the group consisting of acibenzolar-S-methyl, ametoctradin, amisulbrom, azoxystrobin, chlorothalonil, cyazofamid, cyclobutrifluram, cymoxanil, difenoconazole, disodium phosphonate, florylpicoxamid, fluazinam, fludioxonil, fluopicolide, fluoxapiprolin, folpet, mandipropamid, mefentrifluconazole, metalaxyl-M, oxathiapiprolin, picarbutrazox, pydiflumetofen, sedaxane, Streptomyces chrestomyceticus, zoxamide, and Compound Z (feneptamidoquin), wherein the weight ratio of component (A) to component (B) is from 10:1 to 1:10 (or even more preferably, 5:1 to 1:5). In another most preferred composition according to the invention, component (A) is compound no. X.05 (methyl N-[5-[6-[5-(4-fluoro-3-methoxy-phenyl)-1-methyl-pyrazol-4-yl]imidazo[1,2-a]pyridin-3-yl]-2- pyridyl]carbamate) or a salt, or N-oxide thereof, and component (B) is a compound selected from the group consisting of acibenzolar-S-methyl, ametoctradin, amisulbrom, azoxystrobin, chlorothalonil, cyazofamid, cyclobutrifluram, cymoxanil, difenoconazole, disodium phosphonate, florylpicoxamid, fluazinam, fludioxonil, fluopicolide, fluoxapiprolin, folpet, mandipropamid, mefentrifluconazole, metalaxyl-M, oxathiapiprolin, picarbutrazox, pydiflumetofen, sedaxane, Streptomyces chrestomyceticus, zoxamide, and Compound Z (feneptamidoquin), wherein the weight ratio of component (A) to component (B) is from 10:1 to 1:10 (or even more preferably, 5:1 to 1:5). In another most preferred composition according to the invention, component (A) is compound no. X.06 (methyl N-[5-[6-[4-(4-fluoro-3-methoxy-phenyl)-5,6-dihydro-1,2,4-oxadiazin-3-yl]imidazo[1,2-a]pyridin- 3-yl]-2-pyridyl]carbamate) or a salt, or N-oxide thereof, and component (B) is a compound selected from the group consisting of acibenzolar-S-methyl, ametoctradin, amisulbrom, azoxystrobin, chlorothalonil, cyazofamid, cyclobutrifluram, cymoxanil, difenoconazole, disodium phosphonate, florylpicoxamid, fluazinam, fludioxonil, fluopicolide, fluoxapiprolin, folpet, mandipropamid, mefentrifluconazole, metalaxyl-M, oxathiapiprolin, picarbutrazox, pydiflumetofen, sedaxane, Streptomyces chrestomyceticus, zoxamide, and Compound Z (feneptamidoquin), wherein the weight ratio of component (A) to component (B) is from 10:1 to 1:10 (or even more preferably, 5:1 to 1:5). In another most preferred composition according to the invention, component (A) is compound no. X.07 (methyl N-[5-[6-[2-(4-fluoro-3-methoxy-phenyl)-1,2,4-triazol-3-yl]-8-methyl-imidazo[1,2-a]pyridin-3-yl]-2- pyridyl]carbamate) or a salt, or N-oxide thereof, and component (B) is a compound selected from the group consisting of acibenzolar-S-methyl, ametoctradin, amisulbrom, azoxystrobin, chlorothalonil, cyazofamid, cyclobutrifluram, cymoxanil, difenoconazole, disodium phosphonate, florylpicoxamid, fluazinam, fludioxonil, fluopicolide, fluoxapiprolin, folpet, mandipropamid, mefentrifluconazole, metalaxyl-M, oxathiapiprolin, picarbutrazox, pydiflumetofen, sedaxane, Streptomyces chrestomyceticus, zoxamide, and Compound Z (feneptamidoquin), wherein the weight ratio of component (A) to component (B) is from 10:1 to 1:10 (or even more preferably, 5:1 to 1:5). In another most preferred composition according to the invention, component (A) is compound no. X.08 (methyl N-[5-[6-[4-(4-fluoro-3-methoxy-phenyl)-5-methyl-1,2,4-triazol-3-yl]imidazo[1,2-a]pyridin-3-yl]-2- pyridyl]carbamate) or a salt, or N-oxide thereof, and component (B) is a compound selected from the group consisting of acibenzolar-S-methyl, ametoctradin, amisulbrom, azoxystrobin, chlorothalonil, cyazofamid, cyclobutrifluram, cymoxanil, difenoconazole, disodium phosphonate, florylpicoxamid, fluazinam, fludioxonil, fluopicolide, fluoxapiprolin, folpet, mandipropamid, mefentrifluconazole, metalaxyl-M, oxathiapiprolin, picarbutrazox, pydiflumetofen, sedaxane, Streptomyces chrestomyceticus, zoxamide, and Compound Z (feneptamidoquin), wherein the weight ratio of component (A) to component (B) is from 10:1 to 1:10 (or even more preferably, 5:1 to 1:5). In another most preferred composition according to the invention, component (A) is compound no. X.09 (methyl N-[5-[6-[1-(4-fluoro-3-methoxy-phenyl)imidazol-2-yl]imidazo[1,2-a]pyridin-3-yl]-2- pyridyl]carbamate) or a salt, or N-oxide thereof, and component (B) is a compound selected from the group consisting of acibenzolar-S-methyl, ametoctradin, amisulbrom, azoxystrobin, chlorothalonil, cyazofamid, cyclobutrifluram, cymoxanil, difenoconazole, disodium phosphonate, florylpicoxamid, fluazinam, fludioxonil, fluopicolide, fluoxapiprolin, folpet, mandipropamid, mefentrifluconazole, metalaxyl-M, oxathiapiprolin, picarbutrazox, pydiflumetofen, sedaxane, Streptomyces chrestomyceticus, zoxamide, and Compound Z (feneptamidoquin), wherein the weight ratio of component (A) to component (B) is from 10:1 to 1:10 (or even more preferably, 5:1 to 1:5). In another most preferred composition according to the invention, component (A) is compound no. X.10 (methyl N-[5-[6-[2-(4-chloro-3-methoxy-phenyl)-1,2,4-triazol-3-yl]imidazo[1,2-a]pyridin-3-yl]-2- pyridyl]carbamate) or a salt, or N-oxide thereof, and component (B) is a compound selected from the group consisting of acibenzolar-S-methyl, ametoctradin, amisulbrom, azoxystrobin, chlorothalonil, cyazofamid, cyclobutrifluram, cymoxanil, difenoconazole, disodium phosphonate, florylpicoxamid, fluazinam, fludioxonil, fluopicolide, fluoxapiprolin, folpet, mandipropamid, mefentrifluconazole, metalaxyl-M, oxathiapiprolin, picarbutrazox, pydiflumetofen, sedaxane, Streptomyces chrestomyceticus, zoxamide, and Compound Z (feneptamidoquin), wherein the weight ratio of component (A) to component (B) is from 10:1 to 1:10 (or even more preferably, 5:1 to 1:5). In another most preferred composition according to the invention, component (A) is compound no. X.11 (methyl N-[5-[6-[2-(4-fluoro-3-methoxy-phenyl)-1,2,4-triazol-3-yl]imidazo[1,2-a]pyridin-3-yl]-2- pyridyl]carbamate) or a salt, or N-oxide thereof, and component (B) is a compound selected from the group consisting of acibenzolar-S-methyl, ametoctradin, amisulbrom, azoxystrobin, chlorothalonil, cyazofamid, cyclobutrifluram, cymoxanil, difenoconazole, disodium phosphonate, florylpicoxamid, fluazinam, fludioxonil, fluopicolide, fluoxapiprolin, folpet, mandipropamid, mefentrifluconazole, metalaxyl-M, oxathiapiprolin, picarbutrazox, pydiflumetofen, sedaxane, Streptomyces chrestomyceticus, zoxamide, and Compound Z (feneptamidoquin), wherein the weight ratio of component (A) to component (B) is from 10:1 to 1:10 (or even more preferably, 5:1 to 1:5). In another most preferred composition according to the invention, component (A) is compound no. X.12 (methyl N-[5-[6-[4-(4-fluoro-3-methoxy-phenyl)-5-(methoxymethyl)-1,2,4-triazol-3-yl]-8-methyl- imidazo[1,2-a]pyridin-3-yl]-2-pyridyl]carbamate) or a salt, or N-oxide thereof, and component (B) is a compound selected from the group consisting of acibenzolar-S-methyl, ametoctradin, amisulbrom, azoxystrobin, chlorothalonil, cyazofamid, cyclobutrifluram, cymoxanil, difenoconazole, disodium phosphonate, florylpicoxamid, fluazinam, fludioxonil, fluopicolide, fluoxapiprolin, folpet, mandipropamid, mefentrifluconazole, metalaxyl-M, oxathiapiprolin, picarbutrazox, pydiflumetofen, sedaxane, Streptomyces chrestomyceticus, zoxamide, and Compound Z (feneptamidoquin), wherein the weight ratio of component (A) to component (B) is from 10:1 to 1:10 (or even more preferably, 5:1 to 1:5). In any of the preferred compositions according to the invention, the composition may comprise an additional active ingredient component (C), which is different to component (B), and is selected from the group consisting of acetamiprid, acibenzolar-S-methyl, ametoctradin, amisulbrom, azoxystrobin, Bacillus amyloliquefaciens, benzovindiflupyr, broflanilid, chlorothalonil, chlothianidin, chlorantraniliprole, Cis-Jasmone, cyantraniliprole, cyazofamid, cyclobutrifluram, cymoxanil, difenoconazole, disodium phosphonate, ethaboxam, fenpicoxamid, florylpicoxamid, fluazinam, fludioxonil, fluindapyr, fluopicolide, fluopyram, fluoxapiprolin, fluoxytioconazole, fluxametamide, fluxapyroxad, folpet, imidaclprid, inpyrfluxam, ipconazole, ipflufenoquin, isocycloseram, isoflucypram, isotianil, mandipropamid, mefentrifulconazole, metalaxyl, metalaxyl-M (mefenoxam), metyltetraprole, oxathiapiprolin, penflufen, phosphite (phosphonate), picarbutrazox, prothioconazole, pydiflumetofen, pyraclostrobin, quinofumerin, sedaxane, silthiofam, Streptomyces chrestomyceticus, tebuconazole, tetraniliprole, thiabendazole, thiamethoxam, tolprocarb, triticonazole, zoxamide, N-[(1R)-1-benzyl-3-chloro-1-methyl-but-3-enyl]-8- fluoro-quinoline-3-carboxamide, N-[(1S)-1-benzyl-3-chloro-1-methyl-but-3-enyl]-8-fluoro-quinoline-3- carboxamide, N-[(1R)-1-benzyl-3,3,3-trifluoro-1-methyl-propyl]-8-fluoro-quinoline-3-carboxamide, N- [(1S)-1-benzyl-3,3,3-trifluoro-1-methyl-propyl]-8-fluoro-quinoline-3-carboxamide, N-[(1R)-1-benzyl-1,3- dimethyl-butyl]-7,8-difluoro-quinoline-3-carboxamide, N-[(1S)-1-benzyl-1,3-dimethyl-butyl]-7,8-difluoro- quinoline-3-carboxamide, 8-fluoro-N-[(1R)-1-[(3-fluorophenyl)methyl]-1,3-dimethyl-butyl]quinoline-3- carboxamide, 8-fluoro-N-[(1S)-1-[(3-fluorophenyl)methyl]-1,3-dimethyl-butyl]quinoline-3-carboxamide, N-[(1R)-1-benzyl-1,3-dimethyl-butyl]-8-fluoro-quinoline-3-carboxamide, N-[(1S)-1-benzyl-1,3-dimethyl- butyl]-8-fluoro-quinoline-3-carboxamide, N-((1R)-1-benzyl-3-chloro-1-methyl-but-3-enyl)-8-fluoro- quinoline-3-carboxamide, and N-((1S)-1-benzyl-3-chloro-1-methyl-but-3-enyl)-8-fluoro-quinoline-3- carboxamide. The composition according to the present invention can be used in the agricultural sector and related fields of use for controlling plant pests or on non-living materials for control of spoilage microorganisms or organisms potentially harmful to man. The composition can be used to inhibit or destroy the pests that occur on plants or parts of plants (fruit, blossoms, leaves, stems, tubers, roots) of different crops of useful plants, while at the same time protecting also those parts of the plants that grow later e.g. from phytopathogenic microorganisms. It is also possible to use the composition as fungicide. The term “fungicide” as used herein means a compound that controls, modifies, or prevents the growth of fungi. The term “fungicidally effective amount” means the quantity of such a compound or combination of such compounds that is capable of producing an effect on the growth of fungi. Controlling or modifying effects include all deviation from natural development, such as killing, retardation and the like, and prevention includes barrier or other defensive formation in or on a plant to prevent fungal infection. The composition according to the present invention can comprise a fungicidally effective amount of the component A and/or the component B. The term “locus” as used herein means fields in or on which plants are growing, or where seeds of cultivated plants are sown, or where seed will be placed into the soil. It includes soil, seeds, and seedlings, as well as established vegetation. The term “plants” refers to all physical parts of a plant, including seeds, seedlings, saplings, roots, tubers, stems, stalks, foliage, and fruits. It is also possible to use the composition according to the present invention as dressing agents for the treatment of plant propagation material for the protection against fungal infections as well as against phytopathogenic fungi occurring in the soil. The propagation material can be treated with a composition according to the present invention before planting: seed, for example, can be dressed before being sown. The composition according to the present invention can also be applied to grains (coating), either by impregnating the seeds in a liquid formulation or by coating them with a solid formulation. The composition can also be applied to the planting site when the propagation material is being planted, for example, to the seed furrow during sowing. The invention relates also to such methods of treating plant propagation material and to the plant propagation material so treated. The term “plant propagation material” is understood to denote generative parts of the plant, such as seeds, which can be used for the multiplication of the latter, and vegetative material, such as cuttings or tubers, for example potatoes. There may be mentioned for example seeds (in the strict sense), roots, fruits, tubers, bulbs, rhizomes and parts of plants. Germinated plants and young plants which are to be transplanted after germination or after emergence from the soil, may also be mentioned. These young plants may be protected before transplantation by a total or partial treatment by immersion. Preferably “plant propagation material” is understood to denote seeds. Pesticidal agents referred to herein using their common name are known, for example, from "The Pesticide Manual", 19th Ed., British Crop Protection Council 2021. Furthermore the composition accorindg to the present invention can be used for controlling fungi in related areas, for example in the protection of technical materials, including wood and wood related technical products, in food storage, in hygiene management. In addition, the invention could be used to protect non-living materials from fungal attack, e.g. lumber, wall boards and paint. The composition according to the invention is effective against harmful microorganisms, such as microorganisms, that cause phytopathogenic diseases, in particular against phytopathogenic fungi and bacteria. The composition of the invention may be used to control plant diseases caused by a broad spectrum of fungal plant pathogens in the Basidiomycete, Ascomycete, Oomycete and/or Deuteromycete, Blasocladiomycete, Chrytidiomycete, Glomeromycete and/or Mucoromycete classes, and more preferably in the Oomycete classes. The composition of the invention is effective in controlling a broad spectrum of plant diseases, such as foliar pathogens of ornamental, turf, vegetable, field, cereal, and fruit crops. These pathogens may include: Oomycetes, including Phytophthora diseases such as those caused by Phytophthora capsici, Phytophthora infestans, Phytophthora sojae, Phytophthora fragariae, Phytophthora nicotianae, Phytophthora cinnamomi, Phytophthora citricola, Phytophthora citrophthora and Phytophthora erythroseptica; Pythium diseases such as those caused by Pythium aphanidermatum, Pythium arrhenomanes, Pythium graminicola, Pythium irregulare, Pythium sylvaticum and Pythium ultimum; diseases caused by Peronosporales such as Peronospora destructor, Peronospora parasitica, Plasmopara viticola, Plasmopara halstedii, Pseudoperonospora cubensis, Albugo candida, Sclerophthora macrospora and Bremia lactucae; and others such as Aphanomyces cochlioides, Labyrinthula zosterae, Peronosclerospora sorghi and Sclerospora graminicola; Ascomycetes, including blotch, spot, blast or blight diseases and/or rots for example those caused by Pleosporales such as Stemphylium solani, Stagonospora tainanensis, Spilocaea oleaginea, Setosphaeria turcica, Pyrenochaeta lycoperisici, Pleospora herbarum, Phoma destructiva, Phaeosphaeria herpotrichoides, Phaeocryptocus gaeumannii, Ophiosphaerella graminicola, Ophiobolus graminis, Leptosphaeria maculans, Hendersonia creberrima, Helminthosporium triticirepentis, Setosphaeria turcica, Drechslera glycines, Didymella bryoniae, Cycloconium oleagineum, Corynespora cassiicola, Cochliobolus sativus, Bipolaris cactivora, Venturia inaequalis, Pyrenophora teres, Pyrenophora tritici-repentis, Alternaria alternata, Alternaria brassicicola, Alternaria solani and Alternaria tomatophila, Capnodiales such as Septoria tritici, Septoria nodorum, Septoria glycines, Cercospora arachidicola, Cercospora sojina, Cercospora zeae-maydis, Cercosporella capsellae and Cercosporella herpotrichoides, Cladosporium carpophilum, Cladosporium effusum, Passalora fulva, Cladosporium oxysporum, Dothistroma septosporum, Isariopsis clavispora, Mycosphaerella fijiensis, Mycosphaerella graminicola, Mycovellosiella koepkeii, Phaeoisariopsis bataticola, Pseudocercospora vitis, Pseudocercosporella herpotrichoides, Ramularia beticola, Ramularia collo-cygni, Magnaporthales such as Gaeumannomyces graminis, Magnaporthe grisea, Pyricularia oryzae, Diaporthales such as Anisogramma anomala, Apiognomonia errabunda, Cytospora platani, Diaporthe phaseolorum, Discula destructiva, Gnomonia fructicola, Greeneria uvicola, Melanconium juglandinum, Phomopsis viticola, Sirococcus clavigignenti-juglandacearum, Tubakia dryina, Dicarpella spp., Valsa ceratosperma, and others such as Actinothyrium graminis, Ascochyta pisi, Aspergillus flavus, Aspergillus fumigatus, Aspergillus nidulans, Asperisporium caricae, Blumeriella jaapii, Candida spp., Capnodium ramosum, Cephaloascus spp., Cephalosporium gramineum, Ceratocystis paradoxa, Chaetomium spp., Hymenoscyphus pseudoalbidus, Coccidioides spp., Cylindrosporium padi, Diplocarpon malae, Drepanopeziza campestris, Elsinoe ampelina, Epicoccum nigrum, Epidermophyton spp., Eutypa lata, Geotrichum candidum, Gibellina cerealis, Gloeocercospora sorghi, Gloeodes pomigena, Gloeosporium perennans; Gloeotinia temulenta, Griphospaeria corticola, Kabatiella lini, Leptographium microsporum, Leptosphaerulinia crassiasca, Lophodermium seditiosum, Marssonina graminicola, Microdochium nivale, Monilinia fructicola, Monographella albescens, Monosporascus cannonballus, Naemacyclus spp., Ophiostoma novo-ulmi, Paracoccidioides brasiliensis, Penicillium expansum, Pestalotia rhododendri, Petriellidium spp., Pezicula spp., Phialophora gregata, Phyllachora pomigena, Phymatotrichum omnivora, Physalospora abdita, Plectosporium tabacinum, Polyscytalum pustulans, Pseudopeziza medicaginis, Pyrenopeziza brassicae, Ramulispora sorghi, Rhabdocline pseudotsugae, Rhynchosporium secalis, Sacrocladium oryzae, Scedosporium spp., Schizothyrium pomi, Sclerotinia sclerotiorum, Sclerotinia minor; Sclerotium spp., Typhula ishikariensis, Seimatosporium mariae, Lepteutypa cupressi, Septocyta ruborum, Sphaceloma perseae, Sporonema phacidioides, Stigmina palmivora, Tapesia yallundae, Taphrina bullata, Thielviopsis basicola, Trichoseptoria fructigena, Zygophiala jamaicensis; powdery mildew diseases for example those caused by Erysiphales such as Blumeria graminis, Erysiphe polygoni, Uncinula necator, Sphaerotheca fuligena, Podosphaera leucotricha, Podospaera macularis Golovinomyces cichoracearum, Leveillula taurica, Microsphaera diffusa, Oidiopsis gossypii, Phyllactinia guttata and Oidium arachidis; molds for example those caused by Botryosphaeriales such as Dothiorella aromatica, Diplodia seriata, Guignardia bidwellii, Botrytis cinerea, Botryotinia allii, Botryotinia fabae, Fusicoccum amygdali, Lasiodiplodia theobromae, Macrophoma theicola, Macrophomina phaseolina, Phyllosticta cucurbitacearum; anthracnoses for example those caused by Glommerelales such as Colletotrichum gloeosporioides, Colletotrichum lagenarium, Colletotrichum gossypii, Glomerella cingulata, and Colletotrichum graminicola; and wilts or blights for example those caused by Hypocreales such as Acremonium strictum, Claviceps purpurea, Fusarium culmorum, Fusarium graminearum, Fusarium virguliforme, Fusarium oxysporum, Fusarium subglutinans, Fusarium oxysporum f.sp. cubense, Gerlachia nivale, Gibberella fujikuroi, Gibberella zeae, Gliocladium spp., Myrothecium verrucaria, Nectria ramulariae, Trichoderma viride, Trichothecium roseum, and Verticillium theobromae; Basidiomycetes, including smuts for example those caused by Ustilaginales such as Ustilaginoidea virens, Ustilago nuda, Ustilago tritici, Ustilago zeae, rusts for example those caused by Pucciniales such as Cerotelium fici, Chrysomyxa arctostaphyli, Coleosporium ipomoeae, Hemileia vastatrix, Puccinia arachidis, Puccinia cacabata, Puccinia graminis, Puccinia recondita, Puccinia sorghi, Puccinia hordei, Puccinia striiformis f.sp. Hordei, Puccinia striiformis f.sp. Secalis, Pucciniastrum coryli, or Uredinales such as Cronartium ribicola, Gymnosporangium juniperi-viginianae, Melampsora medusae, Phakopsora pachyrhizi, Phragmidium mucronatum, Physopella ampelosidis, Tranzschelia discolor and Uromyces viciae-fabae; and other rots and diseases such as those caused by Cryptococcus spp., Exobasidium vexans, Marasmiellus inoderma, Mycena spp., Sphacelotheca reiliana, Typhula ishikariensis, Urocystis agropyri, Itersonilia perplexans, Corticium invisum, Laetisaria fuciformis, Waitea circinata, Rhizoctonia solani, Thanetephorus cucurmeris, Entyloma dahliae, Entylomella microspora, Neovossia moliniae and Tilletia caries; Blastocladiomycetes, such as Physoderma maydis; Mucoromycetes, such as Choanephora cucurbitarum.; Mucor spp.; Rhizopus arrhizus; as well as diseases caused by other species and genera closely related to those listed above. In addition to their fungicidal activity, the composition accorindg to the present invention may also have activity against bacteria such as Erwinia amylovora, Erwinia caratovora, Xanthomonas campestris, Pseudomonas syringae, Strptomyces scabies and other related species as well as certain protozoa. Within the scope of the present invention, target crops and/or useful plants to be protected typically comprise perennial and annual crops, such as berry plants for example blackberries, blueberries, cranberries, raspberries and strawberries; cereals for example barley, maize (corn), millet, oats, rice, rye, sorghum triticale and wheat; fibre plants for example cotton, flax, hemp, jute and sisal; field crops for example sugar and fodder beet, coffee, hops, mustard, oilseed rape (canola), poppy, sugar cane, sunflower, tea and tobacco; fruit trees for example apple, apricot, avocado, banana, cherry, citrus, nectarine, peach, pear and plum; grasses for example Bermuda grass, bluegrass, bentgrass, centipede grass, fescue, ryegrass, St. Augustine grass and Zoysia grass; herbs such as basil, borage, chives, coriander, lavender, lovage, mint, oregano, parsley, rosemary, sage and thyme; legumes for example beans, lentils, peas and soya beans; nuts for example almond, cashew, ground nut, hazelnut, peanut, pecan, pistachio and walnut; palms for example oil palm; ornamentals for example flowers, shrubs and trees; other trees, for example cacao, coconut, olive and rubber; vegetables for example asparagus, aubergine, broccoli, cabbage, carrot, cucumber, garlic, lettuce, marrow, melon, okra, onion, pepper, potato, pumpkin, rhubarb, spinach and tomato; and vines for example grapes. The useful plants and / or target crops in accordance with the invention include conventional as well as genetically enhanced or engineered varieties such as, for example, insect resistant (e.g. Bt. and VIP varieties) as well as disease resistant, herbicide tolerant (e.g. glyphosate- and glufosinate-resistant maize varieties commercially available under the trade names RoundupReady® and LibertyLink®) and nematode tolerant varieties. By way of example, suitable genetically enhanced or engineered crop varieties include the Stoneville 5599BR cotton and Stoneville 4892BR cotton varieties. The term "useful plants" and/or “target crops” is to be understood as including also useful plants that have been rendered tolerant to herbicides like bromoxynil or classes of herbicides (such as, for example, HPPD inhibitors, ALS inhibitors, for example primisulfuron, prosulfuron and trifloxysulfuron, EPSPS (5- enol-pyrovyl-shikimate-3-phosphate-synthase) inhibitors, GS (glutamine synthetase) inhibitors or PPO (protoporphyrinogen-oxidase) inhibitors) as a result of conventional methods of breeding or genetic engineering. An example of a crop that has been rendered tolerant to imidazolinones, e.g. imazamox, by conventional methods of breeding (mutagenesis) is Clearfield® summer rape (Canola). Examples of crops that have been rendered tolerant to herbicides or classes of herbicides by genetic engineering methods include glyphosate- and glufosinate-resistant maize varieties commercially available under the trade names RoundupReady® , Herculex I® and LibertyLink®. The term "useful plants" and/or “target crops” is to be understood as including those which naturally are or have been rendered resistant to harmful insects. This includes plants transformed by the use of recombinant DNA techniques, for example, to be capable of synthesising one or more selectively acting toxins, such as are known, for example, from toxin-producing bacteria. Examples of toxins which can be expressed include ^-endotoxins, vegetative insecticidal proteins (Vip), insecticidal proteins of bacteria colonising nematodes, and toxins produced by scorpions, arachnids, wasps and fungi. An example of a crop that has been modified to express the Bacillus thuringiensis toxin is the Bt maize KnockOut^ (Syngenta Seeds). An example of a crop comprising more than one gene that codes for insecticidal resistance and thus expresses more than one toxin is VipCot^ (Syngenta Seeds). Crops or seed material thereof can also be resistant to multiple types of pests (so-called stacked transgenic events when created by genetic modification). For example, a plant can have the ability to express an insecticidal protein while at the same time being herbicide tolerant, for example Herculex I^ (Dow AgroSciences, Pioneer Hi-Bred International). The term "useful plants" and/or “target crops” is to be understood as including also useful plants which have been so transformed by the use of recombinant DNA techniques that they are capable of synthesising antipathogenic substances having a selective action, such as, for example, the so-called "pathogenesis-related proteins" (PRPs, see e.g. EP-A-0392225). Examples of such antipathogenic substances and transgenic plants capable of synthesising such antipathogenic substances are known, for example, from EP-A-0392225, WO 95/33818, and EP-A-0353191. The methods of producing such transgenic plants are generally known to the person skilled in the art and are described, for example, in the publications mentioned above. Toxins that can be expressed by transgenic plants include, for example, insecticidal proteins from Bacillus cereus or Bacillus popilliae; or insecticidal proteins from Bacillus thuringiensis, such as ^- endotoxins, e.g. Cry1Ab, Cry1Ac, Cry1F, Cry1Fa2, Cry2Ab, Cry3A, Cry3Bb1 or Cry9C, or vegetative insecticidal proteins (Vip), e.g. Vip1, Vip2, Vip3 or Vip3A; or insecticidal proteins of bacteria colonising nematodes, for example Photorhabdus spp. or Xenorhabdus spp., such as Photorhabdus luminescens, Xenorhabdus nematophilus; toxins produced by animals, such as scorpion toxins, arachnid toxins, wasp toxins and other insect-specific neurotoxins; toxins produced by fungi, such as Streptomycetes toxins, plant lectins, such as pea lectins, barley lectins or snowdrop lectins; agglutinins; proteinase inhibitors, such as trypsin inhibitors, serine protease inhibitors, patatin, cystatin, papain inhibitors; ribosome- inactivating proteins (RIP), such as ricin, maize-RIP, abrin, luffin, saporin or bryodin; steroid metabolism enzymes, such as 3-hydroxysteroidoxidase, ecdysteroid-UDP-glycosyl-transferase, cholesterol oxidases, ecdysone inhibitors, HMG-COA-reductase, ion channel blockers, such as blockers of sodium or calcium channels, juvenile hormone esterase, diuretic hormone receptors, stilbene synthase, bibenzyl synthase, chitinases and glucanases. Further, in the context of the present invention there are to be understood by ^-endotoxins, for example Cry1Ab, Cry1Ac, Cry1F, Cry1Fa2, Cry2Ab, Cry3A, Cry3Bb1 or Cry9C, or vegetative insecticidal proteins (Vip), for example Vip1, Vip2, Vip3 or Vip3A, expressly also hybrid toxins, truncated toxins and modified toxins. Hybrid toxins are produced recombinantly by a new combination of different domains of those proteins (see, for example, WO 02/15701). Truncated toxins, for example a truncated Cry1Ab, are known. In the case of modified toxins, one or more amino acids of the naturally occurring toxin are replaced. In such amino acid replacements, preferably non-naturally present protease recognition sequences are inserted into the toxin, such as, for example, in the case of Cry3A055, a cathepsin-G- recognition sequence is inserted into a Cry3A toxin (see WO03/018810). More examples of such toxins or transgenic plants capable of synthesising such toxins are disclosed, for example, in EP-A-0374753, WO93/07278, WO95/34656, EP-A-0427529, EP-A-451878 and WO03/052073. The processes for the preparation of such transgenic plants are generally known to the person skilled in the art and are described, for example, in the publications mentioned above. CryI-type deoxyribonucleic acids and their preparation are known, for example, from WO 95/34656, EP-A-0367 474, EP-A-0401979 and WO 90/13651. The toxin contained in the transgenic plants imparts to the plants tolerance to harmful insects. Such insects can occur in any taxonomic group of insects, but are especially commonly found in the beetles (Coleoptera), two-winged insects (Diptera) and butterflies (Lepidoptera). Transgenic plants containing one or more genes that code for an insecticidal resistance and express one or more toxins are known and some of them are commercially available. Examples of such plants are: YieldGard^ (maize variety that expresses a Cry1Ab toxin); YieldGard Rootworm^ (maize variety that expresses a Cry3Bb1 toxin); YieldGard Plus^ (maize variety that expresses a Cry1Ab and a Cry3Bb1 toxin); Starlink^ (maize variety that expresses a Cry9C toxin); Herculex I^ (maize variety that expresses a Cry1Fa2 toxin and the enzyme phosphinothricine N-acetyltransferase (PAT) to achieve tolerance to the herbicide glufosinate ammonium); NuCOTN 33B^ (cotton variety that expresses a Cry1Ac toxin); Bollgard I^ (cotton variety that expresses a Cry1Ac toxin); Bollgard II® (cotton variety that expresses a Cry1Ac and a Cry2Ab toxin); VipCot^ (cotton variety that expresses a Vip3A and a Cry1Ab toxin); NewLeaf^ (potato variety that expresses a Cry3A toxin); NatureGard^, Agrisure® GT Advantage (GA21 glyphosate-tolerant trait), Agrisure® CB Advantage (Bt11 corn borer (CB) trait) and Protecta^. Further examples of such transgenic crops are: 1. Bt11 Maize from Syngenta Seeds SAS, Chemin de l'Hobit 27, F-31 790 St. Sauveur, France, registration number C/FR/96/05/10. Genetically modified Zea mays which has been rendered resistant to attack by the European corn borer (Ostrinia nubilalis and Sesamia nonagrioides) by transgenic expression of a truncated Cry1Ab toxin. Bt11 maize also transgenically expresses the enzyme PAT to achieve tolerance to the herbicide glufosinate ammonium. 2. Bt176 Maize from Syngenta Seeds SAS, Chemin de l'Hobit 27, F-31 790 St. Sauveur, France, registration number C/FR/96/05/10. Genetically modified Zea mays which has been rendered resistant to attack by the European corn borer (Ostrinia nubilalis and Sesamia nonagrioides) by transgenic expression of a Cry1Ab toxin. Bt176 maize also transgenically expresses the enzyme PAT to achieve tolerance to the herbicide glufosinate ammonium. 3. MIR604 Maize from Syngenta Seeds SAS, Chemin de l'Hobit 27, F-31 790 St. Sauveur, France, registration number C/FR/96/05/10. Maize which has been rendered insect-resistant by transgenic expression of a modified Cry3A toxin. This toxin is Cry3A055 modified by insertion of a cathepsin-G- protease recognition sequence. The preparation of such transgenic maize plants is described in WO 03/018810. 4. MON 863 Maize from Monsanto Europe S.A. 270-272 Avenue de Tervuren, B-1150 Brussels, Belgium, registration number C/DE/02/9. MON 863 expresses a Cry3Bb1 toxin and has resistance to certain Coleoptera insects. 5. IPC 531 Cotton from Monsanto Europe S.A. 270-272 Avenue de Tervuren, B-1150 Brussels, Belgium, registration number C/ES/96/02. 6. 1507 Maize from Pioneer Overseas Corporation, Avenue Tedesco, 7 B-1160 Brussels, Belgium, registration number C/NL/00/10. Genetically modified maize for the expression of the protein Cry1F for achieving resistance to certain Lepidoptera insects and of the PAT protein for achieving tolerance to the herbicide glufosinate ammonium. 7. NK603 × MON 810 Maize from Monsanto Europe S.A. 270-272 Avenue de Tervuren, B-1150 Brussels, Belgium, registration number C/GB/02/M3/03. Consists of conventionally bred hybrid maize varieties by crossing the genetically modified varieties NK603 and MON 810. NK603 × MON 810 Maize transgenically expresses the protein CP4 EPSPS, obtained from Agrobacterium sp. strain CP4, which imparts tolerance to the herbicide Roundup® (contains glyphosate), and also a Cry1Ab toxin obtained from Bacillus thuringiensis subsp. kurstaki which brings about tolerance to certain Lepidoptera, include the European corn borer. Compounds of formula (I) according to the invention can be made as shown in the following schemes 1 to 20, in which, unless otherwise stated, the definition of each variable is as defined in the present invention. Compounds of formula (I) can be prepared via Suzuki cross coupling of compounds of formula (II), wherein X is Cl, Br or I, and a compound of formula (III), wherein either R8 is independently from each other hydrogen, C1-C6 alkyl or wherein two R8 together can form a C3-C8 cycloalkyl, in the presence of a base, such as Cs2CO3, K2CO3 or NaOtBu, and a suitable palladium catalyst, such as tetrakistriphenylphosphinepalladium, palladium dichloride, [1,1- bis(diphenylphosphino)ferrocene]dichloropalladium(II), palladium acetate, chloro(2- dicyclohexylphosphino-2′,4′,6′-triisopropyl-1,1′-biphenyl)[2-(2′-amino-1,1′-biphenyl)]palladium(II) or bis(diphenylphosphine)palladium(II) chloride), in a suitable solvent, such as dimethylformamide, dioxane, tetrahydrofuran, ethanol or water. This transformation is depicted in Scheme 1. Scheme 1 Compounds of formula (IIa), wherein A1 is a carbon atom in formula II, wherein X is Cl, Br or I, and wherein X is more preferably Cl, can be prepared by the reaction of a compound of formula (Va), wherein X is Cl, Br, I or a triflate group, and wherein X is more preferably Br, I or a triflate group, with a compounds of formula (IV) wherein X is Cl, Br or I, and wherein X is more preferably Cl, and wherein either R8 is independently from each other hydrogen, C1-C6 alkyl or wherein two R8 together can form a C3-C8 cycloalkyl, in the presence of a base, such as Cs2CO3, K2CO3 or NaOtBu, and a suitable palladium catalyst, such as tetrakistriphenylphosphinepalladium, palladium dichloride, [1,1- bis(diphenylphosphino)ferrocene]dichloropalladium(II), palladium acetate or bis(diphenylphosphine)palladium(II) chloride), in a suitable solvent, such as dimethylformamide, dioxane, tetrahydrofuran, ethanol or water. This transformation is depicted in Scheme 2. Scheme 2 Compounds of formula (Va), wherein X is Cl, Br or I, can be prepared by the reaction of a compound of formula (VIa) with a halogenating agent such as N-chlorosuccinimide, N-bromosuccinimide, N- iodosuccinimide, bromine or iodine, and, optionally, a base such as lithium di-isopropylamine or butyl lithium, in a suitable solvent, such as DMF, acetonitrile, dichloromethane, tetrahydrofuran or acetic acid. Alternatively, compounds of formula (Va), wherein X is Cl, Br, I or a triflate group, can be prepared by the reaction of a compound of formula (VIIa) with triflic anhydride and, optionally, a base, such as triethylamine or pyridine, or a halogenating agent such as phosphorus oxychloride, phosphorus oxybromide, or by successive reaction with phosphorus oxychloride and sodium iodide. These transformations are performed neat or in a suitable solvent such as dichloromethane, toluene or xylene. These transformations are depicted in Scheme 3. (VIa) (VIIa) (Va) Scheme 3 Compounds of formula (VIa) and compounds of formula (VIIa) are either commercially available or the person skilled in the art would know that they can be synthesized by known methods. Some methods for the synthesis of such heteroaromatic can be found in the following publication: J.A. Joule and K. Mills (2010), Heterocyclic Chemistry, Fifth Edition, Wiley-Blackwell; V.J. Ram, A. Sethi, M. Nath, R. Pratap (2019) The Chemistry of Heterocycles Nomenclature and Chemistry of Three to Five Membered Heterocycles, 1st Edition, Elsevier; V.J. Ram, A. Sethi, M. Nath, R. Pratap (2019) The Chemistry of Heterocycles Chemistry of Six to Eight Membered N,O,S,P and Se Heterocycles, 1st Edition, Elsevier. Furthermore, the person skilled in the art would also recognize that compounds of formula (VIa) and compounds of formula (VIIa) could easily be obtained by either C-C cross-coupling, C-N cross-coupling or via direct C-H activation. A subset of the vast literature describing such transformations is referenced here: J.-Q. Chen, J.-H. Li, Z.-B. Dong, Adv. Synth Catal.2020, 362, 3311; F. Bellina, R. Rossi, Adv. Synth. Catal. 2010, 1223; E. Kang, H. T. Kim, J.M. Joo, Org. Biomol. Chem.2020, 18, 6192; Q. Yang, Y. Zhao, D. Ma, Org. Process Res. Dev.2022, 26, 1690; H. Kaddouri, V. Vicente, A. Ouali, F. Ouazzani, M. Taillefer, Angew. Chem. Int. Ed. 2009, 48, 333; J. J. Li and G. W. Gribble (2007) Palladium in Heterocyclic Chemistry, Second Edition, Elsevier; A. de Meijere, S. Bräse, M. Oestreich (2014) Metal- Catalyzed Cross-Coupling Reactions and More, Volume 1 to 3, Wiley-VCH. Compounds of formula (IV) wherein X is Cl, Br or I, and wherein X is more preferably Cl, and wherein either R8 is independently from each other hydrogen, C1-C6 alkyl or wherein two R8 together can form a C3-C8 cycloalkyl can be prepared by the reaction of a compound of formula (VIII) with a halogenating agent such as N-chlorosuccinimide, N-bromosuccinimide or N-iodosuccinimide in a suitable solvent, such as DMF, acetonitrile, dichloromethane or tetrahydrofuran. This transformation is depicted in Scheme 4. (VIII) (IV) Scheme 4 Compounds of formula (VIII) wherein either R8 is independently from each other hydrogen, C1-C6 alkyl or wherein two R8 together can form a C3-C8 cycloalkyl can be prepared by the reaction of a compound of formula (IX), wherein X is Cl, Br or I, with a compound of formula (X) wherein either R8 is independently from each other hydrogen, C1-C6 alkyl or wherein two R8 together can form a C3-C8 cycloalkyl, such as bis(pinacolato)diborane, bis(neopentyl glycolato)diboron or diboronic acid, a catalyst, such as dichloro[1,1′-bis(diphenylphosphino)ferrocene]palladium(II) dichloromethane adduct or dichlorobis(tricyclohexylphosphine)palladium and, optionally, a base, such as potassium acetate, in a suitable solvent, such as DMF, acetonitrile, toluene, dioxane or tetrahydrofuran. Alternatively compounds of formula (VIII) wherein either R8 is independently from each other hydrogen, C1-C6 alkyl or wherein two R8 together can form a C3-C8 cycloalkyl can be prepared by the reaction of a compound of formula (IX), wherein X is Cl, Br or I, with a compounds of formula (XI) wherein either R8 is independently from each other hydrogen, C1-C6 alkyl or wherein two R8 together can form a C3-C8 cycloalkyl, such as trimethyl borate, triisopropyl borate, isopropoxy 4,4,5,5-tetramethyl-1,3,2- dioxaborolane, or 2-methoxy-4,4,5,5-tetramethyl-1,3,2-dioxaborolane, and a metal halogen exchange reagent, such as butyl lithium or ethylmagnesium bromide, in a suitable solvent, such as tetrahydrofuran, diethyl ether or dioxane. These transformations are depicted in Scheme 5. Scheme 5 Compounds of formula (IX) are commercially available or, alternatively, can be prepared by the reaction of a compound of formula (XII), wherein X is Cl, Br or I, and a compound of formula (XIII), wherein X is Cl, Br or I, or its corresponding acetal of formula (XIV), wherein X is Cl, Br or I and either R10 is independently from each other C1-C6 alkyl or wherein two R10 together can form a C3-C8 cycloalkyl, in a solvent, such as water, ethanol, acetone or acetonitrile. In some instance, the outcome of the reaction can be improved by using a base, such as sodium bicarbonate or potassium carbonate, or by using an acid, such as p-toluenesulfonic acid or hydrogen bromide. This transformation is depicted in scheme 6. Compounds of formula (XII), wherein X is Cl, Br or I, are prepared by known methods or are commercially available. Alternatively, compounds of formula (II), wherein X is Cl, Br or I, and wherein X is more preferably Cl, can be prepared by the reaction of a compound of formula (XV), with a halogenating agent such as N- chlorosuccinimide, N-bromosuccinimide or N-iodosuccinimide in a suitable solvent, such as DMF, acetonitrile, dichloromethane or tetrahydrofuran. This transformation is depicted in Scheme 7 Scheme 7 Compounds of formula (XVa) wherein A1 is a carbon atom in formula (XV), can be prepared by the reaction of a compound of formula (Va), wherein X is Cl, Br, I or a triflate group, with a compounds of formula (VIII), wherein either R8 is independently from each other hydrogen, C1-C6 alkyl or wherein two R8 together can form a C3-C8 cycloalkyl, in the presence of a base, such as Cs2CO3, K2CO3 or NaOtBu, and a suitable palladium catalyst, such as tetrakistriphenylphosphinepalladium, palladium dichloride, [1,1-bis(diphenylphosphino)ferrocene]dichloropalladium(II), palladium acetate or bis(diphenylphosphine)palladium(II) chloride), in a suitable solvent, such as dimethylformamide, dioxane, tetrahydrofuran, ethanol or water. This transformation is depicted in Scheme 8. Scheme 8 Alternatively compounds of formula (Ia) wherein A1 is a carbon atom in formula (I), herein depicted as compound (Ia) can be prepared via Suzuki cross coupling of compounds of formula (XVI), wherein either R8 is independently from each other hydrogen, C1-C6 alkyl or wherein two R8 together can form a C3-C8 cycloalkyl, and a compound of formula (Va), wherein X is Cl, Br, I or a triflate group, in the presence of a base, such as Cs2CO3, K2CO3 or NaOtBu, and a suitable palladium catalyst, such as tetrakistriphenylphosphinepalladium, palladium dichloride, [1,1- bis(diphenylphosphino)ferrocene]dichloropalladium(II), palladium acetate or bis(diphenylphosphine)palladium(II) chloride), in a suitable solvent, such as dimethylformamide, dioxane, tetrahydrofuran, ethanol or water. This transformation is depicted in Scheme 9. Scheme 9 Compounds of formula (XVI) wherein either R8 is independently from each other hydrogen, C1-C6 alkyl or wherein two R8 together can form a C3-C8 cycloalkyl can be prepared by the reaction of a compound of formula (XVII), wherein X is Cl, Br or I, with a compound of formula (X) wherein either R8 is independently from each other hydrogen, C1-C6 alkyl or wherein two R8 together can form a C3-C8 cycloalkyl, such as bis(pinacolato)diborane, bis(neopentyl glycolato)diboron or diboronic acid, a catalyst, such as dichloro[1,1′-bis(diphenylphosphino)ferrocene]palladium(II) dichloromethane adduct or dichlorobis(tricyclohexylphosphine)palladium and, optionally, a base, such as potassium acetate, in a suitable solvent, such as DMF, acetonitrile, toluene, dioxane or tetrahydrofuran. This transformation is depicted in Scheme 10. Scheme 10 Compounds of formula (XVII), wherein X is Cl, Br or I, can be prepared via Suzuki cross coupling of compounds of formula (III), wherein either R8 is independently from each other hydrogen, C1-C6 alkyl or wherein two R8 together can form a C3-C8 cycloalkyl, and a compound of formula (XVIII), wherein either X independently is Cl, Br or I, in the presence of a base, such as Cs2CO3, K2CO3 or NaOtBu, and a suitable palladium catalyst, such as tetrakistriphenylphosphinepalladium, palladium dichloride, [1,1- bis(diphenylphosphino)ferrocene]dichloropalladium(II), palladium acetate or bis(diphenylphosphine)palladium(II) chloride), in a suitable solvent, such as dimethylformamide, dioxane, tetrahydrofuran, ethanol or water. It is well understood by the person skilled in the art that to obtain compounds of formula (XVII) the halogen X from the imidazole ring of the imidazopyridine bicyclic system should be equally or more reactive than the halogen X from the pyridine ring of the imidazopyridine bicyclic system. The person skilled in the art would recognize that halogen reactivity increases from chloro to bromo to iodo. This transformation is depicted in Scheme 11. Scheme 11 Compounds of formula (XVIII), wherein either X is independently Cl, Br or I, can be prepared by the reaction of a compound of formula (IX), wherein X is Cl, Br or I, with a halogenating agent such as N- chlorosuccinimide, N-bromosuccinimide or N-iodosuccinimide in a suitable solvent, such as DMF, acetonitrile, dichloromethane or tetrahydrofuran. This transformation is depicted in Scheme 12. Scheme 12 Alternatively, compounds of formula (IIa), wherein A1 is a carbon atom in formula (II) wherein X is Cl, Br or I, and wherein X is more preferably Cl, can be prepared by the reaction of a compound of formula (XVIII), wherein either X is independently from each other Cl, Br or I, with a compounds of formula (XIXa) wherein either R8 is independently from each other hydrogen, C1-C6 alkyl or wherein two R8 together can form a C3-C8 cycloalkyl, in the presence of a base, such as Cs2CO3, K2CO3 or NaOtBu, and a suitable palladium catalyst, such as tetrakistriphenylphosphinepalladium, palladium dichloride, [1,1- bis(diphenylphosphino)ferrocene]dichloropalladium(II), palladium acetate or bis(diphenylphosphine)palladium(II) chloride), in a suitable solvent, such as dimethylformamide, dioxane, tetrahydrofuran, ethanol or water. This transformation is depicted in Scheme 13. Compounds of formula (IIb) wherein A2 is a carbon atom in formula (II), wherein either X is Cl, Br or I, and wherein X is more preferably Cl, can be prepared by the reaction of a compound of formula (XXb), wherein either X is independently from each other Cl, Br or I, with a compounds of formula (XXI) wherein either R8 is independently from each other hydrogen, C1-C6 alkyl or wherein two R8 together can form a C3-C8 cycloalkyl, in the presence of a base, such as Cs2CO3, K2CO3 or NaOtBu, and a suitable palladium catalyst, such as tetrakistriphenylphosphinepalladium, palladium dichloride, [1,1- bis(diphenylphosphino)ferrocene]dichloropalladium(II), palladium acetate or bis(diphenylphosphine)palladium(II) chloride), in a suitable solvent, such as dimethylformamide, dioxane, tetrahydrofuran, ethanol or water. This transformation is depicted in Scheme 14. Scheme 14 Compounds or formula (XXI) are either commercially available or can be prepared by the person skilled in the art using very well described procedures. Compounds of formula (XXb), wherein either X is independently from each other Cl, Br or I, can be prepared by the reaction of a compound of formula (XXIIb), wherein X is Cl, Br or I, with a halogenating agent such as N-chlorosuccinimide, N-bromosuccinimide or N-iodosuccinimide in a suitable solvent, such as DMF, acetonitrile, dichloromethane or tetrahydrofuran. This transformation is depicted in Scheme 15. Scheme 15 Compounds of formula (XXIId), wherein A1 and A2 are carbon atoms in formula (XXII), and wherein X is Cl, Br or I, can be prepared via Suzuki cross coupling of compounds of formula (XXIIId), wherein either R8 is independently from each other hydrogen, C1-C6 alkyl or wherein two R8 together can form a C3-C8 cycloalkyl, and a compound of formula (XVIII), wherein either X independently is Cl, Br or I, in the presence of a base, such as Cs2CO3, K2CO3 or NaOtBu, and a suitable palladium catalyst, such as tetrakistriphenylphosphinepalladium, palladium dichloride, [1,1- bis(diphenylphosphino)ferrocene]dichloropalladium(II), palladium acetate or bis(diphenylphosphine)palladium(II) chloride), in a suitable solvent, such as dimethylformamide, dioxane, tetrahydrofuran, ethanol or water. It is well understood by the person skilled in the art that to obtain compounds of formula (XXIId) the halogen X from the pyridine ring of the imidazopyridine bicyclic system should be equally or more reactive than the halogen X from the imidazole ring of the imidazopyridine bicyclic system. The person skilled in the art would recognize that halogen reactivity increases from chloro to bromo to iodo. This transformation is depicted in Scheme 16. Scheme 16 Compounds or formula (XXIIId) are either commercially available or can be prepared by the person skilled in the art using very well described procedures. The person skilled in the art would also recognize that the compounds of formula (I) can alternatively be prepared by the de novo construction of the ring W. Such synthetic routes have been used and are described in the experimental section of the present invention. It is understood by the person skilled in the art that the synthetic routes describing the access to those specific compounds can also be used to synthesize analogous compounds of formula (I) of this specific compound, wherein said compounds have identical ring W. These routes described in the experimental section should thus also be considered as general routes for accessing compounds of formula (I). The below compounds of formula (I-b) and (II-b) can be prepared following the synthetic route used in the examples 4, 7 and 8. The example 4, describes the preparation of methyl N-[5-[6-[4-(4-fluoro-3- methoxy-phenyl)-5-methyl-1,2,4-triazol-3-yl]imidazo[1,2-a]pyridin-3-yl]-2-pyridyl]carbamate (compound X.08),the example 7 describes the preparation of methyl N-[5-[6-[4-(4-fluoro-3-methoxy-phenyl)-5- (methoxymethyl)-1,2,4-triazol-3-yl]-8-methyl-imidazo[1,2-a]pyridin-3-yl]-2-pyridyl]carbamate (compound X.12) and the example 8 describes the preparation of methyl N-[5-[8-cyclopropyl-6-[4-(4- fluoro-3-methoxy-phenyl)-1,2,4-triazol-3-yl]imidazo[1,2-a]pyridin-3-yl]-2-pyridyl]carbamate (example X.01). These synthetic routes describe the de novo synthesis of a compound of formula (I), wherein ring W is a triazole (compounds of formula (I-b)) as well as the synthesis of compounds of formula (II), wherein W is a triazole and X is Cl, Br or I (compounds of formula (II-b)). This methodology can be used in general terms to access analogous compounds of formula (I-b) and formula (II-b). The below compounds of formula (I-c) and (II-c) can be prepared following the synthetic route used in the examples 3 and 6. The example 3 describes the preparation of methyl N-[5-[6-[2-(4-fluoro-3- methoxy-phenyl)-1,2,4-triazol-3-yl]-8-methyl-imidazo[1,2-a]pyridin-3-yl]-2-pyridyl]carbamate (compound X.07) and the example 6 describes the preparation of methyl N-[5-[6-[2-(4-fluoro-3-methoxy- phenyl)-1,2,4-triazol-3-yl]imidazo[1,2-a]pyridin-3-yl]-2-pyridyl]carbamate (compound X.11). These synthetic routes describe the de novo synthesis of a compound of formula (I), wherein ring W is a triazole (compounds of formula (I-c)) as well as the synthesis of compounds of formula (II), wherein W is a triazole and X is Cl, Br or I (compounds of formula (II-c)). These methodologies can be used in general terms to access analogous compounds of formula (I-c) and formula (II-c). The below compounds of formula (I-d) and (II-d) can be prepared following the synthetic route used in the examples 2, 10 and 11. 9. The example 2 describes the preparation of methyl N-[5-[6-[4-(4-fluoro- 3-methoxy-phenyl)-5,6-dihydro-1,2,4-oxadiazin-3-yl]imidazo[1,2-a]pyridin-3-yl]-2-pyridyl]carbamate (compound X.06), the example 10 describes the preparation of methyl N-[5-[6-[4-(4-fluoro-3-methoxy- phenyl)-5,6-dihydro-1,2,4-oxadiazin-3-yl]-8-methyl-imidazo[1,2-a]pyridin-3-yl]-2-pyridyl]carbamate (compound X.03) and example 11 describes the preparation of methyl N-[5-[6-[4-(4-fluorophenyl)-5,6- dihydro-1,2,4-oxadiazin-3-yl]-8-methyl-imidazo[1,2-a]pyridin-3-yl]-2-pyridyl]carbamate (Compound X.04). These synthetic routes describe the de novo synthesis of a compound of formula (I), wherein ring W is an oxadiazine (compounds of formula (I-d)) as well as the synthesis of compounds of formula (II), wherein W is an oxadiazine and X is Cl, Br or I (compounds of formula (II-d)). This methodology can be used in general terms to access analogous compounds of formula (I-d) and formula (II-d). The below compounds of formula (I-g) and (II-g) can be prepared following the synthetic route used in the example 9. The example 9 describes the preparation of methyl N-[5-[6-[1-(4-fluoro-3-methoxy- phenyl)imidazol-2-yl]-8-methyl-imidazo[1,2-a]pyridin-3-yl]-2-pyridyl]carbamate (compound X.02).This synthetic route describes the synthesis of a compound of formula (I), wherein ring W is an imidazole (compounds of formula (I-g)) as well as the synthesis of compounds of formula (II), wherein W is an imidazole and X is Cl, Br or I (compounds of formula (II-g)). This methodology can be used in general terms to access analogous compounds of formula (I-g) and formula (II-g). The below compounds of formula (I-h) and (II-h) can be prepared following the synthetic route used in the example 1. The example 1 describes the preparation of methyl N-[5-[6-[5-(4-fluoro-3-methoxy- phenyl)-1-methyl-pyrazol-4-yl]imidazo[1,2-a]pyridin-3-yl]-2-pyridyl]carbamate (compound X.05).This synthetic route describes the synthesis of a compound of formula (I), wherein ring W is a pyrazole (compounds of formula (I-h)) as well as the synthesis of compounds of formula (II), wherein W is a pyrazole and X is Cl, Br or I (compounds of formula (II-h)). This methodology can be used in general terms to access analogous compounds of formula (I-h) and formula (II-h). In some instances, these de novo synthesis might require using compounds of formula (XVI), wherein X is Cl, Br or I, and R9 is hydrogen or C1-C6 alkyl, or the use of compound of formula (XVII), wherein R9 is hydrogen or C1-C6 alkyl. Compounds of formula (XVI), wherein X is Cl, Br or I and R9 is hydrogen or C1-C6 alkyl, are commercially available or, alternatively, can be prepared from the reaction of a compound of formula (XVII), wherein R9 is a hydrogen or C1-C6 alkyl, and a halogenating agent, such as N-chlorosuccinimide, N- bromosuccinimide, N-iodosuccinimide or bromine in a suitable solvent, such as dichloromethane, chloroform, tetrahydrofuran or acetonitrile. This transformation is depicted in scheme 17. Scheme 17 Compounds of formula (XVII), wherein R9 is hydrogen or C1-C6 alkyl, are commercially available or, alternatively, can be prepared by the reaction of a compound of formula (IX), wherein X is Cl, Br or I, with carbon monoxide and an alcohol R9OH, wherein R9 is a C1-C6 alkyl, or water, in the presence of a catalyst, such as PdCl2dppf, and, optionally, a base such as triethylamine. This transformation is depicted in scheme 18. (IX) (XVII) Scheme 18 Alternatively, compounds of formula (XVII), wherein R9 is hydrogen or C1-C6 alkyl, can be prepared by the reaction of a compound of formula (XXV), wherein R9 is hydrogen or C1-C6 alkyl, and a compound of formula (XIII), wherein X is Cl, Br or I, or its corresponding acetal of formula (XIV), wherein X is Cl, Br or I and either R10 is independently from each other C1-C6 alkyl or wherein two R10 together can form a C3-C8 cycloalkyl, in a solvent, such as water, ethanol, acetone or acetonitrile. In some instance, the outcome of the reaction can be improved by using a base, such as sodium bicarbonate or potassium carbonate, or by using an acid, such as p-toluenesulfonic acid or hydrogen bromide. Compounds of formula (XXV), wherein R9 is hydrogen or C1-C6 alkyl, are prepared by known methods or are commercially available. This transformation is depicted in Scheme 19. Scheme 19 Alternatively, compounds of formula (I) can be obtained by acylation of compounds of formula (XXVI) using an acylation reagent of formula (XXVII), wherein X is Cl or Br, in the presence of a base such as triethylamine, pyridine or potassium carbonate. Compounds of formula (XXVI) can be prepared via Suzuki cross coupling of compounds of formula (II), wherein X is Cl, Br or I, and a compound of formula (XXVIII), wherein either R8 is independently from each other hydrogen, C1-C6 alkyl or wherein two R8 together can form a C3-C8 cycloalkyl, in the presence of a base, such as Cs2CO3, K2CO3 or NaOtBu, and a suitable palladium catalyst, such as tetrakistriphenylphosphinepalladium, palladium dichloride, [1,1-bis(diphenylphosphino)ferrocene]dichloropalladium(II), palladium acetate, chloro(2- dicyclohexylphosphino-2′,4′,6′-triisopropyl-1,1′-biphenyl)[2-(2′-amino-1,1′-biphenyl)]palladium(II) or bis(diphenylphosphine)palladium(II) chloride), in a suitable solvent, such as dimethylformamide, dioxane, tetrahydrofuran, ethanol or water. Compounds of formula (XXVII), wherein X is Cl or Br, and compounds of formula (XXVIII), wherein either R8 is independently from each other hydrogen, C1-C6 alkyl or wherein two R8 together can form a C3-C8 cycloalkyl, are commercially available or are prepared by known methods. This transformation is depicted in Scheme 20. Scheme 20 When the term “compound/compounds according to the invention” is used, then this refers to compounds according to the present invention. Alternatively, the compounds of formula (I) according to the present invention can be obtained by using standard synthesis techniques known to the person skilled in the art. Non-exhaustive examples include oxidation reactions, reduction reactions, hydrolysis reactions, coupling reactions, aromatic nucleophilic or electrophilic substitution reactions, nucleophilic substitution reactions, nucleophilic addition reactions, olefination reactions, oxime formation, alkylation and halogenation reactions. Depending on the choice of the reaction conditions and starting materials which are suitable in each case, it is possible, for example, in one reaction step only to replace one substituent by another substituent according to the invention, or a plurality of substituents can be replaced by other substituents according to the invention in the same reaction step. The composition according to the present invention may be used in unmodified form or, preferably, together with the adjuvants conventionally employed in the art of formulation. To this end they may be conveniently formulated in known manner to emulsifiable concentrates, coatable pastes, directly sprayable or dilutable solutions or suspensions, dilute emulsions, wettable powders, soluble powders, dusts, granulates, and also encapsulations e.g. in polymeric substances. As with the type of the compositions, the methods of application, such as spraying, atomising, dusting, scattering, coating or pouring, are chosen in accordance with the intended objectives and the prevailing circumstances. The compositions may also contain further adjuvants such as stabilizers, antifoams, viscosity regulators, binders or tackifiers as well as fertilizers, micronutrient donors or other formulations for obtaining special effects. Suitable carriers and/or adjuvants, e.g. for agricultural use, can be solid or liquid and are substances useful in formulation technology, e.g. natural or regenerated mineral substances, solvents, dispersants, wetting agents, tackifiers, thickeners, binders or fertilizers. Such carriers are for example described in WO 97/33890. Suspension concentrates are aqueous formulations in which finely divided solid particles of the active compound are suspended. Such formulations include anti-settling agents and dispersing agents and may further include a wetting agent to enhance activity as well an anti-foam and a crystal growth inhibitor. In use, these concentrates are diluted in water and normally applied as a spray to the area to be treated. The amount of active ingredient may range from 0.5% to 95% of the concentrate. Wettable powders are in the form of finely divided particles which disperse readily in water or other liquid carriers. The particles contain the active ingredient retained in a solid matrix. Typical solid matrices include fuller’s earth, kaolin clays, silicas and other readily wet organic or inorganic solids. Wettable powders normally contain from 5% to 95% of the active ingredient plus a small amount of wetting, dispersing or emulsifying agent. Emulsifiable concentrates are homogeneous liquid compositions dispersible in water or other liquid and may consist entirely of the active compound with a liquid or solid emulsifying agent, or may also contain a liquid carrier, such as xylene, heavy aromatic naphthas, isophorone and other non-volatile organic solvents. In use, these concentrates are dispersed in water or other liquid and normally applied as a spray to the area to be treated. The amount of active ingredient may range from 0.5% to 95% of the concentrate. Granular formulations include both extrudates and relatively coarse particles and are usually applied without dilution to the area in which treatment is required. Typical carriers for granular formulations include sand, fuller’s earth, attapulgite clay, bentonite clays, montmorillonite clay, vermiculite, perlite, calcium carbonate, brick, pumice, pyrophyllite, kaolin, dolomite, plaster, wood flour, ground corn cobs, ground peanut hulls, sugars, sodium chloride, sodium sulphate, sodium silicate, sodium borate, magnesia, mica, iron oxide, zinc oxide, titanium oxide, antimony oxide, cryolite, gypsum, diatomaceous earth, calcium sulphate and other organic or inorganic materials which absorb or which can be coated with the active compound. Granular formulations normally contain 5% to 25% of active ingredients which may include surface-active agents such as heavy aromatic naphthas, kerosene and other petroleum fractions, or vegetable oils; and/or stickers such as dextrins, glue or synthetic resins. Dusts are free-flowing admixtures of the active ingredient with finely divided solids such as talc, clays, flours and other organic and inorganic solids which act as dispersants and carriers. Microcapsules are typically droplets or granules of the active ingredient enclosed in an inert porous shell which allows escape of the enclosed material to the surroundings at controlled rates. Encapsulated droplets are typically 1 to 50 microns in diameter. The enclosed liquid typically constitutes 50 to 95% of the weight of the capsule and may include solvent in addition to the active compound. Encapsulated granules are generally porous granules with porous membranes sealing the granule pore openings, retaining the active species in liquid form inside the granule pores. Granules typically range from 1 millimetre to 1 centimetre and preferably 1 to 2 millimetres in diameter. Granules are formed by extrusion, agglomeration or prilling, or are naturally occurring. Examples of such materials are vermiculite, sintered clay, kaolin, attapulgite clay, sawdust and granular carbon. Shell or membrane materials include natural and synthetic rubbers, cellulosic materials, styrene-butadiene copolymers, polyacrylonitriles, polyacrylates, polyesters, polyamides, polyureas, polyurethanes and starch xanthates. Other useful formulations for agrochemical applications include simple solutions of the comopnents A and B in a solvent in which it is completely soluble at the desired concentration, such as acetone, alkylated naphthalenes, xylene and other organic solvents. Pressurised sprayers, wherein the active ingredient is dispersed in finely-divided form as a result of vaporisation of a low boiling dispersant solvent carrier, may also be used. Suitable agricultural adjuvants and/or carriers that are useful in formulating the compositions of the invention in the formulation types described above are well known to those skilled in the art. Liquid carriers that can be employed include, for example, water, toluene, xylene, petroleum naphtha, crop oil, acetone, methyl ethyl ketone, cyclohexanone, acetic anhydride, acetonitrile, acetophenone, amyl acetate, 2-butanone, chlorobenzene, cyclohexane, cyclohexanol, alkyl acetates, diacetonalcohol, 1,2-dichloropropane, diethanolamine, p-diethylbenzene, diethylene glycol, diethylene glycol abietate, diethylene glycol butyl ether, diethylene glycol ethyl ether, diethylene glycol methyl ether, N,N-dimethyl formamide, dimethyl sulfoxide, 1,4-dioxane, dipropylene glycol, dipropylene glycol methyl ether, dipropylene glycol dibenzoate, diproxitol, alkyl pyrrolidinone, ethyl acetate, 2-ethyl hexanol, ethylene carbonate, 1,1,1-trichloroethane, 2-heptanone, alpha pinene, d-limonene, ethylene glycol, ethylene glycol butyl ether, ethylene glycol methyl ether, gamma-butyrolactone, glycerol, glycerol diacetate, glycerol monoacetate, glycerol triacetate, hexadecane, hexylene glycol, isoamyl acetate, isobornyl acetate, isooctane, isophorone, isopropyl benzene, isopropyl myristate, lactic acid, laurylamine, mesityl oxide, methoxy-propanol, methyl isoamyl ketone, methyl isobutyl ketone, methyl laurate, methyl octanoate, methyl oleate, methylene chloride, m-xylene, n-hexane, n-octylamine, octadecanoic acid, octyl amine acetate, oleic acid, oleylamine, o-xylene, phenol, polyethylene glycol (PEG400), propionic acid, propylene glycol, propylene glycol monomethyl ether, p-xylene, toluene, triethyl phosphate, triethylene glycol, xylene sulfonic acid, paraffin, mineral oil, trichloroethylene, perchloroethylene, ethyl acetate, amyl acetate, butyl acetate, methanol, ethanol, isopropanol, and higher molecular weight alcohols such as amyl alcohol, tetrahydrofurfuryl alcohol, hexanol, octanol, etc., ethylene glycol, propylene glycol, glycerine and N-methyl-2-pyrrolidinone. Water is generally the carrier of choice for the dilution of concentrates. Suitable solid carriers include, for example, talc, titanium dioxide, pyrophyllite clay, silica, attapulgite clay, kieselguhr, chalk, diatomaxeous earth, lime, calcium carbonate, bentonite clay, fuller’s earth, cotton seed hulls, wheat flour, soybean flour, pumice, wood flour, walnut shell flour and lignin. A broad range of surface-active agents are advantageously employed in both said liquid and solid compositions, especially those designed to be diluted with carrier before application. These agents, when used, normally comprise from 0.1% to 15% by weight of the formulation. They can be anionic, cationic, non-ionic or polymeric in character and can be employed as emulsifying agents, wetting agents, suspending agents or for other purposes. Typical surface active agents include salts of alkyl sulfates, such as diethanolammonium lauryl sulphate; alkylarylsulfonate salts, such as calcium dodecylbenzenesulfonate; alkylphenol-alkylene oxide addition products, such as nonylphenol-C.sub.18 ethoxylate; alcohol-alkylene oxide addition products, such as tridecyl alcohol-C.sub. 16 ethoxylate; soaps, such as sodium stearate; alkylnaphthalenesulfonate salts, such as sodium dibutylnaphthalenesulfonate; dialkyl esters of sulfosuccinate salts, such as sodium di(2-ethylhexyl) sulfosuccinate; sorbitol esters, such as sorbitol oleate; quaternary amines, such as lauryl trimethylammonium chloride; polyethylene glycol esters of fatty acids, such as polyethylene glycol stearate; block copolymers of ethylene oxide and propylene oxide; and salts of mono and dialkyl phosphate esters. Other adjuvants commonly utilized in agricultural compositions include crystallisation inhibitors, viscosity modifiers, suspending agents, spray droplet modifiers, pigments, antioxidants, foaming agents, anti- foaming agents, light-blocking agents, compatibilizing agents, antifoam agents, sequestering agents, neutralising agents and buffers, corrosion inhibitors, dyes, odorants, spreading agents, penetration aids, micronutrients, emollients, lubricants and sticking agents. Compositions of this invention, including all of the above disclosed embodiments and preferred examples thereof, can be mixed with one or more further pesticides including further fungicides, insecticides, nematocides, bactericides, acaricides, growth regulators, chemosterilants, semiochemicals, repellents, attractants, pheromones, feeding stimulants or other biologically active compounds to form a multi-component pesticide giving an even broader spectrum of agricultural protection. Examples of additional active ingredient component (C) are as follows, wherein the term “TX” represents a compound according to the definition of component (A) of the composition of the present invention selected from compound no. X.01, X.02, X.03, X.04, X.05, X.06, X.07, X.08, X.09, X.10, X.11 or X.12, as defined in the Table X above or Table T1 below): (7E,9Z)-dodeca-7,9-dien-1-yl acetate + TX, (9Z,11E)-tetradeca-9,11-dien-1-yl acetate + TX, (9Z,12E)- tetradeca-9,12-dien-1-yl acetate + TX, (E)-6-methylhept-2-en-4-ol + TX, (E)-dec-5-en-1-yl acetate with (E)-dec-5-en-1-ol + TX, (E)-tridec-4-en-1-yl acetate + TX, (E,Z)-tetradeca-4,10-dien-1-yl acetate + TX, (Z)-dodec-7-en-1-yl acetate + TX, (Z)-hexadec-11-en-1-yl acetate + TX, (Z)-hexadec-11-enal + TX, (Z)- hexadec-13-en-11-yn-1-yl acetate + TX, (Z)-icos-13-en-10-one + TX, (Z)-tetradec-7-en-1-al + TX, (Z)- tetradec-9-en-1-ol + TX, (Z)-tetradec-9-en-1-yl acetate + TX, 1,2-dibromo-3-chloropropane + TX, 1,2- dichloropropane + TX, 1,2-dichloropropane with 1,3-dichloropropene + TX, 1,3-dichloropropene + TX, 14-methyloctadec-1-ene + TX, 1-hydroxy-1H-pyridine-2-thione + TX, 2-(octylthio)ethanol + TX, 2- chlorophenyl N-methylcarbamate (CPMC) + TX, 3-(4-chlorophenyl)-5-methylrhodanine + TX, 3,4- dichlorotetrahydrothiophene 1,1-dioxide + TX, 4-(quinoxalin-2-ylamino)benzenesulfonamide + TX, 4- methylnonan-5-ol with 4-methylnonan-5-one + TX, 5-methyl-6-thioxo-1,3,5-thiadiazinan-3-ylacetic acid + TX, 6-isopentenylaminopurine + TX, 8-hydroxyquinoline sulfate + TX, abamectin + TX, acequinocyl + TX, acetamiprid + TX, acetoprole + TX, acrinathrin + TX, acynonapyr + TX, Adoxophyes orana GV + TX, afidopyropen + TX, afoxolaner + TX, Agrobacterium radiobacter + TX, AKD-3088 + TX, alanycarb + TX, aldicarb + TX, aldoxycarb + TX, allethrin + TX, alpha-cypermethrin + TX, alphamethrin + TX, alpha-multistriatin + TX, Amblyseius spp. + TX, amidoflumet + TX, amino acids + TX, aminocarb + TX, Anagrapha falcifera NPV + TX, Anagrus atomus + TX, Aphelinus abdominalis + TX, Aphidius colemani + TX, Aphidoletes aphidimyza + TX, apholate + TX, Autographa californica NPV + TX, AZ 60541 + TX, azadirachtin + TX, azocyclotin + TX, Bacillus aizawai + TX, Bacillus chitinosporus AQ746 (NRRL Accession No B-21618) + TX, Bacillus firmus + TX, Bacillus kurstaki + TX, Bacillus mycoides AQ726 (NRRL Accession No. B-21664) + TX, Bacillus pumilus (NRRL Accession No B-30087) + TX, Bacillus pumilus AQ717 (NRRL Accession No. B-21662) + TX, Bacillus sp. AQ175 (ATCC Accession No.55608) + TX, Bacillus sp. AQ177 (ATCC Accession No.55609) + TX, Bacillus sp. AQ178 (ATCC Accession No. 53522) + TX, Bacillus sphaericus Neide + TX, Bacillus subtilis AQ153 (ATCC Accession No.55614) + TX, Bacillus subtilis AQ30002 (NRRL Accession No. B-50421) + TX, Bacillus subtilis AQ30004 (NRRL Accession No. B- 50455) + TX, Bacillus subtilis AQ713 (NRRL Accession No. B-21661) + TX, Bacillus subtilis AQ743 (NRRL Accession No. B-21665) + TX, Bacillus subtilis unspecified + TX, Bacillus thuringiensis AQ52 (NRRL Accession No. B-21619) + TX, Bacillus thuringiensis BD#32 (NRRL Accession No B-21530) + TX, Bacillus thuringiensis Berliner + TX, Bacillus thuringiensis subsp. Aizawai + TX, Bacillus thuringiensis subsp. Israelensis + TX, Bacillus thuringiensis subsp. Japonensis + TX, Bacillus thuringiensis subsp. Kurstaki + TX, Bacillus thuringiensis subsp. Tenebrionis + TX, Bacillus thuringiensis subspec. kurstaki BMP 123 + TX, Beauveria bassiana + TX, Beauveria brongniartii + TX, benclothiaz + TX, benomyl + TX, bensultap + TX, benzoximate + TX, benzpyrimoxan + TX, betacyfluthrin + TX, beta-cypermethrin + TX, bethoxazin + TX, bifenazate + TX, bifenthrin + TX, binapacryl + TX, bioallethrin + TX, bioresmethrin + TX, bis(tributyltin) oxide + TX, bisazir + TX, bistrifluron + TX, bisulflufen + TX, brevicomin + TX, broflanilide + TX, brofluthrinate + TX, bromoacetamide + TX, bromophos-ethyl + TX, bronopol + TX, busulfan + TX, butocarboxim + TX, butopyronoxyl + TX, butoxy(polypropylene glycol) + TX, butylpyridaben + TX, cadusafos + TX, calcium arsenate + TX, carbaryl + TX, carbofuran + TX, carbon disulfide + TX, carbosulfan + TX, cartap + TX, CAS number: 1594624-87-9 + TX, CAS number: 1922957-47-8 + TX, CAS number: 1255091-74-7 + TX, CAS number: 1365070-72-9 + TX, CAS number: 1445683-71-5 + TX, CAS number: 1445684-82-1 + TX, CAS number: 1594626-19-3 + TX, CAS number: 1594637-65-6 + TX, CAS number: 1632218-00-8 + TX, CAS number: 1808115-49-2 + TX, CAS number: 1922957-46-7 + TX, CAS number: 1922957-48-9 + TX, CAS number: 1956329-03-5 + TX, CAS number: 1990457-52-7 + TX, CAS number: 1990457-55-0 + TX, CAS number: 1990457-57-2 + TX, CAS number: 1990457-66-3 + TX, CAS number: 1990457-77-6 + TX, CAS number: 1990457-85-6 + TX, CAS number: 2032403-97-5 + TX, CAS number: 2044701-44-0 + TX, CAS number: 2095470-94-1 + TX, CAS Number: 2128706-04-5 + TX, CAS number: 2128706-05-6 + TX, CAS number: 2133042-31-4 + TX, CAS number: 2133042-44-9 + TX, CAS number: 2171099-09-3 + TX, CAS number: 2220132-55-6 + TX, CAS number: 2396747-83-2 + TX, CAS number: 2408220-91-5 + TX, CAS number: 2408220-94-8 + TX, CAS number: 2415706-16-8 + TX, Piperflanilide (CAS number: 2615135-05-0) + TX, CAS number: 2719848-60-7 + TX, CAS number: RNA (Leptinotarsa decemlineata- specific recombinant double-stranded interfering GS2) + TX, chlorantraniliprole + TX, chlordane + TX, chlorfenapyr + TX, chloropicrin + TX, chloroprallethrin + TX, chlorpyrifos + TX, chromafenozide + TX, Chrysoperla carnea + TX, clenpirin + TX, cloethocarb + TX, clothianidin + TX, codlelure + TX, codlemone + TX, copper acetoarsenite + TX, copper dioctanoate + TX, copper hydroxide + TX, copper sulfate + TX, cresol + TX, crufomate + TX, Cryptolaemus montrouzieri + TX, cuelure + TX, cyanofenphos + TX, cyantraniliprole + TX, cybutryne + TX, cyclaniliprole + TX, cyclobutrifluram + TX, cycloprothrin + TX, cycloxaprid + TX, Cydia pomonella GV + TX, cyenopyrafen + TX, cyetpyrafen + TX, cyflumetofen + TX, cyfluthrin + TX, cyhalodiamide + TX, cylohalothrin + TX, cypermethrin + TX, cyphenothrin + TX, cyproflanilide + TX, cyromazine + TX, cytokinins + TX, Dacnusa sibirica + TX, dazomet + TX, DBCP + TX, DCIP + TX, deltamethrin + TX, diafenthiuron + TX, dialifos + TX, diamidafos + TX, dibrom + TX, dibutyl adipate + TX, dibutyl phthalate + TX, dibutyl succinate + TX, dichlofenthion + TX, dichlone + TX, dichlorophen + TX, dicliphos + TX, dicloromezotiaz + TX, diethyltoluamide + TX, diflubenzuron + TX, Diglyphus isaea + TX, dimatif + TX, dimethoate + TX, dimethyl carbate + TX, dimethyl phthalate + TX, dimpropyridaz + TX, dinactin + TX, dinocap + TX, dinotefuran + TX, dioxabenzofos + TX, dipyrithione + TX, disparlure + TX, D-limonene + TX, dodec-8-en-1-yl acetate + TX, dodec-9-en-1-yl acetate + TX, dodeca-8,10-dien-1-yl acetate + TX, dodicin + TX, dominicalure + TX, doramectin + TX, emamectin + TX, emamectin benzoate + TX, empenthrin + TX, Encarsia formosa + TX, endothal + TX, endrin + TX, eprinomectin + TX, epsilon - momfluorothrin + TX, epsilon-metofluthrin + TX, Eretmocerus eremicus + TX, esfenvalerate + TX, ethion + TX, ethiprole + TX, ethoprophos + TX, ethyl 4-methyloctanoate + TX, ethyl hexanediol + TX, ethylene dibromide + TX, etofenprox + TX, etoxazole + TX, etpyrafen + TX, eugenol + TX, Extract of seaweed and fermentation product derived from melasse + TX, Extract of seaweed and fermentation product derived from melasse comprising urea + TX, Extract of seaweed and fermented plant products + TX, Extract of seaweed and fermented plant products comprising phytohormones, vitamins, EDTA-chelated copper, zinc, and iron + TX, famphur + TX, fenaminosulf + TX, fenamiphos + TX, fenazaquin + TX, fenfluthrin + TX, fenitrothion + TX, fenmezoditiaz + TX, fenobucarb + TX, fenothiocarb + TX, fenoxycarb + TX, fenpropathrin + TX, fenpyrad + TX, fenpyroximate + TX, fensulfothion + TX, fenthion + TX, fentin + TX, fentinacetate + TX, fenvalerate + TX, ferric phosphate + TX, fipronil + TX, flometoquin + TX, flonicamid + TX, fluacrypyrim + TX, fluazaindolizine + TX, fluazuron + TX, flubendiamide + TX, flubenzimine + TX, fluchlordiniliprole + TX, flucitrinate + TX, flucycloxuron + TX, flucythrinate + TX, fluensulfone [318290-98-1] + TX, fluensulfone + TX, flufenerim + TX, flufenprox + TX, flufiprole + TX, fluhexafon + TX, flumethrin + TX, fluopyram + TX, flupyradifurone + TX, flupyrimin + TX, flupyroxystrobin + TX, fluralaner + TX, fluvalinate + TX, fluxametamide + TX, formaldehyde + TX, fosthiazate + TX, fosthietan + TX, frontalin + TX, furfural + TX, gamma-cyhalothrin + TX, Gossyplure® (1:1 mixture of the (Z,E) and (Z,Z) isomers of hexadeca-7,11-dien-1-yl-acetate) + TX, grandlure + TX, grandlure I + TX, grandlure II + TX, grandlure III + TX, grandlure IV + TX, Granulovirus + TX, guadipyr + TX, GY-81 + TX, halfenprox + TX, halofenozide + TX, Harpin + TX, Helicoverpa armigera Nucleopolyhedrovirus + TX, Helicoverpa zea NPV + TX, Helicoverpa zea Nucleopolyhedrovirus + TX, Heliothis punctigera Nucleopolyhedrovirus + TX, Heliothis virescens Nucleopolyhedrovirus + TX, hemel + TX, hempa + TX, heptafluthrin + TX, heterophos + TX, Heterorhabditis bacteriophora and H. megidis + TX, hexalure + TX, hexamide + TX, hexythiazox + TX, Hippodamia convergens + TX, hydramethylnon + TX, hydrargaphen + TX, hydrated lime + TX, imicyafos + TX, imidacloprid + TX, imiprothrin + TX, Indazapyroxamet + TX, indoxacarb + TX, iodomethane + TX, iprodione + TX, ipsdienol + TX, ipsenol + TX, isamidofos + TX, isazofos + TX, isocycloseram + TX, Isoflualanam (CAS number: 2892524-05-7) + TX, isothioate + TX, ivermectin + TX, japonilure + TX, kappa-bifenthrin + TX, kappa-tefluthrin + TX, kasugamycin + TX, kasugamycin hydrochloride hydrate + TX, kinetin + TX, lambda-cyhalothrin + TX, ledprona + TX, lepimectin + TX, Leptomastix dactylopii + TX, lineatin + TX, litlure + TX, looplure + TX, lotilaner + TX, lufenuron + TX, Macrolophus caliginosus + TX, Mamestra brassicae NPV + TX, mecarphon + TX, medlure + TX, megatomoic acid + TX, metaflumizone + TX, metaldehyde + TX, metam + TX, metam-potassium + TX, metam-sodium + TX, Metaphycus helvolus + TX, Metarhizium anisopliae var. acridum + TX, Metarhizium anisopliae var. anisopliae + TX, Metarhizium spp. + TX, metepa + TX, methiocarb + TX, methiotepa + TX, methomyl + TX, methoquin-butyl + TX, methoxyfenozide + TX, methyl apholate + TX, methyl bromide + TX, methyl eugenol + TX, methyl isothiocyanate + TX, methylneodecanamide + TX, metofluthrin + TX, metolcarb + TX, mexacarbate + TX, milbemectin + TX, milbemycin oxime + TX, momfluorothrin + TX, morzid + TX, moxidectin + TX, muscalure + TX, Muscodor albus 620 (NRRL Accession No.30547) + TX, Muscodor roseus A3-5 (NRRL Accession No.30548) + TX, Myrothecium verrucaria composition + TX, nabam + TX, NC-184 + TX, Neem tree based products + TX, Neodiprion sertifer NPV and N. lecontei NPV + TX, nickel bis(dimethyldithiocarbamate) + TX, niclosamide + TX, niclosamide-olamine + TX, nicofluprole + TX, nitenpyram + TX, nithiazine + TX, nitrapyrin + TX, octadeca-2,13-dien-1-yl acetate + TX, octadeca- 3,13-dien-1-yl acetate + TX, octhilinone + TX, omethoate + TX, orfralure + TX, Orius spp. + TX, oryctalure + TX, ostramone + TX, oxamate + TX, oxamyl + TX, oxazosulfyl + TX, oxolinic acid + TX, oxytetracycline + TX, Paecilomyces fumosoroseus + TX, Paecilomyces lilacinus + TX, parathion-ethyl + TX, Pasteuria nishizawae + TX, Pasteuria penetrans + TX, Pasteuria ramosa + TX, Pasteuria thornei + TX, Pasteuria usgae + TX, P-cymene + TX, penfluron + TX, pentachlorophenol + TX, permethrin + TX, phenothrin + TX, phorate + TX, phosphamidon + TX, phosphocarb + TX, Phytoseiulus persimilis + TX, picaridin + TX, pioxaniliprole + TX, piperazine + TX, piperonylbutoxide + TX, pirimicarb + TX, pirimiphos-ethyl + TX, pirimiphos-methyl + TX, Plutella xylostella Granulosis virus + TX, Plutella xylostella Nucleopolyhedrovirus + TX, Polyhedrosis virus + TX, potassium and molybdenum and EDTA- chelated manganese + TX, potassium ethylxanthate + TX, potassium hydroxyquinoline sulfate + TX, prallethrin + TX, probenazole + TX, profenofos + TX, profluthrin + TX, propargite + TX, propetamphos + TX, propoxur + TX, prothiophos + TX, protrifenbute + TX, pyflubumide + TX, pymetrozine + TX, pyraclofos + TX, pyrafluprole + TX, pyrethrum + TX, pyridaben + TX, pyridalyl + TX, pyridin-4-amine + TX, pyrifluquinazon + TX, pyrimidifen + TX, pyriminostrobin + TX, pyriprole [394730-71-3] + TX, pyriprole + TX, pyriproxyfen + TX, QRD 420 (a terpenoid blend) + TX, QRD 452 (a terpenoid blend) + TX, QRD 460 (a terpenoid blend) + TX, Quillaja saponaria + TX, quinoclamine + TX, quinonamid + TX, resmethrin + TX, Rhodococcus globerulus AQ719 (NRRL Accession No B-21663) + TX, sarolaner + TX, S- bioallethrin + TX, sebufos + TX, selamectin + TX, siglure + TX, silafluofen + TX, simazine + TX, sodium pentachlorophenoxide + TX, sordidin + TX, spidoxamat + TX, spinetoram + TX, spinosad + TX, spirobudifen + TX, spirodiclofen + TX, spiromesifen + TX, spiropidion + TX, spirotetramat + TX, Spodoptera exigua multicapsid nuclear polyhedrosis virus + TX, Spodoptera frugiperda Nucleopolyhedrovirus + TX, Steinernema bibionis + TX, Steinernema carpocapsae + TX, Steinernema feltiae + TX, Steinernema glaseri + TX, Steinernema riobrave + TX, Steinernema riobravis + TX, Steinernema scapterisci + TX, Steinernema spp. + TX, Streptomyces galbus (NRRL Accession No. 30232) + TX, Streptomyces sp. (NRRL Accession No. B-30145) + TX, streptomycin + TX, streptomycin sesquisulfate + TX, strychnine + TX, sulcatol + TX, sulfiflumin (CAS number: 2377084-09-6) + TX, sulfoxaflor + TX, tazimcarb + TX, tebufenozide + TX, tebufenpyrad + TX, tebupirimiphos + TX, tecloftalam + TX, tefluthrin + TX, temephos + TX, tepa + TX, terbam + TX, terbufos + TX, terpenoid blend + TX, tetrachlorantraniliprole + TX, tetrachlorothiophene + TX, tetradec-11-en-1-yl acetate + TX, tetradiphon + TX, tetramethrin + TX, tetramethylfluthrin + TX, tetranactin + TX, tetraniliprole + TX, theta- cypermethrin + TX, thiacloprid + TX, thiafenox + TX, thiamethoxam + TX, thiocyclam + TX, thiodicarb + TX, thiofanox + TX, thiohempa + TX, thiomersal + TX, thiometon + TX, thionazin + TX, thiophanate + TX, thiosultap + TX, thiotepa + TX, tigolaner + TX, tiorantraniliprole + TX, tioxazafen + TX, tolfenpyrad + TX, toxaphene + TX, tralomethrin + TX, transfluthrin + TX, tretamine + TX, triazamate + TX, triazophos + TX, triazuron + TX, tributyltin oxide + TX, trichlorfon + TX, trichloronate + TX, trichlorphon + TX, Trichogramma spp. + TX, trifenmorph + TX, trifluenfuronate + TX, triflumezopyrim + TX, trimedlure + TX, trimedlure A + TX, trimedlure B1 + TX, trimedlure B2 + TX, trimedlure C + TX, trimethacarb + TX, triphenyltin acetate + TX, triphenyltin hydroxide + TX, trunc-call + TX, tyclopyrazoflor + TX, Typhlodromus occidentalis + TX, uredepa + TX, Verticillium lecanii + TX, Verticillium spp. + TX, xylenols + TX, YI-5302 + TX, zeatin + TX, zeta-Cypermethrin + TX; N-[(1R)-1-benzyl-3-chloro-1-methyl-but-3-enyl]-8-fluoro-quinoline-3-carboxamide + TX, N-[(1S)-1- benzyl-3-chloro-1-methyl-but-3-enyl]-8-fluoro-quinoline-3-carboxamide + TX, N-ethyl-N’-[5-methoxy-2- methyl-4-[(2-trifuoromethyl)tetrahydrofuran-2-yl]phenyl]-N-methyl-formamidine (these compounds may be prepared from the methods described in WO2019/110427) + TX, (3',4',5'-trifluoro-biphenyl-2-yl)- amide + TX, (3-methylisoxazol-5-yl)-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methanone (these compounds may be prepared from the methods described in WO 2017/220485) + TX, (4- phenoxyphenyl)methyl 2-amino-6-methyl-pyridine-3-carboxylate (this compound may be prepared from the methods described in WO 2014/006945) + TX, (5-methyl-2-pyridyl)-[4-[5-(trifluoromethyl)-1,2,4- oxadiazol-3-yl]phenyl]methanone + TX, (7E,9Z)-dodeca-7,9-dien-1-yl acetate + TX, (9Z,11E)-tetradeca- 9,11-dien-1-yl acetate + TX, (9Z,12E)-tetradeca-9,12-dien-1-yl acetate + TX, (E)-6-methylhept-2-en-4- ol + TX, (E)-dec-5-en-1-yl acetate with (E)-dec-5-en-1-ol + TX, (E)-tridec-4-en-1-yl acetate + TX, (E,Z)- tetradeca-4,10-dien-1-yl acetate, + TX, (R)-3-(difluoromethyl)-1-methyl-N-[1,1,3-trimethylindan-4- yl]pyrazole-4-carboxamide + TX, (Z)-dodec-7-en-1-yl acetate + TX, (Z)-hexadec-11-en-1-yl acetate + TX, (Z)-hexadec-11-enal + TX, (Z)-hexadec-13-en-11-yn-1-yl acetate + TX, (Z)-icos-13-en-10-one + TX, (Z)-tetradec-7-en-1-al + TX, (Z)-tetradec-9-en-1-ol + TX, (Z)-tetradec-9-en-1-yl acetate + TX, (Z,2E)-5- [1-(2,4-dichlorophenyl)pyrazol-3-yl]oxy-2-methoxyimino-N,3-dimethyl-pent-3-enamide (this compound may be prepared from the methods described in WO 2018/153707) + TX, (Z,2E)-5-[1-(4- chlorophenyl)pyrazol-3-yl]oxy-2-methoxyimino-N,3-dimethyl-pent-3-enamide + TX, , [2-[3-[2-[1-[2-[3,5- bis(difluoromethyl)pyrazol-1-yl]acetyl]-4-piperidyl]thiazol-4-yl]-4,5-dihydroisoxazol-5-yl]-3-chloro- phenyl] methanesulfonate + TX, 1-(4,5-dimethylbenzimidazol-1-yl)-4,4,5-trifluoro-3,3-dimethyl- isoquinoline + TX, 1-(4,5-dimethylbenzimidazol-1-yl)-4,4-difluoro-3,3-dimethyl-isoquinoline + TX, 1-(6,7- dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,5-trifluoro-3,3-dimethyl-isoquinoline + TX, 1-(6,7- dimethylpyrazolo[1,5-a]pyridin-3-yl)-4,4,6-trifluoro-3,3-dimethyl-isoquinoline + TX, 1-(6-chloro-7-methyl- pyrazolo[1,5-a]pyridin-3-yl)-4,4-difluoro-3,3-dimethyl-isoquinoline (these compounds may be prepared from the methods described in WO2017/025510) + TX, 1,1-bis(4-chlorophenyl)-2-ethoxyethanol + TX, 1,1-dichloro-2,2-bis(4-ethylphenyl)ethane + TX, 1,2-dibromo-3-chloropropane + TX, 1,2- dichloropropane with 1,3-dichloropropene + TX, 1,3-dichloropropene + TX, 1,3-dimethoxy-1-[[4-[5- (trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea + TX, 1-[2-[[1-(4-chlorophenyl)pyrazol-3- yl]oxymethyl]-3-methyl-phenyl]-4-methyl-tetrazol-5-one + TX, 10-dien-1-yl acetate + TX, 14- methyloctadec-1-ene + TX, 1-bromo-2-chloroethane + TX, 1-dichloro-1-nitroethane + TX, 1-hydroxy- 1H-pyridine-2-thione + TX, 1-methoxy-3-methyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3- yl]phenyl]methyl]urea + TX, 1-methyl-4-[3-methyl-2-[[2-methyl-4-(3,4,5-trimethylpyrazol-1- yl)phenoxy]methyl]phenyl]tetrazol-5-one + TX, 2- (difluoromethyl) - N- ((3R) - 1, 1, 3- trimethylindan- 4- yl) pyridine- 3- carboxamide + TX, 2- (difluoromethyl) - N- ((3R) - 1, 1, 3- trimethylindan- 4-yl) pyridine- 3- carboxamide + TX, 2-(1,3-dithiolan-2-yl)phenyl dimethylcarbamate + TX, 2-(2-butoxyethoxy)ethyl piperonylate + TX, 2-(2-butoxyethoxy)ethyl thiocyanate + TX, 2-(4,5-dimethyl-1,3-dioxolan-2-yl)phenyl methylcarbamate + TX, 2-(4-chloro-3,5-xylyloxy)ethanol + TX, 2-(difluoromethyl)-N-(3-ethyl-1,1- dimethyl-indan-4-yl)pyridine-3-carboxamide + TX, 2-(difluoromethyl)-N-[(3R)-3-ethyl-1,1-dimethyl- indan-4-yl]pyridine-3-carboxamide + TX, 2-(difluoromethyl)-N-[(3S)-3-ethyl-1,1-dimethyl-indan-4- yl]pyridine-3-carboxamide (this compound may be prepared from the methods described in WO 2014/095675) + TX, 2-(difluoromethyl)-N-[3-ethyl-1,1-dimethyl-indan-4-yl]pyridine-3-carboxamide + TX, 2-(octylthio)ethanol + TX, 2,2,2-trichloro-1-(3,4-dichlorophenyl)ethyl acetate + TX, 2,2-dichlorovinyl 2- ethylsulfinylethyl methyl phosphate + TX, 2,2-difluoro-N-methyl-2-[4-[5-(trifluoromethyl)-1,2,4- oxadiazol-3-yl]phenyl]acetamide + TX, 2,4-dichlorophenyl benzenesulfonate + TX, 2,6-Dimethyl-1H,5H- [1,4]dithiino[2,3-c:5,6-c']dipyrrole-1,3,5,7(2H,6H)-tetrone (this compound may be prepared from the methods described in WO 2011/138281) + TX, 2-[2-fluoro-6-[(8-fluoro-2-methyl-3- quinolyl)oxy]phenyl]propan-2-ol + TX, 2-[6-(4-bromophenoxy)-2-(trifluoromethyl)-3-pyridyl]-1-(1,2,4- triazol-1-yl)propan-2-ol (this compound may be prepared from the methods described in WO 2017/029179) + TX, 2-[6-(4-chlorophenoxy)-2-(trifluoromethyl)-3-pyridyl]-1-(1,2,4-triazol-1-yl)propan-2- ol (this compound may be prepared from the methods described in WO 2017/029179) + TX, 2- chlorovinyl diethyl phosphate + TX, 2-fluoro-N-methyl-N-1-naphthylacetamide + TX, 2-imidazolidone + TX, 2-isovalerylindan-1,3-dione + TX, 2-methyl(prop-2-ynyl)aminophenyl methylcarbamate + TX, 2-oxo- N-propyl-2-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]acetamide (this compound may be prepared from the methods described in WO 2018/065414) + TX, 2-thiocyanatoethyl laurate + TX, 3- (4,4-difluoro-3,3-dimethyl-1-isoquinolyl)-7,8-dihydro-6H-cyclopenta[e]benzimidazole (these compounds may be prepared from the methods described in WO2016/156085) + TX, 3-(4,4-difluoro-3,4-dihydro- 3,3-dimethylisoquinolin-1-yl)quinolone + TX, 3-(4-chlorophenyl)-5-methylrhodanine + TX, 3- (difluoromethyl)-1-methyl-N-[1,1,3-trimethylindan-4-yl]pyrazole-4-carboxamide + TX, 3,4- dichlorotetrahydrothiophene 1,1-dioxide + TX, 3-[2-(1-chlorocyclopropyl)-3-(2-fluorophenyl)-2-hydroxy- propyl]imidazole-4-carbonitrile (this compound may be prepared from the methods described in WO 2016/156290) + TX, 3-[2-(1-chlorocyclopropyl)-3-(3-chloro-2-fluoro-phenyl)-2-hydroxy- propyl]imidazole-4-carbonitrile (this compound may be prepared from the methods described in WO 2016/156290) + TX, 3-bromo-1-chloroprop-1-ene + TX, 3-chloro-6-methyl-5-phenyl-4-(2,4,6- trifluorophenyl)pyridazine + TX, 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid + TX, 3-ethyl- 1-methoxy-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]urea + TX, 3-methyl-1- phenylpyrazol-5-yl dimethylcarbamate + TX, 4- (2- bromo- 4- fluorophenyl) - N- (2- chloro- 6- fluorophenyl) - 1, 3- dimethyl- 1H- pyrazol- 5- amine + TX, 4-(2,6-difluorophenyl)-6-methyl-5-phenyl- pyridazine-3-carbonitrile + TX, 4-(2-bromo-4-fluoro-phenyl)-N-(2-chloro-6-fluoro-phenyl)-2,5-dimethyl- pyrazol-3-amine + TX, 4-(quinoxalin-2-ylamino)benzenesulfonamide + TX, 4,4-difluoro-1-(5-fluoro-4- methyl-benzimidazol-1-yl)-3,3-dimethyl-isoquinoline + TX, 4,4-difluoro-3,3-dimethyl-1-(6- methylpyrazolo[1,5-a]pyridin-3-yl)isoquinoline + TX, 4,4-difluoro-3,3-dimethyl-1-(7-methylpyrazolo[1,5- a]pyridin-3-yl)isoquinoline + TX, 4,4-dimethyl-2-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3- yl]phenyl]methyl]isoxazolidin-3-one + TX, 4-[[6-[2-(2,4-difluorophenyl)-1,1-difluoro-2-hydroxy-3-(1,2,4- triazol-1-yl)propyl]-3-pyridyl]oxy] benzonitrile + TX, 4-[[6-[2-(2,4-difluorophenyl)-1,1-difluoro-2-hydroxy- 3-(5-sulfanyl-1,2,4-triazol-1-yl)propyl]-3-pyridyl]oxy] benzonitrile + TX, 4-[[6-[2-(2,4-difluorophenyl)-1,1- difluoro-2-hydroxy-3-(5-thioxo-4H-1,2,4-triazol-1-yl)propyl]-3-pyridyl]oxy] benzonitrile + TX, 4-chloro-2- (2-chloro-2-methyl-propyl)-5-[(6-iodo-3-pyridyl)methoxy]pyridazin-3-one + TX, 4-chlorophenyl phenyl sulfone + TX, 4-methyl(prop-2-ynyl)amino-3,5-xylyl methylcarbamate + TX, 4-methylnonan-5-ol with 4- methylnonan-5-one + TX, 5-(1,3-benzodioxol-5-yl)-3-hexylcyclohex-2-enone + TX, 5,5-dimethyl-2-[[4- [5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]isoxazolidin-3-one + TX, 5,5-dimethyl-3- oxocyclohex-1-enyl dimethylcarbamate + TX, 5-amino-1,3,4-thiadiazole-2-thiol zinc salt (2:1) + TX, 5- methyl-6-thioxo-1,3,5-thiadiazinan-3-ylacetic acid + TX, 6-chloro-3-(3-cyclopropyl-2-fluoro-phenoxy)-N- [2-(2,4-dimethylphenyl)-2,2-difluoro-ethyl]-5-methyl-pyridazine-4-carboxamide (may be prepared from the methods described in WO 2020/109391) + TX, 6-chloro-3-(3-cyclopropyl-2-fluoro-phenoxy)-N-[2- (3,4-dimethylphenyl)-2,2-difluoro-ethyl]-5-methyl-pyridazine-4-carboxamide (may be prepared from the methods described in WO 2020/109391) + TX, 6-chloro-4,4-difluoro-3,3-dimethyl-1-(4- methylbenzimidazol-1-yl)isoquinoline + TX, 6-chloro-N-[2-(2-chloro-4-methyl-phenyl)-2,2-difluoro- ethyl]-3-(3-cyclopropyl-2-fluoro-phenoxy)-5-methyl-pyridazine-4-carboxamide (may be prepared from the methods described in WO 2020/109391) + TX, 6-ethyl-5,7-dioxo-pyrrolo[4,5][1,4]dithiino[1,2- c]isothiazole-3-carbonitrile + TX, 6-isopentenylaminopurine + TX, 8-fluoro-N-[(1R)-1-[(3- fluorophenyl)methyl]-1,3-dimethyl-butyl]quinoline-3-carboxamide + TX, 8-fluoro-N-[(1S)-1-[(3- fluorophenyl)methyl]-1,3-dimethyl-butyl]quinoline-3-carboxamide + TX, 8-hydroxyquinoline sulfate + TX, acethion + TX, acetoprole + TX, acibenzolar + TX, acibenzolar-S-methyl + TX, acrylonitrile + TX, Adoxophyes orana GV + TX, Agrobacterium radiobacter + TX, aldoxycarb + TX, aldrin + TX, allosamidin + TX, allyxycarb + TX, alpha-chlorohydrin + TX, alpha-ecdysone + TX, alpha-multistriatin + TX, aluminium phosphide + TX, Amblyseius spp. + TX, amectotractin + TX, ametoctradin + TX, amidithion + TX, amidothioate + TX, aminocarb + TX, aminopyrifen + TX, amisulbrom + TX, amiton + TX, amiton hydrogen oxalate + TX, amitraz + TX, anabasine + TX, Anagrapha falcifera NPV + TX, Anagrus atomus + TX, ancymidol + TX, anilazine + TX, anisiflupurin + TX, anthraquinone + TX, antu + TX, Aphelinus abdominalis + TX, Aphidius colemani + TX, Aphidoletes aphidimyza + TX, apholate + TX, aramite + TX, arsenous oxide + TX, athidathion + TX, Autographa californica NPV + TX, azaconazole + TX, azamethiphos + TX, azobenzene + TX, azothoate + TX, azoxystrobin + TX, Bacillus sphaericus Neide + TX, Bacillus thuringiensis delta endotoxins + TX, barium carbonate + TX, barium hexafluorosilicate + TX, barium polysulfide + TX, barthrin + TX, Bayer 22/190 + TX, Bayer 22408 + TX, Beauveria brongniartii + TX, benalaxyl + TX, benclothiaz + TX, benomyl + TX, benoxafos + TX, benthiavalicarb + TX, benzothiostrobin + TX, benzovindiflupyr + TX, benzyl benzoate + TX, beta-cyfluthrin + TX, beta- cypermethrin + TX, bethoxazin + TX, bioethanomethrin + TX, biopermethrin + TX, bis(2-chloroethyl) ether + TX, bis(tributyltin) oxide + TX, bisazir + TX, bisthiosemi + TX, bitertanol + TX, bixafen + TX, blasticidin-S + TX, borax + TX, bordeaux mixture + TX, boscalid + TX, brevicomin + TX, brodifacoum + TX, brofenvalerate + TX, bromadiolone + TX, bromethalin + TX, bromfenvinfos + TX, bromoacetamide + TX, bromocyclen + TX, bromo-DDT + TX, bromophos + TX, bromopropylate + TX, bromuconazole + TX, bronopol + TX, bufencarb + TX, bupirimate + TX, buprofezin + TX, busulfan + TX, but-3-ynyl N-[6- [[(Z)-[(1-methyltetrazol-5-yl)-phenyl-methylene]amino]oxymethyl]-2-pyridyl]carbamate + TX, butacarb + TX, butathiofos + TX, butocarboxim + TX, butonate + TX, butopyronoxyl + TX, butoxy(polypropylene glycol) + TX, butoxycarboxim + TX, butylpyridaben + TX, calcium arsenate + TX, calcium cyanide + TX, calcium polysulfide + TX, camphechlor + TX, captafol + TX, captan + TX, carbanolate + TX, carbendazim + TX, carbon disulfide + TX, carbon tetrachloride + TX, carbophenothion + TX, carboxin + TX, cartap hydrochloride + TX, CAS Number: 2132414-04-9 + TX, CAS Number: 2344721-61-3 + TX, cevadine + TX, chinomethionat + TX, chloralose + TX, chlorbenside + TX, chlorbicyclen + TX, chlordane + TX, chlordecone + TX, chlordimeform + TX, chlordimeform hydrochloride + TX, chlorfenethol + TX, chlorfenson + TX, chlorfensulfide + TX, chlorobenzilate + TX, chloroform + TX, chloroinconazide + TX, chloromebuform + TX, chloromethiuron + TX, chloroneb + TX, chlorophacinone + TX, chloropicrin + TX, chloropropylate + TX, chlorothalonil + TX, chlorphoxim + TX, chlorprazophos + TX, chlorthiophos + TX, chlozolinate + TX, cholecalciferol + TX, Chrysoperla carnea + TX, cinerin I + TX, cinerin II + TX, cinerins + TX, cismethrin + TX, cis-resmethrin + TX, clocythrin + TX, closantel + TX, codlelure + TX, codlemone + TX, copper acetoarsenite + TX, copper arsenate + TX, copper dioctanoate + TX, copper hydroxide + TX, copper naphthenate + TX, copper oleate + TX, copper oxide + TX, copper oxychloride + TX, copper sulfate + TX, coumachlor + TX, coumafuryl + TX, coumaphos + TX, coumatetralyl + TX, coumethoxystrobin (jiaxiangjunzhi) + TX, coumithoate + TX, coumoxystrobin + TX, cresol + TX, crimidine + TX, crotamiton + TX, crotoxyphos + TX, crufomate + TX, cryolite + TX, Cryptolaemus montrouzieri + TX, CS 708 + TX, cuelure + TX, cufraneb + TX, cyanofenphos + TX, cyanophos + TX, cyanthoate + TX, cyazofamid + TX, cybutryne + TX, cyclethrin + TX, cyclobutrifluram + TX, Cydia pomonella GV + TX, cyflufenamid + TX, cymiazole + TX, cymoxanil + TX, cyproconazole + TX, cyprodinil + TX, cythioate + TX, cytokinins + TX, Dacnusa sibirica + TX, DAEP + TX, dazomet + TX, DCIP + TX, DCPM + TX, DDT + TX, debacarb + TX, decarbofuran + TX, demephion + TX, demephion-O + TX, demephion-S + TX, demeton-methyl + TX, demeton-O + TX, demeton-O-methyl + TX, demeton-S + TX, demeton-S-methyl + TX, demeton-S-methylsulfon + TX, diamidafos + TX, dibutyl adipate + TX, dibutyl phthalate + TX, dibutyl succinate + TX, dicapthon + TX, dichlobentiazox + TX, dichlofenthion + TX, dichlofluanid + TX, dichlone + TX, dichlorophen + TX, dichlorvos + TX, dichlozoline + TX, dicliphos + TX, diclocymet + TX, diclomezine + TX, dicloran + TX, dicresyl + TX, dicyclanil + TX, dicyclopentadiene + TX, dieldrin + TX, dienochlor + TX, diethofencarb + TX, diethyl 5-methylpyrazol-3-yl phosphate + TX, diethyltoluamide + TX, difenacoum + TX, difenoconazole + TX, difethialone + TX, diflovidazin + TX, Diglyphus isaea + TX, dilor + TX, dimatif + TX, dimefluthrin + TX, dimefox + TX, dimetan + TX, dimethirimol + TX, dimethomorph + TX, dimethrin + TX, dimethyl carbate + TX, dimethyl phthalate + TX, dimethylvinphos + TX, dimetilan + TX, dimoxystrobin + TX, dinex + TX, dinex-diclexine + TX, diniconazole + TX, dinocap-4 + TX, dinocap-6 + TX, dinocton + TX, dinopenton + TX, dinoprop + TX, dinosam + TX, dinoseb + TX, dinosulfon + TX, dinoterbon + TX, diofenolan + TX, dioxabenzofos + TX, dioxathion + TX, diphacinone + TX, diphenyl sulfone + TX, dipymetitrone + TX, dipyrithione + TX, disparlure + TX, disulfiram + TX, dithianon + TX, dithicrofos + TX, DNOC + TX, dodec-8-en-1-yl acetate + TX, dodec-9-en-1-yl acetate + TX, dodeca-8 + TX, dodemorph + TX, dodicin + TX, dodine + TX, dofenapyn + TX, dominicalure + TX, doramectin + TX, DSP + TX, d-tetramethrin + TX, ecdysterone + TX, edifenphos + TX, EI 1642 + TX, EMPC + TX, Encarsia formosa + TX, endothal + TX, endothion + TX, enestroburin + TX, enoxastrobin + TX, EPBP + TX, epoxiconazole + TX, eprinomectin + TX, Eretmocerus eremicus + TX, ergocalciferol + TX, etaphos + TX, ethaboxam + TX, ethiofencarb + TX, ethirimol + TX, ethoate-methyl + TX, ethyl 1-[[4-[(Z)-2-ethoxy-3,3,3-trifluoro-prop-1- enoxy]phenyl]methyl]pyrazole-3-carboxylate (may be prepared from the methods described in WO 2020/056090) + TX, ethyl 1-[[4-[[2-(trifluoromethyl)-1,3-dioxolan-2-yl]methoxy]phenyl]methyl]pyrazole- 3-carboxylate (may be prepared from the methods described in WO 2020/056090) + TX, ethyl 1-[[4-[5- (trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]pyrazole-4-carboxylate + TX, ethyl 1-[[5-[5- (trifluoromethyl)-1,2,4-oxadiazol-3-yl]-2-thienyl]methyl]pyrazole-4-carboxylate (this compound may be prepared from the methods described in WO 2018/158365) + TX, ethyl 4-methyloctanoate + TX, ethyl formate + TX, ethyl hexanediol + TX, ethylene dibromide + TX, ethylene dichloride + TX, ethylene oxide + TX, etridiazole + TX, etrimfos + TX, eugenol + TX, EXD + TX, famoxadone + TX, farnesol + TX, farnesol with nerolidol + TX, fenamidone + TX, fenaminosulf + TX, fenaminstrobin + TX, fenarimol + TX, fenazaflor + TX, fenbuconazole + TX, fenbutatin oxide + TX, fenchlorphos + TX, fenethacarb + TX, fenfuram + TX, fenhexamid + TX, fenitrothion + TX, fenothiocarb + TX, fenoxacrim + TX, fenoxanil + TX, fenpiclonil + TX, fenpicoxamid + TX, fenpirithrin + TX, fenpropidin + TX, fenpropimorph + TX, fenpyrad + TX, fenpyrazamine + TX, fenpyroximate + TX, fenson + TX, fensulfothion + TX, fenthion + TX, fenthion-ethyl + TX, fentin + TX, fentrifanil + TX, ferbam + TX, ferimzone + TX, ferric phosphate + TX, flocoumafen + TX, florylpicoxamid + TX, fluazinam + TX, flubeneteram + TX, flubenzimine + TX, flucofuron + TX, flucycloxuron + TX, fludioxonil + TX, fluenetil + TX, flufenoxadiazam + TX, flufenoxystrobin + TX, fluindapyr + TX, flumetylsulforim + TX, flumorph + TX, fluopicolide + TX, fluopimomide + TX, fluopyram + TX, fluorbenside + TX, fluoroacetamide + TX, fluoroimide + TX, fluoxapiprolin + TX, fluoxastrobin + TX, fluoxytioconazole + TX, flupropadine + TX, flupropadine hydrochloride + TX, fluquinconazole + TX, flusilazole + TX, flusulfamide + TX, flutianil + TX, flutolanil + TX, flutriafol + TX, fluxapyroxad + TX, FMC 1137 + TX, folpet + TX, formaldehyde + TX, formetanate + TX, formetanate hydrochloride + TX, formparanate + TX, fosetyl-aluminium + TX, fosmethilan + TX, fospirate + TX, fosthietan + TX, frontalin + TX, fuberidazole + TX, furalaxyl + TX, furametpyr + TX, furathiocarb + TX, furethrin + TX, furfural + TX, gamma-HCH + TX, glyodin + TX, grandlure + TX, grandlure I + TX, grandlure II + TX, grandlure III + TX, grandlure IV + TX, guazatine + TX, guazatine acetates + TX, halfenprox + TX, HCH + TX, hemel + TX, hempa + TX, HEOD + TX, heptachlor + TX, heterophos + TX, Heterorhabditis bacteriophora and H. megidis + TX, hexaconazole + TX, hexadecyl cyclopropanecarboxylate + TX, hexalure + TX, hexamide + TX, HHDN + TX, Hippodamia convergens + TX, hydrargaphen + TX, hydrated lime + TX, hydrogen cyanide + TX, hymexazol + TX, hyquincarb + TX, imanin + TX, imazalil + TX, imibenconazole + TX, iminoctadine + TX, + TX, ipfentrifluconazole + TX, ipflufenoquin + TX, iprobenphos + TX, iprodione + ipsdienol + TX, ipsenol + TX, IPSP + TX, isamidofos + TX, isazofos + TX, isobenzan + TX, isodrin + TX, isofenphos + TX, isofetamid + TX, isoflucypram + TX, isolane + TX, isopyrazam + TX, isotianil + TX, isoxathion + TX, japonilure + TX, jasmolin TX, jodfenphos + TX, juvenile hormone I + TX, juvenile hormone II + TX, juvenile hormone III + TX, kadethrin + TX, kasugamycin + TX, kasugamycin hydrochloride hydrate + TX, kelevan + TX, kinetin + TX, kinoprene + TX, kresoxim-methyl + TX, lead arsenate + TX, Leptomastix dactylopii + TX, leptophos + TX, lindane + TX, lineatin + TX, lirimfos + TX, litlure + TX, looplure + TX, lvbenmixianan + TX, lythidathion + TX, Macrolophus caliginosus + TX, magnesium phosphide + TX, malonoben + TX, Mamestra brassicae NPV + TX, mancopper + TX, mancozeb + TX, mandestrobin + TX, mandipropamid + TX, maneb + TX, mazidox + TX, m-cumenyl methylcarbamate + TX, mecarbam + TX, mecarphon + TX, medlure + TX, mefentrifluconazole + TX, megatomoic acid + TX, menazon + TX, mepanipyrim + TX, meperfluthrin + TX, mephosfolan + TX, mepronil + TX, mercuric oxide + TX, mercurous chloride + TX, mesulfen + TX, mesulfenfos + TX, metalaxyl + TX, metam + TX, metam-potassium + TX, metam- sodium + TX, Metaphycus helvolus + TX, Metarhizium anisopliae var. acridum + TX, Metarhizium anisopliae var. anisopliae + TX, metarylpicoxamid + TX, metconazole + TX, metepa + TX, methacrifos + TX, methanesulfonyl fluoride + TX, methasulfocarb + TX, methiotepa + TX, methocrotophos + TX, methoprene + TX, methoquin-butyl + TX, methothrin + TX, methoxychlor + TX, methyl (Z)-2-(5- cyclohexyl-2-methyl-phenoxy)-3-methoxy-prop-2-enoate + TX, methyl (Z)-2-(5-cyclopentyl-2-methyl- phenoxy)-3-methoxy-prop-2-enoate (these compounds may be prepared from the methods described in WO2020/193387) + TX, methyl (Z)-2-[5-(3-isopropylpyrazol-1-yl)-2-methyl-phenoxy]-3-methoxy- prop-2-enoate + TX, methyl (Z)-3-methoxy-2-[2-methyl-5-(3-propylpyrazol-1-yl)phenoxy]prop-2-enoate + TX, methyl (Z)-3-methoxy-2-[2-methyl-5-(4-propyltriazol-2-yl)phenoxy]prop-2-enoate + TX, methyl (Z)- 3-methoxy-2-[2-methyl-5-[3-(trifluoromethyl)pyrazol-1-yl]phenoxy]prop-2-enoate (these compounds may be prepared from the methods described in WO2020/079111) + TX, methyl (Z)-3-methoxy-2-[2- methyl-5-[4-(trifluoromethyl)triazol-2-yl]phenoxy]prop-2-enoate + TX, methyl apholate + TX, methyl bromide + TX, methyl eugenol + TX, methyl isothiocyanate + TX, methyl N-[[4-[1-(2,6-difluoro-4- isopropyl-phenyl)pyrazol-4-yl]-2-methyl-phenyl]methyl]carbamate (may be prepared from the methods described in WO 2020/097012) + TX, methyl N-[[4-[1-(4-cyclopropyl-2,6-difluoro-phenyl)pyrazol-4-yl]-2- methyl-phenyl]methyl]carbamate (may be prepared from the methods described in WO 2020/097012) + TX, methyl N-[[5-[4-(2,4-dimethylphenyl)triazol-2-yl]-2-methyl-phenyl]methyl]carbamate + TX, methylchloroform + TX, methylene chloride + TX, methylneodecanamide + TX, metiram + TX, metolcarb + TX, metominostrobin + TX, metoxadiazone + TX, metrafenone + TX, metyltetraprole + TX, MGK 264 + TX, milbemycin oxime + TX, mipafox + TX, mirex + TX, monocrotophos + TX, morphothion + TX, morzid + TX, moxidectin + TX, muscalure + TX, myclobutanil + TX, myclozoline + TX, Myrothecium verrucaria composition + TX, N-((1R)-1-benzyl-3-chloro-1-methyl-but-3-enyl)-8-fluoro-quinoline-3- carboxamide (these compounds may be prepared from the methods described in WO2017/153380) + TX, N-((1S)-1-benzyl-3-chloro-1-methyl-but-3-enyl)-8-fluoro-quinoline-3-carboxamide (these compounds may be prepared from the methods described in WO2017/153380) + TX, N'-(2,5-dimethyl- 4-phenoxy-phenyl)-N-ethyl-N-methyl-formamidine + TX, N'-(2-chloro-5-methyl-4-phenoxy-phenyl)-N- ethyl-N-methyl-formamidine + TX, N,2-dimethoxy-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3- yl]phenyl]methyl]propanamide + TX, N,N-dimethyl-1-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3- yl]phenyl]methyl]-1,2,4-triazol-3-amine (THESE COMPOUNDS may be prepared from the methods described in WO 2017/055473, WO 2017/055469, WO 2017/093348 and WO 2017/118689) + TX, N- [(1R)-1-benzyl-1,3-dimethyl-butyl]-7,8-difluoro-quinoline-3-carboxamide + TX, N-[(1R)-1-benzyl-1,3- dimethyl-butyl]-8-fluoro-quinoline-3-carboxamide + TX, N-[(1R)-1-benzyl-3,3,3-trifluoro-1-methyl- propyl]-8-fluoro-quinoline-3-carboxamide + TX, N-[(1S)-1-benzyl-1,3-dimethyl-butyl]-7,8-difluoro- quinoline-3-carboxamide + TX, N-[(1S)-1-benzyl-1,3-dimethyl-butyl]-8-fluoro-quinoline-3-carboxamide + TX, N-[(1S)-1-benzyl-3,3,3-trifluoro-1-methyl-propyl]-8-fluoro-quinoline-3-carboxamide + TX, N-[(E)- methoxyiminomethyl]-4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]benzamide + TX, N-[(Z)- methoxyiminomethyl]-4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]benzamide + TX, N-[[4-[5- (trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide + TX, N-[2-[2,4-dichloro- phenoxy]phenyl]-3-(difluoromethyl)-1-methyl-pyrazole-4-carboxamide + TX, N-[2-[2-chloro-4- (trifluoromethyl)phenoxy]phenyl]-3-(difluoromethyl)-1-methyl-pyrazole-4-carboxamide + TX, N'-[2- chloro-4-(2-fluorophenoxy)-5-methyl-phenyl]-N-ethyl-N-methyl-formamidine (this compound may be prepared from the methods described in WO 2016/202742) + TX, N'-[4-(4,5-dichlorothiazol-2-yl)oxy-2,5- dimethyl-phenyl]-N-ethyl-N-methyl-formamidine + TX, N'-[5-bromo-2-methyl-6-(1-methyl-2-propoxy- ethoxy)-3-pyridyl]-N-ethyl-N-methyl-formamidine + TX, N'-[5-bromo-2-methyl-6-(1-methyl-2-propoxy- ethoxy)-3-pyridyl]-N-isopropyl-N-methyl-formamidine (these compounds may be prepared from the methods described in WO2015/155075) + TX, N'-[5-bromo-2-methyl-6-(2-propoxypropoxy)-3-pyridyl]- N-ethyl-N-methyl-formamidine (this compound may be prepared from the methods described in IPCOM000249876D) + TX, N'-[5-bromo-2-methyl-6-[(1R)-1-methyl-2-propoxy-ethoxy]-3-pyridyl]-N- ethyl-N-methyl-formamidine + TX, N'-[5-bromo-2-methyl-6-[(1S)-1-methyl-2-propoxy-ethoxy]-3-pyridyl]- N-ethyl-N-methyl-formamidine + TX, N'-[5-chloro-2-methyl-6-(1-methyl-2-propoxy-ethoxy)-3-pyridyl]-N- ethyl-N-methyl-formamidine + TX, N-[N-methoxy-C-methyl-carbonimidoyl]-4-[5-(trifluoromethyl)-1,2,4- oxadiazol-3-yl]benzamide (these compounds may be prepared from the methods described in WO 2018/202428) + TX, N’-[4-(1-cyclopropyl-2,2,2-trifluoro-1-hydroxy-ethyl)-5-methoxy-2-methyl-phenyl]- N-isopropyl-N-methyl-formamidine (these compounds may be prepared from the methods described in WO2018/228896) + TX, nabam + TX, naftalofos + TX, naled + TX, naphthalene + TX, NC-170 + TX, Neodiprion sertifer NPV and N. lecontei NPV + TX, nerolidol + TX, N-ethyl-2-methyl-N-[[4-[5- (trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide + TX, N-ethyl-N’-[5-methoxy-2- methyl-4-[(2-trifluoromethyl)oxetan-2-yl]phenyl]-N-methyl-formamidine + TX, nickel bis(dimethyldithiocarbamate) + TX, niclosamide-olamine + TX, nicotine + TX, nicotine sulfate + TX, nifluridide + TX, nikkomycins + TX, N-isopropyl-N’-[5-methoxy-2-methyl-4-(2,2,2-trifluoro-1-hydroxy-1- phenyl-ethyl)phenyl]-N-methyl-formamidine + TX, nithiazine + TX, nitrapyrin + TX, nitrilacarb + TX, nitrilacarb 1:1 zinc chloride complex + TX, nitrothal-isopropyl + TX, N-methoxy-N-[[4-[5-(trifluoromethyl)- 1,2,4-oxadiazol-3-yl]phenyl]methyl]cyclopropanecarboxamide + TX, N-methyl-4-[5-(trifluoromethyl)- 1,2,4-oxadiazol-3-yl]benzamide + TX, N-methyl-4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3- yl]benzenecarbothioamide + TX, norbormide + TX, nuarimol + TX, O,O,O',O'-tetrapropyl dithiopyrophosphate + TX, octadeca-2,13-dien-1-yl acetate + TX, octadeca-3,13-dien-1-yl acetate + TX, octhilinone + TX, ofurace + TX, oleic acid + TX, omethoate + TX, orfralure + TX, Orius spp. + TX, oryctalure + TX, orysastrobin + TX, ostramone + TX, oxadixyl + TX, oxamate + TX, oxathiapiprolin + TX, oxine-copper + TX, oxolinic acid + TX, oxycarboxin + TX, oxydeprofos + TX, oxydisulfoton + TX, oxytetracycline + TX, paclobutrazole + TX, Paecilomyces fumosoroseus + TX, para-dichlorobenzene + TX, parathion + TX, parathion-methyl + TX, pefurazoate + TX, penconazole + TX, pencycuron + TX, penflufen + TX, penfluron + TX, pentachlorophenol + TX, pentachlorophenyl laurate + TX, penthiopyrad + TX, permethrin + TX, PH 60-38 + TX, phenamacril + TX, phenkapton + TX, phosacetim + TX, phosalone + TX, phosdiphen + TX, phosfolan + TX, phosglycin + TX, phosnichlor + TX, phosphamidon + TX, phosphine + TX, phosphorus + TX, phoxim-methyl + TX, phthalide + TX, Phytoseiulus persimilis + TX, picarbutrazox + TX, picaridin + TX, picoxystrobin + TX, pindone + TX, piperazine + TX, piperonyl butoxide + TX, piprotal + TX, pirimetaphos + TX, polychlorodicyclopentadiene isomers + TX, polychloroterpenes + TX, polynactins + TX, polyoxins + TX, potassium arsenite + TX, potassium ethylxanthate + TX, potassium hydroxyquinoline sulfate + TX, potassium thiocyanate + TX, pp'-DDT + TX, precocene I + TX, precocene II + TX, precocene III + TX, primidophos + TX, probenazole + TX, prochloraz + TX, proclonol + TX, procymidone + TX, profluthrin + TX, promacyl + TX, promecarb + TX, propamocarb + TX, propiconazole + TX, propineb + TX, propoxur + TX, propyl isomer + TX, proquinazid + TX, prothidathion + TX, prothioconazole + TX, prothiofos + TX, prothoate + TX, pydiflumetofen + TX, pyraclostrobin + TX, pyrametostrobin + TX, pyraoxystrobin + TX, pyrapropoyne + TX, pyraziflumid + TX, pyrazophos + TX, pyresmethrin + TX, pyrethrin I + TX, pyrethrin II + TX, pyrethrins + TX, pyribencarb + TX, pyridachlometyl + TX, pyridaphenthion + TX, pyridin-4-amine + TX, pyrifenox + TX, pyrimethanil + TX, pyrimitate + TX, pyrimorph + TX, pyrinuron + TX, pyriofenone + TX, pyrisoxazole + TX, pyroquilon + TX, quassia + TX, quinalphos + TX, quinalphos-methyl + TX, quinoclamine + TX, quinofumelin + TX, quinonamid + TX, quinothion + TX, quinoxyfen + TX, quintiofos + TX, quintozene + TX, R-1492 + TX, rafoxanide + TX, resmethrin + TX, Reynoutria sachalinensis extract + TX, ribavirin + TX, Rmetalaxyl + TX, rotenone + TX, ryania + TX, ryanodine + TX, S421 + TX, sabadilla + TX, schradan + TX, scilliroside + TX, seboctylamine + TX, sebufos + TX, sedaxane + TX, selamectin + TX, sesamex + TX, sesasmolin + TX, SI-0009 + TX, siglure + TX, simazine + TX, simeconazole + TX, sodium arsenite + TX, sodium cyanide + TX, sodium fluoride + TX, sodium fluoroacetate + TX, sodium hexafluorosilicate + TX, sodium pentachlorophenoxide + TX, sodium selenate + TX, sodium tetrathiocarbonate + TX, sodium thiocyanate + TX, sophamide + TX, sordidin + TX, spiroxamine + TX, SSI-121 + TX, Steinernema bibionis + TX, Steinernema carpocapsae + TX, Steinernema feltiae + TX, Steinernema glaseri + TX, Steinernema riobrave + TX, Steinernema riobravis + TX, Steinernema scapterisci + TX, Steinernema spp. + TX, streptomycin + TX, streptomycin sesquisulfate + TX, strychnine + TX, sulcatol + TX, sulcofuron + TX, sulcofuron-sodium + TX, sulfiram + TX, sulfluramid + TX, sulfotep + TX, sulfoxide + TX, sulfur + TX, sulfuryl fluoride + TX, sulprofos + TX, tar oils + TX, tau-fluvalinate + TX, tazimcarb + TX, TDE + TX, tebuconazole + TX, tebufloquin + TX, tebupirimfos + TX, tecloftalam + TX, temephos + TX, tepa + TX, TEPP + TX, terallethrin + TX, terbam + TX, tert-butyl N-[6-[[[(1-methyltetrazol-5-yl)- phenyl-methylene]amino]oxymethyl]-2-pyridyl]carbamate + TX, tetrachloroethane + TX, tetrachlorothiophene + TX, tetraconazole + TX, tetradec-11-en-1-yl acetate + TX, tetradifon + TX, tetramethylfluthrin + TX, tetrasul + TX, thallium sulfate + TX, thiabendazole + TX, thiafenox + TX, thiapronil + TX, thicrofos + TX, thifluzamide + TX, thiocarboxime + TX, thiocyclam + TX, thiocyclam hydrogen oxalate + TX, thiodiazole copper + TX, thiofanox + TX, thiohempa + TX, thiomersal + TX, thiometon + TX, thionazin + TX, thiophanate + TX, thiophanate-methyl + TX, thioquinox + TX, thiosultap + TX, thiosultap-sodium + TX, thiotepa + TX, thiram + TX, thuringiensin + TX, tiadinil + TX, tolclofos- methyl + TX, tolprocarb + TX, tolylfluanid + TX, tralomethrin + TX, transpermethrin + TX, tretamine + TX, triadimefon + TX, triadimenol + TX, triamiphos + TX, triarathene + TX, triazamate + TX, triazophos + TX, triazoxide + TX, triazuron + TX, tributyltin oxide + TX, trichlormetaphos-3 + TX, trichloronat + TX, Trichogramma spp. + TX, triclopyricarb + TX, tricyclazole + TX, tridemorph + TX, trifenmorph + TX, trifenofos + TX, trifloxystrobin + TX, triflumizole + TX, triforine + TX, trimedlure + TX, trimedlure A + TX, trimedlure B1 + TX, trimedlure B2 + TX, trimedlure C + TX, trimethacarb + TX, trinactin + TX, trinexapac + TX, triphenyltin acetate + TX, triphenyltin hydroxide + TX, triprene + TX, triticonazole + TX, trunc-call + TX, Typhlodromus occidentalis + TX, uredepa + TX, validamycin + TX, valifenalate + TX, vamidothion + TX, vaniliprole + TX, veratridine + TX, veratrine + TX, verbutin + TX, Verticillium lecanii + TX, vinclozoline + TX, warfarin + TX, XMC + TX, xylenols + TX, zeatin + TX, zetamethrin + TX, zhongshengmycin + TX, zinc naphthenate + TX, zinc phosphide + TX, zinc thiazole + TX, zineb + TX, ziram + TX, zolaprofos + TX; Acinetobacter lwoffii + TX, Acremonium alternatum + TX, Acremonium cephalosporium + TX, Acremonium diospyri + TX, Acremonium obclavatum + TX, Adoxophyes orana granulovirus (AdoxGV) (Capex®) + TX, Agrobacterium radiobacter strain K84 (Galltrol-A®) + TX, Alternaria alternate + TX, Alternaria cassia + TX, Alternaria destruens (Smolder®) + TX, Ampelomyces quisqualis (AQ10®) + TX, Aspergillus flavus AF36 (AF36®) + TX, Aspergillus flavus NRRL 21882 (Aflaguard®) + TX, Aspergillus spp. + TX, Aureobasidium pullulans + TX, Azospirillum (MicroAZ®, TAZO B®) + TX, Azotobacter + TX, Azotobacter chroocuccum (Azotomeal®) + TX, Azotobacter cysts (Bionatural Blooming Blossoms®) + TX, Bacillus amyloliquefaciens + TX, Bacillus cereus + TX, Bacillus chitinosporus strain AQ746 + TX, Bacillus chitinosporus strain CM-1 + TX, Bacillus circulans + TX, Bacillus firmus (BioSafe®, BioNem- WP®) in particular strain CNMC 1-1582 (e.g. VOTIVO® from BASF SE) + TX, Bacillus licheniformis strain 3086 (EcoGuard®, Green Releaf®) + TX, Bacillus licheniformis strain HB-2 (Biostart™ formerly Rhizoboost®) + TX, Bacillus macerans + TX, Bacillus marismortui + TX, Bacillus megaterium + TX, Bacillus mycoides strain AQ726 + TX, Bacillus papillae (Milky Spore Powder®) + TX, Bacillus pumilus spp. + TX, Bacillus pumilus strain AQ717 + TX, Bacillus pumilus strain GB34 (Yield Shield®) + TX, Bacillus pumilus strain QST 2808 (Sonata®, Ballad Plus®) + TX, Bacillus sphaericus (VectoLex®) + TX, Bacillus spp. + TX, Bacillus spp. strain AQ175 + TX, Bacillus spp. strain AQ177 + TX, Bacillus spp. strain AQ178 + TX, Bacillus subtilis strain AQ153 + TX, Bacillus subtilis strain AQ743 + TX, Bacillus subtilis strain QST 713 (CEASE®, Serenade®, Rhapsody®) + TX, Bacillus subtilis strain QST 714 (JAZZ®) + TX, Bacillus subtilis strain QST3002 + TX, Bacillus subtilis strain QST3004 + TX, Bacillus subtilis var. amyloliquefaciens strain FZB24 (Taegro®, Rhizopro®) + TX, Bacillus thuringiensis aizawai GC 91 (Agree®) + TX, Bacillus thuringiensis Cry 2Ae + TX, Bacillus thuringiensis Cry1Ab + TX, Bacillus thuringiensis israelensis (BMP123®, Aquabac®, VectoBac®) + TX, Bacillus thuringiensis kurstaki (Javelin®, Deliver®, CryMax®, Bonide®, Scutella WP®, Turilav WP ®, Astuto®, Dipel WP®, Biobit®, Foray®) + TX, Bacillus thuringiensis kurstaki BMP 123 (Baritone®) + TX, Bacillus thuringiensis kurstaki HD-1 (Bioprotec-CAF / 3P®) + TX, Bacillus thuringiensis strain AQ52 + TX, Bacillus thuringiensis strain BD#32 + TX, Bacillus thuringiensis tenebrionis (Novodor®, BtBooster) + TX, Bacillus thuringiensis var. aizawai (XenTari®, DiPel®) + TX, bacteria spp. (GROWMEND®, GROWSWEET®, Shootup®) + TX, bacteriophage of Clavipacter michiganensis (AgriPhage®, Bakflor®) + TX, Beauveria bassiana (Beaugenic®, Brocaril WP®) + TX, Beauveria bassiana GHA (Mycotrol ES®, Mycotrol O®, BotaniGuard®) + TX, Beauveria brongniartii (Engerlingspilz®, Schweizer Beauveria®, Melocont®) + TX, Beauveria spp. + TX, Botrytis cineria + TX, Bradyrhizobium japonicum (TerraMax®) + TX, Brevibacillus brevis + TX, Burkholderia cepacia (Deny®, Intercept®, Blue Circle®) + TX, Burkholderia gladii + TX, Burkholderia gladioli + TX, Burkholderia spp. + TX, Canadian thistle fungus (CBH Canadian Bioherbicide®) + TX, Candida butyri + TX, Candida famata + TX, Candida fructus + TX, Candida glabrata + TX, Candida guilliermondii + TX, Candida melibiosica + TX, Candida oleophila strain O + TX, Candida parapsilosis + TX, Candida pelliculosa + TX, Candida pulcherrima + TX, Candida reukaufii + TX, Candida saitoana (Bio-Coat®, Biocure®) + TX, Candida sake + TX, Candida spp. + TX, Candida tenius + TX, Cedecea davisae + TX, Cellulomonas flavigena + TX, Chaetomium cochliodes (Nova- Cide®) + TX, Chaetomium globosum (Nova-Cide®) + TX, Chromobacterium subtsugae strain PRAA4- 1T (Grandevo®) + TX, Cladosporium chlorocephalum + TX, Cladosporium cladosporioides + TX, Cladosporium oxysporum + TX, Cladosporium spp. + TX, Cladosporium tenuissimum + TX, Clonostachys rosea (EndoFine®) + TX, Colletotrichum acutatum + TX, Coniothyrium minitans (Cotans WG®) + TX, Coniothyrium spp. + TX, Cryptococcus albidus (YIELDPLUS®) + TX, Cryptococcus humicola + TX, Cryptococcus infirmo-miniatus + TX, Cryptococcus laurentii + TX, Cryptophlebia leucotreta granulovirus (Cryptex®) + TX, Cupriavidus campinensis + TX, Cydia pomonella granulovirus (CYD-X®, Madex®, Madex® Plus, Madex Max, Carpovirusine® + TX, Cylindrobasidium laeve (Stumpout®) + TX, Cylindrocladium + TX, Debaryomyces hansenii + TX, Drechslera hawaiinensis + TX, Enterobacter cloacae + TX, Enterobacteriaceae + TX, Entomophtora virulenta (Vektor®) + TX, Epicoccum nigrum + TX, Epicoccum purpurascens + TX, Epicoccum spp. + TX, Filobasidium floriforme + TX, Fusarium acuminatum + TX, Fusarium chlamydosporum + TX, Fusarium oxysporum (Fusaclean®, Biofox C®) + TX, Fusarium proliferatum + TX, Fusarium spp. + TX, Galactomyces geotrichum + TX, Gliocladium catenulatum (Primastop®, Prestop®) + TX, Gliocladium roseum + TX, Gliocladium spp. (SoilGard®) + TX, Gliocladium virens (Soilgard®) + TX, Granulovirus (Granupom®) + TX, Halobacillus halophilus + TX, Halobacillus litoralis + TX, Halobacillus trueperi + TX, Halomonas spp. + TX, Halomonas subglaciescola + TX, Halovibrio variabilis + TX, Hanseniaspora uvarum + TX, Helicoverpa armigera nucleopolyhedrovirus (Helicovex®) + TX, Helicoverpa zea nuclear polyhedrosis virus (Gemstar®) + TX, Isaria fumosorosea (previously known as Paecilomyces fumosoroseus strain, PFR- 97®, PreFeRal®) + TX, Isoflavone formononetin (Myconate®) + TX, Kloeckera apiculata + TX, Kloeckera spp. + TX, Lagenidium giganteum (Laginex®) + TX, Lecanicillium lecanii (formerly known as Verticillium lecanii (Mycotal®) conidia of strain KV01 (e.g. Vertalec® by Koppert/Arysta) + TX, Lecanicillium longisporum (Vertiblast®) + TX, Lecanicillium muscarium (Vertikil®) + TX, Lymantria Dispar nucleopolyhedrosis virus (Disparvirus®) + TX, Marinococcus halophilus + TX, Meira geulakonigii + TX, Metarhizium anisopliae (Destruxin WP®) + TX, Metarhizium anisopliae (Met52®) + TX, Metschnikowia fruticola (Shemer®) + TX, Metschnikowia pulcherrima + TX, Microdochium dimerum (Antibot®) + TX, Micromonospora coerulea + TX, Microsphaeropsis ochracea + TX, Muscodor albus 620 (Muscudor®) + TX, Muscodor roseus in particular strain A3-5 (Accession No. NRRL 30548) + TX, Mycorrhizae spp. (AMykor®, Root Maximizer®) + TX, Myrothecium verrucaria strain AARC-0255 (DiTera®, BROS PLUS®) + TX, Ophiostoma piliferum strain D97 (Sylvanex®) + TX, Paecilomyces farinosus + TX, Paecilomyces lilacinus strain 251 (MeloCon WG®) + TX, Paecilomyces linacinus (Biostat WP®) + TX, Paenibacillus polymyxa + TX, Pantoea agglomerans (BlightBan C9-1®) + TX, Pantoea spp. + TX, Pasteuria nishizawae in particular strain Pn1 (CLARIVA from Syngenta/ChemChina); + TX, Pasteuria spp. (Econem®) + TX, Penicillium aurantiogriseum + TX, Penicillium billai (Jumpstart®, TagTeam®) + TX, Penicillium brevicompactum + TX, Penicillium frequentans + TX, Penicillium griseofulvum + TX, Penicillium purpurogenum + TX, Penicillium spp. + TX, Penicillium viridicatum + TX, Phlebiopsis gigantean (Rotstop®) + TX, phosphate solubilizing bacteria (Phosphomeal®) + TX, Phytophthora cryptogea + TX, Phytophthora palmivora (Devine®) + TX, Pichia anomala + TX, Pichia guilliermondii + TX, Pichia membranaefaciens + TX, Pichia onychis + TX, Pichia stipites + TX, Pseudomonas aeruginosa + TX, Pseudomonas aureofasciens (Spot-Less Biofungicide®) + TX, Pseudomonas cepacia + TX, Pseudomonas chlororaphis (AtEze®) + TX, Pseudomonas corrugate + TX, Pseudomonas fluorescens (Zequanox®) + TX, Pseudomonas fluorescens strain A506 (BlightBan A506®) + TX, Pseudomonas putida + TX, Pseudomonas reactans + TX, Pseudomonas spp. + TX, Pseudomonas syringae (Bio-Save®) + TX, Pseudomonas viridiflava + TX, Pseudozyma flocculosa strain PF-A22 UL (Sporodex L®) + TX, Puccinia canaliculata + TX, Puccinia thlaspeos (Wood Warrior®) + TX, Pythium paroecandrum + TX, Pythium oligandrum (Polygandron®, Polyversum®) + TX, Pythium periplocum + TX, Rhanella aquatilis + TX, Rhanella spp. + TX, Rhizobia (Dormal®, Vault®) + TX, Rhizoctonia + TX, Rhodococcus globerulus strain AQ719 + TX, Rhodosporidium diobovatum + TX, Rhodosporidium toruloides + TX, Rhodotorula glutinis + TX, Rhodotorula graminis + TX, Rhodotorula mucilagnosa + TX, Rhodotorula rubra + TX, Rhodotorula spp. + TX, Saccharomyces cerevisiae + TX, Salinococcus roseus + TX, Sclerotinia minor (SARRITOR®) + TX, Sclerotinia minor + TX, Scytalidium spp. + TX, Scytalidium uredinicola + TX, Serratia marcescens + TX, Serratia plymuthica + TX, Serratia spp. + TX, Sordaria fimicola + TX, Spodoptera exigua nuclear polyhedrosis virus (Spod-X®, Spexit®) + TX, Spodoptera littoralis nucleopolyhedrovirus (Littovir®) + TX, Sporobolomyces roseus + TX, Stenotrophomonas maltophilia + TX, Streptomyces albaduncus + TX, Streptomyces exfoliates + TX, Streptomyces galbus + TX, Streptomyces griseoplanus + TX, Streptomyces griseoviridis (Mycostop®) + TX, Streptomyces hygroscopicus + TX, Streptomyces lydicus (Actinovate®) + TX, Streptomyces lydicus WYEC-108 (ActinoGrow®) + TX, Streptomyces violaceus + TX, Tilletiopsis minor + TX, Tilletiopsis spp. + TX, Trichoderma asperellum (T34 Biocontrol®) + TX, Trichoderma atroviride (Plantmate®) + TX, Trichoderma gamsii (Tenet®) + TX, Trichoderma hamatum TH 382 + TX, Trichoderma harzianum rifai (Mycostar®) + TX, Trichoderma harzianum T-22 (Trianum- P®, PlantShield HC®, RootShield®, Trianum-G® + TX, Trichoderma harzianum T-39 (Trichodex®) + TX, Trichoderma inhamatum + TX, Trichoderma koningii + TX, Trichoderma lignorum + TX, Trichoderma longibrachiatum + TX, Trichoderma polysporum (Binab T®) + TX, Trichoderma spp. LC 52 (Sentinel®) + TX, Trichoderma taxi + TX, Trichoderma virens (formerly Gliocladium virens GL-21) (SoilGuard®) + TX, Trichoderma virens + TX, Trichoderma viride + TX, Trichoderma viride strain ICC 080 (Remedier®) + TX, Trichosporon pullulans + TX, Trichosporon spp. + TX, Trichothecium roseum + TX, Trichothecium spp. + TX, Typhula phacorrhiza strain 94670 + TX, Typhula phacorrhiza strain 94671 + TX, Ulocladium atrum + TX, Ulocladium oudemansii (Botry-Zen®) + TX, Ustilago maydis + TX, various bacteria and supplementary micronutrients (Natural II®) + TX, various fungi (Millennium Microbes®) + TX, Verticillium chlamydosporium + TX, Vip3Aa20 (VIPtera®) + TX, Virgibaclillus marismortui + TX, Xanthomonas campestris pv. Poae (Camperico®) + TX, Xenorhabdus bovienii + TX, Xenorhabdus nematophilus + TX; AGNIQUE® MMF + TX, azadirachtin (Plasma Neem Oil®, AzaGuard®, MeemAzal®, Molt-X® e.g. AZATIN XL from Certis, US) + TX, Botanical IGR (Neemazad®, Neemix®) + TX, BugOil® + TX, canola oil (Lilly Miller Vegol®) + TX, Chenopodium ambrosioides near ambrosioides (Requiem®) + TX, Chrysanthemum extract (Crisant®) + TX, essentials oils of Labiatae (Botania®) + TX, extract of neem oil (Trilogy®) + TX, extracts of clove rosemary peppermint and thyme oil (Garden insect killer®) + TX, garlic + TX, Glycinebetaine (Greenstim®) + TX, kaolin (Screen®) + TX, lemongrass oil (GreenMatch®) + TX, Melaleuca alternifolia extract (also called tea tree oil) (Timorex Gold®) + TX, mixture of clove pepermint garlic oil and mint (Soil Shot®) + TX, mixture of clove rosemary and peppermint extract (EF 400®) + TX, mixture of rosemary sesame pepermint thyme and cinnamon extracts (EF 300®) + TX, neem oil + TX, Nepeta cataria (Catnip oil) + TX, Nepeta catarina + TX, nicotine + TX, oregano oil (MossBuster®) + TX, Pedaliaceae oil (Nematon®) + TX, pine oil (Retenol®) + TX, pyrethrum + TX, Quillaja saponaria (NemaQ®) + TX, Reynoutria sachalinensis (Regalia®, Sakalia®) + TX, rotenone (Eco Roten®) + TX, Rutaceae plant extract (Soleo®) + TX, soybean oil (Ortho ecosense®) + TX, storage glucam of brown algae (Laminarin®) + TX, thyme oil + TX; (E,Z)-7,9-Dodecadien-1-yl acetate + TX, (E,Z,Z)-3,8,11 Tetradecatrienyl acetate + TX, (Z,Z,E)-7,11,13- Hexadecatrienal + TX, 2-Methyl-1-butanol + TX, Biolure® + TX, blackheaded fireworm pheromone (3M Sprayable Blackheaded Fireworm Pheromone®) + TX, Calcium acetate + TX, Check-Mate® + TX, Codling Moth Pheromone (Paramount dispenser-(CM)/ Isomate C-Plus®) + TX, Entostat powder (extract from palm tree) (Exosex CM®) + TX, Grape Berry Moth Pheromone (3M MEC-GBM Sprayable Pheromone®) + TX, Lavandulyl senecioate + TX, Leafroller pheromone (3M MEC – LR Sprayable Pheromone®) + TX, Muscamone (Snip7 Fly Bait® + TX, Oriental Fruit Moth Pheromone (3M oriental fruit moth sprayable pheromone®) + TX, Peachtree Borer Pheromone (Isomate-P®) + TX, Scenturion® + TX, Starbar Premium Fly Bait®) + TX, Tomato Pinworm Pheromone (3M Sprayable pheromone®) + TX; Acerophagus papaya + TX, Adalia bipunctata (Adalia-System®) + TX, Adalia bipunctata (Adaline®) + TX, Adalia bipunctata (Aphidalia®) + TX, Ageniaspis citricola + TX, Ageniaspis fuscicollis + TX, Amblyseius andersoni (Anderline®, Andersoni-System®) + TX, Amblyseius californicus (Amblyline®, Spical®) + TX, Amblyseius cucumeris (Thripex®, Bugline cucumeris®) + TX, Amblyseius fallacis (Fallacis®) + TX, Amblyseius swirskii (Bugline swirskii®, Swirskii-Mite®) + TX, Amblyseius womersleyi (WomerMite®) + TX, Amitus hesperidum + TX, Anagrus atomus + TX, Anagyrus fusciventris + TX, Anagyrus kamali + TX, Anagyrus loecki + TX, Anagyrus pseudococci (Citripar®) + TX, Anicetus benefices + TX, Anisopteromalus calandrae + TX, Anthocoris nemoralis (Anthocoris-System®) + TX, Aphelinus abdominalis (Apheline®, Aphiline®), + TX, Aphelinus asychis + TX, Aphidius colemani (Aphipar®) + TX, Aphidius ervi (Aphelinus-System®) + TX, Aphidius ervi (Ervipar®) + TX, Aphidius gifuensis + TX, Aphidius matricariae (Aphipar-M®) + TX, Aphidoletes aphidimyza (Aphidend®, Aphidoline®) + TX, Aphytis lingnanensis + TX, Aphytis melinus + TX, Aprostocetus hagenowii + TX, Atheta coriaria (Staphyline®) + TX, Bombus spp. + TX, Bombus terrestris (Beeline®, Tripol®) + TX, Bombus terrestris (Natupol Beehive®) + TX, Cephalonomia stephanoderis + TX, Chilocorus nigritus + TX, Chrysoperla carnea (Chrysoline®, Chrysopa®) + TX, Chrysoperla rufilabris + TX, Cirrospilus ingenuus + TX, Cirrospilus quadristriatus + TX, Citrostichus phyllocnistoides + TX, Closterocerus chamaeleon + TX, Closterocerus spp. + TX, Coccidoxenoides perminutus (Planopar®) + TX, Coccophagus cowperi + TX, Coccophagus lycimnia + TX, Cotesia flavipes + TX, Cotesia plutellae + TX, Cryptolaemus montrouzieri (Cryptobug®, Cryptoline®) + TX, Cybocephalus nipponicus + TX, Dacnusa sibirica (Minusa®, DacDigline®, Minex®) + TX, Delphastus catalinae (Delphastus®) + TX, Delphastus pusillus + TX, Diachasmimorpha krausii + TX, Diachasmimorpha longicaudata + TX, Diaparsis jucunda + TX, Diaphorencyrtus aligarhensis + TX, Diglyphus isaea (Diminex®, Miglyphus®, Digline®) + TX, Diversinervus spp. + TX, Encarsia citrina + TX, Encarsia formosa (Encarsia max®, Encarline®, En- Strip®) + TX, Encarsia guadeloupae + TX, Encarsia haitiensis + TX, Episyrphus balteatus (Syrphidend®) + TX, Eretmoceris siphonini + TX, Eretmocerus californicus + TX, Eretmocerus eremicus (Enermix®, Ercal®, Eretline e®, Bemimix®) + TX, Eretmocerus hayati + TX, Eretmocerus mundus (Bemipar®, Eretline m®) + TX, Eretmocerus siphonini + TX, Exochomus quadripustulatus + TX, Feltiella acarisuga (Feltiline®) + TX, Feltiella acarisuga (Spidend®) + TX, Fopius arisanus + TX, Fopius ceratitivorus + TX, Formononetin (Wirless Beehome®) + TX, Franklinothrips vespiformis (Vespop®) + TX, Galendromus occidentalis + TX, Goniozus legneri + TX, Habrobracon hebetor + TX, Harmonia axyridis (HarmoBeetle®) + TX, Heterorhabditis bacteriophora (NemaShield HB®, Nemaseek®, Terranem-Nam®, Terranem®, Larvanem®, B-Green®, NemAttack ®, Nematop®) + TX, Heterorhabditis megidis (Nemasys H®, BioNem H®, Exhibitline hm®, Larvanem-M®) + TX, Heterorhabditis spp. (Lawn Patrol®) + TX, Hippodamia convergens + TX, Hypoaspis aculeifer (Aculeifer-System®, Entomite-A®) + TX, Hypoaspis miles (Hypoline m®, Entomite-M®) + TX, Lbalia leucospoides + TX, Lecanoideus floccissimus + TX, Lemophagus errabundus + TX, Leptomastidea abnormis + TX, Leptomastix dactylopii (Leptopar®) + TX, Leptomastix epona + TX, Lindorus lophanthae + TX, Lipolexis oregmae + TX, Lucilia caesar (Natufly®) + TX, Lysiphlebus testaceipes + TX, Macrolophus caliginosus (Mirical-N®, Macroline c®, Mirical®) + TX, Mesoseiulus longipes + TX, Metaphycus flavus + TX, Metaphycus lounsburyi + TX, Micromus angulatus (Milacewing®) + TX, Microterys flavus + TX, Muscidifurax raptorellus and Spalangia cameroni (Biopar®) + TX, Neodryinus typhlocybae + TX, Neoseiulus californicus + TX, Neoseiulus cucumeris (THRYPEX®) + TX, Neoseiulus fallacis + TX, Nesideocoris tenuis (NesidioBug®, Nesibug®) + TX, Ophyra aenescens (Biofly®) + TX, Orius insidiosus (Thripor-I®, Oriline i®) + TX, Orius laevigatus (Thripor-L®, Oriline l®) + TX, Orius majusculus (Oriline m®) + TX, Orius strigicollis (Thripor-S®) + TX, Pauesia juniperorum + TX, Pediobius foveolatus + TX, Phasmarhabditis hermaphrodita (Nemaslug®) + TX, Phymastichus coffea + TX, Phytoseiulus macropilus + TX, Phytoseiulus persimilis (Spidex®, Phytoline p®) + TX, Podisus maculiventris (Podisus®) + TX, Pseudacteon curvatus + TX, Pseudacteon obtusus + TX, Pseudacteon tricuspis + TX, Pseudaphycus maculipennis + TX, Pseudleptomastix mexicana + TX, Psyllaephagus pilosus + TX, Psyttalia concolor (complex) + TX, Quadrastichus spp. + TX, Rhyzobius lophanthae + TX, Rodolia cardinalis + TX, Rumina decollate + TX, Semielacher petiolatus + TX, Sitobion avenae (Ervibank®) + TX, Steinernema carpocapsae (Nematac C®, Millenium®, BioNem C®, NemAttack®, Nemastar®, Capsanem®) + TX, Steinernema feltiae (NemaShield®, Nemasys F®, BioNem F®, Steinernema- System®, NemAttack®, Nemaplus®, Exhibitline sf®, Scia-rid®, Entonem®) + TX, Steinernema kraussei (Nemasys L®, BioNem L®, Exhibitline srb®) + TX, Steinernema riobrave (BioVector®, BioVektor®) + TX, Steinernema scapterisci (Nematac S®) + TX, Steinernema spp. + TX, Steinernematid spp. (Guardian Nematodes®) + TX, Stethorus punctillum (Stethorus®) + TX, Tamarixia radiate + TX, Tetrastichus setifer + TX, Thripobius semiluteus + TX, Torymus sinensis + TX, Trichogramma brassicae (Tricholine b®) + TX, Trichogramma brassicae (Tricho-Strip®) + TX, Trichogramma evanescens + TX, Trichogramma minutum + TX, Trichogramma ostriniae + TX, Trichogramma platneri + TX, Trichogramma pretiosum + TX, Xanthopimpla stemmator + TX; abscisic acid + TX, Aminomite® + TX, BioGain® + TX, bioSea® + TX, CAS Number: 2643947-26-4 + TX, Chondrostereum purpureum (Chontrol Paste®) + TX, Colletotrichum gloeosporioides (Collego®) + TX, Copper Octanoate (Cueva®) + TX, Delta traps (Trapline d®) + TX, Erwinia amylovora (Harpin) (ProAct®, Ni-HIBIT Gold CST®) + TX, fatty acids derived from a natural by-product of extra virgin olive oil (FLIPPER®) + TX, Ferri-phosphate (Ferramol®) + TX, Funnel traps (Trapline y®) + TX, Gallex® + TX, Grower's Secret® + TX, Homo-brassonolide + TX, Iron Phosphate (Lilly Miller Worry Free Ferramol Slug & Snail Bait®) + TX, MCP hail trap (Trapline f®) + TX, Microctonus hyperodae + TX, Mycoleptodiscus terrestris (Des-X®) + TX, Nosema locustae (Semaspore Organic Grasshopper Control®) + TX, Pheromone trap (Thripline ams®) + TX, potassium bicarbonate (MilStop®) + TX, potassium iodide + potassiumthiocyanate (Enzicur®) + TX, potassium salts of fatty acids (Sanova®) + TX, potassium silicate solution (Sil-Matrix®) + TX, Spider venom + TX, Sticky traps (Trapline YF®, Rebell Amarillo®) + TX, SuffOil-X® + TX, Traps (Takitrapline y + b®) + TX; Bacillus mojavensis strain R3B (Accession No. NCAIM (P) B001389) (WO 2013/034938) from Certis USA LLC + TX, Bacillus pumilus, in particular strain BU F-33, having NRRL Accession No. 50185 (CARTISSA® from BASF, EPA Reg. No.71840-19) + TX, Bacillus subtilis CX-9060 from Certis USA LLC, Bacillus sp., in particular strain D747 (available as DOUBLE NICKEL® from Kumiai Chemical Industry Co., Ltd.), having Accession No. FERM BP-8234, U.S. Patent No.7,094,592 + TX, Bacillus subtilis strain BU1814, (VELONDIS® PLUS, VELONDIS® FLEX and VELONDIS® EXTRA from BASF SE) + TX, Bacillus subtilis var. amyloliquefaciens strain FZB24 having Accession No. DSM 10271 (available from Novozymes as TAEGRO® or TAEGRO® ECO (EPA Registration No.70127-5)) + TX, Bacillus subtilis, in particular strain QST713/AQ713 (having NRRL Accession No. B-21661 and described in U.S. Patent No.6,060,051, available as SERENADE® OPTI or SERENADE® ASO from Bayer CropScience LP, US) + TX, Paenibacillus polymyxa, in particular strain AC-1 (e.g. TOPSEED® from Green Biotech Company Ltd.) + TX, Paenibacillus sp. strain having Accession No. NRRL B-50972 or Accession No. NRRL B-67129, WO 2016/154297 + TX, Pantoea agglomerans, in particular strain E325 (Accession No. NRRL B-21856) (available as BLOOMTIME BIOLOGICAL™ FD BIOPESTICIDE from Northwest Agri Products) + TX, Pseudomonas proradix (e.g. PRORADIX® from Sourcon Padena) + TX; Aureobasidium pullulans, in particular blastospores of strain DSM14940, blastospores of strain DSM 14941 or mixtures of blastospores of strains DSM14940 and DSM14941 (e.g., BOTECTOR® and BLOSSOM PROTECT® from bio-ferm, CH) + TX, Pseudozyma aphidis (as disclosed in WO2011/151819 by Yissum Research Development Company of the Hebrew University of Jerusalem) + TX, Saccharomyces cerevisiae, in particular strains CNCM No.1-3936, CNCM No.1-3937, CNCM No.1-3938 or CNCM No.1-3939 (WO 2010/086790) from Lesaffre et Compagnie, FR + TX; Agrobacterium radiobacter strain K84 (e.g. GALLTROL-A® from AgBioChem, CA) + TX, Bacillus amyloliquefaciens isolate B246 (e.g. AVOGREEN™ from University of Pretoria) + TX, Bacillus amyloliquefaciens strain F727 (also known as strain MBI110) (NRRL Accession No. B-50768, WO 2014/028521) (STARGUS® from Marrone Bio Innovations) + TX, Bacillus amyloliquefaciens strain FZB42, Accession No. DSM 23117 (available as RHIZOVITAL® from ABiTEP, DE) + TX, Bacillus amyloliquefaciens, in particular strain D747 (available as Double Nickel™ from Kumiai Chemical Industry Co., Ltd., having accession number FERM BP-8234, US Patent No.7,094,592) + TX, Bacillus licheniformis FMCH001 and Bacillus subtilis FMCH002 (QUARTZO® (WG) and PRESENCE® (WP) from FMC Corporation) + TX, Bacillus licheniformis, in particular strain SB3086, having Accession No. ATCC 55406, WO 2003/000051 (available as ECOGUARD® Biofungicide and GREEN RELEAF™ from Novozymes) + TX, Bacillus methylotrophicus strain BAC-9912 (from Chinese Academy of Sciences’ Institute of Applied Ecology) + TX, Bacillus mycoides, isolate, having Accession No. B-30890 (available as BMJ TGAI® or WG and LifeGard™ from Certis USA LLC) + TX, Bacillus pumilus, in particular strain GB34 (available as Yield Shield® from Bayer AG, DE) + TX, Bacillus pumilus, in particular strain QST2808 (available as SONATA® from Bayer CropScience LP, US, having Accession No. NRRL B- 30087 and described in U.S. Patent No.6,245,551) + TX, Bacillus subtilis CX-9060 from Certis USA LLC + TX, Bacillus subtilis IAB/BS03 (AVIV™ from STK Bio-Ag Technologies, PORTENTO® from Idai Nature) + TX, Bacillus subtilis KTSB strain (FOLIACTIVE® from Donaghys) + TX, Bacillus subtilis strain BU1814, (available as VELONDIS® PLUS, VELONDIS® FLEX and VELONDIS® EXTRA from BASF SE) + TX, Bacillus subtilis strain GB03 (available as Kodiak® from Bayer AG, DE) + TX, Bacillus subtilis strain MBI 600 (available as SUBTILEX from BASF SE), having Accession Number NRRL B-50595, U.S. Patent No.5,061,495 + TX, Bacillus subtilis strain Y1336 (available as BIOBAC® WP from Bion- Tech, Taiwan, registered as a biological fungicide in Taiwan under Registration Nos.4764, 5454, 5096 and 5277) + TX, Bacillus subtilis var. amyloliquefaciens strain FZB24 having Accession No. DSM 10271 (available from Novozymes as TAEGRO® or TAEGRO® ECO (EPA Registration No.70127-5)) + TX, Bacillus subtilis Y1336 (available as BIOBAC® WP from Bion-Tech, Taiwan, registered as a biological fungicide in Taiwan under Registration Nos. 4764, 5454, 5096 and 5277) + TX, Paenibacillus epiphyticus (WO 2016/020371) from BASF SE + TX, Paenibacillus polymyxa ssp. plantarum (WO 2016/020371) from BASF SE + TX, Paenibacillus sp. strain having Accession No. NRRL B-50972 or Accession No. NRRL B-67129, WO 2016/154297 + TX, Pseudomonas chlororaphis strain AFS009, having Accession No. NRRL B-50897, WO 2017/019448 (e.g., HOWLER™ and ZIO® from AgBiome Innovations, US) + TX, Pseudomonas chlororaphis, in particular strain MA342 (e.g. CEDOMON®, CERALL®, and CEDRESS® by Bioagri and Koppert) + TX, Pseudomonas fluorescens strain A506 (e.g. BLIGHTBAN® A506 by NuFarm) + TX, Pseudomonas proradix (e.g. PRORADIX® from Sourcon Padena) + TX, Streptomyces griseoviridis strain K61 (also known as Streptomyces galbus strain K61) (Accession No. DSM 7206) (MYCOSTOP® from Verdera, PREFENCE® from BioWorks, cf. Crop Protection 2006, 25, 468-475) + TX, Streptomyces lydicus strain WYEC108 (also known as Streptomyces lydicus strain WYCD108US) (ACTINO-IRON® and ACTINOVATE® from Novozymes) + TX; Trichoderma atroviride strain T11 (IMI352941/ CECT20498) + TX, Ampelomyces quisqualis strain AQ10, having Accession No. CNCM 1-807 (e.g., AQ 10® by IntrachemBio Italia) + TX, Ampelomyces quisqualis, in particular strain AQ 10 (e.g. AQ 10® by IntrachemBio Italia) + TX, Aspergillus flavus strain NRRL 21882 (products known as AFLA-GUARD® from Syngenta/ChemChina) + TX, Aureobasidium pullulans, in particular blastospores of strain DSM 14941 + TX, Aureobasidium pullulans, in particular blastospores of strain DSM14940 + TX, Aureobasidium pullulans, in particular mixtures of blastospores of strains DSM14940 and DSM 14941 (e.g. Botector® by bio-ferm, CH) + TX, Chaetomium cupreum (Accession No. CABI 353812) (e.g. BIOKUPRUM™ by AgriLife) + TX, Chaetomium globosum (available as RIVADIOM® by Rivale) + TX, Cladosporium cladosporioides, strain H39, having Accession No. CBS122244, US 2010/0291039 (by Stichting Dienst Landbouwkundig Onderzoek) + TX, Coniothyrium minitans, in particular strain CON/M/91-8 (Accession No. DSM9660, e.g. Contans ® from Bayer CropScience Biologics GmbH) + TX, Cryptococcus flavescens, strain 3C (NRRL Y-50378), + TX, Dactylaria candida, Dilophosphora alopecuri (available as TWIST FUNGUS®), Fusarium oxysporum, strain Fo47 (available as FUSACLEAN® by Natural Plant Protection) + TX, Gliocladium catenulatum (Synonym: Clonostachys rosea f. catenulate) strain J1446 (e.g. Prestop ® by Lallemand) + TX, Gliocladium roseum (also known as Clonostachys rosea f rosea) strain IK726 (Jensen DF, et al. Development of a biocontrol agent for plant disease control with special emphasis on the near commercial fungal antagonist Clonostachys rosea strain ’IK726’, Australasian Plant Pathol. 2007,36(2):95-101) + TX, Gliocladium roseum (also known as Clonostachys rosea f rosea), in particular strain 321U from Adjuvants Plus, strain ACM941 as disclosed in Xue A.G. (Efficacy of Clonostachys rosea strain ACM941 and fungicide seed treatments for controlling the root tot complex of field pea, Can Jour Plant Sci 2003, 83(3): 519-524) + TX, Metschnikowia fructicola, in particular strain NRRL Y-30752 + TX, Microsphaeropsis ochracea, Penicillium steckii (DSM 27859, WO 2015/067800) from BASF SE + TX, mixtures of Trichoderma asperellum strain ICC 012 (also known as Trichoderma harzianum ICC012), having Accession No. CABI CC IMI 392716 and Trichoderma gamsii (formerly T. viride) strain ICC 080, having Accession No. IMI 392151 (e.g., BIO-TAM™ from Isagro USA, Inc. or BIODERMA® by Agrobiosol de Mexico, S.A. de C.V.) + TX, Penicillium vermiculatum + TX, Phlebiopsis gigantea strain VRA 1992 (ROTSTOP® C from Danstar Ferment) + TX, Pseudozyma flocculosa, strain PF-A22 UL (available as SPORODEX® L by Plant Products Co., CA) + TX, Saccharomyces cerevisiae strain LAS117 cell walls (CEREVISANE® from Lesaffre, ROMEO® from BASF SE) + TX, Saccharomyces cerevisiae strains CNCM No.1-3936, CNCM No.1-3937, CNCM No.1-3938, CNCM No.1-3939 (WO 2010/086790) from Lesaffre et Compagnie, FR + TX, Saccharomyces cerevisiae, in particular strain LASO2 (from Agro-Levures et Dérivés) + TX, Simplicillium lanosoniveum + TX, strain T34 (e.g. T34 Biocontrol by Biocontrol Technologies S.L., ES) or strain ICC 012 from Isagro + TX, strain WRL-076 (NRRL Y-30842), U.S. Patent No.7,579,183 + TX, Talaromyces flavus, strain V117b + TX, Trichoderma asperelloides JM41R (Accession No. NRRL B-50759) (TRICHO PLUS® from BASF SE) + TX, Trichoderma asperellum, in particular strain SKT-1, having Accession No. FERM P-16510 (e.g. ECO- HOPE® from Kumiai Chemical Industry) + TX, Trichoderma asperellum, in particular, strain kd (e.g. T- Gro from Andermatt Biocontrol) + TX, Trichoderma atroviride strain 77B (T77 from Andermatt Biocontrol) + TX, Trichoderma atroviride strain ATCC 20476 (IMI 206040) + TX, Trichoderma atroviride strain LC52 (e.g. Tenet by Agrimm Technologies Limited) + TX, Trichoderma atroviride strain LU132 (e.g. Sentinel from Agrimm Technologies Limited) + TX, Trichoderma atroviride strain NMI no. V08/002388 + TX, Trichoderma atroviride strain NMI no. V08/002389 + TX, Trichoderma atroviride strain NMI no. V08/002390 + TX, Trichoderma atroviride strain no. V08/002387 + TX, Trichoderma atroviride strain SKT-1 (FERM P-16510), JP Patent Publication (Kokai) 11-253151 A + TX, Trichoderma atroviride strain SKT-2 (FERM P-16511), JP Patent Publication (Kokai) 11-253151 A + TX, Trichoderma atroviride strain SKT-3 (FERM P-17021), JP Patent Publication (Kokai) 11-253151 A + TX, Trichoderma atroviride, in particular strain SC1 (Accession No. CBS 122089, WO 2009/116106 and U.S. Patent No.8,431,120 (from Bi-PA)) + TX, Trichoderma atroviride,strain CNCM 1-1237 (e.g. Esquive® WP from Agrauxine, FR) + TX, Trichoderma fertile (e.g. product TrichoPlus from BASF) + TX, Trichoderma gamsii (formerly T. viride) + TX, Trichoderma gamsii (formerly T. viride) strain ICC 080 (IMI CC 392151 CABI) (available as BIODERMA® by AGROBIOSOL DE MEXICO, S.A. DE C.V.), + TX, Trichoderma gamsii strain ICC080 (IMI CC 392151 CABI, e.g. BioDerma by AGROBIOSOL DE MEXICO, S.A. DE C.V.), + TX, Trichoderma harmatum + TX, Trichoderma harmatum, having Accession No. ATCC 28012 + TX, Trichoderma harzianum + TX, Trichoderma harzianum rifai T39 (e.g. Trichodex® from Makhteshim, US) + TX, Trichoderma harzianum strain Cepa SimbT5 (from Simbiose Agro), + TX, Trichoderma harzianum strain DB 103 (available as T-GRO® 7456 by Dagutat Biolab) + TX, Trichoderma harzianum strain ITEM 908 (e.g. Trianum-P from Koppert) + TX, Trichoderma harzianum strain T-22 (e.g. Trianum-P from Andermatt Biocontrol or Koppert) + TX, Trichoderma harzianum strain TH35 (e.g. Root-Pro by Mycontrol) + TX, Trichoderma polysporum strain IMI 206039 (e.g. Binab TF WP by BINAB Bio- Innovation AB, Sweden) + TX, Trichoderma stromaticum having Accession No. Ts3550 (e.g. Tricovab by CEPLAC, Brazil) + TX, Trichoderma virens (also known as Gliocladium virens) in particular strain GL-21 (e.g. SoilGard by Certis, US) + TX, Trichoderma virens strain G-41, formerly known as Gliocladium virens (Accession No. ATCC 20906) (e.g., ROOTSHIELD® PLUS WP and TURFSHIELD® PLUS WP from BioWorks, US) + TX, Trichoderma viride in particular strain B35 (Pietr et al., 1993, Zesz. Nauk. A R w Szczecinie 161: 125-137) + TX, Trichoderma viride strain TV1(e.g. Trianum-P by Koppert) + TX, Ulocladium oudemansii strain U3, having Accession No. NM 99/06216 (e.g., BOTRY-ZEN® by Botry-Zen Ltd, New Zealand and BOTRYSTOP® from BioWorks, Inc.) + TX, Verticillium albo-atrum (formerly V. dahliae) strain WCS850 having Accession No. WCS850, deposited at the Central Bureau for Fungi Cultures (e.g., DUTCH TRIG® by Tree Care Innovations) + TX, Verticillium chlamydosporium + TX; a mixture of Azotobacter vinelandii and Clostridium pasteurianum (available as INVIGORATE® from Agrinos) + TX, a mixture of Bacillus licheniformis FMCH001 and Bacillus subtilis FMCH002 (available as QUARTZO® (WG), PRESENCE® (WP) from FMC Corporation) + TX, Azorhizobium caulinodans, in particular strain ZB-SK-5 + TX, Azospirillum brasilense (e.g., VIGOR® from KALO, Inc.) + TX, Azospirillum lipoferum (e.g., VERTEX-IF™ from TerraMax, Inc.) + TX, Azotobacter chroococcum, in particular strain H23 + TX, Azotobacter vinelandii, in particular strain ATCC 12837 + TX, Bacillus amyloliquefaciens BS27 (Accession No. NRRL B-5015) + TX, Bacillus amyloliquefaciens in particular strain FZB42 (e.g. RHIZOVITAL® from ABiTEP, DE) + TX, Bacillus amyloliquefaciens in particular strain IN937a + TX, Bacillus amyloliquefaciens pm414 (LOLI-PEPTA® from Biofilm Crop Protection) + TX, Bacillus amyloliquefaciens SB3281 (ATCC # PTA-7542, WO 2017/205258) + TX, Bacillus amyloliquefaciens TJ1000 (available as QUIKROOTS® from Novozymes) + TX, Bacillus cereus family member EE128 (NRRL No. B-50917) + TX, Bacillus cereus family member EE349 (NRRL No. B-50928) + TX, Bacillus cereus in particular strain BP01 (ATCC 55675, e.g. MEPICHLOR® from Arysta Lifescience, US) + TX, Bacillus mycoides BT155 (NRRL No. B-50921) + TX, Bacillus mycoides BT46-3 (NRRL No. B-50922) + TX, Bacillus mycoides EE118 (NRRL No. B-50918) + TX, Bacillus mycoides EE141 (NRRL No. B-50916) + TX, Bacillus pumilus in particular strain GB34 (e.g. YIELD SHIELD® from Bayer Crop Science, DE), + TX, Bacillus pumilus in particular strain QST2808 (Accession No. NRRL No. B-30087) + TX, Bacillus siamensis in particular strain KCTC 13613T + TX, Bacillus subtilis in particular strain AQ30002 (Accession No. NRRL No. B-50421 and described in U.S. Patent Application No.13/330,576) + TX, Bacillus subtilis in particular strain AQ30004 (NRRL No. B-50455 and described in U.S. Patent Application No. 13/330,576) + TX, Bacillus subtilis in particular strain MBI 600 (e.g. SUBTILEX® from BASF SE) + TX, Bacillus subtilis rm303 (RHIZOMAX® from Biofilm Crop Protection) + TX, Bacillus subtilis strain BU1814 (available as TEQUALIS® from BASF SE) + TX, Bacillus tequilensis in particular strain NII-0943 + TX, Bacillus thuringiensis BT013A (NRRL No. B-50924) also known as Bacillus thuringiensis 4Q7 + TX, Bradyrhizobium japonicum (e.g. OPTIMIZE® from Novozymes) + TX, Delftia acidovorans in particular strain RAY209 (e.g. BIOBOOST® from Brett Young Seeds) + TX, Lactobacillus sp. (e.g. LACTOPLANT® from LactoPAFI) + TX, Mesorhizobium cicer (e.g., NODULATOR from BASF SE) + TX, Paenibacillus polymyxa in particular strain AC-1 (e.g. TOPSEED® from Green Biotech Company Ltd.) + TX, Pseudomonas aeruginosa in particular strain PN1 + TX, Pseudomonas proradix (e.g. PRORADIX® from Sourcon Padena) + TX, Rhizobium leguminosarium biovar viciae (e.g., NODULATOR from BASF SE) + TX, Rhizobium leguminosarum in particular bv. viceae strain Z25 (Accession No. CECT 4585) + TX, Serratia marcescens in particular strain SRM (Accession No. MTCC 8708), + TX, Sinorhizobium meliloti strain NRG-185-1 (NITRAGIN® GOLD from Bayer CropScience) + TX, Thiobacillus sp. (e.g. CROPAID® from Cropaid Ltd UK) + TX; Myrothecium verrucaria strain AARC-0255 (e.g. DiTera™ from Valent Biosciences) + TX, Penicillium bilaii strain ATCC 22348 (e.g. JumpStart® from Acceleron BioAg) + TX, Penicillium bilaii strain ATCC ATCC20851 + TX, Purpureocillium lilacinum (previously known as Paecilomyces lilacinus) strain 251 (AGAL 89/030550, e.g. BioAct from Bayer CropScience Biologics GmbH) + TX, Pythium oligandrum strain DV74 + TX, Pythium oligandrum strain M1 (ATCC 38472 e.g. Polyversum from Bioprepraty, CZ) + TX, Rhizopogon amylopogon (Myco-Sol from Agri-Enterprise, LLC, formerly Helena Chemical Company) + TX, Rhizopogon fulvigleba (e.g. Myco-Sol from Agri-Enterprise, LLC, formerly Helena Chemical Company) + TX, Talaromyces flavus strain V117b + TX, Trichoderma asperellum strain (Eco- T from Plant Health Products, ZA) + TX, Trichoderma asperellum strain kd (e.g. T-Gro from Andermatt Biocontrol) + TX, Trichoderma atroviride in particular strain no. V08/002387 + TX, Trichoderma atroviride strain CNCM 1-1237 (e.g. Esquive® WP from Agrauxine, FR) + TX, Trichoderma atroviride strain LC52 (also known as Trichoderma atroviride strain LU132, e.g. Sentinel from Agrimm Technologies Limited) + TX, Trichoderma atroviride strain no. NMI No. V08/002388 + TX, Trichoderma atroviride strain no. NMI No. V08/002389 + TX, Trichoderma atroviride strain no. NMI No. V08/002390 + TX, Trichoderma atroviride strain SC1 (described in WO2009/116106) + TX, Trichoderma harzianum strain 1295-22 + TX, Trichoderma harzianum strain ITEM 908 + TX, Trichoderma harzianum strain T-22 (e.g. Trianum-P from Andermatt Biocontrol or Koppert) + TX, Trichoderma harzianum strain TSTh20, + TX, Trichoderma virens strain GI-3 + TX, Trichoderma virens strain GL-21 (e.g. SoilGard® from Certis, USA) + TX, Trichoderma viride strain B35 (Pietr et al., 1993, Zesz. Nauk. A R w Szczecinie 161: 125-137) + TX, Verticillium albo-atrum (formerly V. dahliae) strain WCS850 (CBS 276.92, e.g. Dutch Trig from Tree Care Innovations) + TX; Agrobacterium radiobacter strain K84 (Galltrol from AgBiochem Inc.), + TX, Bacillus amyloliquefaciens in particular strain PTS-4838 (e.g. AVEO from Valent Biosciences, US), + TX, Bacillus mycoides, isolate J. (e.g. BmJ from Certis USA LLC), + TX, Bacillus sphaericus in particular Serotype H5a5b strain 2362 (strain ABTS-1743) (e.g. VECTOLEX® from Valent BioSciences, US), + TX, Bacillus thuringiensis israelensis strain BMP 144 (e.g. AQUABAC® by Becker Microbial Products IL) + TX, Bacillus thuringiensis subsp. aizawai strain GC-91 + TX, Bacillus thuringiensis subsp. aizawai, in particular serotype H-7 (e.g. FLORBAC® WG from Valent BioSciences, US) + TX, Bacillus thuringiensis subsp. aizawai, in particular strain ABTS-1857 (SD-1372, e.g. XENTARI® from Valent BioSciences) + TX, Bacillus thuringiensis subsp. israelensis (serotype H-14) strain AM65-52 (Accession No. ATCC 1276) (e.g. VECTOBAC® by Valent BioSciences, US) + TX, Bacillus thuringiensis subsp. kurstaki strain ABTS 351 + TX, Bacillus thuringiensis subsp. kurstaki strain BMP 123 (from Becker Microbial Products, IL, BARITONE from Bayer CropScience) + TX, Bacillus thuringiensis subsp. kurstaki strain EG 2348 (LEPINOX from Certis, US) + TX, Bacillus thuringiensis subsp. kurstaki strain EG 7841 (CRYMAX from Certis, US) + TX, Bacillus thuringiensis subsp. kurstaki strain HD-1 (e.g. DIPEL® ES from Valent BioSciences, US) + TX, Bacillus thuringiensis subsp. kurstaki strain PB 54 + TX, Bacillus thuringiensis subsp. kurstaki strain SA 11 (JAVELIN from Certis, US) + TX, Bacillus thuringiensis subsp. kurstaki strain SA 12 (THURICIDE from Certis, US) + TX, Bacillus thuringiensis subsp. tenebrionis strain NB 176 (SD-5428, e.g. NOVODOR® FC from BioFa DE) + TX, Bacillus thuringiensis var. Colmeri (e.g. TIANBAOBTC by Changzhou Jianghai Chemical Factory) + TX, Bacillus thuringiensis var. japonensis strain Buibui + TX, Bacillus thuringiensis var. kurstaki strain EVB-113-19 (e.g., BIOPROTEC® from AEF Global) + TX, Brevibacillus laterosporus + TX, Burkholderia spp. in particular Burkholderia rinojensis strain A396 (also known as Burkholderia rinojensis strain MBI 305) (Accession No. NRRL B-50319, WO 2011/106491 and WO 2013/032693, e.g. MBI206 TGAI and ZELTO® from Marrone Bio Innovations), + TX, Chromobacterium subtsugae in particular strain PRAA4-1T (e.g. MBI-203, e.g. GRANDEVO® from Marrone Bio Innovations) + TX, Lecanicillium muscarium Ve6 (MYCOTAL from Koppert) + TX, Paenibacillus popilliae (formerly Bacillus popilliae, e.g. MILKY SPORE POWDER™ or MILKY SPORE GRANULAR™ from St. Gabriel Laboratories) + TX, Serratia entomophila (e.g. INVADE® by Wrightson Seeds) + TX, Serratia marcescens in particular strain SRM (Accession No. MTCC 8708) + TX, Trichoderma asperellum (TRICHODERMAX from Novozymes) + TX, Wolbachia pipientis ZAP strain (e.g., ZAP MALES® from MosquitoMate) + TX; Beauveria bassiana strain ATCC 74040 (e.g. NATURALIS® from Intrachem Bio Italia) + TX, Beauveria bassiana strain ATP02 (Accession No. DSM 24665), Apopka 97 (PREFERAL from SePRO) + TX, Beauveria bassiana strain GHA (Accession No. ATCC74250, e.g. BOTANIGUARD® ES and MYCONTROL-O® from Laverlam International Corporation) + TX, Metarhizium anisopliae 3213-1 (deposited under NRRL accession number 67074 disclosed in WO 2017/066094, Pioneer Hi-Bred International) + TX, Metarhizium robertsii 15013-1 (deposited under NRRL accession number 67073) + TX, Metarhizium robertsii 23013-3 (deposited under NRRL accession number 67075) + TX, Paecilomyces lilacinus strain 251 (MELOCON from Certis, US) + TX; Cydia pomonella (codling moth) granulosis virus (GV) + TX, Helicoverpa armigera (cotton bollworm) nuclear polyhedrosis virus (NPV) + TX, of Adoxophyes orana (summer fruit tortrix) granulosis virus (GV) + TX, Spodoptera exigua (beet armyworm) mNPV + TX, Spodoptera frugiperda (fall armyworm) mNPV + TX; Burkholderia spp. in particular Burkholderia cepacia (formerly known as Pseudomonas cepacia) + TX, Gigaspora spp. + TX, Glomus spp. + TX, Laccaria spp. + TX, LactoBacillus buchneri + TX, Paraglomus spp. + TX, Pisolithus tinctorus + TX, Pseudomonas spp. + TX, Rhizobium spp. in particular Rhizobium trifolii + TX, Rhizopogon spp. + TX, Scleroderma spp. + TX, Streptomyces spp. + TX, Suillus spp. + TX, Agrobacterium spp. + TX, Azorhizobium caulinodans + TX, Azospirillum spp. + TX, Azotobacter spp. + TX, Bradyrhizobium spp. + TX, Gigaspora monosporum + TX; Allium sativum (NEMGUARD from Eco-Spray, BRALIC from ADAMA) + TX, Armour-Zen + TX, Artemisia absinthium + TX, Biokeeper WP + TX, Brassicaceae extract in particular oilseed rape powder or mustard powder + TX, Cassia nigricans + TX, Celastrus angulatus + TX, Chenopodium anthelminticum + TX, Chenopodium quinoa saponin extract from quinoa seeds (e.g. Heads Up® (Saponins of Quinoa) from Heads Up plant Protectants, CA) + TX, Chitin + TX, Dryopteris filix-mas + TX, Equisetum arvense + TX, Fortune Aza + TX, Fungastop + TX, Melaleuca alternifolia extract (TIMOREX GOLD from STK) + TX, naturally occurring Blad polypeptide extracted from Lupin seeds (FRACTURE® from FMC) + TX, naturally occurring Blad polypeptide extracted from Lupin seeds (PROBLAD® from Certis EU) + TX, Pyrethrins + TX, Quassia amara + TX, Quercus + TX, Quillaja extract (QL AGRI 35 from BASF) + TX, REGALIA MAXX from Marrone Bio) + TX, Requiem™ Insecticide + TX, Reynoutria sachalinensis extract (REGALLIA + TX, ryania/ryanodine + TX, Symphytum officinale + TX, Tanacetum vulgare + TX, Thymol + TX, Thymol mixed with Geraniol (CEDROZ from Eden Research) + TX, Thymol mixed with Geraniol and Eugenol (MEVALONE from Eden Research) + TX, Triact 70 + TX, TriCon + TX, Tropaeulum majus + TX, Urtica dioica + TX, Veratrin + TX, Viscum album + TX; mercuric oxide + TX, octhilinone + TX, thiophanate-methyl + TX; MGK 264 + TX, 2-(2-butoxyethoxy)ethyl piperonylate + TX, 2-isovalerylindan-1,3-dione + TX, 4- (quinoxalin-2-ylamino)benzenesulfonamide + TX, 5-(1,3-benzodioxol-5-yl)-3-hexylcyclohex-2-enone + TX, acibenzolar + TX, acibenzolar-S-methyl + TX, alpha-bromadiolone + TX, alpha-chlorohydrin + TX, aluminium phosphide + TX, anthraquinone + TX, antu + TX, arsenous oxide + TX, barium carbonate + TX, benoxacor + TX, bisthiosemi + TX, brodifacoum + TX, bromadiolone + TX, bromethalin + TX, calcium cyanide + TX, chloralose + TX, chlorophacinone + TX, cholecalciferol + TX, cloquintocet (including cloquintocet-mexyl) + TX, copper naphthenate + TX, copper oxychloride + TX, coumachlor + TX, coumafuryl + TX, coumatetralyl + TX, crimidine + TX, cyprosulfamide + TX, diazinon + TX, dichlormid + TX, dicyclopentadiene + TX, difenacoum + TX, difethialone + TX, diphacinone + TX, ergocalciferol + TX, farnesol + TX, farnesol with nerolidol + TX, fenchlorazole (including fenchlorazole- ethyl) + TX, fenclorim + TX, flocoumafen + TX, fluoroacetamide + TX, flupropadine + TX, flupropadine hydrochloride + TX, fluxofenim + TX, furilazole + TX, gamma-HCH + TX, guazatine + TX, guazatine acetates + TX, HCH + TX, hydrogen cyanide + TX, imanin + TX, iodomethane + TX, isoxadifen (including isoxadifen-ethyl) + TX, lindane + TX, magnesium phosphide + TX, MB-599 + TX, mefenpyr (including mefenpyr-diethyl) + TX, metcamifen + TX, methiocarb + TX, methyl bromide + TX, nerolidol + TX, norbormide + TX, petroleum oils + TX, phosacetim + TX, phosphine + TX, phosphorus + TX, pindone + TX, piperonyl butoxide + TX, piprotal + TX, potassium arsenite + TX, probenazole + TX, propyl isomer + TX, pyridin-4-amine + TX, pyrinuron + TX, Reynoutria sachalinensis extract + TX, ribavirin + TX, S421 + TX, scilliroside + TX, sesamex + TX, sesasmolin + TX, sodium arsenite + TX, sodium cyanide + TX, sodium fluoroacetate + TX, strychnine + TX, sulfoxide + TX, thallium sulfate + TX, thiram + TX, trimethacarb + TX, warfarin + TX, zinc naphthenate + TX, zinc phosphide + TX, ziram + TX. The weight ratio of component (A) to component (C) may preferably be from 100:1 to 1:100, from 50:1 to 1:50, from 20:1 to 1:40, from 15:1 to 1:30, from 12:1 to 1:25, from 10:1 to 1:20, from 5:1 and 1:15, from 3:1 to 1:10 or from 2:1 to 1:5. A further aspect of invention is related to a method of controlling or preventing an infestation of plants, e.g. useful plants such as crop plants, propagation material thereof, e.g. seeds, harvested crops, e.g. harvested food crops, or of non-living materials by phytopathogenic or spoilage microorganisms or organisms potentially harmful to man, especially fungal organisms, which comprises the application of a composition according to the present invention to the plants, to parts of the plants or to the locus thereof, to the propagation material thereof, or to any part of the non-living materials. Controlling or preventing means reducing infestation by insects or by phytopathogenic or spoilage microorganisms or organisms potentially harmful to man, especially fungal organisms, to such a level that an improvement is demonstrated. A preferred method of controlling or preventing an infestation of crop plants by phytopathogenic microorganisms, especially fungal organisms, which comprises the application of a composition according to the present invention is foliar application. The frequency of application and the rate of application will depend on the risk of infestation by the corresponding pathogen or insect. However, the compounds A and/or B of the composition according to the present invention can also penetrate the plant through the roots via the soil (systemic action) by drenching the locus of the plant with a liquid formulation, or by applying said compounds in solid form to the soil, e.g. in granular form (soil application). In crops of water rice such granulates can be applied to the flooded rice field. The compounds A and B as defined in the present invention may also be applied to seeds (coating) by impregnating the seeds or tubers either with a liquid formulation of the fungicide or coating them with a solid formulation. The composition according to the present invention may be prepared in a known manner, typically by intimately mixing and/or grinding the compound with extenders, for example solvents, solid carriers and, optionally, surface active compounds (surfactants). The application methods for the compositions, that is the methods of controlling pests of the abovementioned type, such as spraying, atomizing, dusting, brushing on, dressing, scattering or pouring - which are to be selected to suit the intended aims of the prevailing circumstances - and the use of the composition for controlling pests of the abovementioned type are other subjects of the invention. Typical rates of concentration are between 0.1 and 1000 ppm, preferably between 0.1 and 500 ppm, of active ingredient. The rate of application per hectare is preferably 1g to 2000 g of active ingredient per hectare, more preferably 10 to 1000 g/ha, most preferably 10 to 600 g/ha. When used as seed drenching agent, convenient dosages are from 10mg to 1g of active substance per kg of seeds. When the combinations of the present invention are used for treating seed, rates of 0.001 to 50 g of a compound of formula (I) per kg of seed, preferably from 0.01 to 10g per kg of seed are generally sufficient. Suitably, the composition according to the present invention can be applied either preventative, meaning prior to disease development or curative, meaning after disease development. The compositions of the invention may be employed in any conventional form, for example in the form of a twin pack, a powder for dry seed treatment (DS), an emulsion for seed treatment (ES), a flowable concentrate for seed treatment (FS), a solution for seed treatment (LS), a water dispersible powder for seed treatment (WS), a capsule suspension for seed treatment (CF), a gel for seed treatment (GF), an emulsion concentrate (EC), a suspension concentrate (SC), a suspo-emulsion (SE), a capsule suspension (CS), a water dispersible granule (WG), an emulsifiable granule (EG), an emulsion, water in oil (EO), an emulsion, oil in water (EW), a micro-emulsion (ME), an oil dispersion (OD), an oil miscible flowable (OF), an oil miscible liquid (OL), a soluble concentrate (SL), an ultra-low volume suspension (SU), an ultra-low volume liquid (UL), a technical concentrate (TK), a dispersible concentrate (DC), a wettable powder (WP) or any technically feasible formulation in combination with agriculturally acceptable adjuvants. Such compositions may be produced in conventional manner, e.g. by mixing the active ingredients with appropriate formulation inerts (diluents, solvents, fillers and optionally other formulating ingredients such as surfactants, biocides, anti-freeze, stickers, thickeners and compounds that provide adjuvancy effects). Also conventional slow release formulations may be employed where long lasting efficacy is intended. Particularly formulations to be applied in spraying forms, such as water dispersible concentrates (e.g. EC, SC, DC, OD, SE, EW, EO and the like), wettable powders and granules, may contain surfactants such as wetting and dispersing agents and other compounds that provide adjuvancy effects, e.g. the ondensation product of formaldehyde with naphthalene sulphonate, an alkylarylsulphonate, a lignin sulphonate, a fatty alkyl sulphate, and ethoxylated alkylphenol and an ethoxylated fatty alcohol. A seed dressing formulation is applied in a manner known per se to the seeds employing the combination of the invention and a diluent in suitable seed dressing formulation form, e.g. as an aqueous suspension or in a dry powder form having good adherence to the seeds. Such seed dressing formulations are known in the art. Seed dressing formulations may contain the single active ingredients or the combination of active ingredients in encapsulated form, e.g. as slow release capsules or microcapsules. In general, the formulations include from 0.01 to 90% by weight of active ingredients, from 0 to 20% agriculturally acceptable surfactant and 10 to 99.99% solid or liquid formulation inerts and adjuvant(s), the active ingredients consisting of at least the components A and B as defined in the present invention, and optionally other active agents, particularly microbiocides or conservatives or the like. Concentrated forms of compositions generally contain in between about 2 and 80%, preferably between about 5 and 70% by weight of active ingredients. Application forms of formulation may for example contain from 0.01 to 20% by weight, preferably from 0.01 to 5% by weight of active ingredients. Whereas commercial products will preferably be formulated as concentrates, the end user will normally employ diluted formulations. Whereas it is preferred to formulate commercial products as concentrates, the end user will normally use dilute formulations. EXAMPLES The Examples which follow serve to illustrate the invention. The compounds (and compositions) of the invention may be distinguished from known compounds (and compositions) by virtue of greater efficacy at low application rates, which can be verified by the person skilled in the art using the experimental procedures outlined in the Examples, using lower application rates if necessary, for example 50 ppm, 12.5 ppm, 6 ppm, 3 ppm, 1.5 ppm or 0.2 ppm of active ingredient(s). Formulation Examples Wettable powders a) b) c) active ingredients [components (A) and (B)] 25 % 50 % 75 % sodium lignosulfonate 5 % 5 % - sodium lauryl sulfate 3 % - 5 % sodium diisobutylnaphthalenesulfonate - 6 % 10 % phenol polyethylene glycol ether - 2 % - (7-8 mol of ethylene oxide) highly dispersed silicic acid 5 % 10 % 10 % Kaolin 62 % 27 % - The active ingredient is thoroughly mixed with the adjuvants and the mixture is thoroughly ground in a suitable mill, affording wettable powders that can be diluted with water to give suspensions of the desired concentration. Powders for dry seed treatment a) b) c) active ingredients [components (A) and (B)] 25 % 50 % 75 % light mineral oil 5 % 5 % 5 % highly dispersed silicic acid 5 % 5 % - Kaolin 65 % 40 % - Talcum - - 20 % The active ingredient is thoroughly mixed with the adjuvants and the mixture is thoroughly ground in a suitable mill, affording powders that can be used directly for seed treatment. Emulsifiable concentrate active ingredients [components (A) and (B)] 10 % octylphenol polyethylene glycol ether 3 % (4-5 mol of ethylene oxide) calcium dodecylbenzenesulfonate 3 % castor oil polyglycol ether (35 mol of ethylene oxide) 4 % Cyclohexanone 30 % xylene mixture 50 % Emulsions of any required dilution, which can be used in plant protection, can be obtained from this concentrate by dilution with water. Dusts a) b) c) active ingredients [components (A) and (B)] 5 % 6 % 4 % talcum 95 % - - Kaolin - 94 % - mineral filler - - 96 % Ready-for-use dusts are obtained by mixing the active ingredient with the carrier and grinding the mixture in a suitable mill. Such powders can also be used for dry dressings for seed. Extruder granules active ingredients [components (A) and (B)] 15 % sodium lignosulfonate 2 % carboxymethylcellulose 1 % Kaolin 82 % The active ingredient is mixed and ground with the adjuvants, and the mixture is moistened with water. The mixture is extruded and then dried in a stream of air. Coated granules active ingredients [components (A) and (B)] 8 % polyethylene glycol (mol. wt.200) 3 % Kaolin 89 % The finely ground active ingredient is uniformly applied, in a mixer, to the kaolin moistened with polyethylene glycol. Non-dusty coated granules are obtained in this manner. Suspension concentrate active ingredients [components (A) and (B)] 40 % propylene glycol 10 % nonylphenol polyethylene glycol ether (15 mol of ethylene oxide) 6 % Sodium lignosulfonate 10 % carboxymethylcellulose 1 % silicone oil (in the form of a 75 % emulsion in water) 1 % Water 32 % The finely ground active ingredient is intimately mixed with the adjuvants, giving a suspension concentrate from which suspensions of any desired dilution can be obtained by dilution with water. Using such dilutions, living plants as well as plant propagation material can be treated and protected against infestation by microorganisms, by spraying, pouring or immersion. Flowable concentrate for seed treatment active ingredients [components (A) and (B)] 40 % propylene glycol 5 % copolymer butanol PO/EO 2 % tristyrenephenole with 10-20 moles EO 2 % 1,2-benzisothiazolin-3-one (in the form of a 20% solution in water) 0.5 % monoazo-pigment calcium salt 5 % Silicone oil (in the form of a 75 % emulsion in water) 0.2 % Water 45.3 % The finely ground active ingredient is intimately mixed with the adjuvants, giving a suspension concentrate from which suspensions of any desired dilution can be obtained by dilution with water. Using such dilutions, living plants as well as plant propagation material can be treated and protected against infestation by microorganisms, by spraying, pouring or immersion. Slow Release Capsule Suspension 28 parts of a combination of the active ingredients [components (A) and (B)] is mixed with 2 parts of an aromatic solvent and 7 parts of toluene diisocyanate/polymethylene-polyphenylisocyanate-mixture (8:1). This mixture is emulsified in a mixture of 1.2 parts of polyvinylalcohol, 0.05 parts of a defoamer and 51.6 parts of water until the desired particle size is achieved. To this emulsion a mixture of 2.8 parts 1,6-diaminohexane in 5.3 parts of water is added. The mixture is agitated until the polymerization reaction is completed. The obtained capsule suspension is stabilized by adding 0.25 parts of a thickener and 3 parts of a dispersing agent. The capsule suspension formulation contains 28% of the active ingredients. The medium capsule diameter is 8-15 microns. The resulting formulation is applied to seeds as an aqueous suspension in an apparatus suitable for that purpose. Example 1: preparation of methyl N-[5-[6-[5-(4-fluoro-3-methoxy-phenyl)-1-methyl-pyrazol-4- yl]imidazo[1,2-a]pyridin-3-yl]-2-pyridyl]carbamate (compound X.05) (Compound X.05) Step 1: Preparation of 5-(4-fluoro-3-methoIxy-phenyl)-1-methyl-pyrazole To a mixture of 4-bromo-1-fluoro-2-methoxy-benzene (900 mg, 4.39 mmol) and (2-methylpyrazol-3- yl)boronic acid (663 mg, 5.27 mmol, 1.20 eq.) in a pre-mixed solution of dioxane/water (v/v = 4:1, 18.0 mL) was added Pd(dppf)Cl2 (319 mg, 0.439 mmol, 0.100 eq.) and potassium carbonate (1.82 g, 13.2 mmol, 3.00 eq.). The reaction mixture was heated at 80 °C and stirred for 2 hours under a nitrogen atmosphere. The reaction mixture was then cooled, diluted with water and extracted with dichloromethane. The combined organic layers were concentrated under reduced pressure and the crude residue was purified by flash chromatography over silica gel (ethyl acetate/petroleum ether) to afford the desired target which was further purified by trituration with acetonitrile to afford 5-(4-fluoro-3- methoxy-phenyl)-1-methyl-pyrazole as a colorless oil. LC/MS (method A) retention time = 1.03 min; [M+H]+ = 207.1 Step 2: Preparation of 4-bromo-5-(4-fluoro-3-methoxy-phenyl)-1-methyl-pyrazole To a solution of 5-(4-fluoro-3-methoxy-phenyl)-1-methyl-pyrazole (400 mg, 1.94 mmol) in dimethylformamide (5.00 mL) was added 1-bromopyrrolidine-2,5-dione (518 mg, 2.91 mmol, 1.50 eq.). The reaction mixture was stirred at room temperature for 1 hour, after which it was diluted with water and extracted with dichloromethane. The combined organic layers were washed with brine, dried over sodium sulfate, filtered and concentrated under reduced pressure. The crude residue was purified by flash chromatography over silica gel (ethyl acetate/petroleum ether) to afford 4-bromo-5-(4-fluoro-3- methoxy-phenyl)-1-methyl-pyrazole as a light yellow solid. LC/MS (method A) retention time = 1.22 min; [M+H]+ = 284.9 Step 3: Preparation of 3-chloro-6-[5-(4-fluoro-3-methoxy-phenyl)-1-methyl-pyrazol-4-yl]imidazo[1,2- a]pyridine To a mixture of 4-bromo-5-(4-fluoro-3-methoxy-phenyl)-1-methyl-pyrazole (400 mg, 1.40 mmol) and (3- chloroimidazo[1,2-a]pyridin-6-yl)boronic acid (331 mg, 1.68 mmol, 1.20 eq.) in a pre-mixed solution of dioxane/water (v/v = 4:1, 5.00 mL) was added Pd(dppf)Cl2 (102 mg, 0.140 mmol, 0.100 eq.) and potassium carbonate (582 mg, 4.21 mmol, 3.00 eq.). The reaction mixture was heated at 80 °C and stirred for 2 hours under nitrogen atmosphere. The reaction mixture was then cooled, diluted with water, and extracted with dichloromethane/MeOH (v/v = 10:1). The combined organic layers were concentrated under reduced pressure and the resulting residue was purified by flash chromatography over silica gel (dichloromethane/MeOH) to afford the desired target, which was further purified by trituration with acetonitrile to ultimately afford 3-chloro-6-[5-(4-fluoro-3-methoxy-phenyl)-1-methyl-pyrazol-4- yl]imidazo[1,2-a]pyridine as a white solid. LC/MS (method A) retention time = 0.91 min; [M+H]+ = 357 Step 4: Preparation of methyl N-[5-[6-[5-(4-fluoro-3-methoxy-phenyl)-1-methyl-pyrazol-4-yl]imidazo[1,2- a]pyridin-3-yl]-2-pyridyl]carbamate (Compound X.05) A mixture of 3-chloro-6-[5-(4-fluoro-3-methoxy-phenyl)-1-methyl-pyrazol-4-yl]imidazo[1,2-a]pyridine (200 mg, 0.561 mmol, 1.00 eq.) and methyl N-[5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2- pyridyl]carbamate (187 mg, 0.673 mmol, 1.20 eq.) was dissolved in a pre-mixed solution of dioxane/water (v/v= 4:1, 5.00 mL). Brettphos Pd G3 (CAS 1470372-59-8, 51 mg, 0.056 mmol, 0.10 eq.) and potassium carbonate (232 mg, 1.68 mmol, 3.00 eq.) were added and the mixture was heated at 80 °C under an atmosphere of nitrogen for 2 hours. The reaction mixture was cooled down, diluted with water, and extracted with dichloromethane/methanol (v/v = 10:1). The combined organic layers were concentrated under reduced pressure and the crude residue was purified by flash chromatography over silica gel (dichloromethane/MeOH) to afford the desired target, which was further purified by trituration with acetonitrile to afford methyl N-[5-[6-[5-(4-fluoro-3-methoxy-phenyl)-1-methyl-pyrazol-4- yl]imidazo[1,2-a]pyridin-3-yl]-2-pyridyl]carbamate as a white solid. LC/MS (method A) retention time = 0.90 min; [M+H]+ = 473 1H NMR (400 MHz, DMSO-d6, ppm) δ = 10.38 (s, 1H), 8.39 (d, J = 2.4 Hz, 1H), 8.03 (s, 1H), 7.94 (m, 2H), 7.72 (s, 1H), 7.67 (dd, J = 8.7, 2.4 Hz, 1H), 7.61 (d, J = 9.4 Hz, 1H), 7.28 (m, 3H), 6.94 (ddd, J = 8.1, 4.2, 1.8 Hz, 1H), 3.77 (s, 3H), 3.74 (s, 3H), 3.71 (s, 3H). Example 2: preparation of methyl N-[5-[6-[4-(4-fluoro-3-methoxy-phenyl)-5,6-dihydro-1,2,4- oxadiazin-3-yl]imidazo[1,2-a]pyridin-3-yl]-2-pyridyl]carbamate (compound X.06) (Compound X.06) Step 1: Preparation of 2-chloro-N-(-4-fluoro-3-methoxy-phenyl)acetamide To a suspension of 4-fluoro-3-methoxy-aniline (10.0 g, 70.9 mmol) and potassium carbonate (10.8 g, 77.9 mmol, 1.10 eq.) in dimethylformamide (50.0 mL) at 0 °C was added, dropwise, a solution of 2- chloroacetyl chloride (8.80 g, 77.9 mmol, 1.00 eq.) in dimethylformamide (5.00 mL). The reaction mixture was stirred at room temperature for 3 hours, then it was diluted with water and extracted with ethyl acetate. The combined organic layers were washed with water and brine, dried over sodium sulfate, filtered, and concentrated under reduced pressure. The crude residue was purified by flash chromatography over silica gel (petroleum ether/ethyl acetate) to afford 2-chloro-N-(4-fluoro-3-methoxy- phenyl)acetamide as a colorless oil. LC/MS (method A) retention time = 1.03 min; [M+H]+ = 218.1 Step 2: Preparation of N-(2-chloroethyl)-4-fluoro-3-methoxy-aniline To a solution of 2-chloro-N-(4-fluoro-3-methoxy-phenyl)acetamide (10.0 g, 46.0 mmol) in THF (120 mL) at 0°C was added, dropwise, BH3-THF (1.00 mol/L, 68.9 mL, 68.9 mmol, 1.50 eq.). The reaction mixture was warmed to room temperature and stirred for an additional 3 hours, after which it was poured into ice water and extracted with ethyl acetate. The combined organic layer was washed with brine, dried over sodium sulfate, filtered, and concentrated under reduced pressure. The crude residue was purified by flash chromatography over silica gel (petroleum ether/ethyl acetate) to afford N-(2-chloroethyl)-4- fluoro-3-methoxy-aniline as a colorless liquid. LC/MS (method A) retention time = 1.23 min; [M+H]+ = 204.2 Step 3: Preparation of N-[2-(benzhydrylideneamino)oxyethyl]-4-fluoro-3-methoxy-aniline To a stirred suspension of diphenylmethanone oxime (8.14 g, 41.2 mmol, 1.20 eq.) in DMSO (40.0 mL) at room temperature was added potassium hydroxide (9.64 g, 172 mmol, 5.00 eq.). The reaction mixture was stirred for 3 minutes, then a solution of N-(2-chloroethyl)-4-fluoro-3-methoxy-aniline (7.00 g, 34.4 mmol, 1.00 eq.) in DMSO (10.0 mL) was added dropwise. The reaction mixture was stirred at room temperature for 2 hours, then it was poured into ice water. The aqueous layer was extracted with dichloromethane, the combined organic layers were washed with water and brine, dried over sodium sulfate, filtered, and concentrated under reduced pressure. The crude residue was purified by flash chromatography over silica gel (petroleum ether/ethyl acetate) to afford N-[2- (benzhydrylideneamino)oxyethyl]-4-fluoro-3-methoxy-aniline as a viscous oil. LC/MS (method A) retention time = 1.63 min; [M+H]+ = 365.2 Step 4: Preparation of O-[2-(4-fluoro-3-methoxy-anilino)ethyl]hydroxylamine A solution of N-[2-(benzhydrylideneamino)oxyethyl]-4-fluoro-3-methoxy-aniline (5.20 g, 15.6 mmol) in 6M HCl (25.9 mL, 156 mmol) and dioxane (10.0 mL) was refluxed under nitrogen for 8 hours. The resulting mixture was extracted with dichloromethane. The aqueous solution was then adjusted to pH 9 with solid NaHCO3 and extracted with dichloromethane. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The crude residue was purified by flash chromatography over silica gel (petroleum ether/ethyl acetate) to afford O-[2-(4-fluoro-3-methoxy-anilino)ethyl]hydroxylamine as a light yellow liquid. LC/MS (method A) retention time = 0.66 min; [M+H]+ = 201.1 Step 5: Preparation of ethyl 3-bromoimidazo[1,2-a]pyridine-6-carboximidate To a solution of 3-bromoimidazo[1,2-a]pyridine-6-carbonitrile (3.00 g, 13.5 mmol) in ethanol/dichloromethane (v/v=1/4, 200 mL,) at 0 °C was added sodium ethanethiolate (0.568 g, 6.76 mmol). The reaction mixture was then warmed to room temperature and stirred for an additional 16 hours. The reaction mixture was concentrated to dryness under reduced pressure and the crude residue was purified by flash chromatography over silica gel (dichloromethane/MeOH) to afford ethyl 3- bromoimidazo[1,2-a]pyridine-6-carboximidate as white solid. LC/MS (method A) retention time = 0.75; [M+H]+ = 270.0 Step 6: Preparation of 3-(3-bromoimidazo[1,2-a]pyridin-6-yl)-4-(4-fluoro-3-methoxy-phenyl)-5,6- dihydro-1,2,4-oxadiazine To a stirred solution of ethyl 3-bromoimidazo[1,2-a]pyridine-6-carboximidate (700 mg, 2.61 mmol) in acetic acid (25.0 mL) was added O-[2-(4-fluoro-3-methoxy-anilino)ethyl]hydroxylamine (549 mg, 2.74 mmol, 1.05 eq.) portion wise at 23 °C. The solution was stirred at room temperature for 4 hours, then stirred at 90 °C for another 10 hours. After completion, the resulting mixture was quenched with water (10.0 mL), concentrated and the residual was extracted with dichloromethane/MeOH (20.0 mL x 3, v/v=10:1). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, concentrated by reduced pressure and purified over silica gel cartridge (dichloromethane/methanol) to afford 3-(3-bromoimidazo[1,2-a]pyridin-6-yl)-4-(4-fluoro-3-methoxy-phenyl)-5,6-dihydro-1,2,4- oxadiazine as a brown solid. LC/MS (method A) retention time = 1.08 min; [M+H]+ = 407.0 Step 7: Preparation of methyl N-[5-[6-[4-(4-fluoro-3-methoxy-phenyl)-5,6-dihydro-1,2,4-oxadiazin-3- yl]imidazo[1,2-a]pyridin-3-yl]-2-pyridyl]carbamate (Compound X.06) To a stirred mixture of 3-(3-bromoimidazo[1,2-a]pyridin-6-yl)-4-(4-fluoro-3-methoxy-phenyl)-5,6-dihydro- 1,2,4-oxadiazine (300 mg, 0.740 mmol) and methyl N-[5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)- 2-pyridyl]carbamate (216 mg, 0.777 mmol, 1.05 eq.) in pre-mixed solution of dioxane/water (v/v = 5:1, 6.00 mL) was added Pd(dppf)Cl2 (54.2 mg, 0.074 mmol, 0.100 eq.) and potassium carbonate (256 mg, 1.85 mmol, 2.50 eq.). The mixture was stirred at 45 °C for 1 hour under atmosphere of nitrogen, then it was concentrated under reduced pressure and the residue was diluted with brine (10.0 mL) and extracted with dichloromethane/MeOH (30.0 mL x 3, v/v = 10:1). The combined organic layers were concentrated under reduced pressure. The residual was purified by silica gel column chromatography (eluting with dichloromethane/MeOH) to obtain desired compound, which was further purified by trituration with acetonitrile to afford methyl N-[5-[6-[4-(4-fluoro-3-methoxy-phenyl)-5,6-dihydro-1,2,4- oxadiazin-3-yl]imidazo[1,2-a]pyridin-3-yl]-2-pyridyl]carbamate as a white powder. LC/MS (method A) retention time = 0.95 min; [M+H]+ = 477.2 1H NMR (400 MHz, DMSO-d6, ppm) δ = 10.47 (s, 1H), 8.43 (d, J = 1.6 Hz, 2H), 8.01 (d, J = 8.6 Hz, 1H), 7.81 (dd, J = 8.6, 2.4 Hz, 1H), 7.78 (s, 1H), 7.51 (d, J = 9.4 Hz, 1H), 7.15 (dd, J = 9.4, 1.6 Hz, 1H), 7.10 (dd, J = 7.8, 2.4 Hz, 1H), 7.03 (dd, J = 11.4, 8.8Hz, 1H), 6.73 - 6.47 (m, 1H), 4.16 (t, J = 4.4 Hz, 2H), 3.82 (t, J = 4.4 Hz, 2H), 3.73 (s, 3H), 3.71 (s, 3H). Example 3: preparation of methyl N-[5-[6-[2-(4-fluoro-3-methoxy-phenyl)-1,2,4-triazol-3-yl]-8- methyl-imidazo[1,2-a]pyridin-3-yl]-2-pyridyl]carbamate (compound X.07) (Compound X.07) Step 1: Preparation of methyl 8-methylimidazo[1,2-a]pyridine-6-carboxylate To a stirred solution of methyl 8-bromoimidazo[1,2-a]pyridine-6-carboxylate (500 mg, 1.76 mmol) and methylboronic acid (216 mg, 3.53 mmol) in THF was added potassium carbonate (488 mg, 3.53 mmol) and Pd(dppf)Cl2 (129 mg, 0.176 mmol), and the reaction mixture was degassed with argon for 2 min. The reaction mixture was heated at 80 °C and stirred for 16 hours. The reaction mixture was then cooled to room temperature, filtered through a pad of celite, and the filtrate was washed with water, brine, dried over sodium sulfate, filtered and concentrated under reduced pressure. The crude residue was purified by flash chromatography over silica gel (ethyl acetate/hexane) to afford methyl 8- methylimidazo[1,2-a]pyridine-6-carboxylate as an off white solid. 1H NMR (400 MHz, CDCl3, ppm) δ = 2.64 (s, 3H), 3.94 (s, 3H), 7.53 (s, 1H), 7.63 - 7.67 (m, 1H), 7.67 - 7.71 (m, 1H), 8.80 (s, 1H). Step 2: Preparation of methyl 3-bromo-8-methyl-imidazo[1,2-a]pyridine-6-carboxylate To a mixture methyl 8-methylimidazo[1,2-a]pyridine-6-carboxylate (0.50 g, 2.6 mmol) in acetonitrile (13 mL) under an atmosphere of argon at room temperature was added N-bromosuccinimide (0.53 g, 2.9 mmol, 1.1 eq.) The reaction mixture was stirred for 45 min and then quenched with 1M sodium sulfite aqueous solution and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over sodium sulfate, filtered, and concentrated under reduced pressure to afford 3-bromo-8- methyl-imidazo[1,2-a]pyridine-6-carboxylate as a pale beige solid. 1H NMR (400 MHz, CDCl3, ppm) δ = 8.78 (d, J = 0.7 Hz, 1H), 7.69 (s, 1H), 7.58 - 7.65 (m, 1H), 3.99 (s, 3H), 2.65 (s, 3H) Step 3: Preparation of 3-bromo-8-methyl-imidazo[1,2-a]-6-carboxylic acid To a solution of 3-bromo-8-methyl-imidazo[1,2-a]pyridine-6-carboxylate (0.10 g, 0.37 mmol, 1.0 eq.) in THF (2.2 mL) / water (0.74 mL) was added lithium hydroxide monohydrate (0.018 g, 0.74 mmol, 2.0 eq.) and the reaction mixture was stirred for 18 hours at room temperature. The reaction mixture was then diluted with ethyl acetate, acidified with aqueous 2 M HCl solution, and the aqueous layer was extracted with ethyl acetate. The water layer was concentrated in vacuo and dried by several azeotropic evaporations using toluene which afforded 3-bromo-8-methyl-imidazo[1,2-a]-6-carboxylic acid as light beige solid which was used for the next step without further purification. 1H NMR (400 MHz, DMSO-d6, ppm) δ = 8.66 - 8.70 (m, 1H), 8.03 (s, 1H), 7.73 (s, 1H), 2.58 (s, 3H). Step 4: Preparation of 3-bromo-8-methyl-imidazo[1,2-a]pyridine-6-carboxamide To a stirred solution of 3-bromo-8-methyl-imidazo[1,2-a]pyridine-6-carboxylic acid ( 1.1 g, 4.1 mmol) in THF (14 mL) was added dimethylformamide (0.1 mL), follow by the slow addition of oxalyl chloride ( 584 mg, 4.51 mmol, 1.10 eq.), after which the reaction mixture heated to 50 °C and stirred for 1 hour. The reaction mixture was then cooled to room temperature, and an ammonium hydroxide solution (25% in water), (2.30 g, 16.4 mmol) was added dropwise. The reaction mixture was then again heated to 50 °C and stirred for 30 min. After cooling down to room temperature the reaction mixture was added to cold water. The precipitate was filtered and dried under reduced pressure to afford 3-bromo-8-methyl- imidazo[1,2-a]pyridine-6-carboxamide as an off-white solid which was used for the next step without further purification. 1H NMR (400 MHz, DMSO-d6, ppm) δ = 8.72 (s, 1H), 8.24 (br s, 1H), 7.79 (s, 1H), 7.63 (s, 1H), 7.56 (br s, 1H), 2.50 (s, 3H). Step 5: Preparation of (N)-3-bromo-N-(dimethylaminomethylene)-8-methyl-imidazo[1,2-a]pyridine-6- carboxamide To a stirred solution of 3-bromo-8-methyl-imidazo[1,2-a]pyridine-6-carboxamide (2.40 g, 8.97 mmol) in N.N-dimethylformamide dimethyl acetal (18.4 mL) was added acetic acid (1.13 g, 17.9 mmol, 2.00 eq.) and the reaction mixture was heated at 95 °C and stirred for 3 hours. The reaction mixture was cooled and slowly poured onto water, the precipitate that formed was filtered, and dried under reduced pressure to afford (N)-3-bromo-N-(dimethylaminomethylene)-8-methyl-imidazo[1,2-a]pyridine-6-carboxamide as an off-white solid. 1H NMR (400 MHz, DMSO-d6, ppm) δ = 8.91 (s, 1H), 8.69 (s, 1H), 7.79 (app s, 2H), 3.18 (s, 3H), 3.23 (s, 3H), 2.52 (s, 3H). Step 6: Preparation of 3-bromo-6-[2-(4-fluoro-3-methoxy-phenyl)-1,2,4-triazol-3-yl]-8-methyl- imidazo[1,2-a]pyridine To a stirred solution of (N)-3-bromo-N-(dimethylaminomethylene)-8-methyl-imidazo[1,2-a]pyridine-6- carboxamide (300 mg, 0.922 mmol) in dimethylformamide (3.00 mL) was added (4-fluoro-3-methoxy- phenyl)hydrazine hydrochloride (199 mg, 1.01 mmol, 1.10 eq.). The reaction mixture was heated at 95 °C and stirred for 3 hours before being slowly poured onto water. The water phase extracted with ethyl acetate, the combined organic layers were washed with water and brine (20.0 mL), dried over sodium sulfate, filtered and concentrated under reduced pressure. The crude residue was purified by flash chromatography over silica gel (ethyl acetate/hexane) to afford 3-bromo-6-[2-(4-fluoro-3-methoxy- phenyl)-1,2,4-triazol-3-yl]-8-methyl-imidazo[1,2-a]pyridine as a yellow solid. 1H NMR (400 MHz, DMSO-d6, ppm) δ = 8.32 (s, 1H), 8.16 (dd, J = 1.6, 0.8 Hz, 1H), 7.76 (s, 1H), 7.48 (dd, J = 7.6, 2.4 Hz, 1H), 7.40 - 7.35 (m, 1H), 7.29 (t, J = 1.2 Hz, 1H), 7.09 - 7.06 (m, 1H), 3.81 (s, 3H), 2.47 (s, 3H). Step 7: Preparation of methyl N-[5-[6-[2-(4-fluoro-3-methoxy-phenyl)-1,2,4-triazol-3-yl]-8-methyl- imidazo[1,2-a]pyridin-3-yl]-2-pyridyl]carbamate (Compound X.07) To a stirred solution of 3-bromo-6-[2-(4-fluoro-3-methoxy-phenyl)-1,2,4-triazol-3-yl]-8-methyl- imidazo[1,2-a]pyridine (400 mg, 0.975 mmol), methyl N-[5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)- 2-pyridyl]carbamate (332 mg, 1.17 mmol, 1.20 eq.) in 1,4-dioxane/water (v/v = 3:1, 6.00 mL) was added cesium carbonate (646 mg, 1.95 mmol, 2.00 eq.). The mixture was degassed with argon for 2 minutes, then added Cataxium-A-Pd-G3 (36.2 mg, 0.0487 mmol, 0.050 eq.) was added and the reaction mixture kept under inert atmosphere. The resulting reaction mixture was heated at 110 ºC and stirred for 1 hour under microwave condition. The reaction mixture was filtered through a pad of celite, and the celite was further washed with ethyl acetate. The filtrate was washed with water and brine, dried over sodium sulfate, filtered and concentrated under reduced pressure. The crude residue was purified by silica gel column chromatography (dichloromethane/MeOH) to afford a solid that was further washed with pentane and dried under reduced pressure to afford the desired pure product methyl N-[5-[6-[2-(4-fluoro- 3-methoxy-phenyl)-1,2,4-triazol-3-yl]-8-methyl-imidazo[1,2-a]pyridin-3-yl]-2-pyridyl]carbamate as an off-white solid. LC/MS (Method F) retention time = 1.59 min; [M+H]+ = 474 1H NMR (400 MHz, DMSO-d6, ppm) δ = 10.42 (s, 1H), 8.37 (d, J = 2.0 Hz, 1H), 8.28 (s, 1H), 8.13 (s, 1H), 7.94 (d, J = 8.4 Hz, 1H), 7.79 (s, 1H), 7.62 (dd, J = 11.2, 2.4 Hz, 1H), 7.40 (dd, J = 10.0, 2.4 Hz, 1H), 7.37 (s, 1H), 7.33-7.28 (m, 1H), 7.04-7.00 (m, 1H), 3.77 (s, 3H), 3.74 (s, 3H), 2.52 (s, 3H). Example 4: preparation of methyl N-[5-[6-[4-(4-fluoro-3-methoxy-phenyl)-5-methyl-1,2,4-triazol-3- yl]imidazo[1,2-a]pyridin-3-yl]-2-pyridyl]carbamate (compound X.08) (Compound X.08) Step 1: Preparation of 3-bromoimidazo[1,2-a]pyridine-6-carbohydrazide To a solution of methyl 3-bromoimidazo[1,2-a]pyridine-6-carboxylate (1.00 g, 3.80 mmol) in methanol (5.43 mL) was added hydrazine hydrate (0.226 mL, 4.56 mmol, 1.20 eq.). The reaction mixture was stirred overnight at 70 °C, then it was cooled down to room temperature, water was added and the precipitate was filtered and washed with water to afford 3-bromoimidazo[1,2-a]pyridine-6- carbohydrazide as a white solid. LC/MS (method A) retention time = 0.19 min; [M+H]+ = 255 1H NMR (400 MHz, DMSO-d6, ppm) δ = 10.07 (br s, 1H), 8.79 (s, 1H), 7.82 (s, 1H), 7.72 - 7.77 (m, 1H), 7.67 - 7.72 (m, 1H), 4.58 (br s, 2H). Step 2: Preparation of 2-(3-bromoimidazo[1,2-a]pyridin-6-yl)-5-methyl-1,3,4-oxadiazole To 3-bromoimidazo[1,2-a]pyridine-6-carbohydrazide (500 mg, 1.96 mmol) was added triethyl orthoacetate (3.67 mL, 19.6 mmol, 10.0 eq.) and the reaction mixture was heated at 130 °C and stirred for 90 min. The reaction mixture was cooled and 1,8-diazabicyclo[5.4.0]undec-7-ene (0.359 mL, 2.35 mmol, 1.20 eq.) was added. The reaction mixture was heated again at 130 °C and stirred for an additional 20 min. After completion the mixture was cooled down to room temperature, water was added, and the precipitate that formed was filtered and washed with water to afford 2-(3-bromoimidazo[1,2- a]pyridin-6-yl)-5-methyl-1,3,4-oxadiazole as a beige solid. LC/MS (method A) retention time = 0.63 min; [M+H]+ = 279 1H NMR (400 MHz, DMSO-d6, ppm) δ = 8.71 - 8.81 (m, 1H), 7.88 - 7.92 (m, 1H), 7.84 - 7.87 (m, 2H), 2.60 - 2.66 (s, 3H). Step 3: Preparation of 3-bromo-6-[4-(4-fluoro-3-methoxy-phenyl)-5-methyl-1,2,4-triazol-3- yl]imidazo[1,2-a]pyridine To a solution of 2-(3-bromoimidazo[1,2-a]pyridin-6-yl)-5-methyl-1,3,4-oxadiazole (200 mg, 0.717 mmol) in acetic acid (2.39 mL) was added 4-fluoro-3-methoxyaniline (532 mg, 3.58 mmol, 5.00 eq.). The reaction mixture was heated at 130 °C and stirred for 45 minutes. The reaction mixture was then cooled down to room temperature and slowly quenched with a saturated NaHCO3 solution. The aqueous phase was extracted with ethyl acetate, and the combined organic layers were washed with brine, dried over sodium sulfate, filtered and concentrated under reduced pressure. The crude residue was purified by flash chromatography over silica gel (ethylacetate/EtOH/cyclohexane) to afford 3-bromo-6-[4-(4-fluoro- 3-methoxy-phenyl)-5-methyl-1,2,4-triazol-3-yl]imidazo[1,2-a]pyridine as a beige solid. LC/MS (method A) retention time = 0.76 min; [M+H]+ = 402 1H NMR (400 MHz, CDCl3, ppm) δ = 8.24 (dd, J = 1.6, 0.9 Hz, 1H), 7.63 (s, 1H), 7.54 (dd, J = 9.4, 1.1 Hz, 1H), 7.36 (dd, J = 9.4, 1.8 Hz, 1H), 7.30 (d, J = 9.1 Hz, 1H), 6.81 - 6.92 (m, 2H), 3.89 (s, 3H), 2.41 (s, 3H). Step 4: Preparation of methyl N-[5-[6-[4-(4-fluoro-3-methoxy-phenyl)-5-methyl-1,2,4-triazol-3- yl]imidazo[1,2-a]pyridin-3-yl]-2-pyridyl]carbamate (Compound X.08) In a microwave test tube was added 3-bromo-6-[4-(4-fluoro-3-methoxy-phenyl)-5-methyl-1,2,4-triazol-3- yl]imidazo[1,2-a]pyridine (260 mg, 0.646 mmol), 2-methoxycarbonylaminopyridine-5-boronic acid pinacol ester (265 mg, 0.905 mmol, 1.40 eq.), cesium carbonate (319 mg, 0.970 mmol, 1.50 eq.), 2- methyltetrahydrofuran (8.40 mL), water (2.80 mL) and tetrakis(triphenylphosphine)palladium(0) (7.70 mg, 0.0323 mmol, 0.05 eq.). The reaction mixture was purged with argon and heated at 100 °C for 30 min under microwave irradiation. The suspension was cooled to room temperature, petroleum ether was added, the suspension was filtered and successively washed with water and petroleum ether. The precipitate was dissolved in chloroform at 50 °C and filtered. The filtrate was concentrated to give methyl N-[5-[6-[4-(4-fluoro-3-methoxy-phenyl)-5-methyl-1,2,4-triazol-3-yl]imidazo[1,2-a]pyridin-3-yl]-2- pyridyl]carbamate as a white solid. LC/MS (method A) retention time = 0.65 min; [M+H]+ = 474 1H NMR (400 MHz, DMSO-d6, ppm) δ = 10.39 (s, 1H), 8.33 - 8.40 (m, 1H), 8.10 (dd, J = 1.6, 0.9 Hz, 1H), 7.96 (dd, J = 8.7, 0.7 Hz, 1H), 7.79 (s, 1H), 7.70 (dd, J = 9.4, 0.7 Hz, 1H), 7.66 (dd, J = 8.5, 2.4 Hz, 1H), 7.53 (dd, J = 9.4, 1.8 Hz, 1H), 7.44 (dd, J = 7.6, 2.5 Hz, 1H), 7.30 (dd, J = 11.1, 8.5 Hz, 1H), 6.99 - 7.06 (m, 1H), 3.77 (s, 3H), 3.74 (s, 3H), 2.25 (s, 3H). In a microwave vial charged with copper(I) chloride (113 mg, 1.12 mmol, 0.100 eq.), potassium carbonate (1.64 g, 11.8 mmol, 1.05 eq.), acetylacetone (0.290 mL, 2.80 mmol, 0.250 eq.) and NMP (2.24 mL) was added under argon imidazole (924 mg, 13.4 mmol, 1.20 eq.) and 1-bromo-4- fluorobenzene (1.26 mL, 11.2 mmol). The reaction mixture was heated at 120 °C and stirred. The reaction mixture was then cooled down to room temperature, mixed with saturated aqueous NaHCO3 solution and dichloromethane and stirred for 15 minutes at room temperature. The suspension was filtered through a pad of celite, and the filtrate was extracted with dichloromethane. The combined organic layers were washed with brine, dried over sodium sulfate, filtered, and concentrated under reduced pressure. The crude residue was purified by flash chromatography over silica gel (ethyl acetate/ethanol) to afford 1-(4-fluorophenyl)imidazole as a yellow liquid. LC/MS (method A) retention time = 0.22 min; [M+H]+ = 163 1H NMR (400 MHz, CDCl3, ppm) δ = ppm 7.78 (s, 1H), 7.33 - 7.44 (m, 2H), 7.12 - 7.27 (m, 4H). To a solution of 1-(4-fluorophenyl)imidazole (300 mg, 1.85 mmol) in THF (2.50 mL) at 0°C under argon was added, dropwise, n-buthyllithium in hexane (2.50 mol/L, 0.890 mL, 2.22 mmol, 1.20 eq.). The reaction mixture was stirred for 30 minutes at 0 °C, then zinc chloride in methyl tetrahydrofuran (1.90 mol/L, 1.60 mL, 2.96 mmol, 1.60 eq.) was added and stirring continued for 30 minutes at room temperature. The reaction mixture was then concentrated to remove half of the solvent, and to that mixture was added dry toluene (1.85 mL), 3-bromo-6-iodoimidazo[1,2-a]pyridine (677 mg, 2.04 mmol, 1.10 eq.) and Pd(PPh3)4 (108 mg, 0.093 mmol, 0.05 eq.). The reaction mixture was heated at 100 °C and stirred overnight, then it was cooled to room temperature and stirred in a mixture of saturated aqueous NaHCO3 solution and ethyl acetate for 20 minutes. The mixture was then extracted with ethyl acetate, and the combined organic layers were washed with brine, dried over sodium sulfate, filtered, and concentrated under reduced pressure. The crude residue was purified by flash chromatography over silica gel (cyclohexane/ethyl acetate/ethanol) to afford 3-bromo-6-[1-(4-fluorophenyl)imidazol-2- yl]imidazo[1,2-a]pyridine as a yellow solid. LC/MS (method A) retention time = 0.72 min; [M+H]+ = 357 1H NMR (400 MHz, DMSO-d6, ppm) δ = 8.07 (dd, J = 1.8, 1.1 Hz, 1H), 7.74 (s, 1H), 7.60 (dd, J = 9.4, 1.1 Hz, 1H), 7.58 (d, J = 1.1 Hz, 1H), 7.48 - 7.55 (m, 2H), 7.37 (t, J = 8.7 Hz, 2H), 7.29 (dd, J = 9.4, 1.8 Hz, 1H), 7.25 (d, J = 1.5 Hz, 1H). Step 3: Preparation of methyl N-[5-[6-[1-(4-fluorophenyl)imidazol-2-yl]imidazo[1,2-a]pyridin-3-yl]-2- pyridyl]carbamate In a microwave test tube was added 3-bromo-6-[1-(4-fluorophenyl) imidazol-2-yl]imidazo[1,2-a]pyridine (80.0 mg, 0.220 mmol) followed by 2-methoxycarbonylaminopyridine-5-boronic acid, pinacol ester (92.0 mg, 0.310 mmol.1.40 eq.), cesium carbonate (110 mg, 0.340 mmol, 1.50 eq.), 2-methyltetrahydrofuran (2.90 mL), water (0.970 mL) and tetrakis(triphenylphosphine) palladium(0) (13.0 mg, 0.011 mmol, 0.0500 eq.). The reaction mixture was purged with argon and heated at 100 °C for 30 minutes under microwave irradiation. The solution was cooled to room temperature, water was added, and the solution was extracted with ethyl acetate. The combined organic layers were washed with brine, dried over sodium sulfate, filtered, and concentrated under reduced pressure. The crude residue was purified by flash chromatography over silica gel (dichloromethane/methanol) to afford methyl N-[5-[6-[1-(4- fluorophenyl)imidazol-2-yl]imidazo[1,2-a]pyridin-3-yl]-2-pyridyl]carbamate as a white solid. LC/MS (method A) retention time = 0.67 min; [M+H]+ = 429 1H NMR (400 MHz, DMSO-d6, ppm) δ = 10.40 (s, 1H), 8.31 - 8.40 (m, 1H), 8.05 (d, J = 1.8 Hz, 1H), 7.91 - 7.96 (m, 1H), 7.77 (s, 1H), 7.61 - 7.69 (m, 2H), 7.51 (d, J = 1.1 Hz, 1H), 7.45 - 7.49 (m, 2H), 7.42 (dd, J = 9.3, 1.6 Hz, 1H), 7.27 - 7.34 (m, 2H), 7.21 (d, J = 1.5 Hz, 1H), 3.74 (s, 3H), 3.31 (s, 2H). The above-mentioned synthesis related to example 5 can be used to prepare the compound X.09 in using 3-bromo-6-fluoroanisole in step 1 Example 6: preparation of methyl N-[5-[6-[2-(4-fluoro-3-methoxy-phenyl)-1,2,4-triazol-3- yl]imidazo[1,2-a]pyridin-3-yl]-2-pyridyl]carbamate (compound X.11) (Compound X.11) Step 1: Preparation of (NE)-3-bromo-N-(dimethylaminomethylene)imidazo[1,2-a]pyridine-6- carboxamide To a suspension of 3-bromoimidazo[1,2-a]pyridine-6-carboxamide (see synthetic example 25, step 1; 0.82 g, 3.41 mmol) in N,N-dimethylformamide dimethyl acetal (0.623 g, 0.695 mL, 5.12 mmol) was added acetic acid (0.041 g, 0.039 mL, 0.683 mmol). The reaction mixture was heated to 95 °C and stirred for 10 min. The reaction mixture was then cooled to room temperature, water was added and the precipitate was filtered to give (NE)-3-bromo-N-(dimethylaminomethylene)imidazo[1,2-a]pyridine-6- carboxamide as a white solid. The product was used for the next step without further purification. LC/MS (method A) retention time = 0.59 min; [M+H]+ = 295 1H NMR (400 MHz, DMSO-d6, ppm) δ = 9.00 - 9.04 (m, 1H), 8.69 (s, 1H), 7.95 (dd, J = 9.4, 1.8 Hz, 1H), 7.82 (s, 1H), 7.66 (dd, J = 9.3, 0.9 Hz, 1H), 3.24 (s, 3H), 3.19 (s, 3H). a]pyridine (Intermediate I-1) (Intermediate I-1) To a solution of (NE)-3-bromo-N-(dimethylaminomethylene)imidazo[1,2-a]pyridine-6-carboxamide (750 mg, 2.54 mmol) in dimethylformamide (25.4 mL) was added 1-(4-fluoro-3-methoxyphenyl)hydrazine hydrochloride (618 mg, 3.05 mmol, 1.20 eq.). The reaction mixture was heated at 90 °C and stirred overnight. After cooling down to room temperature, water was added, and the solution was extracted with ethyl acetate. The combined organic layers were washed with brine, dried over sodium sulfate, filtered and concentrated under reduced pressure. The crude residue was purified by flash chromatography over silica gel (cyclohexane/ethyl acetate) to afford 3-bromo-6-[2-(4-fluoro-3-methoxy- phenyl)-1,2,4-triazol-3-yl]imidazo[1,2-a]pyridine. LC/MS (method A) retention time = 0.82 min; [M+H]+ = 388 1H NMR (400 MHz, DMSO-d6, ppm) δ = 8.38 - 8.42 (m, 1H), 8.33 (s, 1H), 7.82 (s, 1H), 7.69 (d, J = 9.4 Hz, 1H), 7.47 (dd, J = 7.8, 2.4 Hz, 1H), 7.38 (dd, J = 11.1, 8.5 Hz, 1H), 7.32 (dd, J = 9.4, 1.8 Hz, 1H), 7.05 - 7.11 (m, 1H), 3.81 (s, 3H). Step 3: Preparation of methyl N-[5-[6-[2-(4-fluoro-3-methoxy-phenyl)-1,2,4-triazol-3-yl]imidazo[1,2- a]pyridin-3-yl]-2-pyridyl]carbamate (Compound X.11) In a microwave test tube 3-bromo-6-[2-(4-fluoro-3-methoxy-phenyl)-1,2,4-triazol-3-yl]imidazo[1,2- a]pyridine (Intermediate I-1, 785 mg, 1.92 mmol) and methyl N-[5-(4,4,5,5-tetramethyl-1,3,2- dioxaborolan-2-yl)-2-pyridyl]carbamate (748 mg, 2.69 mmol, 1.40 eq.) were dissolved in 2- methyltetrahydrofuran (11.5 mL) and water (3.84 mL). Then cesium carbonate (939 mg, 2.88 mmol, 1.50 eq.) was added and the mixture was purged with a stream of argon for 5 minutes before tetrakis(triphenylphosphine) palladium(0) (114 mg, 0.096 mmol, 0.05 eq.) was added. The mixture heated under microwave irradiation at 100 °C for 30 minutes, then it was cooled to room temperature, water was added, and the solution was extracted with ethyl acetate. The combined organic layers were washed with brine, dried over sodium sulfate, filtered, and concentrated under reduced pressure. The crude residue was purified by flash chromatography over silica gel (ethyl acetate/ethanol in cyclohexane) to afford methyl N-[5-[6-[2-(4-fluoro-3-methoxy-phenyl)-1,2,4-triazol-3-yl]imidazo[1,2- a]pyridin-3-yl]-2-pyridyl]carbamate. LC/MS (method A) retention time = 0.71 min; [M+H]+ = 460 1H NMR (400 MHz, DMSO-d6, ppm) δ = 10.40 (s, 1H), 8.41 (dd, J=2.5, 0.7 Hz, 1 H), 8.36 - 8.39 (m, 1 H), 8.28 (s, 1H), 7.96 (d, J = 8.7 Hz, 1H), 7.84 (s, 1H), 7.70 - 7.77 (m, 2H), 7.39 - 7.45 (m, 2H), 7.31 (dd, J = 11.3, 8.7 Hz, 1H), 6.99 - 7.09 (m, 1H), 3.78 (s, 3H), 3.74 (s, 3H). Example 7: Preparation of methyl N-[5-[6-[4-(4-fluoro-3-methoxy-phenyl)-5-(methoxymethyl)- 1,2,4-triazol-3-yl]-8-methyl-imidazo[1,2-a]pyridin-3-yl]-2-pyridyl]carbamate (Compound X.12) (Compound X.12) Step 1: Preparation of 6-Bromo-8-methylimidazo[1,2-a]pyridine A solution of 2-amino-5-bromo-3-methylpyridine (2.0 g, 10.7 mmol) in ethanol (42.8 mL) was stirred under nitrogen atmosphere. Then chloroacetaldehyde solution (2.33 g, 13.37 mmol, 1.89 mL, 1.25 eq.) was added. The resulting reaction mixture was refluxed at 100 °C for 5 hours and then at 55 °C overnight. The reaction mixture was concentrated. Then ethyl acetate was added.The suspension was filtered and the solid collected and dried, to afford 6-bromo-8-methylimidazo[1,2-a]pyridine as a brown solid. LC/MS (method B) retention time = 0.66 min; [M+H] += 211 Step 2: Preparation of methyl 8-methylimidazo[1,2-a]pyridine-6-carboxylate To a mixture of 6-bromo-8-methyl-imidazo[1,2-a]pyridine (9.00 g, 42.6 mmol) in methanol (100.0 mL) was added 1,1'-bis(diphenylphosphino)ferrocene-palladium(II)dichloride dichloromethane complex (1.73 g, 2.13 mmol, 0.05 eq.) and N,N-diethylethanamine (12.9 g, 128 mmol, 3.00 eq.). The bomb was then flushed with carbon monoxide, sealed, and pressurized to 2.5 MPa with carbon monoxide. The reaction was stirred at 100 °C for 8 hours. The vessel was then cooled to room temperature and the pressure released. The reaction mixture was concentrated to dryness and purified by silica gel column chromatography (eluting with dichloromethane/MeOH) to obtain the methyl 8-methylimidazo[1,2- a]pyridine-6-carboxylate as a brown solid. LC/MS (method B) retention time = 0.19 min; [M+H] += 191 1H-NMR (400 MHz, DMSO-d6, ppm) δ = 9.20 (s, 1H), 8.10 (s, 1H), 7.65 (s, 1H), 7.45 (s, 1H), 3.88 (s, 3H), 2.52 (s, 3H). Step 3: Preparation of methyl 3-bromo-8-methyl-imidazo[1,2-a]pyridine-6-carboxylate To a mixture methyl 8-methylimidazo[1,2-a]pyridine-6-carboxylate (0.50 g, 2.6 mmol) in acetonitrile (13 mL) under an atmosphere of argon at room temperature was added N-bromosuccinimide (0.53 g, 2.9 mmol, 1.1 eq.) The reaction mixture was stirred for 45 min and then quenched with 1 M aqueous sodium sulfite solution and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over sodium sulfate, filtered, and concentrated under reduced pressure to afford 3-bromo-8- methyl-imidazo[1,2-a]pyridine-6-carboxylate as a pale beige solid. 1H NMR (400 MHz, CDCl3, ppm) δ = 8.78 (d, J = 0.7 Hz, 1H), 7.69 (s, 1H), 7.58 - 7.65 (m, 1H), 3.99 (s, 3H), 2.65 (s, 3H) Step 4: Preparation of 3-bromo-8-methyl-imidazo[1,2-a]pyridine-6-carbohydrazide (Intermediate I-2) (Intermediate I-2) To a solution of methyl 3-bromoimidazo[1,2-a]pyridine-6-carboxylate (1.00 g, 3.80 mmol) in methanol (5.43 mL) was added hydrazine hydrate (0.226 mL, 4.56 mmol, 1.20 eq.). The reaction mixture was stirred overnight at 70 °C, then it was cooled down to room temperature, water was added and the precipitate was filtered and washed with water to afford 3-bromoimidazo[1,2-a]pyridine-6- carbohydrazide as a white solid. LC/MS (method B) retention time = 0.19 min; [M+H] += 255 1H NMR (400 MHz, DMSO-d6, ppm) δ = 10.07 (br s, 1H), 8.79 (s, 1H), 7.82 (s, 1H), 7.72 - 7.77 (m, 1H), 7.67 - 7.72 (m, 1H), 4.58 (br s, 2H). Step 5: Preparation of 2-(3-bromo-8-methyl-imidazo[1,2-a]pyridin-6-yl)-5-(methoxymethyl)-1,3,4- oxadiazole To a solution of 3-bromo-8-methyl-imidazo[1,2-a]pyridine-6-carbohydrazide (Intermediate I-2, 0.50 g, 2.0 mmol) was added toluene (7 mL) 1,1,1,2-tetramethoxyethane (0.30 g, 0.30 mL, 2.0 mmol) and the reaction mixture was stirred for 1h at 100 °C. The reaction mixture was concentrated under vacuo, the residue was washed with pentane and tert-butyl methyl ether, dried under vacuo to afford 2-(3-bromo- 8-methyl-imidazo[1,2-a]pyridin-6-yl)-5-(methoxymethyl)-1,3,4-oxadiazole as an off white solid. LC/MS (method B) retention time = 1.05 min; [M+H]+ = 325 Step 6: Preparation of 3-bromo-6-[4-(4-fluoro-3-methoxy-phenyl)-5-(methoxymethyl)-1,2,4-triazol-3-yl]- 8-methyl-imidazo[1,2-a]pyridine A solution of 2-(3-bromo-8-methyl-imidazo[1,2-a]pyridin-6-yl)-5-(methoxymethyl)-1,3,4-oxadiazole (0.27 g, 0.84 mmol) in acetic acid (2.9 mL) was treated with 4-fluoro-3-methoxy-aniline (0.35 g, 2.52 mmol, 3.0 eq.) and the mixture was heated and stirred at 120 °C for 1 hour. The reaction mixture was cooled down to room temperature and concentrated under reduced pressure. The residue was purified on neutral alumina (eluting methanol/ethyl acetate) to afford 3-bromo-6-[4-(4-fluoro-3-methoxy-phenyl)-5- (methoxymethyl)-1,2,4-triazol-3-yl]-8-methyl-imidazo[1,2-a]pyridine as a solid. LC/MS (method B) retention time = 0.99 min; [M+H] += 447 Step 7: Preparation of methyl N-[5-[6-[4-(4-fluoro-3-methoxy-phenyl)-5-(methoxymethyl)-1,2,4-triazol-3- yl]-8-methyl-imidazo[1,2-a]pyridin-3-yl]-2-pyridyl]carbamate (Compound X.12) A mixture of 3-bromo-6-[4-(4-fluoro-3-methoxy-phenyl)-5-(methoxymethyl)-1,2,4-triazol-3-yl]-8-methyl- imidazo[1,2-a]pyridine (0.30 g, 0.67 mmol) and methyl N-[5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2- yl)-2-pyridyl]carbamate (0.28 g, 1.00 mmol, 1.5 eq.) was dissolved in acetonitrile (5.37 mL). Sodium carbonate (0.213 g, 2.02 mmol, 3.00 eq.) dissolved in water (2.68 mL) was added. The resulting reaction mixture was purged with nitrogen for 15 mins. Chloro(2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'- biphenyl)[2-(2'-amino-1,1'-biphenyl)]palladium(II) (0.054 g, 0.067 mmol, 0.10 eq.) was added. The reaction mixture was irradiated with microwave radiation for 1 hour at 100 °C. The reaction mixture was filtered through celite, and the filtrate was concentrate. The crude residue was purified by flash chromatography on neutral alumina (5-10% methanol in ethyl acetate) to afford an off white solid, which was further washed with tert-butyl methyl ether to afford methyl N-[5-[6-[4-(4-fluoro-3-methoxy-phenyl)- 5-(methoxymethyl)-1,2,4-triazol-3-yl]-8-methyl-imidazo[1,2-a]pyridin-3-yl]-2-pyridyl]carbamate as an off white solid LC/MS (method B) retention time = 0.93 min; [M+H] += 518.2 1H NMR (400 MHz, CD3OD, ppm) δ = 8.23 (d, 1 H), 8.07 (d, 1 H), 7.94 (s, 1 H), 7.69 (s, 1 H), 7.55 - 7.60 (m, 2 H), 7.31(dd, 1 H), 7.23 (dd, 1 H), 6.92 - 6.97 (m, 1 H), 4.48 (s, 2 H), 3.84 (s, 3 H), 3.80 (s, 3 H), 3.30 (s, 3 H), 2.60 (s, 3 H) Example 8: Preparation of methyl N-[5-[8-cyclopropyl-6-[4-(4-fluoro-3-methoxy-phenyl)-1,2,4- triazol-3-yl]imidazo[1,2-a]pyridin-3-yl]-2-pyridyl]carbamate (compound X.01) (Compound X.01) Step 1: Preparation of methyl 8-bromoimidazo[1,2-a]pyridine-6-carboxylate A solution of methyl 6-amino-5-bromonicotinate (4.00 g, 21.4 mmol) in ethanol (86 mL) was stirred under nitrogen atmosphere. Then chloroacetaldehyde solution (26.7 mmol, 3.78 mL, 1.25 eq.) was added. The resulting reaction mixture was refluxed at 100 °C for 5 hours and then at 55 °C overnight. The reaction mixture was concentrated, then ethyl acetate was added. The suspension was filtered, the solid was collected and dried to get methyl 8-bromoimidazo[1,2-a]pyridine-6-carboxylate as a brown solid. LC/MS (method B) retention time = 0.59 min; [M+H] += 257 Step 2: Preparation of methyl 8-cyclopropylimidazo[1,2-a]pyridine-6-carboxylate To a solution of methyl 8-bromoimidazo[1,2-a]pyridine-6-carboxylate (5.00 g, 17.6 mmol) in cyclopentyl methyl ether (50 mL) were added cyclopropylboronic acid;hydrate (2.89 g, 26.4 mmol, 1.50 eq.) and potassium carbonate (6.10 g, 44.0 mmol, 2.50 eq.). The mixture was degassed with nitrogen for 30 min. [1,1'-bis(diphenylphosphino)ferrocene] dichloropalladium(II) (0.645 g, 0.88 mmol, 0.05 eq.) was then added. The resulting mixture was stirred at 85 °C overnight. Then additional cyclopropylboronic acid;hydrate (2.89 g, 26.4 mmol, 1.50 eq.) and [1,1'-bis(diphenylphosphino)ferrocene] dichloropalladium(II) (0.645 g, 0.88 mmol, 0.05 eq.) were added. The reaction mixture was cooled down to room temperature and then water was added. The aqueous layer was extracted ethyl acetate and the combined organic layers were washed with brine, dried over sodium sulfate, filtered, and concentrated under reduced pressure. The crude residue was purified over a silica gel cartridge (cyclohexane/ethyl acetate, 3:2) to afford methyl 8-cyclopropylimidazo[1,2-a]pyridine-6-carboxylate as brown solid. LC/MS (method B) retention time = 0.37 min; [M+H] += 217 1H NMR (400 MHz, CDCl3, ppm) δ = 0.96 - 1.07 (m, 2 H) 1.13 - 1.23 (m, 2 H) 2.51 - 2.68 (m, 1 H) 3.96 (s, 3 H) 7.22 - 7.28 (m, 1 H) 7.64 - 7.71 (m, 1 H) 7.72 - 7.77 (m, 1 H) 8.70 - 8.89 (m, 1 H) Step 3: Preparation of 8-cyclopropylimidazo[1,2-a]pyridine-6-carbohydrazide To a solution of methyl 8-cyclopropylimidazo[1,2-a]pyridine-6-carboxylate (1.99 g, 9.20 mmol) in methanol (13.1 mL) was added hydrazine hydrate (1.46 mL, 46.0 mmol, 5 eq.). The reaction mixture was stirred at 75 °C for 5 hours, then at 45 °C for 18 hours. The reaction mixture was concentrated and the crude residue was used as such in the next step. LC/MS (method B) retention time = 0.14 min; [M+H] += 217 Step 4: Preparation of 2-(8-cyclopropylimidazo[1,2-a]pyridin-6-yl)-1,3,4-oxadiazole To a mixture of 8-cyclopropylimidazo[1,2-a]pyridine-6-carbohydrazide (1.9 g, 8.8 mmol) and diethoxymethoxyethane (16.5 ml, 88 mmol, 10 eq.) was added 1,8-diazabicyclo[5.4.0]undec-7-ene (1.6 mL, 11 mmol, 1.2 eq.). The reaction mixture was stirred for overnight at 120 °C. The reaction mixture was cooled down to room temperature and then water was added. The aqueous layer was extracted with ethyl acetate and the combined organic layers were washed with brine, dried over sodium sulfate, filtered, and concentrated under reduced pressure. The crude residue was purified over a silica gel cartridge (eluting cyclohexane/ethyl acetate, 3:7) to afford 2-(8-cyclopropylimidazo[1,2-a]pyridin-6-yl)- 1,3,4-oxadiazole as white solid. LC/MS (method B) retention time = 0.14 min; [M+H] += 227 Step 5: Preparation of 2-(3-bromo-8-cyclopropyl-imidazo[1,2-a]pyridin-6-yl)-1,3,4-oxadiazole To a solution of 2-(8-cyclopropylimidazo[1,2-a]pyridin-6-yl)-1,3,4-oxadiazole (1.14 g, 5.04 mmol) in acetonitrile (11.4 mL) was added N-bromosuccinimide (0.997 g, 5.54 mmol, 1.10 eq.). The reaction mixture was stirred at room temperature for 90 min, then water was added. The aqueous layer was extracted with ethyl acetate, the combined organic layers were washed with sodium thiosulphate pentahydrate, dried over sodium sulfate, filtered, and concentrated under reduced pressure. The crude was purified by flash chromatography over silical gel (eluting cyclohexane/ethyl acetate, 8:2) to afford ethyl acetate 2-(3-bromo-8-cyclopropyl-imidazo[1,2-a]pyridin-6-yl)-1,3,4-oxadiazole as a yellow solid. LC/MS (method B) retention time = 0.66 min; [M+H] += 307 Step 6: Preparation of methyl N-[5-[8-cyclopropyl-6-(1,3,4-oxadiazol-2-yl)imidazo[1,2-a]pyridin-3-yl]-2- pyridyl]carbamate To a solution of 2-(3-bromo-8-cyclopropyl-imidazo[1,2-a]pyridin-6-yl)-1,3,4-oxadiazole (200 mg, 0.49 mmol) in acetonitrile (3.93 mL) were added 2-methoxycarbonylaminopyridine-5-boronic acid, pinacol ester (0.187 g, 0.64 mmol, 1.30 eq.), water (1.97 mL) and sodium carbonate (0.156 g, 1.47 mmol, 3.00 eq.). The mixture was degassed with nitrogen for 10 min. Then chloro(2-dicyclohexylphosphino-2',4',6'- triisopropyl-1,1'-biphenyl)[2-(2'-amino-1,1'-biphenyl)]palladium(II) (0.0399 g, 0.0490 mmol, 0.100 eq.) was added. The mixture was irradiated with microwave radiations at 100 °C for 2 hours. The reaction mixture was cooled down to room temperature, then water was added. The aqueous layer was extracted ethyl acetate, the combined organic layers were washed with brine, dried over sodium sulfate, filtered, and concentrated under reduced pressure. The crude residue was purified via reverse phase chromatography (eluting water/acetonitrile, 3:7) to afford methyl N-[5-[8-cyclopropyl-6-(1,3,4-oxadiazol- 2-yl)imidazo[1,2-a]pyridin-3-yl]-2-pyridyl]carbamate as white solid . LC/MS (method B) retention time = 0.35 min; [M+H] += 377 1H NMR (400 MHz, CD3OD, ppm) δ = 1.12 - 1.21 (m, 4 H), 2.56 - 2.66 (m, 1 H), 3.73 (s, 3 H), 7.37 (s, 1 H), 7.90 (s, 1 H), 8.05 (d, J = 8.56 Hz, 1 H), 8.13 - 8.21 (m, 1 H), 8.60 (d, J = 1.96 Hz, 1 H), 8.77 (s, 1 H), 9.38 (s, 1 H), 10.51 (s, 1 H) Step 7: Preparation of methyl N-[5-[8-cyclopropyl-6-[4-(4-fluoro-3-methoxy-phenyl)-1,2,4-triazol-3- yl]imidazo[1,2-a]pyridin-3-yl]-2-pyridyl]carbamate (Compound X.01) To a solution of methyl N-[5-[8-cyclopropyl-6-(1,3,4-oxadiazol-2-yl)imidazo[1,2-a]pyridin-3-yl]-2- pyridyl]carbamate (0.030 g, 0.079 mmol) in acetic acid (0.28 mL) was added 4-fluoro-2-methoxyaniline (0.0337 g, 0.239 mmol, 3.00 eq.). The resulting reaction mixture was heated at 120 °C for 1 hour. The reaction mixture was concentrated under reduced pressure. The crude was purified over silica gel (ethyl acetate/methanol, 95:5) to afford methyl N-[5-[8-cyclopropyl-6-[4-(4-fluoro-3-methoxy-phenyl)-1,2,4- triazol-3-yl]imidazo[1,2-a]pyridin-3-yl]-2-pyridyl]carbamate as brown solid. LC/MS (method B) retention time = 0.90 min; [M+H] += 500 1H NMR (400 MHz, DMSO-d6, ppm) δ = 3.74 (s, 3 H), 3.78 (s, 3 H), 6.93 (d, 1 H), 7.31 (t, 1 H), 7.46 (dd, 1 H), 7.56 (1H, d), 7.72 (d, 1 H), 7.79 (s, 1 H), 7.96 (d, 1 H), 8.11 (d, 1 H), 8.40 (d, 1 H), 8.87 (s, 1 H), 10.44 (s, 1 H) Example 9: Preparation of methyl N-[5-[6-[1-(4-fluoro-3-methoxy-phenyl)imidazol-2-yl]-8-methyl- imidazo[1,2-a]pyridin-3-yl]-2-pyridyl]carbamate (compound X.02) To a stirred solution of 5-iodo-3-methyl-pyridin-2-amine (20.0 g, 85.5 mmol) in EtOH (200 mL) was added 2-chloroacetaldehyde (30.2 g, 385 mmol) and sodium hydrogen carbonate (12.9 g, 154 mmol) at room temperature. The reaction mixture was stirred at 80 °C for 16 hours. The reaction mixture was then concentrated under reduced pressure. Saturated aqueous NaHCO3 and dichloromethane were added. The aqueous layer was extracted with dichloromethane, the combined organic phases were dried with sodium sulfate, filtered and concentrated under reduced pressure. The residual was purified by silica gel column chromatography (eluting with ethyl acetate/petroleum ether, 0% to 75%) to afford 6-iodo-8-methyl-imidazo[1,2-a]pyridine as a yellow solid. LC/MS (method A) retention time = 0.52 min; [M+H] += 259.1 1H NMR (400 MHz, DMSO-d6, ppm) δ = 8.78 (s, 1H), 7.86 (s, 1H), 7.49 (s, 1H), 7.26 (s, 1H), 2.51 (s, 3H) Step 2: Preparation of 3-bromo-6-iodo-8-methyl-imidazo[1,2-a]pyridine To a solution of 6-iodo-8-methyl-imidazo[1,2-a]pyridine (Intermediate I-4, 2.00 g, 7.75 mmol) in dimethylformamide (50.0 mL) was added 1-bromopyrrolidine-2,5-dione (1.52 g, 8.53 mmol). The mixture was stirred at room temperature for 12 hours. Then the resulting mixture was diluted with water (50 mL) and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over sodium sulfate, and concentrated under vacuum. The residue was purified by silica gel column chromatography (eluting with ethyl acetate /petroleum ether, 0% to 35%) to give 3-bromo-6-iodo-8- methyl-imidazo[1,2-a]pyridine as a yellow solid. LC/MS (method A) retention time = 1.35 min; [M+H] += 338 Step 3: Preparation of 1-(4-fluoro-3-methoxy-phenyl)imidazole To a solution of 4-bromo-1-fluoro-2-methoxy-benzene (5.00 g, 24.4 mmol) in 1-methylpyrrolidin-2-one (50.0 mL) was added imidazole (1.83 g, 26.8 mmol), K2CO3 (3.53 g, 25.6 mmol, 1.10 eq.), iodocopper (0.464 g, 2.44 mmol, 0.10 eq.) and pentane-2,4-dione (0.610 g, 6.10 mmol, 0.25 eq.) at 25 °C. The mixture was heated at 120 °C for 12 hours. Then the reaction mixture was diluted with water and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over sodium sulfate, and concentrated under vacuum. The residue was purified by silica gel column chromatography (eluting with dichloromethane/MeOH, 0% to 4%) to give 1-(4-fluoro-3-methoxy-phenyl)imidazole as a colorless oil. LC/MS (method A) retention time = min; [M+H] += 193 Step 4: Preparation of 3-bromo-6-[1-(4-fluoro-3-methoxy-phenyl)imidazol-2-yl]-8-methyl-imidazo[1,2- a]pyridine To a solution of 1-(4-fluoro-3-methoxy-phenyl)imidazole (0.700 g, 3.64 mmol) in dry THF (10.0 mL) was added n-BuLi (2.5M in hexane, 1.7 mL, 4.37 mmol, 1.2 eq.) dropwise at -78 °C under an atmosphere of N2. After addition, the solution was stirred at -78 °C for 30 minutes. Then zinc dichloride (0.993 g, 7.28 mmol, 2 eq.) in dry THF (10.0 mL) was added dropwise at -78 °C under an atmosphere of N2. After addition, the solution was stirred at -78 °C for 30 minutes. Then 3-bromo-6-iodo-8-methyl-imidazo[1,2- a]pyridine (1.23 g, 3.64 mmol, 1 eq.) in toluene (10.0 mL) and tetrakis(triphenylphosphine)palladium(0) (0.421 g, 0.364 mmol, 0.10 eq.) was added dropwise at room temperature under an atmosphere of N2 . The reaction was heated at 100 °C for 12 hours. The reaction mixture was quenched with saturated aqueous NH4Cl solution and extracted with dichloromethane. The combined organic layers were washed with water and brine, dried with sodium sulfate, and concentrated under vacuum. The residue was purified by silica gel column chromatography (eluting with MeOH/dichloromethane, 0% to 5%) to give 3-bromo-6-[1-(4-fluoro-3-methoxy-phenyl)imidazol-2-yl]-8-methyl-imidazo[1,2-a]pyridine as a yellow solid. LC/MS (method A) retention time = min; [M+H]+= 403 Step 5: Preparation of methyl N-[5-[6-[1-(4-fluoro-3-methoxy-phenyl)imidazol-2-yl]-8-methyl- imidazo[1,2-a]pyridin-3-yl]-2-pyridyl]carbamate (Compound X.02) A mixture of 3-bromo-6-[1-(4-fluoro-3-methoxy-phenyl)imidazol-2-yl]-8-methyl-imidazo[1,2-a]pyridine (0.3 g, 0.67 mmol) and methyl N-[5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2-pyridyl]carbamate ( 0.280 g, 1.00 mmol, 1.50 eq.) was dissolved in acetonitrile (5.37 mL). Sodium carbonate (0.213 g, 2.02 mmol, 3.00 eq.) dissolved in water (2.68 mL) was added. The resulting reaction mixture was purged with nitrogen for 15 mins. Chloro(2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)[2-(2'- amino-1,1'-biphenyl)]palladium(II) (0.054 g, 0.067 mmol, 0.10 eq.) was added. The reaction mixture was irradiated with microwave radiation for 1 hour at 100 °C. The reaction mixture was filtered through celite and the filtrate was concentrated. The residue was purified on neutral alumina (eluting in 5-10% methanol/ethyl acetate) to afford an off white solid, which was further washed with tert-butyl methyl ether to afford methyl N-[5-[6-[1-(4-fluoro-3-methoxy-phenyl)imidazol-2-yl]-8-methyl-imidazo[1,2-a]pyridin-3- yl]-2-pyridyl]carbamate as an off white solid. LC/MS (method A) retention time = 0.94 min; [M+H] += 473 1H NMR (400 MHz, DMSO-d6, ppm) δ = 10.38 (s, 1H), 8.33 (d, J = 2.2 Hz, 1H), 7.93 (d, J = 8.6 Hz, 1H), 7.86 (s, 1H), 7.72 (s, 1H), 7.55 (dd, J = 8.6, 2.4 Hz, 1H), 7.50 (s, 1H), 7.40 (s, 1H), 7.32 (dd, J = 7.6, 2.4 Hz, 1H), 7.24 (dd, J = 11.0, 8.6 Hz, 1H), 7.20 (s, 1H), 6.88 (dt, J = 8.4, 3.2 Hz, 1H), 3.77 (s, 3H), 3.74 (s, 3H), 2.5 (s, 3H). Example 10: Preparation of methyl N-[5-[6-[4-(4-fluoro-3-methoxy-phenyl)-5,6-dihydro-1,2,4- oxadiazin-3-yl]-8-methyl-imidazo[1,2-a]pyridin-3-yl]-2-pyridyl]carbamate (compound X.03) (Compound X.03) Step 1: Preparation of 8-methylimidazo[1,2-a]pyridine-6-carbonitrile To a solution of 6-iodo-8-methyl-imidazo[1,2-a]pyridine (Intermediate I-4, 17.0 g, 59.3 mmol), zinc cyanide (13.9 g, 119 mmol, 2 eq.) and 1,1'-bis(diphenylphosphino)ferrocene (3.29 g, 5.93 mmol, 0.10 eq.) in dimethylformamide (300 mL) was added Pd2(dba)3 (2.71 g, 2.96 mmol, 0.05 eq.) under nitrogen at room temperature. The reaction mixture was stirred at 120 °C for 3 hours under nitrogen. After being cooled to room temperature, the reaction mixture was diluted with water and the mixture was filtered through celite. The filtrate was extracted with ethyl acetate, the combined organic layers were washed with water and brine, dried with sodium sulfate, and concentrated under vacuum. The residue was purified by silica gel column chromatography (eluting with dichloromethane/MeOH, 2% to 5%) to provide 8-methylimidazo[1,2-a]pyridine-6-carbonitrile as a brown solid. LC/MS (method A) retention time = 0.374 min; [M+H] += 158 Step 2: Preparation of 3-bromo-8-methyl-imidazo[1,2-a]pyridine-6-carbonitrile To a solution of methyl 8-methylimidazo[1,2-a]pyridine-6-carbonitrile (5.00 g, 31.8 mmol) in dimethylformamide (40 mL) was added 1-bromopyrrolidine-2,5-dione (5.95 g, 33.4 mmol, 1.05 eq.) by portions at room temperature. The mixture was stirred at room temperature for 2 hours then diluted with water (200 mL). The precipitate was collected by filtration, washed with water and dried under vacuum to afford 3-bromo-8-methyl-imidazo[1,2-a]pyridine-6-carbonitrile as a brown solid. LC/MS (method A) retention time = 1.084 min; [M+H] += 238 Step 3: Preparation of ethyl 3-bromo-8-methyl-imidazo[1,2-a]pyridine-6-carboximidate (Intermediate I- 5) (Intermediate I-5) To a solution of 3-bromo-8-methyl-imidazo[1,2-a]pyridine-6-carbonitrile (2.00 g, 8.47 mmol) in ethanol/dichloromethane (1:2, 50.0 mL) was added ethanethiolate (0.356 g, 4.24 mmol, 0.50 eq.). The mixture was stirred at 25 °C for 10 hours. Then the reaction mixture was concentrated and purified by silica gel column (dichloromethane/MeOH) to afford ethyl 3-bromo-8-methyl-imidazo[1,2-a]pyridine-6- carboximidate an off-white solid. LCMS (method A) retention time = 0.818; [M+H] += 284.0 Step 4: Preparation of 2-chloro-N-(4-fluoro-3-methoxy-phenyl)acetamide To a suspension of 4-fluoro-3-methoxy-aniline (10.0 g, 70.9 mmol) and potassium carbonate (10.8 g, 77.9 mmol, 1.10 eq.) in dimethylformamide (50.0 mL) at 0 °C was added, dropwise, a solution of 2- chloroacetyl chloride (8.80 g, 77.9 mmol, 1.00 eq.) in dimethylformamide (5.00 mL). The reaction mixture was stirred at room temperature for 3 hours, then it was diluted with water and extracted with ethyl acetate. The combined organic layers were washed with water and brine, dried over sodium sulfate, filtered, and concentrated under reduced pressure. The crude residue was purified by flash chromatography over silical gel (petroleum ether/ethyl acetate) to afford 2-chloro-N-(4-fluoro-3-methoxy- phenyl)acetamide as a colorless oil. LC/MS (method B) retention time = 1.03 min; [M+H]+= 218.1 Step 5: Preparation of N-(2-chloroethyl)-4-fluoro-3-methoxy-aniline To a solution of 2-chloro-N-(4-fluoro-3-methoxy-phenyl)acetamide (10.0 g, 46.0 mmol) in THF (120 mL) at 0 °C was added, dropwise, BH3-THF (1.00 mol/L, 68.9 mL, 68.9 mmol, 1.50 eq.). The reaction mixture was warmed to room temperature and stirred for an additional 3 hours, after which it was poured into ice water and extracted with ethyl acetate. The combined organic layer was washed with brine, dried over sodium sulfate, filtered, and concentrated under reduced pressure. The crude residue was purified by flash chromatography over silica gel (petroleum ether/ethyl acetate) to afford N-(2-chloroethyl)-4- fluoro-3-methoxy-aniline as a colorless liquid. LC/MS (method B) retention time = 1.23 min; [M+H]+= 204.2 Step 6: Preparation of N-[2-(benzhydrylideneamino)oxyethyl]-4-fluoro-3-methoxy-aniline To a stirred suspension of diphenylmethanone oxime (CAS 574-66-3, 8.14 g, 41.2 mmol, 1.20 eq.) in DMSO (40.0 mL) at room temperature was added potassium hydroxide (9.64 g, 172 mmol, 5.00 eq.). The reaction mixture was stirred for 3 minutes, then a solution of N-(2-chloroethyl)-4-fluoro-3-methoxy- aniline (7.00 g, 34.4 mmol, 1.00 eq.) in DMSO (10.0 mL) was added dropwise. The reaction mixture was stirred at room temperature for 2 hours, then it was poured into ice water. The aqueous layer was extracted with dichloromethane, the combined organic layers were washed with water and brine, dried over sodium sulfate, filtered, and concentrated under reduced pressure. The crude residue was purified by flash chromatography over silica gel (petroleum ether/ethyl acetate) to afford N-[2- (benzhydrylideneamino)oxyethyl]-4-fluoro-3-methoxy-aniline as a viscous oil. LC/MS (method B) retention time = 1.63 min; [M+H]+= 365.2 Step 7: Preparation of O-[2-(4-fluoro-3-methoxy-anilino)ethyl]hydroxylamine A solution of N-[2-(benzhydrylideneamino)oxyethyl]-4-fluoro-3-methoxy-aniline (5.20 g, 15.6 mmol) in 6 M HCl (25.9 mL, 156 mmol) and dioxane (10.0 mL) was refluxed under nitrogen for 8 hours. The resulting mixture was extracted with dichloromethane. The aqueous solution was then adjusted to pH 9 with solid NaHCO3 and extracted with dichloromethane. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The crude residue was purified by flash chromatography over silica gel (petroleum ether/ethyl acetate) to afford O- [2-(4-fluoro-3-methoxy-anilino)ethyl]hydroxylamine as a light yellow liquid. LC/MS (method B) retention time = 0.66 min; [M+H]+= 201.1 Step 8: Preparation of 3-(3-bromo-8-methyl-imidazo[1,2-a]pyridin-6-yl)-4-(4-fluoro-3-methoxy-phenyl)- 5,6-dihydro-1,2,4-oxadiazine To a solution of ethyl 3-bromo-8-methyl-imidazo[1,2-a] pyridine-6-carboximidate (Intermediate I-5, 0.100 g, 0.354 mmol) in acetic acid (2.00 mL) was added O-[2-(4-fluoro-3-methoxy-anilino) ethyl] hydroxylamine (0.0710 g, 0.354 mmol, 1.0 eq.). The mixture was stirred at 90 °C for 16 hours. The reaction mixture was quenched with water and concentrated under reduced pressure. The residue was extracted with dichloromethane/MeOH (10:1). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated by reduced pressure. The residue was purified over silica gel (dichloromethane/methanol) to afford 3-(3-bromo-8-methyl-imidazo[1,2-a]pyridin- 6-yl)-4-(4-fluoro-3-methoxy-phenyl)-5,6-dihydro-1,2,4-oxadiazine as a brown solid. LC/MS (method A) retention time =1.491 min; [M+H] += 421 Step 9: Preparation of methyl N-[5-[6-[4-(4-fluoro-3-methoxy-phenyl)-5,6-dihydro-1,2,4-oxadiazin-3-yl]- 8-methyl-imidazo[1,2-a]pyridin-3-yl]-2-pyridyl]carbamate (Compound X.03) To a mixture of 3-(3-bromo-8-methyl-imidazo[1,2-a]pyridin-6-yl)-4-(4-fluoro-3-methoxy-phenyl)-5,6- dihydro-1,2,4-oxadiazine (0.0200 g, 0.0477 mmol) and methyl N-[5-(4,4,5,5-tetramethyl-1,3,2- dioxaborolan-2-yl)-2-pyridyl]carbamate (0.0172 g, 0.0620 mmol, 1.30 eq.) in dioxane/H2O (4:1) was added BrettPhosPdG3 (0.00432 g, 0.00477 mmol, 0.100 eq.) and K2CO3 (0.0198 g, 0.143 mmol, 3.00 eq.). The mixture was stirred at 45 °C for 2 hours under N2 atmosphere, then it was concentrated under reduced pressure and the residue was diluted with brine (10.0 mL) and extracted with dichloromethane/MeOH (10:1). The combined organic layers were concentrated under reduced pressure. The residue was purified by silica gel column chromatography (eluting with dichloromethane/MeOH) then further purified by trituration with acetonitrile to afford methyl N-[5-[6-[4- (4-fluoro-3-methoxy-phenyl)-5,6-dihydro-1,2,4-oxadiazin-3-yl]-8-methyl-imidazo[1,2-a]pyridin-3-yl]-2- pyridyl]carbamate as a white powder. LC/MS (method A) retention time =1.460 min; [M+H] + = 491 1H NMR (400 MHz, DMSO-d6, ppm) δ = 10.44 (s, 1H), 8.37 (d, J = 2.2 Hz, 1H), 8.22 (s, 1H), 7.99 (d, J = 8.6 Hz, 1H), 7.73 (s, 1H), 7.70 (dd, J = 8.6, 2.4 Hz, 1H), 7.11 - 7.00 (m, 3H), 6.63 - 6.57 (m, 1H), 4.14 (t, J = 4.4 Hz, 2H), 3.84 - 3.78 (m, 2H), 3.73 (s, 3H), 3.72 (s, 3H), 2.42 (s, 3H). Example 11: Preparation of methyl N-[5-[6-[4-(4-fluorophenyl)-5,6-dihydro-1,2,4-oxadiazin-3-yl]- 8-methyl-imidazo[1,2-a]pyridin-3-yl]-2-pyridyl]carbamate (Compound X.04) (Compound X.04) Step 1: Preparation of N-(2-chloroethyl)-4-fluoro-aniline To a solution of 4-fluoroaniline (2.00 g, 18.0 mmol) in a mixture of methanol (30 mL) and acetic acid (1.03 mL, 18.0 mmol, 1.00 eq.) at room temperature was added portionwise sodium cyanoborohydride (1.79 g, 27.0 mmol, 1.50 eq.) followed by 2-chloroacetaldehyde (2.59 mL, 21.6 mmol, 1.20 eq.). The reaction mixture was stirred at room temperature for 12 hours. The reaction was quenched with ice water and then extracted using ethyl acetate. The combined organic layers were washed with brine, dried over sodium sulfate, filtered and concentrated under reduced pressure. The crude residue was purified by flash chromatography over neutral alumina (eluting cyclohexane/ethyl acetate, 9:1) to afford N-(2-chloroethyl)-4-fluoro-aniline as a brown oil. LC/MS (method B) retention time = 1.11 min; [M+H]+= 174.1 Step 2: Preparation of N-[2-(benzhydrylideneamino)oxyethyl]-4-fluoro-aniline To a stirred suspension of diphenylmethanone oxime (CAS 574-66-3, 0.855 g, 4.33 mmol) in DMSO (13.0 mL) at room temperature was added sodium hydroxide (0.347 g, 8.67 mmol, 2.00 eq.). Then a solution of N-(2-chloroethyl)-4-fluoro-aniline (0.828 g, 4.77 mmol, 1.10 eq.) in DMSO (2.0 mL) was added dropwise. The reaction mixture was stirred at room temperature for 12 hours, then it was poured into ice water. The aqueous layer was extracted with ethyl acetate, the combined organic layers were washed with water and brine, dried over sodium sulfate, filtered, and concentrated under reduced pressure. The crude residue was purified by flash chromatography on neutral alumina (cyclohexane/ethyl acetate) to afford N-[2-(benzhydrylideneamino)oxyethyl]-4-fluoro-aniline. 1H NMR (400 MHz, CDCl3, ppm) δ = 7.43 - 7.52 (m, 5 H), 7.31 - 7.42 (m, 5 H), 6.89 (br t, J = 8.76 Hz, 2 H), 6.51 - 6.57 (m, 2 H), 4.36 - 4.43 (m, 2 H), 3.39 - 3.44 (m, 2 H). Step 3: Preparation of O-[2-(4-fluoroanilino)ethyl]hydroxylamine N-[2-(benzhydrylideneamino)oxyethyl]-4-fluoro-aniline (3.80 g, 11.4 mmol) in 6 M HCl (80.0 mL) was refluxed under nitrogen for 12 hours. Saturated aqueous NaHCO3 was added. The aqueous layer was extracted with dichloromethane. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The crude residue was purified by flash chromatography on silica gel (petroleum ether/ethyl acetate) to afford O-[2-(4- fluoroanilino)ethyl]hydroxylamine as a viscous oil. LC/MS (method A) retention time = 1.07 min; [M+H]+= 171.2 Step 4: Preparation of 3-(3-bromo-8-methyl-imidazo[1,2-a]pyridin-6-yl)-4-(4-fluorophenyl)-5,6-dihydro- 1,2,4-oxadiazine O-[2-(4-fluoroanilino)ethyl]hydroxylamine (0.633 g, 3.72 mmol, 1.05 eq.) was added to solution of ethyl 3-bromo-8-methyl-imidazo[1,2-a]pyridine-6-carboximidate (Intermediate I-5, 1.00 g, 3.54 mmol) in acetic acid (20.0 mL). The solution was stirred at room temperature for 4 hours, then at 95 °C for 5 hours. The reaction mixture was cooled down to room temperature, and water was added. The mixture was concentrated under reduced pressure. The residue was taken up in dichloromethane, then washed with brine, dried over sodium sulfate and concentrated. The residue was purified by flash chromatography over silica gel (eluting dichloromethane/MeOH) to afford 3-(3-bromo-8-methyl-imidazo[1,2-a]pyridin-6- yl)-4-(4-fluorophenyl)-5,6-dihydro-1,2,4-oxadiazine as a brown solid. LC/MS (method A) retention time = 1.13 min; [M+H]+= 389.1 Step 5: Preparation of methyl N-[5-[6-[4-(4-fluorophenyl)-5,6-dihydro-1,2,4-oxadiazin-3-yl]-8-methyl- imidazo[1,2-a]pyridin-3-yl]-2-pyridyl]carbamate (Compound X.04) To a mixture of 3-(3-bromo-8-methyl-imidazo[1,2-a]pyridin-6-yl)-4-(4-fluorophenyl)-5,6-dihydro-1,2,4- oxadiazine (0.500 g, 1.28 mmol) and methyl N-[5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2- pyridyl]carbamate (0.536 g, 1.93 mmol, 1.50 eq.) in dioxane/H2O (5:1, 18.00 mL) was added Pd(dppf)Cl2 (0.094 g, 0.128 mmol, 0.100 eq.) and potassium carbonate (0.444 g, 3.21 mmol, 3.00 eq.). The mixture was stirred at 45 °C for 1 hour under N2 atmosphere. Water was added to the reaction mixture which was concentrated under reduced pressure. The residue was extracted with dichloromethane/MeOH (10:1). The combined organic layers were washed with brine, dried over sodium sulfate, filtered and concentrated under. Purification over silica gel (dichloromethane/methanol) followed by trituration with acetonitrile afforded methyl N-[5-[6-[4-(4-fluorophenyl)-5,6-dihydro-1,2,4-oxadiazin-3-yl]-8-methyl- imidazo[1,2-a]pyridin-3-yl]-2-pyridyl]carbamate as a grey solid. LC/MS (method A) retention time = 0.92 min; [M+H]+ = 461.2 1H NMR (400 MHz, DMSO-d6, ppm) δ = 10.46 (s, 1 H), 8.38 (d, J = 2.4 Hz, 1 H), 8.22 (d, J = 1.5 Hz, 1 H), 8.00 (d, J = 8.7 Hz, 1 H), 7.75 (d, J = 8.7 Hz, 2 H), 7.25 - 7.15 (m, 2 H), 7.10 (d, J = 8.7 Hz, 2 H), 7.01 (s, 1 H), 4.14 (t, J = 4.4 Hz, 2 H), 3.80 (d, J = 4.4 Hz, 2 H), 3.73 (s, 3 H), 2.39 (s, 3 H). Analytical Methods Method A: Equipment: Shimadzu LCMS 2020 Mass Spectrometer; Column: HALO C182.7 µm, 3.0 mm × 30 mm; Mobile Phase: MeCN (with either 0.05% HCOOH or 0.05% TFA) - Water (with either 0.05% HCOOH or 0.05% TFA); Gradient: MeCN from 5% to 95% over 1.4 min, hold 0.6 min, total run time is 2.5 min; Flow rate: 1.8 mL/min; Column temperature: 50 °C; Wavelength: 214 and 254 nm PDA. Method B: Spectra were recorded on a Mass Spectrometer from Waters (Acquity QDa Mass Spectrometer) equipped with an electrospray source (Polarity: Positive and Negative Polarity Switch), Capillary: 0.8 kV, Cone range: 25 V, Extractor: V (No extractor voltage for QDa detector) Source Temperature: 120°C, Desolvation Temperature: 600°C, Cone Gas Flow: 50 L/h, Desolvation Gas Flow: 1000 L/h, Mass range: 110 to 850 Da) and an Acquity UPLC from Waters: Quaternary solvent manager, heated column compartment , diode-array detector. Column: Acquity UPLC HSS T3 C18, 1.8 µm, 30 x 2.1 mm, Temp: 40 °C, DAD Wavelength range (nm): 200 to 400, Solvent Gradient: A = water + 5% Acetonitrile + 0.1 % HCOOH, B= Acetonitrile + 0.05 % HCOOH: gradient: 0 min 10% B; 0.-0.2 min 10-50% B; 0.2-0.6 min 50-100% B; 0.6-1.3 min 100% B; 1.3-1.4 min 100-10% B; 1.4-1.6 min 10% B; Flow (mL/min) 0.6. Method C: Spectra were recorded on a Mass Spectrometer from Waters Corporation (SQD, SQDII or QDA Single quadrupole mass spectrometer) equipped with an electrospray source (Polarity: positive and negative ions), Capillary: 0.8-3.00 kV, Cone: 5-30 V, Source Temperature: 120-150°C, Desolvation Temperature: 350-600°C, Cone Gas Flow: 50-150 l/h, Desolvation Gas Flow: 650-1000 l/h, Mass range: 110 to 950 Da and an Acquity UPLC from Waters Corporation: Binary pump, heated column compartment, diode- array detector and ELSD. Column: Waters UPLC HSS T3, 1.8 µm, 30 x 2.1 mm, Temp: 60 °C, DAD Wavelength range (nm): 210 to 400, Runtime: 1.5 min; Solvents: A = water + 5% MeOH + 0.05 % HCOOH, B= Acetonitrile + 0.05 % HCOOH; Flow (mL/min) 0.85, Gradient: 10% B isocratic for 0.2 min, then 10-100% B in 1.0 min, 100% B isocratic for 0.2min, 100-10% B in 0.05min, 10% B isocratic for 0.05 min Method D: Spectra were recorded on a ACQUITY Mass Spectrometer from Waters Corporations (SQD or SQDII Single quadrupole mass spectrometer) equipped with an electrospray source (Polarity: positive or negative ions, Capillary: 3.0 kV, Cone: 30V, Extractor: 3.00 V, Source Temperature: 150°C, Desolvation Temperature: 400°C, Cone Gas Flow: 60 L/hr, Desolvation Gas Flow: 700 L/hr, Mass range: 140 to 800 Da) and an ACQUITY UPLC from Waters Corporations with solvent degasser, binary pump, heated column compartment and diode-array detector. Column: Waters UPLC HSS T3, 1.8 µm, 30 x 2.1 mm, Temp: 60 °C, DAD Wavelength range (nm): 210 to 400, Solvent Gradient: A = Water/Methanol 9:1 + 0.1% formic acid, B= Acetonitrile + 0.1% formic acid, gradient: 0-100% B in 2.5 min; Flow (mL/min) 0.75. Method E: Spectra were recorded on a Mass Spectrometer from Agilent (Single quad mass spectrometer) equipped with a Multimode- Electron Spray and APCI (Polarity: positive and negative ions), Capillary: 4.00 kV, Corona Current 4.0 µA, Charging Voltage: 2.00 kV, Nitrogen Gas Flow: 12.0 L/min, Nebulizer Pressure: 40 psig, Mass range: 100 to 1000 m/z), dry gas temperature 250 °C, Vaporizer temperature 200 °C and an UPLC from Waters: quaternary pump, heated column compartment, Variable wave length detector. Column: X-Bridge BEH C18, 2.5 µm (2.1*50 mm), column Temp: Ambient, Wavelength (nm): 215 nm, Gradient: A = 0.05% TFA in water, B = 0.05% TFA in Acetonitrile. Gradient: time/%B: 0/5, 1/5, 5/70, 7/95, 8.5/95, 8.6/5, 10/5; Flow rate: 0.6 mL/min. Method F: Spectra were recorded on a on a Mass Spectrometer from Agilent (Single quad mass spectrometer) equipped with Electron Spray (Polarity: positive and negative ions), Capillary: 4.00 kV, Charging Voltage: 2.00 kV, Nitrogen Gas Flow: 12.0 L/min, Nebulizer Pressure: 40 psig, Mass range: 100 to 1000 m/z, dry gas temperature 250 °C, Vaporizer temperature 200 °C and an UPLC from Waters: quaternary pump, heated column compartment, Variable wave length detector. Column: Kinetex Evo_50 mm, 1.7 µm (2.1*50 mm) column, Temp: Ambient, Wavelength (nm): 200-400 nm, Gradient: A = acetonitrile, B = 10 mM ammonium formate in water. Gradient time/%A: 0/2, 0.2/2, 1.5/45, 2.4/95, 3.3/2, 3.5/2; Flow rate: 0.5 mL/min. The below Table A gathers for compounds of formula (I): - LC/MS data, such as retention time (RT), [M+H]+, - the type of methods, and/or - melting point (MP). Table T1: Entry Compound name Molecule RT [M+H] Method MP (min) (measured) (°C) X.01 methyl N-[5-[8-cyclopropyl-6- 0.90 500 A 226- [4-(4-fluoro-3-methoxy- 228 phenyl)-1,2,4-triazol-3- yl]imidazo[1,2-a]pyridin-3-yl]- 2-pyridyl]carbamate X.02 methyl N-[5-[6-[1-(4-fluoro-3- 0.93 473 A 198- methoxy-phenyl)imidazol-2- 200 yl]-8-methyl-imidazo[1,2- a]pyridin-3-yl]-2- pyridyl]carbamate X.03 methyl N-[5-[6-[4-(4-fluoro-3- 0.93 491 A 157- methoxy-phenyl)-5,6-dihydro- 161 1,2,4-oxadiazin-3-yl]-8- methyl-imidazo[1,2-a]pyridin- 3-yl]-2-pyridyl]carbamate Entry Compound name Molecule RT [M+H] Method MP (min) (measured) (°C) X.04 methyl N-[5-[6-[4-(4- 0.92 461 A 236- fluorophenyl)-5,6-dihydro- 239 1,2,4-oxadiazin-3-yl]-8- methyl-imidazo[1,2-a]pyridin- 3-yl]-2-pyridyl]carbamate X.05 methyl N-[5-[6-[5-(4-fluoro-3- 0.90 473 A 192 methoxy-phenyl)-1-methyl- – pyrazol-4-yl]imidazo[1,2- 195 a]pyridin-3-yl]-2- pyridyl]carbamate X.06 methyl N-[5-[6-[4-(4-fluoro-3- 0.95 477 A 206- methoxy-phenyl)-5,6-dihydro- 207 1,2,4-oxadiazin-3- yl]imidazo[1,2-a]pyridin-3-yl]- 2-pyridyl]carbamate X.07 methyl N-[5-[6-[2-(4-fluoro-3- 1.59 474 F 245- methoxy-phenyl)-1,2,4-triazol- 250 3-yl]-8-methyl-imidazo[1,2- a]pyridin-3-yl]-2- pyridyl]carbamate X.08 methyl N-[5-[6-[4-(4-fluoro-3- 0.65 474 C methoxy-phenyl)-5-methyl- 1,2,4-triazol-3-yl]imidazo[1,2- a]pyridin-3-yl]-2- pyridyl]carbamate X.09 methyl N-[5-[6-[1-(4-fluoro-3- 0.67 459 C 190- methoxy-phenyl)imidazol-2- 213 yl]imidazo[1,2-a]pyridin-3-yl]- 2-pyridyl]carbamate X.10 methyl N-[5-[6-[2-(4-chloro-3- 0.73 476 C 220- methoxy-phenyl)-1,2,4-triazol- 222 3-yl]imidazo[1,2-a]pyridin-3- yl]-2-pyridyl]carbamate X.11 methyl N-[5-[6-[2-(4-fluoro-3- 0.71 460 C 123- methoxy-phenyl)-1,2,4-triazol- 133 3-yl]imidazo[1,2-a]pyridin-3- yl]-2-pyridyl]carbamate Entry Compound name Molecule RT [M+H] Method MP (min) (measured) (°C) X.12 methyl N-[5-[6-[4-(4-fluoro-3- 1.00 518 B 215- methoxy-phenyl)-5- 217 (methoxymethyl)-1,2,4-triazol- 3-yl]-8-methyl-imidazo[1,2- a]pyridin-3-yl]-2- pyridyl]carbamate BIOLOGICAL EXAMPLES: General examples of leaf disk tests in well plates: Leaf disks or leaf segments of various plant species are cut from plants grown in a greenhouse. The cut leaf disks or segments are placed in multiwell plates (24-well format) onto water agar. The leaf disks are sprayed with a test solution before (preventative) or after (curative) inoculation. Compounds to be tested are prepared as DMSO solutions (max.10 mg/ml) which are diluted to the appropriate concentration with 0.025% Tween20 just before spraying. The inoculated leaf disks or segments are incubated under defined conditions (temperature, relative humidity, light, etc.) according to the respective test system. A single evaluation of disease level is carried out 3 to 14 days after inoculation, depending on the pathosystem. Percent disease control relative to the untreated check leaf disks or segments is then calculated. General examples of liquid culture tests in well plates: Mycelia fragments or conidia suspensions of a fungus prepared either freshly from liquid cultures of the fungus or from cryogenic storage, are directly mixed into nutrient broth. DMSO solutions of the test compound (max.10 mg/ml) are diluted with 0.025% Tween20 by a factor of 50 and 10 µl of this solution is pipetted into a microtiter plate (96-well format). The nutrient broth containing the fungal spores/mycelia fragments is then added to give an end concentration of the tested compound. The test plates are incubated in the dark at 24°C and 96% relative humidity. The inhibition of fungal growth is determined photometrically after 2 to 7 days, depending on the pathosystem, and percent antifungal activity relative to the untreated check is calculated. Example A1: Activity against Phytophthora infestans / tomato / leaf disc preventative (late blight) Tomato leaf disks are placed on water agar in multiwell plates (24-well format) and sprayed with the formulated test compound diluted in water. The leaf disks are inoculated with a spore suspension of the fungus 1 day after application. The inoculated leaf disks are incubated at 16 °C and 75% rh under a light regime of 24 h darkness followed by 12 h light / 12 h darkness in a climate cabinet and the activity of a compound is assessed as percent disease control compared to untreated when an appropriate level of disease damage appears in untreated check leaf disks (5 - 7 days after application). The following compounds (from Table T1) gave at least 80% control of Phytophthora infestans at 200 ppm when compared to untreated control under the same conditions, which showed extensive disease development: X.01, X.02, X.03, X.04, X.05, X.06, X.07, X.08, X.09, X.10, X.11 and X.12. Example A2: Activity against Plasmopara viticola / grape / leaf disc preventative (late blight) Grape vine leaf disks are placed on water agar in multiwell plates (24-well format) and sprayed with the formulated test compound diluted in water. The leaf disks are inoculated with a spore suspension of the fungus 1 day after application. The inoculated leaf disks are incubated at 19 °C and 80% rh under a light regime of 12 h light / 12 h darkness in a climate cabinet and the activity of a compound is assessed as percent disease control compared to untreated when an appropriate level of disease damage appears in untreated check leaf disks (6 - 8 days after application). The following compounds (from Table T1) gave at least 80% control of Plasmopara viticola at 200 ppm when compared to untreated control under the same conditions, which showed extensive disease development: X.01, X.02, X.03, X.04, X.05, X.06, X.07, X.08, X.09, X.10, X.11 and X.12. Example A3: Activity against Pythium ultimum / liquid culture (seedling damping off) Mycelia fragments and oospores of a newly grown liquid culture of the fungus are directly mixed into nutrient broth (PDB potato dextrose broth). After placing a (DMSO) solution of test compound into a microtiter plate (96-well format), the nutrient broth containing the fungal mycelia/spore mixture is added. The test plates are incubated at 24 °C and the inhibition of growth is determined photometrically 2-3 days after application. The following compounds (from Table T1) gave at least 80% control of Pythium ultimum at 20 ppm when compared to untreated control under the same conditions, which showed extensive disease development: X.01, X.02, X.03, X.04, X.05, X.06, X.07, X.08, X.09, X.10, X.11 and X.12. In the below examples, the source and fermentation of Streptomyces chrestomyceticus CBS149411 (used as Component B) are as follows: - Fermentation of Streptomyces sp.: Streptomyces sp. Saigon413, isolated in Vietnam before 1961, was deposited at the Westerdijk institute under accession number CBS149411. The deposit was made by Syngenta Ltd., Jealott’s Hill Research International Centre, Bracknell, Berkshire, RG426EY, UK under the terms of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure. The Streptomyces was cultivated in Erlenmeyer flasks with a liquid medium consisting of (g / l) casein hydrolysate 10, glucose 40, K2HPO41.25, soytone 2, tryptone, 8 and incubated at 28ºC in an incubator shaking 150 rpm with 25 mm throw for 4 days. - Large scale fermentations: For large scale production, standard procedures were applied for cultivating Streptomyces chrestomyceticus CBS149411 to high cell density using fed-batch fermentation. After harvesting, the broth was spray dried or freeze dried according to methods known to a person skilled in the art. The final product (TGAI) after spray- or freeze drying had a cell count of 1*105 to 1*1013 CFU/g dry mass. TGAI: technical grade active ingredient (unformulated product). Example B1: Activity against Pythium ultimum (Damping off) Mycelial fragments of the pathogen, prepared from a fresh liquid culture, were directly mixed into nutrient broth (PDB potato dextrose broth). After placing a (DMSO) solution of the test compounds into a microtiter plate (96-well format) the nutrient broth containing the fungal spores was added. The test plates were incubated at 24 C and the inhibition of growth was determined photometrically after 48 hrs. The following mixture compositions (A:B) at the reported concentration (in ppm) gave at least 80% disease control in this test. Component A Conc. (ppm) Component B Ratio A:B (Compound) (A : B) X.07 oxathiapiprolin 3.3:1 20:6 X.07 oxathiapiprolin 33.3:1 20:0.6 X.07 oxathiapiprolin 1:3 2:6 X.07 oxathiapiprolin 3.3:1 2:0.6 X.07 fluoxapiprolin 3.3:1 20:6 X.07 fluoxapiprolin 33.3:1 20:0.6 X.07 fluoxapiprolin 1:3 2:6 X.07 fluoxapiprolin 3.3:1 2:0.6 X.07 metalaxyl-M 3.3:1 20:6 X.07 metalaxyl-M 33.3:1 20:0.6 X.07 metalaxyl-M 1:3 2:6 X.07 metalaxyl-M 3.3:1 2:0.6 X.07 picarbutrazox 3.3:1 20:6 X.07 picarbutrazox 33.3:1 20:0.6 X.07 picarbutrazox 1:3 2:6 X.07 picarbutrazox 3.3:1 2:0.6 X.07 azoxystrobin 3.3:1 20:6 X.07 azoxystrobin 33.3:1 20:0.6 X.07 azoxystrobin 1:3 2:6 X.07 azoxystrobin 3.3:1 2:0.6 X.07 cymoxanil 3.3:1 20:6 X.07 cymoxanil 33.3:1 20:0.6 X.07 cymoxanil 1:3 2:6 X.07 cymoxanil 3.3:1 2:0.6 X.07 mandipropamid 3.3:1 20:6 X.07 mandipropamid 33.3:1 20:0.6 X.07 mandipropamid 1:3 2:6 X.07 mandipropamid 3.3:1 2:0.6 X.07 fluazinam 3.3:1 20:6 X.07 fluazinam 33.3:1 20:0.6 X.07 fluazinam 1:3 2:6 X.07 fluazinam 3.3:1 2:0.6 X.07 fludioxonil 3.3:1 20:6 X.07 fludioxonil 33.3:1 20:0.6 X.07 fludioxonil 1:3 2:6 X.07 fludioxonil 3.3:1 2:0.6 X.07 fluopicolide 3.3:1 20:6 X.07 fluopicolide 33.3:1 20:0.6 X.07 fluopicolide 1:3 2:6 X.07 fluopicolide 3.3:1 2:0.6 X.07 zoxamide 3.3:1 20:6 X.07 zoxamide 33.3:1 20:0.6 X.07 zoxamide 1:3 2:6 X.07 zoxamide 3.3:1 2:0.6 X.07 sedaxane 3.3:1 20:6 X.07 sedaxane 33.3:1 20:0.6 X.07 sedaxane 1:3 2:6 X.07 sedaxane 3.3:1 2:0.6 X.07 disodium phosphonate 3.3:1 20:6 X.07 disodium phosphonate 33.3:1 20:0.6 X.07 disodium phosphonate 1:3 2:6 X.07 disodium phosphonate 3.3:1 2:0.6 X.07 difenoconazole 3.3:1 20:6 X.07 difenoconazole 33.3:1 20:0.6 X.07 difenoconazole 1:3 2:6 X.07 difenoconazole 3.3:1 2:0.6 X.07 mefentrifluconazole 3.3:1 20:6 X.07 mefentrifluconazole 33.3:1 20:0.6 X.07 mefentrifluconazole 1:3 2:6 X.07 mefentrifluconazole 3.3:1 2:0.6 X.07 folpet 3.3:1 20:6 X.07 folpet 33.3:1 20:0.6 X.07 folpet 1:3 2:6 X.07 folpet 3.3:1 2:0.6 X.07 cyclobutrifluram 3.3:1 20:6 X.07 cyclobutrifluram 33.3:1 20:0.6 X.07 cyclobutrifluram 1:3 2:6 X.07 cyclobutrifluram 3.3:1 2:0.6 X.07 florylpicoxamid 3.3:1 20:6 X.07 florylpicoxamid 33.3:1 20:0.6 X.07 florylpicoxamid 1:3 2:6 X.07 florylpicoxamid 3.3:1 2:0.6 X.07 Streptomyces 3.3:1 20:6 chrestomyceticus CBS149411 X.07 Streptomyces 33.3:1 20:0.6 chrestomyceticus CBS149411 X.07 Streptomyces 1:3 2:6 chrestomyceticus CBS149411 X.07 Streptomyces 3.3:1 2:0.6 chrestomyceticus CBS149411 X.07 Compound Z 3.3:1 20:6 X.07 Compound Z 33.3:1 20:0.6 X.07 Compound Z 1:3 2:6 X.07 Compound Z 3.3:1 2:0.6 X.07 pydiflumetofen 3.3:1 20:6 X.07 pydiflumetofen 33.3:1 20:0.6 X.07 pydiflumetofen 1:3 2:6 X.07 pydiflumetofen 3.3:1 2:0.6 Component A Conc. (ppm) Component B Ratio A:B (Compound) (A : B) X.11 oxathiapiprolin 3.3:1 20:6 X.11 oxathiapiprolin 33.3:1 20:0.6 X.11 oxathiapiprolin 1:3 2:6 X.11 oxathiapiprolin 3.3:1 2:0.6 X.11 fluoxapiprolin 3.3:1 20:6 X.11 fluoxapiprolin 33.3:1 20:0.6 X.11 fluoxapiprolin 1:3 2:6 X.11 fluoxapiprolin 3.3:1 2:0.6 X.11 metalaxyl-M 3.3:1 20:6 X.11 metalaxyl-M 33.3:1 20:0.6 X.11 metalaxyl-M 1:3 2:6 X.11 metalaxyl-M 3.3:1 2:0.6 X.11 picarbutrazox 3.3:1 20:6 X.11 picarbutrazox 33.3:1 20:0.6 X.11 picarbutrazox 1:3 2:6 X.11 picarbutrazox 3.3:1 2:0.6 X.11 azoxystrobin 3.3:1 20:6 X.11 azoxystrobin 33.3:1 20:0.6 X.11 azoxystrobin 1:3 2:6 X.11 azoxystrobin 3.3:1 2:0.6 X.11 cymoxanil 3.3:1 20:6 X.11 cymoxanil 33.3:1 20:0.6 X.11 cymoxanil 1:3 2:6 X.11 cymoxanil 3.3:1 2:0.6 X.11 mandipropamid 3.3:1 20:6 X.11 mandipropamid 33.3:1 20:0.6 X.11 mandipropamid 1:3 2:6 X.11 mandipropamid 3.3:1 2:0.6 X.11 fluazinam 3.3:1 20:6 X.11 fluazinam 33.3:1 20:0.6 X.11 fluazinam 1:3 2:6 X.11 fluazinam 3.3:1 2:0.6 X.11 fludioxonil 3.3:1 20:6 X.11 fludioxonil 33.3:1 20:0.6 X.11 fludioxonil 1:3 2:6 X.11 fludioxonil 3.3:1 2:0.6 X.11 fluopicolide 3.3:1 20:6 X.11 fluopicolide 33.3:1 20:0.6 X.11 fluopicolide 1:3 2:6 X.11 fluopicolide 3.3:1 2:0.6 X.11 zoxamide 3.3:1 20:6 X.11 zoxamide 33.3:1 20:0.6 X.11 zoxamide 1:3 2:6 X.11 zoxamide 3.3:1 2:0.6 X.11 sedaxane 3.3:1 20:6 X.11 sedaxane 33.3:1 20:0.6 X.11 sedaxane 1:3 2:6 X.11 sedaxane 3.3:1 2:0.6 X.11 disodium phosphonate 3.3:1 20:6 X.11 disodium phosphonate 33.3:1 20:0.6 X.11 disodium phosphonate 1:3 2:6 X.11 disodium phosphonate 3.3:1 2:0.6 X.11 difenoconazole 3.3:1 20:6 X.11 difenoconazole 33.3:1 20:0.6 X.11 difenoconazole 1:3 2:6 X.11 difenoconazole 3.3:1 2:0.6 X.11 mefentrifluconazole 3.3:1 20:6 X.11 mefentrifluconazole 33.3:1 20:0.6 X.11 mefentrifluconazole 1:3 2:6 X.11 mefentrifluconazole 3.3:1 2:0.6 X.11 folpet 3.3:1 20:6 X.11 folpet 33.3:1 20:0.6 X.11 folpet 1:3 2:6 X.11 folpet 3.3:1 2:0.6 X.11 cyclobutrifluram 3.3:1 20:6 X.11 cyclobutrifluram 33.3:1 20:0.6 X.11 cyclobutrifluram 1:3 2:6 X.11 cyclobutrifluram 3.3:1 2:0.6 X.11 florylpicoxamid 3.3:1 20:6 X.11 florylpicoxamid 33.3:1 20:0.6 X.11 florylpicoxamid 1:3 2:6 X.11 florylpicoxamid 3.3:1 2:0.6 X.11 Streptomyces 3.3:1 20:6 chrestomyceticus CBS149411 X.11 Streptomyces 33.3:1 20:0.6 chrestomyceticus CBS149411 X.11 Streptomyces 1:3 2:6 chrestomyceticus CBS149411 X.11 Streptomyces 3.3:1 2:0.6 chrestomyceticus CBS149411 X.11 Compound Z 3.3:1 20:6 X.11 Compound Z 33.3:1 20:0.6 X.11 Compound Z 1:3 2:6 X.11 Compound Z 3.3:1 2:0.6 X.11 pydiflumetofen 3.3:1 20:6 X.11 pydiflumetofen 33.3:1 20:0.6 X.11 pydiflumetofen 1:3 2:6 X.11 pydiflumetofen 3.3:1 2:0.6 Component A Component B Ratio A:B Conc. (ppm) (Compound) (A : B) X.03 oxathiapiprolin 3.3:1 20:6 X.03 oxathiapiprolin 33.3:1 20:0.6 X.03 oxathiapiprolin 1:3 2:6 X.03 oxathiapiprolin 3.3:1 2:0.6 X.03 fluoxapiprolin 3.3:1 20:6 X.03 fluoxapiprolin 33.3:1 20:0.6 X.03 fluoxapiprolin 1:3 2:6 X.03 fluoxapiprolin 3.3:1 2:0.6 X.03 metalaxyl-M 3.3:1 20:6 X.03 metalaxyl-M 33.3:1 20:0.6 X.03 metalaxyl-M 1:3 2:6 X.03 metalaxyl-M 3.3:1 2:0.6 X.03 picarbutrazox 3.3:1 20:6 X.03 picarbutrazox 33.3:1 20:0.6 X.03 picarbutrazox 1:3 2:6 X.03 picarbutrazox 3.3:1 2:0.6 X.03 azoxystrobin 3.3:1 20:6 X.03 azoxystrobin 33.3:1 20:0.6 X.03 azoxystrobin 1:3 2:6 X.03 azoxystrobin 3.3:1 2:0.6 X.03 cymoxanil 3.3:1 20:6 X.03 cymoxanil 33.3:1 20:0.6 X.03 cymoxanil 1:3 2:6 X.03 cymoxanil 3.3:1 2:0.6 X.03 mandipropamid 3.3:1 20:6 X.03 mandipropamid 33.3:1 20:0.6 X.03 mandipropamid 1:3 2:6 X.03 mandipropamid 3.3:1 2:0.6 X.03 fluazinam 3.3:1 20:6 X.03 fluazinam 33.3:1 20:0.6 X.03 fluazinam 1:3 2:6 X.03 fluazinam 3.3:1 2:0.6 X.03 fludioxonil 3.3:1 20:6 X.03 fludioxonil 33.3:1 20:0.6 X.03 fludioxonil 1:3 2:6 X.03 fludioxonil 3.3:1 2:0.6 X.03 fluopicolide 3.3:1 20:6 X.03 fluopicolide 33.3:1 20:0.6 X.03 fluopicolide 1:3 2:6 X.03 fluopicolide 3.3:1 2:0.6 X.03 zoxamide 3.3:1 20:6 X.03 zoxamide 33.3:1 20:0.6 X.03 zoxamide 1:3 2:6 X.03 zoxamide 3.3:1 2:0.6 X.03 sedaxane 3.3:1 20:6 X.03 sedaxane 33.3:1 20:0.6 X.03 sedaxane 1:3 2:6 X.03 sedaxane 3.3:1 2:0.6 X.03 disodium phosphonate 3.3:1 20:6 X.03 disodium phosphonate 33.3:1 20:0.6 X.03 disodium phosphonate 1:3 2:6 X.03 disodium phosphonate 3.3:1 2:0.6 X.03 difenoconazole 3.3:1 20:6 X.03 difenoconazole 33.3:1 20:0.6 X.03 difenoconazole 1:3 2:6 X.03 difenoconazole 3.3:1 2:0.6 X.03 mefentrifluconazole 3.3:1 20:6 X.03 mefentrifluconazole 33.3:1 20:0.6 X.03 mefentrifluconazole 1:3 2:6 X.03 mefentrifluconazole 3.3:1 2:0.6 X.03 folpet 3.3:1 20:6 X.03 folpet 33.3:1 20:0.6 X.03 folpet 1:3 2:6 X.03 folpet 3.3:1 2:0.6 X.03 cyclobutrifluram 3.3:1 20:6 X.03 cyclobutrifluram 33.3:1 20:0.6 X.03 cyclobutrifluram 1:3 2:6 X.03 cyclobutrifluram 3.3:1 2:0.6 X.03 florylpicoxamid 3.3:1 20:6 X.03 florylpicoxamid 33.3:1 20:0.6 X.03 florylpicoxamid 1:3 2:6 X.03 florylpicoxamid 3.3:1 2:0.6 X.03 Streptomyces 3.3:1 20:6 chrestomyceticus CBS149411 X.03 Streptomyces 33.3:1 20:0.6 chrestomyceticus CBS149411 X.03 Streptomyces 1:3 2:6 chrestomyceticus CBS149411 X.03 Streptomyces 3.3:1 2:0.6 chrestomyceticus CBS149411 X.03 Compound Z 3.3:1 20:6 X.03 Compound Z 33.3:1 20:0.6 X.03 Compound Z 1:3 2:6 X.03 Compound Z 3.3:1 2:0.6 X.03 pydiflumetofen 3.3:1 20:6 X.03 pydiflumetofen 33.3:1 20:0.6 X.03 pydiflumetofen 1:3 2:6 X.03 pydiflumetofen 3.3:1 2:0.6 Example B2: Activity against Phytophthora infestans (late blight of potato/tomato) Sporangia of the pathogen from cryogenic storage were directly mixed into nutrient broth (pea medium). After placing a (DMSO) solution of the test compounds into a microtiter plate (96-well format) the nutrient broth containing the fungal spores was added. The test plates were incubated at 24 C and the inhibition of growth was determined photometrically after 5 days. The following mixture compositions (A:B) at the reported concentration (in ppm) gave at least 80% disease control in this test. Component A Conc. (ppm) Component B Ratio A:B (Compound) (A : B) X.07 oxathiapiprolin 3.3:1 20:6 X.07 oxathiapiprolin 33.3:1 20:0.6 X.07 oxathiapiprolin 1:3 2:6 X.07 oxathiapiprolin 3.3:1 2:0.6 X.07 fluoxapiprolin 3.3:1 20:6 X.07 fluoxapiprolin 33.3:1 20:0.6 X.07 fluoxapiprolin 1:3 2:6 X.07 fluoxapiprolin 3.3:1 2:0.6 X.07 metalaxyl-M 3.3:1 20:6 X.07 metalaxyl-M 33.3:1 20:0.6 X.07 metalaxyl-M 1:3 2:6 X.07 metalaxyl-M 3.3:1 2:0.6 X.07 picarbutrazox 3.3:1 20:6 X.07 picarbutrazox 33.3:1 20:0.6 X.07 picarbutrazox 1:3 2:6 X.07 picarbutrazox 3.3:1 2:0.6 X.07 azoxystrobin 3.3:1 20:6 X.07 azoxystrobin 33.3:1 20:0.6 X.07 azoxystrobin 1:3 2:6 X.07 azoxystrobin 3.3:1 2:0.6 X.07 cymoxanil 3.3:1 20:6 X.07 cymoxanil 33.3:1 20:0.6 X.07 cymoxanil 1:3 2:6 X.07 cymoxanil 3.3:1 2:0.6 X.07 mandipropamid 3.3:1 20:6 X.07 mandipropamid 33.3:1 20:0.6 X.07 mandipropamid 1:3 2:6 X.07 mandipropamid 3.3:1 2:0.6 X.07 fluazinam 3.3:1 20:6 X.07 fluazinam 33.3:1 20:0.6 X.07 fluazinam 1:3 2:6 X.07 fluazinam 3.3:1 2:0.6 X.07 fludioxonil 3.3:1 20:6 X.07 fludioxonil 33.3:1 20:0.6 X.07 fludioxonil 1:3 2:6 X.07 fludioxonil 3.3:1 2:0.6 X.07 fluopicolide 3.3:1 20:6 X.07 fluopicolide 33.3:1 20:0.6 X.07 fluopicolide 1:3 2:6 X.07 fluopicolide 3.3:1 2:0.6 X.07 zoxamide 3.3:1 20:6 X.07 zoxamide 33.3:1 20:0.6 X.07 zoxamide 1:3 2:6 X.07 zoxamide 3.3:1 2:0.6 X.07 sedaxane 3.3:1 20:6 X.07 sedaxane 33.3:1 20:0.6 X.07 sedaxane 1:3 2:6 X.07 sedaxane 3.3:1 2:0.6 X.07 disodium phosphonate 3.3:1 20:6 X.07 disodium phosphonate 33.3:1 20:0.6 X.07 disodium phosphonate 1:3 2:6 X.07 disodium phosphonate 3.3:1 2:0.6 X.07 difenoconazole 3.3:1 20:6 X.07 difenoconazole 33.3:1 20:0.6 X.07 difenoconazole 1:3 2:6 X.07 difenoconazole 3.3:1 2:0.6 X.07 mefentrifluconazole 3.3:1 20:6 X.07 mefentrifluconazole 33.3:1 20:0.6 X.07 mefentrifluconazole 1:3 2:6 X.07 mefentrifluconazole 3.3:1 2:0.6 X.07 folpet 3.3:1 20:6 X.07 folpet 33.3:1 20:0.6 X.07 folpet 1:3 2:6 X.07 folpet 3.3:1 2:0.6 X.07 cyclobutrifluram 3.3:1 20:6 X.07 cyclobutrifluram 33.3:1 20:0.6 X.07 cyclobutrifluram 1:3 2:6 X.07 cyclobutrifluram 3.3:1 2:0.6 X.07 florylpicoxamid 3.3:1 20:6 X.07 florylpicoxamid 33.3:1 20:0.6 X.07 florylpicoxamid 1:3 2:6 X.07 florylpicoxamid 3.3:1 2:0.6 X.07 Streptomyces 3.3:1 20:6 chrestomyceticus CBS149411 X.07 Streptomyces 33.3:1 20:0.6 chrestomyceticus CBS149411 X.07 Streptomyces 1:3 2:6 chrestomyceticus CBS149411 X.07 Streptomyces 3.3:1 2:0.6 chrestomyceticus CBS149411 X.07 Compound Z 3.3:1 20:6 X.07 Compound Z 33.3:1 20:0.6 X.07 Compound Z 1:3 2:6 X.07 Compound Z 3.3:1 2:0.6 X.07 pydiflumetofen 3.3:1 20:6 X.07 pydiflumetofen 33.3:1 20:0.6 X.07 pydiflumetofen 1:3 2:6 X.07 pydiflumetofen 3.3:1 2:0.6 Component A Conc. (ppm) Component B Ratio A:B (Compound) (A : B) X.11 oxathiapiprolin 3.3:1 20:6 X.11 oxathiapiprolin 33.3:1 20:0.6 X.11 oxathiapiprolin 1:3 2:6 X.11 oxathiapiprolin 3.3:1 2:0.6 X.11 fluoxapiprolin 3.3:1 20:6 X.11 fluoxapiprolin 33.3:1 20:0.6 X.11 fluoxapiprolin 1:3 2:6 X.11 fluoxapiprolin 3.3:1 2:0.6 X.11 metalaxyl-M 3.3:1 20:6 X.11 metalaxyl-M 33.3:1 20:0.6 X.11 metalaxyl-M 1:3 2:6 X.11 metalaxyl-M 3.3:1 2:0.6 X.11 picarbutrazox 3.3:1 20:6 X.11 picarbutrazox 33.3:1 20:0.6 X.11 picarbutrazox 1:3 2:6 X.11 picarbutrazox 3.3:1 2:0.6 X.11 azoxystrobin 3.3:1 20:6 X.11 azoxystrobin 33.3:1 20:0.6 X.11 azoxystrobin 1:3 2:6 X.11 azoxystrobin 3.3:1 2:0.6 X.11 cymoxanil 3.3:1 20:6 X.11 cymoxanil 33.3:1 20:0.6 X.11 cymoxanil 1:3 2:6 X.11 cymoxanil 3.3:1 2:0.6 X.11 mandipropamid 3.3:1 20:6 X.11 mandipropamid 33.3:1 20:0.6 X.11 mandipropamid 1:3 2:6 X.11 mandipropamid 3.3:1 2:0.6 X.11 fluazinam 3.3:1 20:6 X.11 fluazinam 33.3:1 20:0.6 X.11 fluazinam 1:3 2:6 X.11 fluazinam 3.3:1 2:0.6 X.11 fludioxonil 3.3:1 20:6 X.11 fludioxonil 33.3:1 20:0.6 X.11 fludioxonil 1:3 2:6 X.11 fludioxonil 3.3:1 2:0.6 X.11 fluopicolide 3.3:1 20:6 X.11 fluopicolide 33.3:1 20:0.6 X.11 fluopicolide 1:3 2:6 X.11 fluopicolide 3.3:1 2:0.6 X.11 zoxamide 3.3:1 20:6 X.11 zoxamide 33.3:1 20:0.6 X.11 zoxamide 1:3 2:6 X.11 zoxamide 3.3:1 2:0.6 X.11 sedaxane 3.3:1 20:6 X.11 sedaxane 33.3:1 20:0.6 X.11 sedaxane 1:3 2:6 X.11 sedaxane 3.3:1 2:0.6 X.11 disodium phosphonate 3.3:1 20:6 X.11 disodium phosphonate 33.3:1 20:0.6 X.11 disodium phosphonate 1:3 2:6 X.11 disodium phosphonate 3.3:1 2:0.6 X.11 difenoconazole 3.3:1 20:6 X.11 difenoconazole 33.3:1 20:0.6 X.11 difenoconazole 1:3 2:6 X.11 difenoconazole 3.3:1 2:0.6 X.11 mefentrifluconazole 3.3:1 20:6 X.11 mefentrifluconazole 33.3:1 20:0.6 X.11 mefentrifluconazole 1:3 2:6 X.11 mefentrifluconazole 3.3:1 2:0.6 X.11 folpet 3.3:1 20:6 X.11 folpet 33.3:1 20:0.6 X.11 folpet 1:3 2:6 X.11 folpet 3.3:1 2:0.6 X.11 cyclobutrifluram 3.3:1 20:6 X.11 cyclobutrifluram 33.3:1 20:0.6 X.11 cyclobutrifluram 1:3 2:6 X.11 cyclobutrifluram 3.3:1 2:0.6 X.11 florylpicoxamid 3.3:1 20:6 X.11 florylpicoxamid 33.3:1 20:0.6 X.11 florylpicoxamid 1:3 2:6 X.11 florylpicoxamid 3.3:1 2:0.6 X.11 Streptomyces 3.3:1 20:6 chrestomyceticus CBS149411 X.11 Streptomyces 33.3:1 20:0.6 chrestomyceticus CBS149411 X.11 Streptomyces 1:3 2:6 chrestomyceticus CBS149411 X.11 Streptomyces 3.3:1 2:0.6 chrestomyceticus CBS149411 X.11 Compound Z 3.3:1 20:6 X.11 Compound Z 33.3:1 20:0.6 X.11 Compound Z 1:3 2:6 X.11 Compound Z 3.3:1 2:0.6 X.11 pydiflumetofen 3.3:1 20:6 X.11 pydiflumetofen 33.3:1 20:0.6 X.11 pydiflumetofen 1:3 2:6 X.11 pydiflumetofen 3.3:1 2:0.6 Component A Conc. (ppm) Component B Ratio A:B (Compound) (A : B) X.03 oxathiapiprolin 3.3:1 20:6 X.03 oxathiapiprolin 33.3:1 20:0.6 X.03 oxathiapiprolin 1:3 2:6 X.03 oxathiapiprolin 3.3:1 2:0.6 X.03 fluoxapiprolin 3.3:1 20:6 X.03 fluoxapiprolin 33.3:1 20:0.6 X.03 fluoxapiprolin 1:3 2:6 X.03 fluoxapiprolin 3.3:1 2:0.6 X.03 metalaxyl-M 3.3:1 20:6 X.03 metalaxyl-M 33.3:1 20:0.6 X.03 metalaxyl-M 1:3 2:6 X.03 metalaxyl-M 3.3:1 2:0.6 X.03 picarbutrazox 3.3:1 20:6 X.03 picarbutrazox 33.3:1 20:0.6 X.03 picarbutrazox 1:3 2:6 X.03 picarbutrazox 3.3:1 2:0.6 X.03 azoxystrobin 3.3:1 20:6 X.03 azoxystrobin 33.3:1 20:0.6 X.03 azoxystrobin 1:3 2:6 X.03 azoxystrobin 3.3:1 2:0.6 X.03 cymoxanil 3.3:1 20:6 X.03 cymoxanil 33.3:1 20:0.6 X.03 cymoxanil 1:3 2:6 X.03 cymoxanil 3.3:1 2:0.6 X.03 mandipropamid 3.3:1 20:6 X.03 mandipropamid 33.3:1 20:0.6 X.03 mandipropamid 1:3 2:6 X.03 mandipropamid 3.3:1 2:0.6 X.03 fluazinam 3.3:1 20:6 X.03 fluazinam 33.3:1 20:0.6 X.03 fluazinam 1:3 2:6 X.03 fluazinam 3.3:1 2:0.6 X.03 fludioxonil 3.3:1 20:6 X.03 fludioxonil 33.3:1 20:0.6 X.03 fludioxonil 1:3 2:6 X.03 fludioxonil 3.3:1 2:0.6 X.03 fluopicolide 3.3:1 20:6 X.03 fluopicolide 33.3:1 20:0.6 X.03 fluopicolide 1:3 2:6 X.03 fluopicolide 3.3:1 2:0.6 X.03 zoxamide 3.3:1 20:6 X.03 zoxamide 33.3:1 20:0.6 X.03 zoxamide 1:3 2:6 X.03 zoxamide 3.3:1 2:0.6 X.03 sedaxane 3.3:1 20:6 X.03 sedaxane 33.3:1 20:0.6 X.03 sedaxane 1:3 2:6 X.03 sedaxane 3.3:1 2:0.6 X.03 disodium phosphonate 3.3:1 20:6 X.03 disodium phosphonate 33.3:1 20:0.6 X.03 disodium phosphonate 1:3 2:6 X.03 disodium phosphonate 3.3:1 2:0.6 X.03 difenoconazole 3.3:1 20:6 X.03 difenoconazole 33.3:1 20:0.6 X.03 difenoconazole 1:3 2:6 X.03 difenoconazole 3.3:1 2:0.6 X.03 mefentrifluconazole 3.3:1 20:6 X.03 mefentrifluconazole 33.3:1 20:0.6 X.03 mefentrifluconazole 1:3 2:6 X.03 mefentrifluconazole 3.3:1 2:0.6 X.03 folpet 3.3:1 20:6 X.03 folpet 33.3:1 20:0.6 X.03 folpet 1:3 2:6 X.03 folpet 3.3:1 2:0.6 X.03 cyclobutrifluram 3.3:1 20:6 X.03 cyclobutrifluram 33.3:1 20:0.6 X.03 cyclobutrifluram 1:3 2:6 X.03 cyclobutrifluram 3.3:1 2:0.6 X.03 florylpicoxamid 3.3:1 20:6 X.03 florylpicoxamid 33.3:1 20:0.6 X.03 florylpicoxamid 1:3 2:6 X.03 florylpicoxamid 3.3:1 2:0.6 X.03 Streptomyces 3.3:1 20:6 chrestomyceticus CBS149411 X.03 Streptomyces 33.3:1 20:0.6 chrestomyceticus CBS149411 X.03 Streptomyces 1:3 2:6 chrestomyceticus CBS149411 X.03 Streptomyces 3.3:1 2:0.6 chrestomyceticus CBS149411 X.03 Compound Z 3.3:1 20:6 X.03 Compound Z 33.3:1 20:0.6 X.03 Compound Z 1:3 2:6 X.03 Compound Z 3.3:1 2:0.6 X.03 pydiflumetofen 3.3:1 20:6 X.03 pydiflumetofen 33.3:1 20:0.6 X.03 pydiflumetofen 1:3 2:6 X.03 pydiflumetofen 3.3:1 2:0.6 Example B3: Activity against Plasmopara viticola (downy mildew of grapevine) Grape vine leaf disks are placed on agar in multiwell plates (24-well format) and sprayed with test solutions. After drying, the leaf disks are inoculated with a spore suspension of the pathogen. After appropriate incubation the activity of a compound is assessed 7 dpi (days after inoculation) as preventive fungicidal activity. The following mixture compositions (A:B) at the reported concentration (in ppm) gave at least 80% disease control in this test. Component A Conc. (ppm) Component B Ratio A:B (Compound) (A : B) X.07 oxathiapiprolin 10:1 200:20 X.07 oxathiapiprolin 100:1 200:2 X.07 oxathiapiprolin 3:1 60:20 X.07 oxathiapiprolin 30:1 60:2 X.07 fluoxapiprolin 10:1 200:20 X.07 fluoxapiprolin 100:1 200:2 X.07 fluoxapiprolin 3:1 60:20 X.07 fluoxapiprolin 30:1 60:2 X.07 metalaxyl-M 1:1 200:200 X.07 metalaxyl-M 10:1 200:20 X.07 metalaxyl-M 1:3.3 60:200 X.07 metalaxyl-M 3:1 60:20 X.07 picarbutrazox 1:1 200:200 X.07 picarbutrazox 10:1 200:20 X.07 picarbutrazox 1:3.3 60:200 X.07 picarbutrazox 3:1 60:20 X.07 azoxystrobin 1:1 200:200 X.07 azoxystrobin 10:1 200:20 X.07 azoxystrobin 1:3.3 60:200 X.07 azoxystrobin 3:1 60:20 X.07 cymoxanil 1:1 200:200 X.07 cymoxanil 10:1 200:20 X.07 cymoxanil 1:3.3 60:200 X.07 cymoxanil 3:1 60:20 X.07 mandipropamid 1:1 200:200 X.07 mandipropamid 10:1 200:20 X.07 mandipropamid 1:3.3 60:200 X.07 mandipropamid 3:1 60:20 X.07 fluazinam 1:1 200:200 X.07 fluazinam 10:1 200:20 X.07 fluazinam 1:3.3 60:200 X.07 fluazinam 3:1 60:20 X.07 fludioxonil 1:1 200:200 X.07 fludioxonil 10:1 200:20 X.07 fludioxonil 1:3.3 60:200 X.07 fludioxonil 3:1 60:20 X.07 fluopicolide 1:1 200:200 X.07 fluopicolide 10:1 200:20 X.07 fluopicolide 1:3.3 60:200 X.07 fluopicolide 3:1 60:20 X.07 zoxamide 1:1 200:200 X.07 zoxamide 10:1 200:20 X.07 zoxamide 1:3.3 60:200 X.07 zoxamide 3:1 60:20 X.07 sedaxane 1:1 200:200 X.07 sedaxane 10:1 200:20 X.07 sedaxane 1:3.3 60:200 X.07 sedaxane 3:1 60:20 X.07 disodium phosphonate 1:1 200:200 X.07 disodium phosphonate 10:1 200:20 X.07 disodium phosphonate 1:3.3 60:200 X.07 disodium phosphonate 3:1 60:20 X.07 difenoconazole 1:1 200:200 X.07 difenoconazole 10:1 200:20 X.07 difenoconazole 1:3.3 60:200 X.07 difenoconazole 3:1 60:20 X.07 mefentrifluconazole 1:1 200:200 X.07 mefentrifluconazole 10:1 200:20 X.07 mefentrifluconazole 1:3.3 60:200 X.07 mefentrifluconazole 3:1 60:20 X.07 folpet 1:1 200:200 X.07 folpet 10:1 200:20 X.07 folpet 1:3.3 60:200 X.07 folpet 3:1 60:20 X.07 cyclobutrifluram 1:1 200:200 X.07 cyclobutrifluram 10:1 200:20 X.07 cyclobutrifluram 1:3.3 60:200 X.07 cyclobutrifluram 3:1 60:20 X.07 florylpicoxamid 1:1 200:200 X.07 florylpicoxamid 10:1 200:20 X.07 florylpicoxamid 1:3.3 60:200 X.07 florylpicoxamid 3:1 60:20 X.07 Streptomyces 1:1 200:200 chrestomyceticus CBS149411 X.07 Streptomyces 10:1 200:20 chrestomyceticus CBS149411 X.07 Streptomyces 1:3.3 60:200 chrestomyceticus CBS149411 X.07 Streptomyces 3:1 60:20 chrestomyceticus CBS149411 X.07 Compound Z 1:1 200:200 X.07 Compound Z 10:1 200:20 X.07 Compound Z 1:3.3 60:200 X.07 Compound Z 3:1 60:20 X.07 pydiflumetofen 1:1 200:200 X.07 pydiflumetofen 10:1 200:20 X.07 pydiflumetofen 1:3.3 60:200 X.07 pydiflumetofen 3:1 60:20 Component A Conc. (ppm) Component B Ratio A:B (Compound) (A : B) X.11 oxathiapiprolin 10:1 200:20 X.11 oxathiapiprolin 100:1 200:2 X.11 oxathiapiprolin 3:1 60:20 X.11 oxathiapiprolin 30:1 60:2 X.11 fluoxapiprolin 10:1 200:20 X.11 fluoxapiprolin 100:1 200:2 X.11 fluoxapiprolin 3:1 60:20 X.11 fluoxapiprolin 30:1 60:2 X.11 metalaxyl-M 1:1 200:200 X.11 metalaxyl-M 10:1 200:20 X.11 metalaxyl-M 1:3.3 60:200 X.11 metalaxyl-M 3:1 60:20 X.11 picarbutrazox 1:1 200:200 X.11 picarbutrazox 10:1 200:20 X.11 picarbutrazox 1:3.3 60:200 X.11 picarbutrazox 3:1 60:20 X.11 azoxystrobin 1:1 200:200 X.11 azoxystrobin 10:1 200:20 X.11 azoxystrobin 1:3.3 60:200 X.11 azoxystrobin 3:1 60:20 X.11 cymoxanil 1:1 200:200 X.11 cymoxanil 10:1 200:20 X.11 cymoxanil 1:3.3 60:200 X.11 cymoxanil 3:1 60:20 X.11 mandipropamid 1:1 200:200 X.11 mandipropamid 10:1 200:20 X.11 mandipropamid 1:3.3 60:200 X.11 mandipropamid 3:1 60:20 X.11 fluazinam 1:1 200:200 X.11 fluazinam 10:1 200:20 X.11 fluazinam 1:3.3 60:200 X.11 fluazinam 3:1 60:20 X.11 fludioxonil 1:1 200:200 X.11 fludioxonil 10:1 200:20 X.11 fludioxonil 1:3.3 60:200 X.11 fludioxonil 3:1 60:20 X.11 fluopicolide 1:1 200:200 X.11 fluopicolide 10:1 200:20 X.11 fluopicolide 1:3.3 60:200 X.11 fluopicolide 3:1 60:20 X.11 zoxamide 1:1 200:200 X.11 zoxamide 10:1 200:20 X.11 zoxamide 1:3.3 60:200 X.11 zoxamide 3:1 60:20 X.11 sedaxane 1:1 200:200 X.11 sedaxane 10:1 200:20 X.11 sedaxane 1:3.3 60:200 X.11 sedaxane 3:1 60:20 X.11 disodium phosphonate 1:3.3 60:200 X.11 disodium phosphonate 3:1 60:20 X.11 difenoconazole 1:1 200:200 X.11 difenoconazole 10:1 200:20 X.11 difenoconazole 1:3.3 60:200 X.11 difenoconazole 3:1 60:20 X.11 mefentrifluconazole 1:1 200:200 X.11 mefentrifluconazole 10:1 200:20 X.11 mefentrifluconazole 1:3.3 60:200 X.11 mefentrifluconazole 3:1 60:20 X.11 folpet 1:1 200:200 X.11 folpet 10:1 200:20 X.11 folpet 1:3.3 60:200 X.11 folpet 3:1 60:20 X.11 cyclobutrifluram 1:1 200:200 X.11 cyclobutrifluram 10:1 200:20 X.11 cyclobutrifluram 1:3.3 60:200 X.11 cyclobutrifluram 3:1 60:20 X.11 florylpicoxamid 1:1 200:200 X.11 florylpicoxamid 10:1 200:20 X.11 florylpicoxamid 1:3.3 60:200 X.11 florylpicoxamid 3:1 60:20 X.11 Streptomyces 10:1 200:20 chrestomyceticus CBS149411 X.11 Streptomyces 1:3.3 60:200 chrestomyceticus CBS149411 X.11 Streptomyces 3:1 60:20 chrestomyceticus CBS149411 X.11 X.11 Compound Z 1:1 200:200 X.11 Compound Z 10:1 200:20 X.11 Compound Z 1:3.3 60:200 X.11 Compound Z 3:1 60:20 X.11 pydiflumetofen 1:1 200:200 X.11 pydiflumetofen 10:1 200:20 X.11 pydiflumetofen 1:3.3 60:200 X.11 pydiflumetofen 3:1 60:20 Component A Conc. (ppm) Component B Ratio A:B (Compound) (A : B) X.03 oxathiapiprolin 10:1 200:20 X.03 oxathiapiprolin 100:1 200:2 X.03 oxathiapiprolin 3:1 60:20 X.03 oxathiapiprolin 30:1 60:2 X.03 fluoxapiprolin 10:1 200:20 X.03 fluoxapiprolin 100:1 200:2 X.03 fluoxapiprolin 3:1 60:20 X.03 fluoxapiprolin 30:1 60:2 X.03 metalaxyl-M 1:1 200:200 X.03 metalaxyl-M 10:1 200:20 X.03 metalaxyl-M 1:3.3 60:200 X.03 metalaxyl-M 3:1 60:20 X.03 picarbutrazox 1:1 200:200 X.03 picarbutrazox 10:1 200:20 X.03 picarbutrazox 1:3.3 60:200 X.03 picarbutrazox 3:1 60:20 X.03 azoxystrobin 1:1 200:200 X.03 azoxystrobin 10:1 200:20 X.03 azoxystrobin 1:3.3 60:200 X.03 azoxystrobin 3:1 60:20 X.03 cymoxanil 1:1 200:200 X.03 cymoxanil 10:1 200:20 X.03 cymoxanil 1:3.3 60:200 X.03 cymoxanil 3:1 60:20 X.03 mandipropamid 1:1 200:200 X.03 mandipropamid 10:1 200:20 X.03 mandipropamid 1:3.3 60:200 X.03 mandipropamid 3:1 60:20 X.03 fluazinam 1:1 200:200 X.03 fluazinam 10:1 200:20 X.03 fluazinam 1:3.3 60:200 X.03 fluazinam 3:1 60:20 X.03 fludioxonil 1:1 200:200 X.03 fludioxonil 10:1 200:20 X.03 fludioxonil 1:3.3 60:200 X.03 fludioxonil 3:1 60:20 X.03 fluopicolide 1:1 200:200 X.03 fluopicolide 10:1 200:20 X.03 fluopicolide 1:3.3 60:200 X.03 fluopicolide 3:1 60:20 X.03 zoxamide 1:1 200:200 X.03 zoxamide 10:1 200:20 X.03 zoxamide 1:3.3 60:200 X.03 zoxamide 3:1 60:20 X.03 sedaxane 1:1 200:200 X.03 sedaxane 10:1 200:20 X.03 sedaxane 1:3.3 60:200 X.03 sedaxane 3:1 60:20 X.03 disodium phosphonate 1:1 200:200 X.03 disodium phosphonate 10:1 200:20 X.03 disodium phosphonate 1:3.3 60:200 X.03 disodium phosphonate 3:1 60:20 X.03 difenoconazole 1:1 200:200 X.03 difenoconazole 10:1 200:20 X.03 difenoconazole 1:3.3 60:200 X.03 difenoconazole 3:1 60:20 X.03 mefentrifluconazole 1:1 200:200 X.03 mefentrifluconazole 10:1 200:20 X.03 mefentrifluconazole 1:3.3 60:200 X.03 mefentrifluconazole 3:1 60:20 X.03 folpet 1:1 200:200 X.03 folpet 10:1 200:20 X.03 folpet 1:3.3 60:200 X.03 folpet 3:1 60:20 X.03 cyclobutrifluram 1:1 200:200 X.03 cyclobutrifluram 10:1 200:20 X.03 cyclobutrifluram 1:3.3 60:200 X.03 cyclobutrifluram 3:1 60:20 X.03 florylpicoxamid 1:1 200:200 X.03 florylpicoxamid 10:1 200:20 X.03 florylpicoxamid 1:3.3 60:200 X.03 florylpicoxamid 3:1 60:20 X.03 Streptomyces 1:1 200:200 chrestomyceticus CBS149411 X.03 Streptomyces 10:1 200:20 chrestomyceticus CBS149411 X.03 Streptomyces 1:3.3 60:200 chrestomyceticus CBS149411 X.03 Streptomyces 3:1 60:20 chrestomyceticus CBS149411 X.03 Compound Z 1:1 200:200 X.03 Compound Z 10:1 200:20 X.03 Compound Z 1:3.3 60:200 X.03 Compound Z 3:1 60:20 X.03 pydiflumetofen 1:1 200:200 X.03 pydiflumetofen 10:1 200:20 X.03 pydiflumetofen 1:3.3 60:200 X.03 pydiflumetofen 3:1 60:20

Claims
Claims 1. A fungicidal composition comprising components (A) and (B) as active ingredients, wherein component (A) is a compound of formula (I): wherein A1 is a carbon atom; A2 is a carbon atom or a nitrogen atom; ring W is selected from , ring W being unsubstituted or substituted with one substituent selected from R1, R1 being selected from C1-6alkyl and C1-6alkoxy-C1-6alkyl, and preferably R1 being CH3 or -CH2OCH3; R2a is H; R2b is selected from H, CN, C1-6alkyl, C3-6cycloalkyl, C1-6alkoxy-C1-6alkyl, amino, and -NHC(O)C1-6alkyl; R2c is H; A31 is CR31; R31 is selected from H, C1-6alkyl, C1-6alkoxy, and halogen; A32 is N or CR32; R32 is halogen or CN; A is CH or N; and R4 is selected from C1-6alkyl, C1-6alkoxy, C3-6cycloalkyl, C1-6alkylamino, C1-6alkoxyamino, and C1-6alkylC1- 6alkoxyamino; or a salt or N-oxide thereof; and component (B) is a compound selected from the group consisting of acetamiprid, acibenzolar-S-methyl, ametoctradin, amisulbrom, azoxystrobin, Bacillus amyloliquefaciens, benzovindiflupyr, broflanilid, chlorothalonil, chlothianidin, chlorantraniliprole, Cis-Jasmone, cyantraniliprole, cyazofamid, cyclobutrifluram, cymoxanil, difenoconazole, disodium phosphonate, ethaboxam, fenpicoxamid, florylpicoxamid, fluazinam, fludioxonil, fluindapyr, fluopicolide, fluopyram, fluoxapiprolin, fluoxytioconazole, fluxametamide, fluxapyroxad, folpet, imidaclprid, inpyrfluxam, ipconazole, ipflufenoquin, isocycloseram, isoflucypram, isotianil, mandipropamid, mefentrifulconazole, metalaxyl, metalaxyl-M (mefenoxam), metyltetraprole, oxathiapiprolin, penflufen, phosphite (phosphonate), picarbutrazox, prothioconazole, pydiflumetofen, pyraclostrobin, quinofumerin, sedaxane, silthiofam, Streptomyces chrestomyceticus, tebuconazole, tetraniliprole, thiabendazole, thiamethoxam, tolprocarb, triticonazole, zoxamide, N-[(1R)-1-benzyl-3-chloro-1-methyl-but-3-enyl]-8-fluoro-quinoline-3- carboxamide, N-[(1S)-1-benzyl-3-chloro-1-methyl-but-3-enyl]-8-fluoro-quinoline-3-carboxamide, N- [(1R)-1-benzyl-3,3,3-trifluoro-1-methyl-propyl]-8-fluoro-quinoline-3-carboxamide, N-[(1S)-1-benzyl- 3,3,3-trifluoro-1-methyl-propyl]-8-fluoro-quinoline-3-carboxamide, N-[(1R)-1-benzyl-1,3-dimethyl-butyl]- 7,8-difluoro-quinoline-3-carboxamide, N-[(1S)-1-benzyl-1,3-dimethyl-butyl]-7,8-difluoro-quinoline-3- carboxamide, 8-fluoro-N-[(1R)-1-[(3-fluorophenyl)methyl]-1,3-dimethyl-butyl]quinoline-3-carboxamide, 8-fluoro-N-[(1S)-1-[(3-fluorophenyl)methyl]-1,3-dimethyl-butyl]quinoline-3-carboxamide, N-[(1R)-1- benzyl-1,3-dimethyl-butyl]-8-fluoro-quinoline-3-carboxamide, N-[(1S)-1-benzyl-1,
3-dimethyl-butyl]-8- fluoro-quinoline-3-carboxamide, N-((1R)-1-benzyl-3-chloro-1-methyl-but-3-enyl)-8-fluoro-quinoline-3- carboxamide, and N-((1S)-1-benzyl-3-chloro-1-methyl-but-3-enyl)-8-fluoro-quinoline-3-carboxamide. 2. The fungicidal composition according claim 1, wherein: A is N; R2a is H; R2b is selected from H, CH3, cyclopropyl, -CH2OCH3, NH2, and -NHC(O)CH3; R2c is H; R31 is selected from H, CH3, -OCH3, and fluoro; R32 is selected from chloro, fluoro, and CN; and R4 is selected from CH3, cyclopropyl, and -OCH3. 3. The fungicidal composition according claim 1 or 2, wherein the component (A) is a compound selected from: methyl N-[5-[8-cyclopropyl-6-[4-(4-fluoro-3-methoxy-phenyl)-1,2,4-triazol-3-yl]imidazo[1,2-a]pyridin-3- yl]-2-pyridyl]carbamate, methyl N-[5-[6-[1-(4-fluoro-3-methoxy-phenyl)imidazol-2-yl]-8-methyl-imidazo[1,2-a]pyridin-3-yl]-2- pyridyl]carbamate, methyl N-[5-[6-[4-(4-fluoro-3-methoxy-phenyl)-5,6-dihydro-1,2,4-oxadiazin-3-yl]-8-methyl-imidazo[1,2- a]pyridin-3-yl]-2-pyridyl]carbamate, methyl N-[5-[6-[4-(4-fluorophenyl)-5,6-dihydro-1,2,4-oxadiazin-3-yl]-8-methyl-imidazo[1,2-a]pyridin-3- yl]-2-pyridyl]carbamate, methyl N-[5-[6-[5-(4-fluoro-3-methoxy-phenyl)-1-methyl-pyrazol-4-yl]imidazo[1,2-a]pyridin-3-yl]-2- pyridyl]carbamate, methyl N-[5-[6-[4-(4-fluoro-3-methoxy-phenyl)-5,6-dihydro-1,2,4-oxadiazin-3-yl]imidazo[1,2-a]pyridin-3- yl]-2-pyridyl]carbamate, methyl N-[5-[6-[2-(4-fluoro-3-methoxy-phenyl)-1,2,4-triazol-3-yl]-8-methyl-imidazo[1,2-a]pyridin-3-yl]-2- pyridyl]carbamate, methyl N-[5-[6-[4-(4-fluoro-3-methoxy-phenyl)-5-methyl-1,2,4-triazol-3-yl]imidazo[1,2-a]pyridin-3-yl]-2- pyridyl]carbamate, methyl N-[5-[6-[1-(4-fluoro-3-methoxy-phenyl)imidazol-2-yl]imidazo[1,2-a]pyridin-3-yl]-2- pyridyl]carbamate, methyl N-[5-[6-[2-(4-chloro-3-methoxy-phenyl)-1,2,4-triazol-3-yl]imidazo[1,2-a]pyridin-3-yl]-2- pyridyl]carbamate, methyl N-[5-[6-[2-(4-fluoro-3-methoxy-phenyl)-1,2,4-triazol-3-yl]imidazo[1,2-a]pyridin-3-yl]-2- pyridyl]carbamate, and methyl N-[5-[6-[4-(4-fluoro-3-methoxy-phenyl)-5-(methoxymethyl)-1,2,4-triazol-3-yl]-8-methyl- imidazo[1,2-a]pyridin-3-yl]-2-pyridyl]carbamate. 4. The fungicidal composition according to any one of the preceding claims, wherein the component (A) is: methyl N-[5-[6-[4-(4-fluoro-3-methoxy-phenyl)-5,6-dihydro-1,2,4-oxadiazin-3-yl]-8-methyl-imidazo[1,2- a]pyridin-3-yl]-2-pyridyl]carbamate, or methyl N-[5-[6-[2-(4-fluoro-3-methoxy-phenyl)-1,2,4-triazol-3-yl]-8-methyl-imidazo[1,2-a]pyridin-3-yl]-2- pyridyl]carbamate, or methyl N-[5-[6-[2-(4-fluoro-3-methoxy-phenyl)-1,2,
4-triazol-3-yl]imidazo[1,2-a]pyridin-3-yl]-2- pyridyl]carbamate.
5. The fungicidal composition according to any one of the preceding claims, wherein the component (B) is a compound selected from acibenzolar-S-methyl, ametoctradin, amisulbrom, azoxystrobin, chlorothalonil, cyazofamid, cyclobutrifluram, cymoxanil, difenoconazole, disodium phosphonate, florylpicoxamid, fluazinam, fludioxonil, fluopicolide, fluoxapiprolin, folpet, mandipropamid, mefentrifluconazole, metalaxyl-M, oxathiapiprolin, picarbutrazox, pydiflumetofen, sedaxane, Streptomyces chrestomyceticus, zoxamide, N-[(1R)-1-benzyl-1,3-dimethyl-butyl]-8-fluoro-quinoline-3- carboxamide, and N-[(1S)-1-benzyl-1,3-dimethyl-butyl]-8-fluoro-quinoline-3-carboxamide.
6. The fungicidal composition according to any one of the preceding claims, wherein the weight ratio of component (A) to component (B) is from 100:1 to 1:100.
7. The fungicidal composition according to any one of the preceding claims, wherein the weight ratio of component (A) to component (B) is from 20:1 to 1:40.
8. The fungicidal composition according to any one of the preceding claims, wherein the weight ratio of component (A) to component (B) is from 12:1 to 1:25.
9. The fungicidal composition according to any one of the preceding claims, wherein the weight ratio of component (A) to component (B) is from 5:1 and 1:15.
10. The fungicidal composition according to any one of the preceding claims, wherein the weight ratio of component (A) to component (B) is from 2:1 to 1:5. 11. The fungicidal composition according to any one of the preceding claims, wherein the composition further comprises an additional active ingredient component (C), which is different to component (B), selected from the group consisting of acetamiprid, acibenzolar-S-methyl, ametoctradin, amisulbrom, azoxystrobin, Bacillus amyloliquefaciens, benzovindiflupyr, broflanilid, chlorothalonil, chlothianidin, chlorantraniliprole, Cis-Jasmone, cyantraniliprole, cyazofamid, cyclobutrifluram, cymoxanil, difenoconazole, disodium phosphonate, ethaboxam, fenpicoxamid, florylpicoxamid, fluazinam, fludioxonil, fluindapyr, fluopicolide, fluopyram, fluoxapiprolin, fluoxytioconazole, fluxametamide, fluxapyroxad, folpet, imidaclprid, inpyrfluxam, ipconazole, ipflufenoquin, isocycloseram, isoflucypram, isotianil, mandipropamid, mefentrifulconazole, metalaxyl, metalaxyl-M (mefenoxam), metyltetraprole, oxathiapiprolin, penflufen, phosphite (phosphonate), picarbutrazox, prothioconazole, pydiflumetofen, pyraclostrobin, quinofumerin, sedaxane, silthiofam, Streptomyces chrestomyceticus, tebuconazole, tetraniliprole, thiabendazole, thiamethoxam, tolprocarb, triticonazole, zoxamide, N-[(1R)-1-benzyl-3- chloro-1-methyl-but-3-enyl]-8-fluoro-quinoline-3-carboxamide, N-[(1S)-1-benzyl-3-chloro-1-methyl-but- 3-enyl]-8-fluoro-quinoline-3-carboxamide, N-[(1R)-1-benzyl-3,3,3-trifluoro-1-methyl-propyl]-8-fluoro- quinoline-3-carboxamide, N-[(1S)-1-benzyl-3,3,3-trifluoro-1-methyl-propyl]-8-fluoro-quinoline-3- carboxamide, N-[(1R)-1-benzyl-1,3-dimethyl-butyl]-7,8-difluoro-quinoline-3-carboxamide, N-[(1S)-1- benzyl-1,3-dimethyl-butyl]-7,8-difluoro-quinoline-3-carboxamide, 8-fluoro-N-[(1R)-1-[(3- fluorophenyl)methyl]-1,3-dimethyl-butyl]quinoline-3-carboxamide, 8-fluoro-N-[(1S)-1-[(3- fluorophenyl)methyl]-1,3-dimethyl-butyl]quinoline-3-carboxamide, N-[(1R)-1-benzyl-1,3-dimethyl-butyl]- 8-fluoro-quinoline-3-carboxamide, N-[(1S)-1-benzyl-1,3-dimethyl-butyl]-8-fluoro-quinoline-3- carboxamide, N-((1R)-1-benzyl-3-chloro-1-methyl-but-3-enyl)-8-fluoro-quinoline-3-carboxamide, and N- ((1S)-1-benzyl-3-chloro-1-methyl-but-3-enyl)-8-fluoro-quinoline-3-carboxamide. 12. The fungicidal composition according to any one of the preceding claims, wherein the composition further comprises an agriculturally acceptable carrier and, optionally, a surfactant and/or formulation adjuvants. 13. A method of controlling or preventing phytopathogenic diseases, especially phytopathogenic fungi, on useful plants or on propagation material thereof, which comprises applying to the useful plants, the locus thereof or propagation material thereof the fungicidal composition as defined in any one of claims 1 to 12. 14. A method according to claim 13, wherein the components (A) and (B) are applied in a sequential manner.
PCT/EP2025/065673 2024-06-12 2025-06-05 Fungicidal compositions Pending WO2025257023A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP24181580.2 2024-06-12
EP24181580 2024-06-12

Publications (1)

Publication Number Publication Date
WO2025257023A1 true WO2025257023A1 (en) 2025-12-18

Family

ID=91530356

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2025/065673 Pending WO2025257023A1 (en) 2024-06-12 2025-06-05 Fungicidal compositions

Country Status (1)

Country Link
WO (1) WO2025257023A1 (en)

Citations (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0353191A2 (en) 1988-07-29 1990-01-31 Ciba-Geigy Ag DNA sequences encoding polypeptides having beta-1,3-glucanase activity
EP0367474A1 (en) 1988-11-01 1990-05-09 Mycogen Corporation Novel bacillus thuringiensis isolate denoted b.t. ps81gg, active against lepidopteran pests, and a gene encoding a lepidopteran-active toxin
EP0374753A2 (en) 1988-12-19 1990-06-27 American Cyanamid Company Insecticidal toxines, genes coding therefor, antibodies binding them, transgenic plant cells and plants expressing these toxines
EP0392225A2 (en) 1989-03-24 1990-10-17 Ciba-Geigy Ag Disease-resistant transgenic plants
WO1990013651A1 (en) 1989-05-09 1990-11-15 Imperial Chemical Industries Plc Bacterial genes
EP0401979A2 (en) 1989-05-18 1990-12-12 Mycogen Corporation Novel bacillus thuringiensis isolates active against lepidopteran pests, and genes encoding novel lepidopteran-active toxins
EP0427529A1 (en) 1989-11-07 1991-05-15 Pioneer Hi-Bred International, Inc. Larvicidal lectins and plant insect resistance based thereon
EP0451878A1 (en) 1985-01-18 1991-10-16 Plant Genetic Systems, N.V. Modifying plants by genetic engineering to combat or control insects
US5061495A (en) 1988-03-07 1991-10-29 Agricultural Genetics Company Limited Antibiotic derived from b. subtilis
WO1993007278A1 (en) 1991-10-04 1993-04-15 Ciba-Geigy Ag Synthetic dna sequence having enhanced insecticidal activity in maize
WO1995033818A2 (en) 1994-06-08 1995-12-14 Ciba-Geigy Ag Genes for the synthesis of antipathogenic substances
WO1995034656A1 (en) 1994-06-10 1995-12-21 Ciba-Geigy Ag Novel bacillus thuringiensis genes coding toxins active against lepidopteran pests
WO1997033890A1 (en) 1996-03-11 1997-09-18 Novartis Ag Pyrimidin-4-one derivatives as pesticide
JPH11253151A (en) 1997-11-13 1999-09-21 Kumiai Chem Ind Co Ltd Rice seedling raising disease control agent
US6060051A (en) 1997-05-09 2000-05-09 Agraquest, Inc. Strain of bacillus for controlling plant diseases and corn rootworm
US6245551B1 (en) 1999-03-30 2001-06-12 Agraquest, Inc. Strain of Bacillus pumilus for controlling plant diseases caused by fungi
WO2002015701A2 (en) 2000-08-25 2002-02-28 Syngenta Participations Ag Bacillus thuringiensis crystal protein hybrids
WO2003000051A2 (en) 2001-06-22 2003-01-03 Drahos David J Novel biofungicide
WO2003018810A2 (en) 2001-08-31 2003-03-06 Syngenta Participations Ag Modified cry3a toxins and nucleic acid sequences coding therefor
WO2003052073A2 (en) 2001-12-17 2003-06-26 Syngenta Participations Ag Novel corn event
US7094592B2 (en) 2001-11-26 2006-08-22 Kumiai Chemical Industry Co., Ltd. Bacillus sp. D747 strain, plant disease controlling agents and insect pest controlling agents using the same and control method using the agents
US7579183B1 (en) 2006-12-01 2009-08-25 The United States Of America As Represented By The Secretary Of Agriculture Saprophytic yeast, Pichia anomala
WO2009116106A1 (en) 2008-03-21 2009-09-24 Trentino Sviluppo S.P.A. Trichoderma atroviride sc1 for biocontrol of fungal diseases in plants
WO2010086790A1 (en) 2009-01-27 2010-08-05 Lesaffre Et Compagnie Saccharomyces cerevisiae strains with phytosanitary capabilities
US20100291039A1 (en) 2007-12-14 2010-11-18 Kohl Jurgen Anton Novel micro-organisms controlling plant pathogens
WO2011106491A2 (en) 2010-02-25 2011-09-01 Marrone Bio Innovations, Inc. Isolated bacterial strain of the genus burkholderia and pesticidal metabolites therefrom
WO2011138281A2 (en) 2010-05-06 2011-11-10 Bayer Cropscience Ag Process for the preparation of dithiine tetracarboxydiimides
WO2011151819A2 (en) 2010-06-01 2011-12-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Pseudozyma aphidis as a biocontrol agent against various plant pathogens
WO2013032693A2 (en) 2011-08-27 2013-03-07 Marrone Bio Innovations, Inc. Isolated bacterial strain of the genus burkholderia and pesticidal metabolites therefrom-formulations and uses
WO2013034938A2 (en) 2011-09-08 2013-03-14 Szegedi Tudományegyetem A copper resistant, fengycin-producing bacillus mojavensis strain for controlling vegetable pathogens, its use and compositions containing it
WO2014006945A1 (en) 2012-07-04 2014-01-09 アグロカネショウ株式会社 2-aminonicotinic acid ester derivative and bactericide containing same as active ingredient
WO2014028521A1 (en) 2012-08-14 2014-02-20 Marrone Bio Innovations, Inc. Bacillus sp. strain with antifungal, antibacterial and growth promotion activity
WO2014095675A1 (en) 2012-12-19 2014-06-26 Bayer Cropscience Ag Difluoromethyl-nicotinic-indanyl carboxamides as fungicides
WO2015067800A1 (en) 2013-11-11 2015-05-14 Basf Se Antifungal penicillium strains, fungicidal extrolites thereof, and their use
WO2015155075A1 (en) 2014-04-11 2015-10-15 Syngenta Participations Ag Fungicidal n'-[2-methyl-6-[2-alkoxy-ethoxy]-3-pyridyl]-n-alkyl-formamidine derivatives for use in agriculture
WO2016020371A1 (en) 2014-08-04 2016-02-11 Basf Se Antifungal paenibacillus strains, fusaricidin-type compounds, and their use
WO2016154297A1 (en) 2015-03-26 2016-09-29 Bayer Cropscience Lp A novel paenibacillus strain, antifungal compounds, and methods for their use
WO2016156290A1 (en) 2015-04-02 2016-10-06 Bayer Cropscience Aktiengesellschaft Novel 5-substituted imidazole derivatives
WO2016156085A1 (en) 2015-03-27 2016-10-06 Syngenta Participations Ag Microbiocidal heterobicyclic derivatives
WO2016202742A1 (en) 2015-06-15 2016-12-22 Bayer Cropscience Aktiengesellschaft Halogen-substituted phenoxyphenylamidines and the use thereof as fungicides
WO2017019448A1 (en) 2015-07-24 2017-02-02 AgBiome, Inc. Modified biological control agents and their uses
WO2017025510A1 (en) 2015-08-12 2017-02-16 Syngenta Participations Ag Microbiocidal heterobicyclic derivatives
WO2017029179A1 (en) 2015-08-14 2017-02-23 Bayer Cropscience Aktiengesellschaft Triazole derivatives, intermediates thereof and their use as fungicides
WO2017055469A1 (en) 2015-10-02 2017-04-06 Syngenta Participations Ag Microbiocidal oxadiazole derivatives
WO2017055473A1 (en) 2015-10-02 2017-04-06 Syngenta Participations Ag Microbiocidal oxadiazole derivatives
WO2017066094A1 (en) 2015-10-12 2017-04-20 Pioneer Hi-Bred International, Inc. Biologicals and their use in plants
WO2017093348A1 (en) 2015-12-02 2017-06-08 Syngenta Participations Ag Microbiocidal oxadiazole derivatives
WO2017118689A1 (en) 2016-01-08 2017-07-13 Syngenta Participations Ag Microbiocidal oxadiazole derivatives
WO2017153380A1 (en) 2016-03-10 2017-09-14 Syngenta Participations Ag Microbiocidal quinoline (thio)carboxamide derivatives
WO2017205258A1 (en) 2016-05-26 2017-11-30 Novozymes Bioag A/S Bacillus and lipochitooligosaccharide for improving plant growth
WO2017220485A1 (en) 2016-06-21 2017-12-28 Syngenta Participations Ag Microbiocidal oxadiazole derivatives
WO2018065414A1 (en) 2016-10-06 2018-04-12 Syngenta Participations Ag Microbiocidal oxadiazole derivatives
WO2018153707A1 (en) 2017-02-22 2018-08-30 Basf Se Crystalline forms of a strobilurin type compound for combating phytopathogenic fungi
WO2018158365A1 (en) 2017-03-03 2018-09-07 Syngenta Participations Ag Microbiocidal oxadiazole derivatives
WO2018202428A1 (en) 2017-05-02 2018-11-08 Basf Se Fungicidal mixture comprising substituted 3-phenyl-5-(trifluoromethyl)-1,2,4-oxadiazoles
WO2018228896A1 (en) 2017-06-14 2018-12-20 Syngenta Participations Ag Fungicidal compositions
WO2019110427A1 (en) 2017-12-04 2019-06-13 Syngenta Participations Ag Microbiocidal phenylamidine derivatives
WO2020056090A1 (en) 2018-09-14 2020-03-19 Fmc Corporation Fungicidal halomethyl ketones and hydrates
WO2020079111A1 (en) 2018-10-18 2020-04-23 Syngenta Crop Protection Ag Microbiocidal compounds
WO2020097012A1 (en) 2018-11-06 2020-05-14 Fmc Corporation Substituted tolyl as fungicides
WO2020109391A1 (en) 2018-11-28 2020-06-04 Bayer Aktiengesellschaft Pyridazine (thio)amides as fungicidal compounds
WO2020193387A1 (en) 2019-03-22 2020-10-01 Syngenta Crop Protection Ag Fungicidal compounds
WO2023061838A1 (en) * 2021-10-14 2023-04-20 Syngenta Crop Protection Ag Imidazo[1,2-a]pyridine derivatives
WO2024126404A1 (en) * 2022-12-14 2024-06-20 Syngenta Crop Protection Ag Imidazo[1,2-a]pyridine derivatives

Patent Citations (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0451878A1 (en) 1985-01-18 1991-10-16 Plant Genetic Systems, N.V. Modifying plants by genetic engineering to combat or control insects
US5061495A (en) 1988-03-07 1991-10-29 Agricultural Genetics Company Limited Antibiotic derived from b. subtilis
EP0353191A2 (en) 1988-07-29 1990-01-31 Ciba-Geigy Ag DNA sequences encoding polypeptides having beta-1,3-glucanase activity
EP0367474A1 (en) 1988-11-01 1990-05-09 Mycogen Corporation Novel bacillus thuringiensis isolate denoted b.t. ps81gg, active against lepidopteran pests, and a gene encoding a lepidopteran-active toxin
EP0374753A2 (en) 1988-12-19 1990-06-27 American Cyanamid Company Insecticidal toxines, genes coding therefor, antibodies binding them, transgenic plant cells and plants expressing these toxines
EP0392225A2 (en) 1989-03-24 1990-10-17 Ciba-Geigy Ag Disease-resistant transgenic plants
WO1990013651A1 (en) 1989-05-09 1990-11-15 Imperial Chemical Industries Plc Bacterial genes
EP0401979A2 (en) 1989-05-18 1990-12-12 Mycogen Corporation Novel bacillus thuringiensis isolates active against lepidopteran pests, and genes encoding novel lepidopteran-active toxins
EP0427529A1 (en) 1989-11-07 1991-05-15 Pioneer Hi-Bred International, Inc. Larvicidal lectins and plant insect resistance based thereon
WO1993007278A1 (en) 1991-10-04 1993-04-15 Ciba-Geigy Ag Synthetic dna sequence having enhanced insecticidal activity in maize
WO1995033818A2 (en) 1994-06-08 1995-12-14 Ciba-Geigy Ag Genes for the synthesis of antipathogenic substances
WO1995034656A1 (en) 1994-06-10 1995-12-21 Ciba-Geigy Ag Novel bacillus thuringiensis genes coding toxins active against lepidopteran pests
WO1997033890A1 (en) 1996-03-11 1997-09-18 Novartis Ag Pyrimidin-4-one derivatives as pesticide
US6060051A (en) 1997-05-09 2000-05-09 Agraquest, Inc. Strain of bacillus for controlling plant diseases and corn rootworm
JPH11253151A (en) 1997-11-13 1999-09-21 Kumiai Chem Ind Co Ltd Rice seedling raising disease control agent
US6245551B1 (en) 1999-03-30 2001-06-12 Agraquest, Inc. Strain of Bacillus pumilus for controlling plant diseases caused by fungi
WO2002015701A2 (en) 2000-08-25 2002-02-28 Syngenta Participations Ag Bacillus thuringiensis crystal protein hybrids
WO2003000051A2 (en) 2001-06-22 2003-01-03 Drahos David J Novel biofungicide
WO2003018810A2 (en) 2001-08-31 2003-03-06 Syngenta Participations Ag Modified cry3a toxins and nucleic acid sequences coding therefor
US7094592B2 (en) 2001-11-26 2006-08-22 Kumiai Chemical Industry Co., Ltd. Bacillus sp. D747 strain, plant disease controlling agents and insect pest controlling agents using the same and control method using the agents
WO2003052073A2 (en) 2001-12-17 2003-06-26 Syngenta Participations Ag Novel corn event
US7579183B1 (en) 2006-12-01 2009-08-25 The United States Of America As Represented By The Secretary Of Agriculture Saprophytic yeast, Pichia anomala
US20100291039A1 (en) 2007-12-14 2010-11-18 Kohl Jurgen Anton Novel micro-organisms controlling plant pathogens
WO2009116106A1 (en) 2008-03-21 2009-09-24 Trentino Sviluppo S.P.A. Trichoderma atroviride sc1 for biocontrol of fungal diseases in plants
US8431120B2 (en) 2008-03-21 2013-04-30 Trentino Sviluppo S.P.A. Trichoderma atroviride SC1 for biocontrol of fungal diseases in plants
WO2010086790A1 (en) 2009-01-27 2010-08-05 Lesaffre Et Compagnie Saccharomyces cerevisiae strains with phytosanitary capabilities
WO2011106491A2 (en) 2010-02-25 2011-09-01 Marrone Bio Innovations, Inc. Isolated bacterial strain of the genus burkholderia and pesticidal metabolites therefrom
WO2011138281A2 (en) 2010-05-06 2011-11-10 Bayer Cropscience Ag Process for the preparation of dithiine tetracarboxydiimides
WO2011151819A2 (en) 2010-06-01 2011-12-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Pseudozyma aphidis as a biocontrol agent against various plant pathogens
WO2013032693A2 (en) 2011-08-27 2013-03-07 Marrone Bio Innovations, Inc. Isolated bacterial strain of the genus burkholderia and pesticidal metabolites therefrom-formulations and uses
WO2013034938A2 (en) 2011-09-08 2013-03-14 Szegedi Tudományegyetem A copper resistant, fengycin-producing bacillus mojavensis strain for controlling vegetable pathogens, its use and compositions containing it
WO2014006945A1 (en) 2012-07-04 2014-01-09 アグロカネショウ株式会社 2-aminonicotinic acid ester derivative and bactericide containing same as active ingredient
WO2014028521A1 (en) 2012-08-14 2014-02-20 Marrone Bio Innovations, Inc. Bacillus sp. strain with antifungal, antibacterial and growth promotion activity
WO2014095675A1 (en) 2012-12-19 2014-06-26 Bayer Cropscience Ag Difluoromethyl-nicotinic-indanyl carboxamides as fungicides
WO2015067800A1 (en) 2013-11-11 2015-05-14 Basf Se Antifungal penicillium strains, fungicidal extrolites thereof, and their use
WO2015155075A1 (en) 2014-04-11 2015-10-15 Syngenta Participations Ag Fungicidal n'-[2-methyl-6-[2-alkoxy-ethoxy]-3-pyridyl]-n-alkyl-formamidine derivatives for use in agriculture
WO2016020371A1 (en) 2014-08-04 2016-02-11 Basf Se Antifungal paenibacillus strains, fusaricidin-type compounds, and their use
WO2016154297A1 (en) 2015-03-26 2016-09-29 Bayer Cropscience Lp A novel paenibacillus strain, antifungal compounds, and methods for their use
WO2016156085A1 (en) 2015-03-27 2016-10-06 Syngenta Participations Ag Microbiocidal heterobicyclic derivatives
WO2016156290A1 (en) 2015-04-02 2016-10-06 Bayer Cropscience Aktiengesellschaft Novel 5-substituted imidazole derivatives
WO2016202742A1 (en) 2015-06-15 2016-12-22 Bayer Cropscience Aktiengesellschaft Halogen-substituted phenoxyphenylamidines and the use thereof as fungicides
WO2017019448A1 (en) 2015-07-24 2017-02-02 AgBiome, Inc. Modified biological control agents and their uses
WO2017025510A1 (en) 2015-08-12 2017-02-16 Syngenta Participations Ag Microbiocidal heterobicyclic derivatives
WO2017029179A1 (en) 2015-08-14 2017-02-23 Bayer Cropscience Aktiengesellschaft Triazole derivatives, intermediates thereof and their use as fungicides
WO2017055469A1 (en) 2015-10-02 2017-04-06 Syngenta Participations Ag Microbiocidal oxadiazole derivatives
WO2017055473A1 (en) 2015-10-02 2017-04-06 Syngenta Participations Ag Microbiocidal oxadiazole derivatives
WO2017066094A1 (en) 2015-10-12 2017-04-20 Pioneer Hi-Bred International, Inc. Biologicals and their use in plants
WO2017093348A1 (en) 2015-12-02 2017-06-08 Syngenta Participations Ag Microbiocidal oxadiazole derivatives
WO2017118689A1 (en) 2016-01-08 2017-07-13 Syngenta Participations Ag Microbiocidal oxadiazole derivatives
WO2017153380A1 (en) 2016-03-10 2017-09-14 Syngenta Participations Ag Microbiocidal quinoline (thio)carboxamide derivatives
WO2017205258A1 (en) 2016-05-26 2017-11-30 Novozymes Bioag A/S Bacillus and lipochitooligosaccharide for improving plant growth
WO2017220485A1 (en) 2016-06-21 2017-12-28 Syngenta Participations Ag Microbiocidal oxadiazole derivatives
WO2018065414A1 (en) 2016-10-06 2018-04-12 Syngenta Participations Ag Microbiocidal oxadiazole derivatives
WO2018153707A1 (en) 2017-02-22 2018-08-30 Basf Se Crystalline forms of a strobilurin type compound for combating phytopathogenic fungi
WO2018158365A1 (en) 2017-03-03 2018-09-07 Syngenta Participations Ag Microbiocidal oxadiazole derivatives
WO2018202428A1 (en) 2017-05-02 2018-11-08 Basf Se Fungicidal mixture comprising substituted 3-phenyl-5-(trifluoromethyl)-1,2,4-oxadiazoles
WO2018228896A1 (en) 2017-06-14 2018-12-20 Syngenta Participations Ag Fungicidal compositions
WO2019110427A1 (en) 2017-12-04 2019-06-13 Syngenta Participations Ag Microbiocidal phenylamidine derivatives
WO2020056090A1 (en) 2018-09-14 2020-03-19 Fmc Corporation Fungicidal halomethyl ketones and hydrates
WO2020079111A1 (en) 2018-10-18 2020-04-23 Syngenta Crop Protection Ag Microbiocidal compounds
WO2020097012A1 (en) 2018-11-06 2020-05-14 Fmc Corporation Substituted tolyl as fungicides
WO2020109391A1 (en) 2018-11-28 2020-06-04 Bayer Aktiengesellschaft Pyridazine (thio)amides as fungicidal compounds
WO2020193387A1 (en) 2019-03-22 2020-10-01 Syngenta Crop Protection Ag Fungicidal compounds
WO2023061838A1 (en) * 2021-10-14 2023-04-20 Syngenta Crop Protection Ag Imidazo[1,2-a]pyridine derivatives
WO2024126404A1 (en) * 2022-12-14 2024-06-20 Syngenta Crop Protection Ag Imidazo[1,2-a]pyridine derivatives

Non-Patent Citations (13)

* Cited by examiner, † Cited by third party
Title
"The Pesticide Manual", 2021, BRITISH CROP PROTECTION COUNCIL
A. DE MEIJERES. BRASEM. OESTREICH: "Metal-Catalyzed Cross-Coupling Reactions and More", 2014, WILEY-VCH
CROP PROTECTION, vol. 25, no. 2643947-26-4, 2006, pages 468 - 475
E. KANGH. T. KIMJ.M. JOO, ORG. BIOMOL. CHEM., vol. 18, 2020, pages 6192
F. BELLINAR. ROSSI, ADV. SYNTH. CATAL., 2010, pages 1223
H. KADDOURIV. VICENTEA. OUALIF. OUAZZANIM. TAILLEFER, ANGEW. CHEM. INT. ED., vol. 48, 2009, pages 333
J.-Q. CHENJ.-H. LI, Z.-B. DONG, ADV. SYNTH CATAL., vol. 362, 2020, pages 3311
JENSEN DF ET AL.: "Development of a biocontrol agent for plant disease control with special emphasis on the near commercial fungal antagonist Clonostachys rosea strain 'IK726", AUSTRALASIAN PLANT PATHOL, vol. 1-3, no. 2, 2007, pages 95 - 101
no. 1470372-59-8
PIETR ET AL., ZESZ. NAUK. A R W SZCZECINIE, vol. 161, 1993, pages 125 - 137
Q. YANGY. ZHAOD. MA, ORG. PROCESS RES. DEV., vol. 26, 2022, pages 1690
V.J. RAMA. SETHIM. NATHR. PRATAP: "The Chemistry of Heterocycles Nomenclature and Chemistry of Three to Five Membered Heterocycles", 2019, ELSEVIER
XUE A.G.: "Efficacy of Clonostachys rosea strain ACM941 and fungicide seed treatments for controlling the root tot complex of field pea", CAN JOUR PLANT SCI, vol. 83, no. 3, 2003, pages 519 - 524

Similar Documents

Publication Publication Date Title
AU2022364034B2 (en) Imidazo[1,2-a]pyridine derivatives
AU2022325463B2 (en) Fungicide mixture
WO2024126407A1 (en) Benzimidazole derivatives
WO2024126404A1 (en) Imidazo[1,2-a]pyridine derivatives
WO2025257023A1 (en) Fungicidal compositions
AU2024255817A1 (en) Fungicidal compositions
WO2025257024A1 (en) Fungicidal compositions
WO2025021537A1 (en) Benzimidazole derivatives
WO2024213650A1 (en) Imidazo[1,2-a]pyridine derivatives
WO2024213653A1 (en) Imidazo[1,2-a]pyridine derivatives
AU2024251657A1 (en) Imidazo bicyclic derivatives
WO2024213651A1 (en) Imidazo[1,2-a]pyridine derivatives
WO2024213659A1 (en) Imidazo[1,2-a]pyrazine derivatives
WO2024213663A1 (en) Pyrazolo[1,5-a]pyridine derivatives
WO2024213656A1 (en) Imidazo[1,2-a]pyrazine derivatives
WO2024213662A1 (en) Pyrazolo[1,5-a]pyridine derivatives
WO2024017788A1 (en) Solid form of a heterocyclic amide derivative

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 25732048

Country of ref document: EP

Kind code of ref document: A1